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Abstract 
Implementation of AUSDRISK screening for T2DM in older 
adults. 
The research described in this thesis was undertaken in 2014–15. At that time, the World 
Diabetes Federation estimated there were 1.7 million Australians with diabetes (all types) 
which was predicted to increase to 2.3 million by 2035. A further 2 million Australians were 
estimated to have pre-diabetes (preDM), which doubles the risk of developing type 2 
diabetes mellitus (T2DM). Type 2 diabetes is an age-related condition and life expectancy of 
the Australian population is increasing. Together they form the perfect storm. In 2014–15, the 
overall prevalence of T2DM in Australia was 4.1% with the prevalence of T2DM in the older 
age cohort ranging between 9.0% in the 55–64 year age group, and rising to 16.0% in the 
65–74 year age group. 
In Tasmania, the older age cohort is the most rapidly increasing. Diabetes Tasmania, the 
peak non-Government body representing individuals with or at risk for diabetes, reported that 
in calendar year 2014–15, 1,471 individuals had been newly diagnosed with T2DM in 
Tasmania, with 78.5% of those newly diagnosed being over 50 years and over. Of those, 
22.3% were first diagnosed in their 70’s, 80’s and 90’s. As of 30 June 2018, 29.0% of newly 
diagnosed T2DM were over 70 years, reflecting a dramatic increase in this older cohort. 
In Australia there is no national population screening for early identification of those with, or 
at high risk (HR) for T2DM, and no systematic T2DM screening in primary care settings by 
general practitioners (GPs). 
In 2010, the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) was developed 
to identify individuals at HR for T2DM, with recommendations for blood glucose testing to 
confirm glycaemic status. National Health and Medical Guidelines recommend that the 
AUSDRISK be used as the first step in a 2–3 step screening process, but the uptake is 
limited. In 2015, the Australian National Diabetes Strategy Advisory Group (NDSAG), 
8 
recommended a wider use of the AUSDRISK assessment in primary health settings, 
community health and non-health settings and online health services in state and federal 
health departments to identify individuals at high risk for T2DM. 
In 2011, prior to the NDSAG recommendation, I conducted a small T2DM screening trial, and 
found that AUSDRISK could be distributed and completed via community healthcare 
settings. The objectives of this current study in 2014–15 were to verify the procedures and 
findings of the earlier study with a larger sample size of older adults, by distributing the 
AUSDRISK via 3 different community settings. The AUSDRISK was presented face-to-face 
in the 2 community health settings, and indirectly via a statewide mail-out specifically for 
older adults. The aim was to determine the feasibility, acceptability and effectiveness of using 
the AUSDRISK as the first step in T2DM screening of community-living older individuals, and 
to follow those at HR through to biomedical assessment.  
The purpose of the study is to identify the number of older individuals at High Risk (HR) for 
T2DM and to determine if there were any differences in participation between a face-to-face 
presentation of AUSDRISK compared with receiving an AUSDRISK via mail out. The number 
of HR participants identified, and their baseline characteristics were established for those in 
each setting/recruitment method (direct/indirect). Differences in gender, age, family history of 
diabetes, the number and frequency of AUSDRISK HR score levels (HR1, HR2 HR3) were 
recorded and results were analysed. 
The major findings of this 2014–15 study were that, although local and statewide distribution 
of AUSDRISK was feasible, older individuals did not find completion of the AUSDRISK to be 
acceptable. This lack of acceptability was associated with ignorance that older age was a risk 
factor for T2DM, and therefore the relevance of AUSDRISK was not apparent. There was no 
statistically significant association between the HR participants’ HR score levels (HR1; HR2; 
HR3) and subsequently assessed glycaemic status. Of those assessed on the AUSDRISK 
as being at HR, 85.7% (42/49) were found to be normoglycaemic on biomedical assessment 
and 14.3% HR (7/49) were identified with Elevated Blood Glucose (EBG) frequently referred 
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to as preDM. The participants with EBG had scores spread across all HR levels (HR1–HR3). 
The average risk score of those assessed as having EBG was only 0.95 units higher 
(p=0.50) than those assessed as normoglycaemic. 
The older age participants’ knowledge of T2DM and AUSDRISK showed that 75.0% had 
never heard of the AUSDRISK, and 90.0% had never completed an AUSDRISK. Most 
participants were unaware of the concept of risk, as opposed to diagnosis, and considered 
being normoglycaemic on biomedical assessment meant they would never get T2DM. 
This Real-World study demonstrated the limitations of utilizing AUSDRISK in T2DM 
screening for older age individuals. The results showed that scoring HR on the AUSDRISK 
had no significant predictive value as a first-step filter in T2DM screening in identifying those 
older adults who would require a confirmatory blood glucose test from those who did not. The 
results of this study were compared with other studies using AUSDRISK in a young to mid 
age population and with international T2DM screening studies using a greater number of 
biomedical assessments for older age individuals. 
It is acknowledged that there may be responder bias associated with results in this ultimately 
small number of HR participants who completed the full screening process. However, the 
findings in this study were consistent with international studies using Risk Assessment Tools 
to identify HR for T2DM in the older age cohort. 
In the light of these findings, and the importance of effective screening, consideration was 
given for direct implementation of a national system of regular/rolling biomedical glycaemic 
assessments on a 3–5 year basis for all older age individuals from age 60–74 years, along 
the lines of the 5-yearly UK National Health Service Health Check which includes 
cardiovascular and diabetes components. Implementing regular biomedical assessments 
would identify a pattern of increasing glycaemic results over time, and interventions, whether 
lifestyle and/or medication, could be implemented at an earlier stage of dysglycaemia to 
avert progression to T2DM. 
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Prologue 
The thesis that follows is for a Professional Doctorate completed at the University of 
Tasmania. The purpose of this section is to introduce myself and explain how the concept of 
project originated and how it was implemented. I hope that with an understanding of my 
background, the context of the study will be clear from the beginning. 
I trained initially as a physiotherapist and practiced for many years and then worked as a 
manager of allied health services in a rehabilitation centre. The multidisciplinary approach to 
the management of acute and chronic conditions highlighted the importance of blending the 
psychological and physical approaches for successful health outcomes. I moved to the 
Population Health unit of the Tasmanian Department of Health and Human Services (DHHS) 
as the Diabetes Policy and Program manager which covered both state-based and national 
diabetes policy and project management. After several years, the area of Ageing was added 
to my portfolio to manage a Falls Prevention initiative for older people. 
Ageing is a major non-modifiable risk factor for type 2 diabetes (T2DM), and increasing age, 
T2DM and sarcopaenia (loss of muscle mass and strength) are major risk factors for falls. 
Vascular complications (cardiovascular and cerebrovascular), lower limb sensory loss and 
muscle weakness associated with long-term or poorly managed or undiagnosed T2DM, are 
also risk factors for falls. Both T2DM and sarcopaenia impact negatively on the health and 
well-being of older adults. 
The Australian Bureau of Statistics Australian Health Survey 2011–12 indicated that 
“individuals aged 60 years or older account for 70% of all persons with T2DM”. Tasmania has 
the oldest population of all states and nationally in Australia. Registrations on the National 
Diabetes Services Scheme (NDSS) database in Tasmania showed that over 50.0% of patients 
newly diagnosed with T2DM were aged over 65 years with 17.4% in the 70–79 year age 
group. These figures may indicate that many older individuals are not being identified with 
T2DM or pre Diabetes (preDM) until well into their older years or that preDM and T2DM do not 
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occur until the latter years. Without a regular screening program, that would identify 
progression from a preDM state, diabetes is difficult to diagnose. Type 2 diabetes has a long 
latent period (5-10 years) when the blood glucose level is increasing but not yet in the diabetes 
range. There are few signs and symptoms associated with increasing blood glucose, so 
individuals usually are not alerted to their status of High Risk (HR) or undiagnosed T2DM. 
Most individuals are diagnosed with T2DM or its precursor preDM via opportunistic screening 
by their GP. The usual procedure of opportunistic screening (blood test) for T2DM (every 3 
years from age 45 years for those individuals at HR) via general practitioner services, was not 
identifying all these “mid-old” (75–84 years) to “old-old” (85 years+) individuals at an earlier 
age. If individuals in the earlier years of the so-called “young-old” (60–74 years) period could 
be identified, and if found to be at HR, provided with medication/lifestyle interventions, this 
management could stop/delay/reduce the impact of their HR, or undiagnosed T2DM. It could 
also reduce the diabetes elements in their risk for falls. 
In Australia there is no national screening program for type 2 diabetes. The NHMRC 
Guidelines state that, although whole of population screening is not cost effective, targeted 
screening in High Risk groups is cost effective. If individuals were not attending their GP on a 
regular basis, or if GPs did not regularly screen their patients for type 2 diabetes, there would 
be very limited opportunity to identify those at High Risk or undiagnosed T2DM. 
Internationally, and to a limited extent nationally in Australia, introduction of community-
based screening programs via pharmacies, social/community groups have been used to 
raise awareness of T2DM and supplement the lack of systematic screening for T2DM. 
The study reported in this thesis tested the feasibility, acceptability and effectiveness of 
implementing the AUSDRISK via community settings to screen adults aged 50 years and 
over (mean age 65.5 years) for undiagnosed T2DM or at HR. 
15 
Overview 
Introduction to the study 
The research described in this thesis was undertaken in 2014–15 as part of the virtual 
Tasmanian Academic Health Science Precinct project. At that time, the International 
Diabetes Federation estimated there were 1.7 million Australians with diabetes (all types) 
which was predicted to increase to 2.3 million by 2035 (Guariguata et al., 2014, International 
Diabetes Federation Guideline Development Group, 2014). A further 2 million individuals 
were estimated to have pre-diabetes (preDM) which doubles the risk of developing type 2 
diabetes (T2DM). Chronic hyperglycaemia due to undiagnosed or poorly managed T2DM 
increases the risk for microvascular and macrovascular complications such as blindness, 
kidney disease, cardiac dysfunction, stroke and amputation (Caspersen et al., 2015). The 
increase in T2DM was expected to be due to the increased prevalence of risk factors for 
T2DM, such as overweight/obesity, insufficient physical activity to gain a health benefit and 
the rapid ageing of the Australian population (Statistics, 2017). From 2014–15 onwards, the 
highest prevalence and incidence of T2DM in Australia is in the older age population – those 
aged 60 years and over (Australian Government Department of Health, 2016).This increase 
in the older age cohort with age-related chronic conditions such as T2DM is a global 
phenomenon (Beagley et al., 2014). In the US, Corriere et al (Corriere et al., 2013) described 
the developing situation as an emerging public health burden of diabetes and diabetes 
complications in the elderly. The overall risk for developing pre-DM/T2DM is determined by a 
variable combination of epigenetic, genetic, environmental and lifestyle factors (Dankner et 
al., 2009 ; Dankner & Roth 2015). This risk is heightened by physiological dysfunction more 
frequently occurring in older age – increase in insulin resistance, and decreases in 
pancreatic β cell function, β cell mass, and insulin secretion (De Tata, 2014, Halter et al., 
2014, Imamura et al., 2013, Kalyani et al., 2013, Ling et al., 2019, Waugh et al., 2013). 
Older Australians are recognised as a high-risk cohort for preDM and T2DM. In 2014–15 the 
older age cohort had an estimated prevalence of T2DM of between 9.0% in the 55–64 year 
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age group rising to 16.0% in the 65–74 year age group. The state of Tasmania has the oldest 
and increasingly ageing population of all Australian states/territories. 
Unlike many first-world countries – for example, the United States of America (US), the 
United Kingdom (UK) and many European countries – Australia has no national population 
screening for pre-DM/T2DM, no systematic T2DM screening in General Practice and no data 
system nationally. The Australian National Health & Medical Research Council (NHMRC) 
Evidence-based Guideline for Case Detection and Diagnosis of Type 2 Diabetes 
(2009)(Backholer et al., 2012, Colagiuri et al., 2009a) recommends opportunistic screening 
via a 2-step procedure for detecting people with or at High Risk (HR) for undiagnosed T2DM 
– the first step is to complete a short 10-question Risk Assessment Tool (RAT) – the
AUSDRISK – the Australian Type 2 Diabetes Risk Assessment Tool (Australian Government 
Department of Health and Ageing, 2008, Chen et al., 2010) to identify those at HR followed 
by biomedical assessments (NHMRC recommended blood test is a Fasting Blood Glucose 
test – FBG) to confirm their glycaemic status. The Royal Australian College of General 
Practitioners (Royal Australian College of General Practitioners, 2018) Guidelines for 
Preventive Activity in General Practice recommend following the NHMRC guidelines. 
However, in practice the AUSDRISK has not been systematically implemented by GPs 
(Wong et al., 2011), with most (GPs) using a patient’s clinic presentation to opportunistically 
implement a biomedical assessment of the patient’s glycaemic status, if the GP considers 
the patient to be at HR for T2DM. 
Type 2 diabetes has an asymptomatic latent period of 5–10 years during which risk factors 
and blood glucose levels increase but as there are no specific signs and symptoms to 
identify the ongoing and progressive nature of glycaemic dysfunction pre-DM/T2DM 
individuals are not alerted to their increasing risk factor burden for developing pre-DM/T2DM 
by experiencing early symptomatology (Olafsdottir et al., 2009, Waugh et al., 2013). 
Currently, the life expectancy of older individuals is greater than any previous generation and 
the healthcare emphasis needs to be on ensuring they retain a good quality of life, effectively 
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manage their health, and prevent or reduce the impact of age-related conditions such as 
preDM/T2DM (World Health Organisation, 2015). The WHO World Report on Ageing and 
Health (Beard et al., 2016a) recognises the older age group as ranging from 60 to 100+ 
years. Within that 30–40 year time-frame, individuals are likely to have changing health 
needs and therefore there is benefit in delineating 3 major “health needs” groups within the 
older cohort viz “young-old “(60–74 years); “mid- old” (75–85 years) and “old-old” (85+ 
years). 
Diabetes Tasmania, the peak non-Government body representing those individuals with or at 
risk for diabetes in Tasmania, reported that in calendar year 2014–15, 1,471 individuals had 
been newly diagnosed with T2DM in Tasmania, with 78.5% in the older age group (50 years 
and over). Of these, 22.3% were first diagnosed with T2DM in their 70s 80s and 90s. 
This finding would suggest that by implementing a T2DM screening program there is 
potential to identify those at HR for T2DM at an earlier age than 70 years and implement 
appropriate lifestyle changes and/or medication to prevent progression to T2DM. 
In 2015, the National Diabetes Strategy Advisory Group (NDSAG)(Australian Government, 
2015), comprising key stakeholders and the Australian Health Ministers’ Advisory Council, 
recommended that individuals at HR for T2DM be identified using the AUSDRISK 
assessment in primary health settings, community health centres, community pharmacies, 
optometrists, dentists and online health services in state and federal health departments. 
Implementing a T2DM community-based screening program using the AUSDRISK to identify 
older individuals at HR for T2DM, with advice to seek a confirmatory biomedical assessment, 
would be the first step towards effective management of their risk or to the identification of 
undiagnosed pre-DM/T2DM (Chamnan et al., 2012, Colagiuri et al., 2009c, Cos et al., 2015, 
Lee et al., 2016). This is of particular importance for the “young-old” cohort aged 60–74 years 
(Beard et al., 2016a) who have a potential life expectancy of a further 15–25 years and with 
undiagnosed glycaemic dysfunction (preDM/T2DM) would likely experience more immediate 
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adverse impacts and increased risk for other age-related conditions such as cancer, 
cardiovascular diseases, Alzheimer’s Disease and frailty, with consequent reduction in their 
quality of life (Corriere et al., 2013, Halter et al., 2014, Kalyani et al., 2013, Wong et al., 
2016).  
The AUSDRISK has been available for self-assessment of T2DM risk since 2010 (in print 
and web-based), on government and non-government diabetes-related organisation sites 
(Australian Government Department of Health and Ageing, 2008). However, with no national 
T2DM screening initiative, the AUSDRISK has not been systematically promoted to the 
general public to raise awareness of risk factors (modifiable/non-modifiable) for pre-
DM/T2DM nor well utilised to identify the recommended process for self-assessment of 
T2DM risk with follow-up biomedical assessment, if required. In 2014 the AUSDRISK had 
been used to identify HR individuals to participate in a limited number of lifestyle modification 
programs for T2DM prevention in a number of Australian states, including Victoria, NSW, 
Queensland and Western Australia, but not Tasmania (Dunbar et al., 2015, Malo et al., 
2015). These programs addressed the modifiable lifestyle risk factors for T2DM – 
overweight/obesity; insufficient physical activity/increased sedentary behaviour; and 
poor/over nutrition, but increasing age was rarely mentioned as a significant risk factor for 
preDM/T2DM, despite its acknowledgement by NHMRC guidelines and in research 
(Colagiuri et al., 2009a, Halter et al., 2014, Kalyani et al., 2013, World Health Organisation, 
2015). 
Although the NHMRC guideline (Colagiuri et al., 2009a) does not recommend mass 
screening for T2DM, there is acknowledgement in this guideline that targeted screening in 
designated high-risk populations had been found to be cost-effective. 
In 2011, as part of my role as Diabetes Policy and Program manager in the Tasmanian 
Department of Health, I conducted a small study implementing the Australian Diabetes Risk 
Assessment tool -AUSDRISK- to identify those at high risk for T2DM in individuals attending 
health services in a community health centre (public health) and 2 optometry practices 
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(private health). The age range of participants was 50–80 years. This study found that 
implementation of the AUSDRISK was feasible in these non-medical health settings as part 
of a new patient assessment. Individuals identified as HR, indicated they would attend their 
GP for a blood glucose test, but the study did not have the capacity to determine whether 
they had followed through with their intent or not. 
The objectives of this study in 2014–15 sought to verify the procedures and findings of the 
earlier study with a larger sample size of older adults. The same non-medical health settings 
(as in 2011 study) were used to recruit older individuals and a statewide mail out recruitment 
strategy was added in an attempt to reach individuals who may not be regularly attending a 
GP. This study also sought to identify individual and methodological issues which may 
facilitate or adversely impact on older individuals participating in T2DM screening using 
AUSDRISK (Colagiuri et al., 2009c). 
This study utilised a multi-method design to explore the feasibility of using community-based 
settings for implementing the AUSDRISK assessment tool as the first step in T2DM 
screening for individuals aged 50 years and over. For those participants identified as HR, this 
study wished to investigate whether they had used the Risk Score to promote them to attend 
their GP for a biomedical assessment (within a 5-6 week period post survey completion) and 
if they had attended, whether they had been diagnosed with EBG or T2DM or had a normal 
blood glucose level. Following this introduction chapter, the subsequent chapters reflect the 
background to the study: Chapter 2: Literature Review; Chapter 3: Methodology and 
Methods of Data collection i.e. recruitment processes and survey questionnaire; Chapter 4: 
provides the recruitment outcomes and analysis of participation by older adults; Chapter 5: 
Comprises the results and analysis of follow-up activities completed/not completed by HR 
participants post AUSDRISK completion, and the effectiveness and accuracy of AUSDRISK 
is assessed by comparison with the blood glucose test results. The chapter concludes by 
reviewing the comments made by older HR participants on their knowledge and acceptability 
of AUSDRISK as the initial step in identifying those at HR for T2DM; Chapter 6: Discussion 
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of study findings and recommendations, and Chapter 7: Policy and Future Directions for 
T2DM screening for older adults. 
To my knowledge the AUSDRISK had not been used in Australia in a systematic manner as 
the first step in a targeted population screening procedure in a cohort of older individuals, 
and to follow them through to biomedical assessment. The aim of this study was to 
determine the feasibility and effectiveness of implementing the AUSDRISK, including follow-
up biomedical assessment if recommended, in a real world T2DM screening scenario 
(Wareham et al., 2011) using community-based settings in Tasmania to initially recruit older 
age individuals to complete an AUSDRISK to assess their risk for T2DM. 
 Chapter 2 Literature review 
This chapter presents a review of prior literature which explores the themes of this thesis. 
Included in these are the definitions of T2DM and preDM and an exploration of the 
prevalence and pathophysiology of T2DM in all ages and specifically in the older age group 
(aged 60 years and over). The principles and practice of screening, and how they have been 
progressively developed to include age-appropriate screening will be discussed, along with 
both the positive and negative effects of T2DM screening. International T2DM screening and 
prevention programs will be explored and compared with the opportunistic approach for 
identification and case finding of T2DM in Australia. The history of the Australian Type 2 
Diabetes Risk Assessment Tool (AUSDRISK) and its usage to date will be examined. In 
addition, the adverse impact of the lack of regular/routine T2DM population screening in 
Australia will be reviewed.  
Finally, the Australian Government health policy directives and strategies to address the 
increasing prevalence of Non-Communicable Chronic Diseases (NCCD)(Australian Bureau 
of Statistics, 2013) are introduced with particular emphasis on T2DM, including 
recommendations to increase use of AUSDRISK to identify those at risk for T2DM. 
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 Chapter 3 Methodology and methods 
Chapter 3 provides the philosophical viewpoint, theoretical underpinning, ethical 
considerations and rationale for the methods utilised in this research project. The methods 
for the Literature Review and the AUSDRISK project will be presented in detail. The choice 
of the multiple method approach in this research was determined by aiming to achieve a 
comprehensive pragmatic approach (complementarity, completeness, development, 
expansion and confirmation) in relation to implementing the Type 2 Diabetes Risk 
Assessment Tool – AUSDRISK – for community-based screening to identify older age 
individuals with (undiagnosed) or at high risk for developing Type 2 Diabetes (T2DM). 
The multiple methods framework for this study implements a process similar to that designed 
for mixed methods with the following steps – Exploratory Sequential at the design level, then 
via multi-stage inputs from each of the recruitment settings. Quantitative analysis of the first 
stage allows for identification of the number of those older age participants who scored High 
Risk on the AUSDRISK. After completion of the AUSDRISK the participants who scored HR 
were invited to voluntarily provide details on their follow-up actions to attend/not attend their 
GP. This information was gathered in Phase 2 and served to form/build the next database 
which expanded on the quantitative data collected in Phase 1.  
In addition, HR participants in Phase 2 were invited to provide their knowledge and 
experiences (beliefs and attitudes) towards screening for T2DM risk using the AUSDRISK as 
the first step in the screening process. The quantitative data and qualitative data were then 
considered separately and in combination.  
 Chapter 4 Methods of data collection and analysis (phase 1) 
The study aimed to replicate a real-life T2DM screening initiative for older individuals in 
community settings in which they were advised the importance of knowing their risk for 
T2DM and inviting them to complete an AUSDRISK risk assessment. Those who scored HR 
were advised that scoring HR was not a diagnosis of T2DM, but that they were advised to 
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follow the instructions on the AUSDRISK and attend their GP to have a blood glucose test. 
This chapter describes Phase 1 (quantitative elements) of the multi-method study which 
included the number of AUSDRISK  risk assessment tests distributed in three different 
community settings (2 health-related settings and a statewide mail out), and the number of 
the AUSDRISK completed by older adults residing in the community. The purpose of this 
phase of the study was to identify the number of older individuals at High Risk (HR) for 
T2DM, to determine if there were any differences in participation between a face-to-face 
presentation of AUSDRISK compared with receiving an AUSDRISK via mail out. During this 
phase of the study the number of HR participants and their baseline characteristics were 
established for those in each setting/recruitment method (direct/indirect). Differences in 
gender, age, family history, the number and frequency of AUSDRISK HR score levels (HR1, 
HR2 HR3) were recorded and results were analysed. 
 Chapter 5 Results of high risk participants’ follow-up survey and 
effectiveness of the AUSDRISK 
This chapter covers the qualitative components of the study – the results of those 
participants identified by their AUSDRISK score as being at HR, who subsequently 
completed the follow-up survey reporting on the reasons they provided for attending or not 
attending their GP; the GPs’ response to those HR participants who attended their GP 
following completion of an AUSDRISK; the glycaemic status of those HR participants who 
had a blood test; and HR participants comments on their experience of completing an 
AUSDRISK. 
 Chapter 6 Discussion and findings 
This chapter synthesises the findings of the study sequentially from initial distribution of 
AUSDRISK to older age adults, to participation/non-participation in the full screening 
process. The results are interpreted in relation to AUSDRISK presentation and scoring and in 
relation to the older age participants’ capacity to self-assess their risk for T2DM. The overall 
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significance of the findings is discussed with reference to the use of AUSDRISK in different 
age-range cohorts and with reference to other screening to prevention initiatives in Australia 
and other T2DM screening strategies internationally. 
 Chapter 7 Conclusions, recommendations and future directions 
This chapter reviews the major findings of this research and considers them in the light of 
proposals and initiatives subsequent to completion of my research, for T2DM screening in 
Australia, generally and particularly for older individuals. As with many health-related 
initiatives, progress to achieve T2DM screening has been slow. The reasons for this will be 
discussed and compared with screening and management initiatives, such as the systematic 
approach of NHS Health Check and personalised medicine approach for diagnosis and 
management of T2DM advocated by international researchers. 
Since 2015, there has been a large volume of research which has prompted major changes 
in considering the pathology of T2DM from it being a lifestyle disease to it being a complex 
heterogeneous condition involving epigenetic, genetic, ageing and environmental factors. 
This chapter covers the T2DM initiatives and issues (government and non-government) 
considered in Australia since this research in 2014–15. These initiatives include: 
1. The commencement of a Medicare funded annual diagnostic HbA1c test for 
asymptomatic individuals considered to be at HR by their GPs. 
2. The impact of current situation with reference to an ongoing lack of a national 
system for T2DM prevention and screening in Australia. 
3. The most recent 2017–18 Australian Health Survey (Australian Bureau of Statistics, 
2018) – diabetes (all types) and T2DM results which show little change in the 
prevalence of T2DM and age of T2DM diagnosis since 2015. Whilst there has been 
virtually no change in T2DM incidence overall there has been a significant increase 
newly diagnosed older individuals aged 70 years and over. 
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4. The potential impact of Australia’s My Health Record system – as from December 
2018, all Australians will be recorded on the digital My Health record system but be 
able to “opt out” should they wish. Current issues – individual privacy; benefits of 
access to GPs, hospitals, other health professionals. 
5. Rationale for and consideration of a Diabetes/CVD health check for “young-old” 
individuals from age 60–74 years or (50–70 years) along the lines of the National 
Health Service (NHS) Health Check program in the UK (Martin et al., 2018, Robson 
et al., 2016, Usher-Smith et al., 2017) will be presented. 
6. Rationale for the move away from identifying established T2DM, towards the 
identification and treatment of prediabetes (with lifestyle intervention and/or 
medication). This approach is now considered as being essential for achieving 
T2DM prevention in US, UK and many European countries (Apolzan et al., 2019). 
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 Literature review 
 Introduction 
In the 7th International Diabetes Federation Diabetes Atlas 2015 the following prediction was 
made: 
The prevalence of diabetes (all types) worldwide is estimated to be 415 million adults 
aged 20–79 years, including 193 million adults who are undiagnosed. A further 318 
million adults are estimated to have impaired glucose tolerance, which puts them at 
high risk of developing the disease. By the end of this year (2015), diabetes will have 
caused 5.0 million deaths and have cost between USD673 billion and USD1, 197 
billion in healthcare spending. If this rise is not halted, by 2040 there will be 642 
million people living with the disease.(International Diabetes Federation Diabetes 
Atlas Committee, 2015). 
The prevalence of diagnosed diabetes and HR for diabetes, along with the associated costs 
for healthcare management in Australia, follow a similar pattern to that observed worldwide. 
The prevalence of diabetes (all types) is expected to increase to 2.3 million people by 2035 
(Guariguata et al., 2014, International Diabetes Federation Diabetes Atlas Committee, 2015). 
The results from the most recent completed Australian Health Survey (AHS) 2011–12: 
Biomedical Results for Chronic Diseases (Australian Bureau of Statistics, 2011-12) showed 
1.2 million (5.1%) Australians aged 18 years and over had diabetes, comprising 4.2% with 
known diabetes and 0.9% with diabetes newly diagnosed from their results of a fasting 
plasma glucose test. 
Thus, there was approximately one newly diagnosed case of diabetes for every four 
diagnosed cases. In addition, 3.1% of adults had IFG, placing them at high risk for 
developing diabetes. Thus, for every four persons diagnosed with diabetes, there were an 
additional three people at high risk for diabetes. 
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Diabetes was more common among men than women in 2011–12 (6.3% men compared with 
3.9% women). This was the case for both diagnosed diabetes (4.9% compared with 3.4%) 
and newly diagnosed diabetes (1.4% compared with 0.4%). 
There are two main types of diabetes – Type 1 and Type 2 (Diabetes Australia, 2017a). 
Type 1 diabetes (T1DM) (approximately 8-9% total diabetes) is an autoimmune condition 
causing rapid loss of beta cell function in the pancreas with consequent loss of insulin 
requiring lifelong insulin replacement. Type 1 diabetes is predominantly a disease of young 
persons. Type 2 diabetes (T2DM) (approximately 85–88% total diabetes) is affected by both 
genetic and environmental factors with a gradual increase in blood glucose levels over a 
period of 5 to 10 years. In 2017, Chattterjee et al (Chatterjee et al., 2017) described this 
relationship as genetic factors exerting their effect following exposure to an obesogenic 
environment characterised by sedentary behaviour and energy dense diets. 
The prevalence of T2DM increases with advancing age. People aged 65–74 years had the 
highest rate (15.0%) of T2DM. People aged between 55–74 years had the highest rates of 
newly diagnosed T2DM (2.3%). The proportion of people at HR for T2DM also steadily 
increased with the highest “HR” group being those aged 75 years and over (7.5%)(Australian 
Bureau of Statistics, 2011-12, Diabetes Australia, 2017b). 
The 2011–12 AHS Biomedical Results for Chronic Disease (Australian Bureau of Statistics, 
2013) also showed that people who were obese had much higher rates of diabetes (11.2%) 
than those who were overweight (4.1%) or normal or underweight (1.6%). Similarly, for 
individuals assessed as being at HR, those who were obese had the highest risk (5.8%) for 
developing T2DM, compared of those of normal weight or underweight whose risk was 0.9%. 
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Individuals with a family history of diabetes were also more likely to have, or be at high risk 
for, diabetes. Results (Australian Bureau of Statistics, 2011-12) showed that 54.4% of those 
with diabetes and 39.9% of those at high risk, had a close family member who had the 
condition. However, research by Aujla et al 2013; Lavielle et al 2014, had shown those with a 
Family History have an ambivalent attitude to confirming, or not, their diabetes status. This 
was due to the individuals’ perception of threat and feelings of vulnerability to the 
development of T2DM, which was influenced by the individuals’ environment and previous 
experience with diabetes.  
Diabetes (all types) is also a major risk factor for cardiovascular disease. Individuals with 
diabetes were twice as likely as those without, to have abnormal (low) levels of beneficial 
HDL (48.6% compared to 21.7% without diabetes) and higher levels of triglycerides. Those 
individuals with elevated blood glucose which places them at high risk for developing type 2 
diabetes also show abnormal levels of HDL and triglycerides. 
The Australian National Health Survey (NHS): First Results, 2014–15 ((Australian Bureau of 
Statistics, 2015b) released December 2015) showed that in Tasmania the levels of diabetes  
was similar to the national percentage of DM at 5.1% but the risks for type 2 diabetes were 
higher than in most other states/territories and nationally. Tasmania had the highest levels of 
heart disease (National 5.2%;Tasmania 7.7%), high cholesterol (National 7.1%: Tasmania 
9.4%), hypertension (National 11.3%: Tasmania 16.4%) and kidney disease (National 0.9%: 
Tasmania 1.5%) . It was acknowledged that these high levels may be in part be due to the 
fact that Tasmania has the oldest population of any Australian jurisdiction. However, 
Tasmania also has the highest proportion (state/territory and nationally) of men and women 
aged 18 years and over who are overweight or obese (male 74.1%; female 60.9%; Total 
67.5%) as compared to nationally (70.8%; 56.3%; 63.4%). Furthermore, individuals in 
Tasmania reported the lowest levels of physical activity sufficient for a health benefit in 
Australia (for both men (44.3%) and women (42.0%) in comparison to the national average of 
47.7%)(Australian Bureau of Statistics, 2015b). 
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Based on these findings, the Tasmanian population would be expected to have the highest 
risk level for developing type 2 diabetes/prediabetes, and the lowest level of protective 
factors (sufficient physical activity for a health benefit, normal weight) in both modifiable 
factors (lifestyle, body weight and physical activity) and non-modifiable factors (age) of all 
Australian jurisdictions. 
Since the completion of my research there have been two  National Health Surveys 
conducted and reported by the Australian Bureau of Statistics (ABS) - in 2014-15 and the 
most recent in 2017-18 which was reported in 2019.  
The 2017-18 National Health Survey was designed to collect a range of information about 
the health of Australians, including: 
§ prevalence of long-term health conditions; 
§ health risk factors such as smoking, overweight and obesity, alcohol consumption and 
physical activity; and  
§ demographic and socioeconomic characteristics.  
 
The survey was conducted in all states and territories and across urban, rural and remote 
areas of Australia (excluding very remote areas) from July 2017 to June 2018. The survey 
included around 21,000 people in over 16,000 private dwellings. 
In 2017-18, one in twenty Australians (4.9% or 1.2 million people) had diabetes. Since 2001, 
this rate has increased from 3.3%, however, has remained relatively stable since 2014-15 
(5.1%). 
Diabetes continued to be more common among males than females (5.5% and 4.3% 
respectively). The prevalence of diabetes has increased for both males and females since 
2001 (both 3.3%).  
As found with many chronic health conditions, the rate of diabetes increased with age. Since 
2001, the rate of diabetes has remained fairly consistent up to age 64 years whilst older 
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adults have experienced increases. The rate of diabetes amongst adults aged 65-74 year 
olds increased from 12.5% in 2001 to 15.4% in 2017-18. Meanwhile, of adults aged 75 years 
and over, almost one in five (18.7%) had diabetes in 2017-18; which was an increase from 
11.2% in 2001.  
Since 2001, the rate of diabetes amongst men aged 65-74 years increased from 11.8% to 
18.7% and for those aged 75 years and over from 11.2% to 20.7%. Similarly, the rate of 
diabetes amongst women has increased for those aged 75 years and over from 11.2% in 
2001 to 17.0% in 2017-18.  
 
 Background 
 Australian Government health policy 
In response to the increasing prevalence of diabetes, the Australian Government released 
the Strategic Framework for Action – Advice to Government on development of the 
Australian National Diabetes Strategy 2016–2020 (Group, 2015) with aims and directives to 
prioritise Australia’s response to diabetes (all types) and identify approaches and action 
areas to reduce the impact of diabetes in the community by effective prevention, detection 
and management of diabetes (all types). 
In 2015, the National Diabetes Strategy Advisory Group (Australian Government, 2015) 
provided expert policy advice on diabetes prevention and care, in consultation with key 
stakeholders and the Australian Health Ministers’ Advisory Council. The NDSAG defined 7 
high-level Goals for the Australian National Diabetes Strategy 2016–2020. The first two goals 
addressed prevention and earlier detection of individuals with or at high risk of type 1 or type 
2 diabetes. 
Goal 1 addressed issues to reduce the number of people developing type 2 diabetes – 
taking a whole-of-population approach to encourage and enable healthier lifestyles. 
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Goal 2 was aimed at promoting earlier detection of type 1 and type 2 diabetes – to facilitate 
earlier diagnosis and earlier treatment for all forms of diabetes. In relation to earlier detection 
of type 2 diabetes the following initiatives were recommended: 
• Establish a nationally coordinated detection program to identify high-risk 
individuals using the AUSDRISK screening tool 
• Establish multiple avenues for the dissemination of AUSDRISK, using Primary 
health networks, community health centres, community pharmacies, 
optometrists, dentists and online health services in state and federal health 
departments 
• Promote increased use of the AUSDRISK screening tool among all age groups – 
with the acknowledgement that this may require calibration of scoring on the 
AUSDRISK tool for different age ranges 
• Integrating the AUSDRISK screening tool with risk assessment for other chronic 
conditions, including absolute cardiovascular and kidney disease risk, such as 
has been achieved in the UK with the National Health Service (NHS) Health 
Check (Robson et al., 2016) in primary care 
• Improving the health literacy of the community with particular reference to risk for 
type 2 diabetes – both modifiable risk (lifestyle) and non-modifiable (age and 
genetic) 
• Educating primary health care practitioners about who should be screened 
• Reviewing biomedical screening methods (e.g. the use of HbA1c in the screening 
algorithm procedure) 
 The National Strategic Framework for Chronic Conditions 2017 
The National Strategic Framework for Chronic Conditions does not replace current policies or 
strategies, such as the National Diabetes Strategy (NDS) 2016–2020 but provides guidance 
to enhance current disease-specific policies and develop new and innovative approaches to 
address chronic conditions. According to the council, chronic conditions are threatening to 
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overwhelm Australia’s health budget, the capacity of health services and the health 
workforce (Council, 2017, Group, 2015). 
In 2014–2015 more than 50 per cent of Australians reported having at least one chronic 
condition. Almost 1 in 3 Australians (29 per cent) aged over 65 reported having three or more 
chronic diseases, compared with just 2.4 per cent of those aged under 45 years. (Australian 
National Health Survey (NHS): First Results, 2014–15 (Australian Bureau of Statistics, 
2015a, Australian Bureau of Statistics, 2015b) (released December 2015). 
Priority Populations are those that are negatively impacted by chronic conditions more than 
the public. Not surprisingly, older Australians are considered a Priority Population. Critical life 
stages are critical periods throughout life where exposure to risk factors and determinants of 
health can independently and interactively impact on long-term health outcomes. For older 
individuals, retirement is a critical transition point which can be a catalyst for deteriorating 
health and wellbeing (Council, 2017). 
Targeting opportunities to tackle chronic conditions at critical life stages, including through 
action to address risk factors and improve determinants of health can positively influence 
individual and population health outcomes (Council, 2017). 
Risk factor screening for T2DM has been named as a strategic priority area, alone or in 
conjunction with other risk factors for cardiovascular disease as T2DM is both a disease 
entity and a major risk factor for developing cardiovascular disease. 
 Screening for type 2 diabetes in Australia 
Currently in Australia, there is no whole of population screening for preDM/T2DM. The 
Australian National Health & Medical Research Council Evidence-based Guideline (NHMRC 
Guideline) for Case Detection and Diagnosis of Type 2 Diabetes (2009)(Colagiuri et al., 
2009a, Colagiuri et al., 2009c), and the Royal Australian College of General Practitioners 
Guidelines for Preventive Activity in General Practice (Royal Australian College of General 
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Practitioners and Diabetes Australia, 2016-18) recommend opportunistic screening in 
general practice (Shaw, 2017) for T2DM every 3 years for adults ≥ 40 years who have risk 
factors for T2DM, most frequently obesity and physical activity insufficient for a health 
benefit, with/without family history of diabetes. 
Opportunistic screening occurs when an individual attends a GP, often for a condition 
unrelated to diabetes, and the GP takes the opportunity to assess the individual’s diabetes 
risk. Both the NHMRC and the RACGP guidelines are recommendations, and 
implementation is not mandatory. The Guidelines recommend a 2–3 step screening process 
for T2DM with initial completion of a risk factor questionnaire, the Australian Type 2 Diabetes 
Risk Assessment Tool (AUSDRISK) (Australian Government Department of Health and 
Ageing, 2008, Chen et al., 2010) to identify those at HR. Those identified as HR were 
advised to have a biomedical assessment (blood glucose test, since 2014, the HbA1c test 
has been more frequently ordered) to determine their glycaemic status whether that is 
normal, elevated but not in the diabetes range (PreDM), or elevated to or above the blood 
glucose level indicating T2DM. Further blood testing – repeat HbA1c, Fasting Blood Glucose 
(FBG) or Oral Glucose Tolerance Test (OGTT) – may be done if the initial result does not 
indicate a definitive diagnosis (Royal Australian College of General Practitioners and 
Diabetes Australia, 2016-18). 
 Australian Diabetes Obesity and Lifestyle Study (AUSDIAB) 2000 
The first national Australian Diabetes Obesity and Lifestyle Study (AUSDIAB – 1) was 
conducted in 1999–2000, and its 5-year follow–up study in 2005 (AUSDIAB – 2) of 70 
percent of the original cohort. Both studies gathered medical and lifestyle data from a 
stratified sample of 11,247 Australians aged 25 years and over in 42 randomly selected 
urban and non-urban areas of the six states of Australia (Dunstan et al., 2002b). 
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK), based on the findings 
of the AUSDIAB and AUSDIAB–2 studies, was developed in 2008 as a screening tool to 
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identify those at High Risk (HR) for developing T2DM (Chen et al., 2010). The AUSDRISK 
has been validated as a predictor of diabetes risk at 5-year follow-up and has been 
acknowledged internationally as a valid and reliable pre-screening test to identify people at 
HR for developing T2DM (Noble et al., 2011). 
The Australian National Evidence Based Guideline for the Primary Prevention of Type 2 
Diabetes (Colagiuri et al., 2009b) notes that: 
Using an AUSDRISK score of ≥ 15 has a sensitivity of 54.3%, specificity of 83.1% 
and a PPV of 16.9% for predicting development of T2DM over the next five years. An 
AUSDRISK score of ≥ 15 identifies approximately 15% of the total population at HR 
for developing T2DM within five years. 
Chen et al (Chen et al., 2010) reported that the area under the receiver operating curve 
(AROC) of the AUSDRISK tool was 0.78 (95% CI, 0.76–0.81) and the Hosmer-Lemeshow 
goodness of fit test for logistic regression (HL) χ2 statistic was 4.1 (P=0.85). Using a score 
≥12 (maximum, 35), (the point at which the sensitivity and specificity were maximised) the 
sensitivity, specificity and positive predictive value for identifying incident diabetes were 
74.0%, 67.7% and 12.7%, respectively. Australian diabetes prevention programs needing to 
account for cost and feasibility of the program have chosen a threshold of ≥ 15 as the entry 
point for participation. The AUSDRISK performance was assessed by applying it to other 
Australian cohorts. In relation to discriminative ability the AUSDRISK and was found to have 
performed moderately in the Blue Mountains Eye Study (BMES) of an older age population 
(Cugati et al., 2007) whereas the discrimination was good in the North West Adelaide Health 
Study (Colagiuri et al., 2009b) with a wider age range. It was noted that “the weighting of the 
age categories is likely to be smaller when a score derived from a wider age group is applied 
to a population with limited age range”. It was noted that the AUSDRISK calibrated well in the 
BMES cohort (HL χ2 statistic, 9.2; P=0.32). However it had less discrimination in predicting 
incident diabetes with an AROC of 0.66 (95% CI 0.60–0.71) lower than in the original 
AusDiab cohort (AROC of 0.75 (0.72–0.78) (Chen et al., 2010). 
34 
 Type 2 Diabetes Risk Assessment tool (AUSDRISK) 
At the time of my research the AUSDRISK was only available as a paper-based screening 
tool. It has subsequently been made available on the Australian Government health website 
(https://www1.health.gov.au/internet/main/publishing.nsf/Content/diabetesRiskAssessmentTool)    
Risk factors (modifiable and non-modifiable) for T2DM are each given a weighted numeric 
value and the total of the Risk Factor points provides an estimate of the risk for an 
individual’s development of T2DM over a 5–7 year period. The risk factors included in the 
AUSDRISK are very similar if not the same as nominated risk factors in the NHMRC 
Guidelines for Case Detection and Diagnosis of T2DM (Colagiuri et al., 2009c) and the 
RACGP Guidelines for Preventive Activities (Royal Australian College of General 
Practitioners, 2018). An algorithm is used (based on results from the AusDIab –1 and 
AusDiab –2 studies) to weight the risk factors individually and in combination that makes the 
AUSDRISK an effective screening tool for identifying risk for T2DM in the Australian adult 
population. The quantified total risk levels are designated Low risk (5 points or less), 
Intermediate risk (6–11 points) and High risk (12 points or more). On the more recent on-line 
version of AUSDRISK there have been some minor changes in the recommendations 
associated with particular scores - Low risk ( 5 points or less); Moderate risk (6 – 8; 9 – 11); 
High risk (12-15; 16-19); Very High risk (20+). Individuals scoring HR would be advised to 
attend their General Practitioner for a biomedical assessment of their diabetes status. 
Although use of the AUSDRISK is recommended as the first step for T2DM screening, it has 
not been systematically used for individual screening by GPs, who prefer to use direct 
biomedical assessment as the first step (Shaw 2017; Lee et al 2016). The AUSDRISK has 
never been used for whole-of-population screening.  
In a 2015 editorial, Colagiuri (Colagiuri, 2015) predicted that in future screening protocols 
may begin with completion of a non-invasive risk assessment tool, followed by HbA1c testing 
in the high-risk group to detect undiagnosed diabetes, and high-risk non-diabetic individuals. 
Those identified as with or at very high risk of diabetes would then be referred to lifestyle 
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modification-based diabetes prevention programs. However, this prediction is yet to 
eventuate and the AUSDRISK has been mainly utilised in Australian states and territories for 
self-assessment during diabetes health promotion events to raise awareness of risk for 
T2DM. It has also been used to provide the criteria (score) for inclusion of HR participants in 
a number of diabetes “screen and treat” prevention programs for individuals aged 40–49 
years in some Australian states but not Tasmania (Dunbar, 2017, Dunbar et al., 2015, Malo 
et al., 2015, Vita et al., 2016). 
 Population ageing 
The cohort of older adults is the fastest growing section of the Australian population. The 
Australian Bureau of Statistics, Census on Population and Housing (Australian Bureau of 
Statistics, 2015a) reported there were 3.7 million (15%) Australians aged 65 years and over 
– increasing from 319,000 (5%) in 1926 and 1.3 million (9%) in 1976. By 2056, it is projected 
there will be 8.7 million older Australians (22% of the population) and 12.8 million (25%) by 
2096 (Australian Bureau of Statistics, 2015a). 
Currently Tasmania has the highest proportion (18.0%) of persons aged 65 years and over of 
any Australian jurisdiction. i.e. almost one in five of the population (Australian Bureau of 
Statistics, 2015a). 
Life expectancy of older individuals is longer than in any previous generation. The increasing 
proportion of older Australians is due partly to the increasing life expectancy of older adults. 
For example, in 2011–13, a 65-year-old man could expect to live another 19 years and a 65-
year-old woman, another 22 years – 7 years longer for both sexes than in the mid-1960s. To 
best respond to the increased requirements of this larger aged population, the health system 
needs to understand and address the most common health conditions experienced by older 
Australians. 
The World Report on Ageing and Health (Beard et al., 2016b) recognised the older age 
cohort as ranging from 60 to 100+ years. Within that 30–40-year time frame, individuals are 
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likely to have changing health priorities. Therefore, there is benefit in delineating 3 major 
“health needs” groups within the older cohort viz “young-old” (60–74 years); “mid- old” (75–
85 years) and “old-old” (85+ years). 
At the time of conducting this research the results of the 2011–12 Australian Health Survey 
(Australian Bureau of Statistics, 2011-12) showed the most commonly reported chronic 
condition (excluding short- and long-sightedness) was arthritis, affecting half of people aged 
65 years and over. Other conditions that had higher prevalence rates in older Australians 
included vascular diseases (Ischaemic Heart Disease, Cerebrovascular disease and 
dementia), T2DM; and osteoporosis. Whilst each condition is reported separately, they 
frequently occur as comorbidities or confounders adversely impacting on the overall health 
and wellbeing of older individuals. In order to achieve effective management of these multiple 
and interacting chronic conditions, there is increased demand for, and on, primary care 
medical and allied health services.  
The AHS 2011-12 results reported the prevalence of diabetes in the older age cohort 
increased from 4.0% for the general Australian population to approximately 9.0% in the 55–
64-year cohort and increased further to 16.0% in the 65–74-year cohort – the highest rate of 
diabetes recorded in the AHS 2011-12 results. 
In 2011-12, 4.0% of the Australian population (875,400 people) reported having some type of 
diabetes (excluding persons with gestational diabetes). The prevalence of diabetes remained 
stable between 2007-08 and 2011-12 (both 4.0%).  
Of persons who reported diabetes, the majority had Type 2 diabetes (85.3%), while 12.4% 
had Type 1 diabetes and the remainder had an unspecified type of diabetes (2.3%). 
More men reported having diabetes than women (4.3% of all men compared with 3.6% of all 
women) and as with many health conditions, the rate of diabetes increased with age.  
The National Diabetes Services Scheme (NDSS) dataset of individuals with diagnosed 
diabetes (all forms) (Australian Government Department of Health, 2016) records individuals 
in their late 60’s 70’s and 80’s as being newly diagnosed with T2DM. It is unknown how 
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many in the older age group have remained undiagnosed with T2DM over many years, or 
whether those individuals diagnosed with T2DM in their older years have had increasing 
levels of hyperglycaemia, which finally reached the level for a diagnosis of T2DM. 
Prolonged hyperglycaemia, whether due to prolonged preDM, undiagnosed T2DM or 
diagnosed T2DM with poorly controlled glycaemic status, causes significant increased risk 
for cardio-metabolic conditions (macro- and microvascular complications – heart attack, 
stroke, nephropathy, retinopathy), cancers, vertebral fragility and fractures (Sanches et al., 
2017), falls and dementia (vascular and Alzheimer’s disease). T2DM is associated with 
significant increased risk for disability, compared to people without T2DM (Koye et al., 2017, 
Schneider et al., 2016, Schneider et al., 2013, Wong et al., 2016). Australian research by 
Wong et al (Wong et al., 2016) showed people with T2DM had 50.0%–80.0% increased risk 
of disability and hospitalisations compared to those without T2DM. As the number of older 
people living in Australia continues to increase, optimizing their health and wellbeing 
(Schneider et al., 2016) (Beard et al., 2016b) is an increasingly important economic and 
medical necessity, and challenge for society. 
Since completion of this research, the Australian Health Survey 2017-18 reported that whilst 
the rate of diabetes has remained steady for adults up to age 64 years, there has been an 
increase in the 65-74 year group from 15.0% to 15.4% and for those in the 75+ group the 
rate has reached 18.7%. 
 T2DM screening for older individuals in Australia 
As there is no systematic national screening for T2DM and preDM, the prevalence of risk for 
T2DM in older adults, that is elevated blood glucose (EBG)/preDM, is unknown due to lack of 
national recording. Estimates of the prevalence of abnormal glycaemia from the US and UK 
(Twito et al., 2015) state the prevalence of preDM to be close to 50% in older adults. 
Although the NHMRC Guideline for Case Detection and Diagnosis of Type 2 Diabetes 
(Colagiuri et al., 2009c) does not recommend mass/whole of population screening for T2DM, 
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there is acknowledgement that targeted screening in designated high-risk populations has 
been found to be cost-effective. (Colagiuri, 2012, Lee et al., 2013). 
In Australia, adults with or at high risk for T2DM are most frequently identified by their 
General Practitioners. The guidelines for preventive activities in general practice recommend 
that adults >40 years of age and being overweight or obese, and/or with an AUSDRISK 
score of 12 points or more, should be screened by having an HbA1c test or FPG test every 3 
years. However, there is no national funded or independently managed program to support 
this, unlike for example, with breast and colon cancer screening. Patients with or at HR for 
T2DM are identified when they attend a GP for a matter relating or not to T2DM risk, and the 
GP takes the opportunity to implement a blood test – so-called “opportunistic screening”.   
Implementing a national T2DM risk-screening program in Australia to identify elevated blood 
glucose levels in “young-old” individuals, age 60–74 years, would be the first step towards 
improving awareness of preDM/T2DM and facilitate effective management of older 
individuals’ level of risk for, or presence of, undiagnosed pre-DM/T2DM (Caspersen et al., 
2015, Chamnan et al., 2012, Cos et al., 2015, Lee et al., 2016). Ideally such a program 
would commence by identifying the glycaemic status of older individuals aged 60–65 years. 
Those identified as having preDM or T2DM would be advised to commence lifestyle 
modification and/or medical management. Currently the guidelines for preventive activities in 
general practice recommend that those individuals at HR, but not yet meeting the diagnostic 
criteria for preDM or T2DM conditions, should receive lifestyle advice and be reviewed in one 
to three years by their general practitioner. However, the lack of a national - funded initiative 
to support these recommendations also impedes the consistent implementation of these 
recommendations. 
The following literature review will address the issues pertinent to T2DM screening in older 
adults. 
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 Literature search methodology 
 Methods 
A detailed literature search, nationally and internationally, was undertaken to review the 
rationale, risk assessment procedures, the facilitators, and barriers to the uptake of health 
screening for older individuals, with particular emphasis on T2DM and its precursors 
preDM/non-diabetic hyperglycaemia. 
 Search strategy 
The online databases PubMed, CINAHL, and SCOPUS were searched using the following 
terms: Diabetes Mellitus, type 2: prediabetic state: hyperglycaemia AND risk factors: 
precipitating factors AND asymptomatic: undiagnosed AND surveys and questionnaires: 
health status indicators: risk assessment: screening; risk assessment tool AND aged: older 
adults: people over 60 years: young-old: seniors. 
The starting point of 1990 was chosen to cover T2DM screening prior to the use of Risk 
Assessment Tools. 
Additional searches comprised follow-on references in articles already in hand, and from 
government, non-government sources and policy documents relating to prevention and 
management of type 2 diabetes. 
The search retrieved information for 1235 articles. After title scanning 671 articles were 
selected as potentially relevant. Abstracts were reviewed with 639 being relevant for a full 
review. Additionally, papers were identified through ancestral searches of bibliographies and 
cited research articles. 
 Inclusion/exclusion criteria 
Articles included related to one of the following topics: 
• Type 2 diabetes and prediabetes 
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o Pathophysiology – all ages; specifically, in the older age group 
o Prevalence – all ages; specifically, in the older age group 
o Complications and increased risk for other medical conditions 
• Screening Guidelines and policies 
• Screening interventions 
o Screening via medical practitioners 
o Screening via other health practitioners 
o Non-medical/non-health screening interventions 
o Screening type – opportunistic, targeted, population 
o Screening – specifically older age cohort 
• Risk Assessment 
o Risk assessment tool prior to biomedical assessment 
o Assessment of known risks – biomedical 
• Qualitative impacts on participation and outcome of screening 
o Socioeconomic 
o Perception of diabetes risk 
o Diabetes awareness, Health literacy 
• Economic 
o Cost of screening 
o Cost of type 2 diabetes/prediabetes 
 
• Articles excluded: 
o Non-English language  
o Any papers with risk assessment not covering 60–74-year age range 
o Any papers with participant mean age less than 65 years 
o Type 1 diabetes, Gestational Diabetes Mellitus, LADA 
o Genetic factors only 
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 Article selection 
The titles and key words section of the articles identified by the searches were examined and 
those which were not on the topic for consideration were excluded. The abstracts of the 
remaining articles based on the major inclusion criteria were read again; any articles, which 
appeared potentially relevant were kept for further examination. The process was reviewed 
and accepted by 2 of my earlier supervisors who for various reasons moved on. The work 
was part of my confirmation. The search strategy followed a systematic process using the 
PRISMA as a guide but was not a systematic review.  
The remaining articles were then examined fully (the whole text) for the specific topic 
relevance for which they would be used. 
The following literature review critically reviews and discusses the literature identified, first to 
situate the range of elements involved in T2DM and preDM screening; ageing and increasing 
longevity and the impact of both elements on the community and society. Key findings and 
their possible implications are then summarised and discussed. 
 What are type 2 diabetes (T2DM) and prediabetes? 
“Approximately 85 per cent of people with diabetes have type 2 diabetes which is both a 
disease entity and a risk factor for other diseases, predominantly cardiovascular and 
cerebrovascular disease.”  (Colagiuri et al (2009c)) 
Diabetes is not a single homogeneous disease but composed of many conditions with 
hyperglycaemia as a common feature. Leslie et al (Leslie et al., 2017, Leslie et al., 2016) 
notes that four factors have historically been utilised to describe this diversity namely: age of 
onset; the severity of the disease (i.e. the degree of loss of b cell function); the degree of 
insulin resistance, and the presence of diabetes-associated autoantibodies. Based on these 
factors there are two major types – type 1 diabetes mellitus and type 2 diabetes mellitus. 
However recent and ongoing research has found that both major types of diabetes have 
common features. Type 1 diabetes is a so-called exclusive disease in that the term 
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encompasses individuals with diabetes-associated autoantibodies, who are dependent on 
exogenous insulin. Whereas T2DM, is an inclusive disease. It has a complex aetiology that 
cannot be defined by a single feature. In fact, T2DM broadly covers any form of diabetes that 
is not T1DM, MODY (maturity onset of the young) or secondary diabetes (Leslie et al., 2017, 
Leslie et al., 2016). 
 Pathophysiology of type 2 diabetes (T2DM) 
Normal regulation of glucose metabolism is determined by a complex feedback loop 
involving dietary intake, the islet β-cell, counter-regulatory hormones (including adrenaline 
and noradrenaline, glucagon, cortisol and growth hormone) and insulin-sensitive tissues. The 
β-cells are located in the pancreas as one of at least five different types of islet cells in the 
islets of Langerhans. They produce, store and release the hormone insulin. (Diabetes UK 
2019)  
In normal situations, insulin acts to drive down the blood glucose level, which has risen in 
response to diet or other metabolic needs (e.g. stress). When tissues become resistant to the 
effects of insulin (as occurs in PreDM and T2DM) the β-cell responds, in the initial phase, by 
producing more insulin. It is only when the β-cell, is incapable of releasing sufficient insulin in 
the presence of insulin resistance that glucose levels rise (Kahn et al 2014). Hyperglycaemia 
develops in type 2 diabetesT2DM when there is an imbalance of glucose production and 
glucose intake (food ingestion) as opposed to insulin-stimulated glucose uptake in target 
tissues, mainly skeletal muscle. The influence of aging on this process is considered to be 
through impairment of β-cell function, resulting in a decline in insulin secretion (Lee et al., 
2017). While β-cell dysfunction has a clear genetic component, complex genetic/lifestyle 
conditions such as obesity play a vital role (Kahn et al., 2014). 
The presence of risk factors for T2DM, and increasing levels of non-diabetic glycaemia, are 
evident more than a decade before onset of T2DM (Olafsdottir et al., 2009). Family history, 
predominantly (but not exclusively) epigenetic maternal transmission, and higher Body Mass 
43 
Index (BMI), increased triglyceride (TG) and systolic blood pressure levels in late mid-life are 
associated with development of T2DM in later life (Feng et al., 2016, Olafsdottir et al., 2009). 
Insulin resistance and β-cell dysfunction are known to be the major pathophysiologic 
functions driving T2DM – however these factors come into play at different time courses 
(Waugh et al., 2013). Insulin resistance in skeletal muscle is the earliest detectable 
abnormality of T2DM (Petersen KF, Dufour, Morino K et al, 2012 ) as quoted in (Taylor, 
2013). In contrast, changes in insulin secretion determine both the onset of hyperglycaemia 
and the progression towards insulin therapy (Cali M, Man CD, Cobelli C et al 2009 as quoted 
by Taylor R 2013). 
Imamura, Mukamal Meigs et al (Imamura et al., 2013) found that in older adults, the 
combination of risk factors causing T2DM depended on whether T2DM was preceded mainly 
by insulin resistance, or β-cell dysfunction or both. 
Prediabetes, defined as IGT, IFG, or raised HbA1c, is not a benign state and is associated 
with an increased risk of cardiovascular disease/complications. The health risk is considered 
to be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or 
HbA1c of 39 mmol/mol/HbA1c 6.1-6.5% (Huang et al., 2016). 
In individuals with preDM, raised plasma insulin levels compensate and allow normal plasma 
glucose control. However, because higher insulin levels stimulate the process of lipogenesis, 
the scene is set for hepatic fat accumulation. Excess fat deposition in the liver is present 
before the onset of and during T2DM. Individual tolerance of different degrees of fat 
exposure varies, and understanding this lipo-susceptibility is estimated to underpin the future 
understanding of genetically determined risk in any given environment (Feng et al., 2016). 
There is increasing interest in the role of elevated serum fasting triglycerides (Olafsdottir et 
al., 2009, Riediger et al., 2017) as an early sign for elevated risk for developing T2DM. 
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Hjellvik et al (Hjellvik et al., 2012) considered the interactions between obesity, triglycerides 
(TG), diastolic blood pressure (DBP) and blood glucose levels in late middle-age (50-59 
years) reflected high risk for development of T2DM. Research by Dankner et al and Zou et al 
found T2DM was resultant from the interactions between older age, TG and non-alcoholic 
fatty liver disease (NAFLD) (Zou et al., 2017) (Dankner et al., 2009). 
Caspersen et al (Caspersen et al., 2015) noted that between the 1999–2005 and 2006–2010 
National Health and Nutrition Examination Surveys (NHANES) preDM had significantly 
increased for US adults aged from 50–64 years 38.5% to 45.9% (p=0.003) and from 65–74 
years 41.3% to 47.9% (p = 0.016). Whilst older men had the greater prevalence of preDM, 
there was a significant increase in preDM for women in these two age range groups and 
HbA1c increased significantly for both sexes. In recognition of the increasing prevalence and 
impact of preDM and T2DM, screening and prevention initiatives need to target older adults, 
particularly in the “young-old” group (60–74 years). 
 Principles of screening for unrecognised high risk and undiagnosed 
T2DM 
Type 2 diabetes is both a disease entity and a risk factor for developing, among others, 
cardiovascular and cerebrovascular disease (Colagiuri et al., 2009a). The precursor of T2DM 
– preDM is also a risk factor for the same vascular diseases. Consequently, all aspects of the 
impact of chronic/persistent hyperglycaemia need to be considered in evaluating 
recommendations for active case detection of undiagnosed T2DM. The rationale for 
screening in asymptomatic individuals, is to identify those with T2DM, preDM or scoring 12 
points or more on the AUSDRISK, in association with other high risk factors such as obesity, 
and implement lifestyle changes and/or medication to prevent the onset, or reduce the 
impact of, preDM or T2DM (Colagiuri et al., 2009a, Sheehy et al., 2009). 
In 1966, the World Health Organization published a monograph by Wilson and Jungner, The 
Principles and Practice of Screening for Disease (Wilson et al., 1966) (Sheehy et al., 2009). 
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The monograph proposed 10 principles for evaluation of screening programs which have 
proved to be very influential (Table 2.1). They have held up well as has been shown by 
evaluations performed by Andermann et al (Andermann et al., 2008), whose suggested 
refinements were mainly in relation to genetic counselling. In 2009, Sheehy et al (Sheehy et 
al., 2009) revisited Wilson & Jungner and applied the principles and practice as the basis for 
proposing an improved approach to screening for T2DM in the US, which would include “risk 
stratification, laboratory evaluation, probability analysis and genomic testing”. In 2011, Harris 
et al (Harris et al., 2011), proposed that screening programs be “visualised as a balance 
between benefits and harms” where the net benefits to the individual and community 
outweigh the resources required from Health services in the public and private sectors. 
Harris et al (2011) considered that this balanced approach improved certainty in decision-
making about implementing screening programs. Rather than using the checklist approach of 
Wilson and Jungner, Harris et al provided a Summary of Steps in Evaluating Proposed 
Screening Programs (Harris et al., 2011), which if followed, would provide the minimal 
evidence sufficient to estimate benefits and harms of screening programs with at least 
moderate certainty. 
Within the Summary of Steps in Evaluating Proposed Screening Programs, the three main 
issues to be considered were: 
• The probability of an adverse health outcome in the population if screening were not 
implemented. 
• The degree to which screening identified all people who would suffer an adverse 
health outcome i.e. the accuracy of the screening program. 
• The magnitude of the incremental health benefit of earlier versus later treatment 
resulting from screening. 
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Table 2.1 Summary of Wilson and Jungner Criteria (Sheehy et al., 2009) 
Principle Further explanation by Wilson and Jungner 
The condition should be an 
important health problem 
Does not depend on prevalence only; must consider from the 
point of view of the individual and community; conditions with 
serious consequences for either individuals or the community 
may both justify screening  
There should be an accepted 
treatment for patients with 
recognised disease. 
Perhaps most important criterion; unless there is an effective 
treatment, actual harm may be done; requires answering 2 
questions: 1) Does treatment at the pre-symptomatic borderline 
stage of a disease affect its course and prognosis? 2) Does 
treatment of the developed clinical condition at an earlier stage 
than normal affect its course and prognosis? If the answer to 
question 1 is not clearly yes, then there is no case for 
screening. For question 2, effective treatment is usually 
‘‘assumed.’’ 
Facilities for diagnosis and 
treatment should be available. 
Must have facilities available for the diagnosis and treatment of 
people found positive by screening. 
There should be a recognizable 
latent or early symptomatic stage. 
Must be a reasonable asymptomatic period in the natural 
history of the condition. 
There should be a suitable test or 
examination 
Test must be easy and quick, may be less sensitive and 
specific than a diagnostic test. In a screening test, one may 
accept a higher false-positive rate, but a high false-negative 
rate would not be acceptable. 
The test should be acceptable to 
the population. 
Acceptability is related to the nature of the risk involved and the 
extent to which ‘‘the ground is prepared previously by health 
education.’’ 
The natural history of the condition, 
including development from latent 
to declared disease, should be 
adequately understood 
It is necessary to have conducted enough research to know 1) 
What changes should be regarded as pathologic and what 
should be considered physiologic variations? and 2) are early 
pathologic changes progressive? 
There should be an agreed policy 
on whom to treat as patients. 
It is necessary to know: Is there an effective treatment that can 
be shown either to halt or to reverse the early pathologic 
changes? We must be careful to heed the Hippocratic principle 
of “do no harm”. There is a ‘‘borderline’’ problem whereby 
people are found by screening who are neither clearly normal 
nor abnormal. It is important to have a clear policy for either 
treatment or follow-up of these people. 
The cost of case finding (including 
diagnosis) should be economically 
balanced in relation to possible 
expenditure on medical care as a 
whole 
There are 2 general aims of screening: to improve health and to 
reduce costs. It is not certain that screening will reduce costs; 
there is a need for randomised controlled trials of screening to 
determine this, although these trials are difficult to conduct. 
Case finding should be a continuing 
process and not a ‘‘once and for 
all’’ project. 
The benefit of ‘‘single-occasion’’ screening is limited. 
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 Types of screening for Type 2 diabetes 
Screening in medicine is a strategy used in a population/specific population cohort to identify 
unrecognised disease in individuals without signs or symptoms. As such, screening tests are 
performed on persons in apparent good health. 
Screening interventions are designed to identify disease in a community early, thus enabling 
earlier intervention and management, with the aim of reducing mortality and suffering from a 
disease. Although screening may lead to earlier diagnosis, not all screening tests have been 
shown to benefit the person being screened: over-diagnosis; misdiagnosis, and creating a 
false sense of security are some potential adverse effects of screening (Barry et al., 2017). 
For these reasons, a test used in a screening program must have good sensitivity, in addition 
to acceptable specificity. 
Universal screening applies to all individuals of a certain category for example, the Guthrie 
heel prick blood test for all newborns in Australia to identify phenylketonuria. 
Targeted screening has been implemented nationally in Australia for groups known to be at 
higher risk for particular conditions. For adults national screening is offered for the following 
conditions – bowel cancer screening commenced in 2006 (5 yearly for individuals aged 55 – 
74 years) (Flitcroft et al., 2010); breast cancer screening commenced 1991 (every 2–3 years 
for women aged 45–74 years (and older if advised), and, somewhat more controversially, 
prostate cancer screening for men aged 55 -74 years commenced 1994 (Royal Australian 
College of General Practitioners, 2014). The national cervical cancer screening program is 
available for people aged 25 – 74 years. Since December 2017, the two yearly Pap test has 
been replaced by a five-yearly human papillomavirus (HPV) test.  
In Australia, there is no national whole-of-population health screening program for T2DM as 
this is not considered to be cost-effective (Colagiuri et al., 2009a, Shaw, 2017) particularly 
when it was considered there were high levels of opportunistic screening and insufficient 
evidence of the benefit of introducing a national screening approach (Shaw, 2017). However 
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there are some researchers who consider that the current opportunistic screening 
approaches could be improved to identify individuals earlier to improve risk factor control 
once dysglycaemia is detected (Simmons et al., 2017). 
Currently case finding for T2DM or preDM in Australia, involves screening individuals or 
smaller groups of people based on the presence of specific and/or observable risk factors, 
for example, overweight/obesity, limited physical activity, presence of family members having 
been diagnosed  with T2DM or preDM. The NHMRC National Evidence Based Guideline for 
Case Detection and Diagnosis of Type 2 Diabetes(Colagiuri et al., 2009c) and the Evidence 
Based Guideline for the Primary Prevention of Type 2 Diabetes (Colagiuri et al., 2009b) 
recommend a 2–3 step procedure using a Risk Assessment Tool (AUSDRISK) as the first 
step to initially identify adults at High Risk for developing T2DM followed by biomedical 
assessment. This process is essentially ‘opportunistic screening’ based on observed risk 
factors and/or age (over 45 years), conducted by GPs. The RACGP Guidelines for 
Management of Type 2 Diabetes (Royal Australian College of General Practitioners and 
Diabetes Australia, 2016-18) are consistent with the NHMRC Guidelines. The guidelines 
recommend three yearly screening with an FBG or HbA1c test  from 40 – 80 years for those 
with evidencing signs of being at HR or scoring HR on the. Those who have previously 
shown to be at HR by recording IGT or IFG, should be re-tested annually. However, unlike 
previously discussed screening programs, T2DM screening is not organised nationally and is 
dependent on each GP, GP practice and the attendance by individuals. It is unknown how 
many individuals are not identified until the later stages of experiencing dysglycaemia. 
There are infrequent, short-term, local health promotion initiatives for World Diabetes Day or 
National Diabetes Week to raise awareness of T2DM conducted by non-Government 
organisations such as Diabetes Australia and its state-based branches. In addition, there 
have been pharmacy programs (Kilkenny et al., 2014, Krass et al., 2017, Krass et al., 2007) 
which have conducted screening studies utilizing AUSDRISK. Self-assessment via the 
AUSDRISK risk factor questionnaire may be accessed via the non-Government organisation 
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(NGO) Diabetes Australia, and by state and federal government web-sites (Australian 
Government Department of Health and Ageing, 2008). The AUSDRISK has been used to 
identify mid-aged adults (40 - 69 years) likely to be at HR for T2DM as the entry point for 
participation in time-limited lifestyle modification T2DM prevention programs (Dunbar, 2017, 
Johnson et al., 2015, Johnson et al., 2013, Malo et al., 2015, Vita et al., 2016) which have 
been conducted in other Australian states, but not in Tasmania. 
 Does screening for type 2 diabetes in the “young-old” age cohort, 
meet the principles of screening as set out by the Wilson and 
Jungner criteria? 
 The condition should be an important public health problem 
Diabetes ranks highly on the international health agenda as a global pandemic and as a 
threat to human health and global economies. Over the past three decades the number of 
people with T2DM has doubled globally, making it one of the most important public health 
challenges to all nations (Chen et al., 2012). In Australia, T2DM is the fastest growing 
chronic condition (Australian Bureau of Statistics, 2011-12) with prevalence influenced by 
increased obesity and an ageing population (Australian Bureau of Statistics, 2011-12). The 
total prevalence of diagnosed T2DM in the Australian population is 4.4%. Results of the 
2011–12 Australian Health Survey (Australian Bureau of Statistics, 2011-12) showed the 
prevalence of T2DM in the older age cohort increases from 4.1% in the 45-54 year cohort to 
approximately 9.0% in the 55–64-year cohort and rising further to 16.0–18.0% in the 65–74-
year cohort. Data for 75+ cohort shows that prevalence of T2DM for males in this cohort 
remains at approximately 16.0% ,but for females T2DM decreases to approximately 13.0%. 
However, some 4-5 years later than the 2011-12 ABS findings, the National Diabetes 
Services Scheme (NDSS) dataset (Australian Government Department of Health, 2016) 
records individuals in their late 60’s, 70’s and 80’s as being newly diagnosed with T2DM. 
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 There should be an accepted treatment for patients with recognised 
disease 
In Australia, there are national guidelines for diagnosis and treatment of T2DM. These 
recommended guidelines form the basis for the RACGP and Diabetes Australia guidelines 
for the management of Type 2 diabetes 2016-18 in primary care (Royal Australian College of 
General Practitioners and Diabetes Australia, 2016-18). 
Within the overarching NHMRC and RACGP guidelines there is the concept of individualised 
treatment for T2DM, along the lines advocated by Dankner and Roth (Dankner et al., 2015) 
and Sinclair et al (Sinclair et al., 2015). Treatment for preDM and T2DM in older persons is 
‘tailored’ based on person’s age at diagnosis and period of abnormal glycaemic status, if 
known. Initial medication is usually Metformin, and some other more recent medications. 
Lifestyle measures include weight reduction if overweight/obese; increase in physical activity 
and improvement in nutrition and reduction of portion sizes, which have proved to be 
effective in the treatment of preDM by stabilising blood glucose levels to reduce progression 
to T2DM, as well as reducing complications in older adults with T2DM (Kiefer et al., 2015). 
This is supported by the work by Bouchard (Bouchard et al., 2012), which showed that 
although older adults had reduced readiness to change lifestyle measures, individualised 
management balancing medication and lifestyle would likely achieve desired outcomes. 
Diabetes education and coaching programs, although limited, are conducted in most 
Australian states including Tasmania, by Credentialed Diabetes Nurse Educators (CDNE), 
Dietitians, podiatrists and exercise physiologists to support self-management for preDM and 
T2DM (Diabetes Australia, 2017b, Ski et al., 2015). 
Individuals diagnosed with diabetes (all types) may access Medicare funded Care Plans 
(www.health.gov.au) which provide quarterly access to lifestyle interventions and quarterly 
blood glucose tests (FPG; HbA1c) to monitor progress. 
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 Facilities for diagnosis and treatment should be available 
In Australia, there are Medicare funded services available for both diagnosis and treatment 
for individuals with diagnosed diabetes (all types). These services are provided by the 
Australian network of GPs, community health services, allied health services (podiatry, 
psychology, dietitians, physiotherapists), pathology service, subsidised pharmacology and 
medications and services through the non-government Diabetes Australia and the National 
Diabetes Services Scheme (NDSS)(Australian Government Department of Health, 2016). 
Under the RACGP Guidelines for Diagnosis and Management of Type 2 Diabetes in primary 
care, there are medical and pathology services available for diagnosis and management 
(Colagiuri, 2015, D’emden et al., 2015) (Dunbar et al., 2015, Wong et al., 2011). Costs for 
management of T2DM such as blood glucose meters and medication are subsidised via the 
NDSS but are means tested. (Australian Government Department of Health, 2016). 
However, there is no national system for facilitating and supporting regular screening, 
reporting and registration of those individuals with or at HR for undiagnosed T2DM. The 
Government-funded Medicare system provides one HbA1c blood test per year for diagnosing 
T2DM/preDM in asymptomatic adults. This may be implemented by GPs as part of 
opportunistic screening. There is limited treatment/management for those with preDM. 
Diabetes Australia provides information for preDM on their website and there are a small 
number of programs conducted by private health insurance companies for their members 
with ancillary service benefits. Government-funded health promotion initiatives may be 
utilised to increase physical activity and improve nutrition, but these are not diabetes-specific. 
 There should be a latent stage of the disease – an early asymptomatic 
stage exists 
It has been modelled that there is a period of 5-10 years of increasing and variable glycaemic 
load, during which time patients are either asymptomatic, or have symptoms that do not 
identify the condition with sufficient precision (Olafsdottir et al., 2009). 
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Type 2 diabetes typically develops slowly, with progression from normal blood glucose to 
glucose abnormalities identified as non-diabetes hyperglycaemia or preDM and, if not 
treated, finally progress to T2DM. Prior to the onset of T2DM individuals may experience 
dysglycaemia for many years (Twito et al., 2015). 
 There should be a suitable test or examination for the condition 
 Diagnostic Blood tests 
Diagnostic criteria for type 2 diabetes (General practice management of type 2 diabetes 2016-18) 
• Fasting blood glucose (FBG) ³ 7.0 mmol/L or random blood glucose ³11.1 mmol/L 
confirmed by a second abnormal FBG on a separate day;  
• FBG < 5.5 mmol/L: diabetes unlikely 
• FBG 5.5 – 6.9 mmol/L: may need to perform an OGTT. 
• Oral glucose tolerance test (OGTT) before (fasting) and two hours after an oral 75 g 
glucose load is taken. Blood glucose is measured. Diabetes is diagnosed as FBG ³ 
7.0 mmol/L or two-hour blood glucose is ³11.1 mmol/L 
• Glycated haemoglobin (HbA1c) ³ 48 mmol/mol (6.5%; on two separate occasions) 
These are via venous sampling under laboratory methodology 
A random blood glucose test may be utilised but this is usually done when a person has 
symptoms of diabetes. 
Since 2014, when the Australian Government introduced a Medicare-funded annual HbA1c 
test, it has become the most frequent initial test for blood glucose assessment and diagnosis 
of hyperglycaemia, with or without an established diagnosis of diabetes. 
A Fasting Plasma Glucose (FPG) test requires an overnight fast followed by blood test and 
then a wait of 1–2 days for pathology testing and reporting. There are advantages in that 
other blood components which require fasting, (e.g. blood lipids) can be tested in addition to 
assessing the glycaemic status. 
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The Oral Glucose Tolerance Test (OGTT) – 2-hour post glucose challenge or the recent 1–
hour OGTT is considered the gold standard for diagnosis of type 2 diabetes. It involves an 
overnight fast followed by drinking 75 ml of a glucose drink; sitting (not moving) for 2 hours (1 
hour) and having blood tests every 30 mins for a 2-hour (1-hour) period. For a variety of 
reasons (work, family responsibilities) individuals find this process difficult in terms of time 
allocated for the test. 
The HbA1c test, which reflects the average blood glucose levels over the previous 3 months, 
does not require an overnight fast and has a faster reporting time. It is convenient (it can be 
taken any time of day) with less day-to-day variability and international standardisation of the 
assay. However, the HbA1c test does not reflect the range of highs and lows of the blood 
glucose level nor the pattern occurring as the blood glucose returns or attempts to return to 
the individual’s baseline level of blood glucose.  
There are some limitations associated with an HbA1c test. It is not suitable for people with 
certain blood conditions, such as those with genetic, haematologic and illness-related factors 
that influence its measurement. Neither is it suitable for patients taking medication that may 
cause rapid glucose to rise such as steroids, and antipsychotics. The HbA1c level is reported 
to increase with age independently of mean glycaemia (Rothberg et al., 2015); the HbA1c 
test only measures blood glucose levels whereas a FPG test allows for a full blood sample 
analysis covering blood glucose test along with the possibility of also testing fasting lipids 
which if elevated reflect additional T2DM risk. 
Rothberg and Halter (Rothberg et al., 2015) comment that although there may be a subset of 
individuals identified by either FPG or HbA1c, the identification of preDM or T2DM in the 
older population may need to rely on both measures, as those with an elevated HbA1c may 
be a different group from those with an abnormal FPG. Systematic point-of-care HbA1c 
testing has been found to be an effective method of initially identifying persons who are 
unaware of their hyperglycaemic status including T2DM and preDM (Whitley et al., 2017). 
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 Risk assessment tests 
The AUSDRISK is not a test of T2DM but rather an assessment of an individual’s risk for 
developing T2DM over a 5-year period. If the AUSDRISK score is in the high range (12 
points and above). Within the HR range there are 3 score levels reflecting the level of HR viz: 
Low HR score 12-15; Medium HR score 16-19; High HR score  20 points and above. 
 The score of HR (at any level) is an indicator that an individual should receive a biomedical 
assessment (blood test) to determine their current glycaemic status (blood glucose level). 
From a cost-benefit viewpoint, the AUSDRISK score first identifies the person/group at High 
Risk. This effectively reduces the number of individuals to those most likely to develop T2DM 
within a 5-year period. Completing an AUSDRISK has the added benefit of highlighting risk 
factors for T2DM thus improving health literacy regarding the modifiable and non-modifiable 
risks for T2DM. If an AUSDRISK is completed as a one-off event or infrequently, the HR 
result does not necessarily provide the incentive for individuals to attend their GP for a 
biomedical assessment. Regular completion of an AUSDRISK (e.g. every 2-3 years) would 
provide more motivation to attend their GP for a medical assessment if the individual 
observed their HR score was unchanged or increasing. 
Many diabetes risk assessment tests have been developed worldwide since the early. Each 
test has been found to be most predictive if used in the population from which the test was 
derived (Noble et al., 2011). Each test is derived from a set of risk factors for T2DM. Different 
combinations of risk factors in different tools have shown to identify different levels of risk 
even within the same population (Gray et al., 2015), so risk tests/tools are an assessment of 
risk, not a diagnostic test but they do have the capacity to delineate different levels of risk for 
a particular condition within a target population. 
 The test should be acceptable to the population 
Details have been discussed in point 2.2.3 where individual acceptability of each test was 
reviewed. Across the different T2DM diagnostic tests, acceptability was highest for the 
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HBA1c test – non-fasting and rapid reporting. However, “acceptability” also includes 
“perception of risk” associated with an individual’s health status. International studies have 
assessed and documented the impact of perceived risk for diabetes on participation with 
screening for T2DM and preDM and ongoing monitoring of diagnosed T2DM and preDM 
(Abbasi et al., 2012, Godino et al., 2014a) and found that “heightened perception of an 
adverse outcome” that is, a finding of T2DM or high T2DM risk, has a major negative 
influence on participation in screening for T2DM (Lavielle et al, 2014), and particularly for 
men (Davey et al., 2015). Screening appears not to be recognised by participants for its 
benefits i.e. early identification of potential ill-health with opportunity to reduce/avoid, but 
rather for its possible end-stage outcome. This may be due to the direction taken by health 
service providers (Mainous 3rd et al., 2019). 
 The natural history of the disease should be adequately understood 
This has been covered in the pathophysiology section previously where the trajectory of 
T2DM if undiagnosed, is compared with trajectory of T2DM if diagnosed and managed 
correctly. 
 There should be an agreed policy on whom to treat 
This has been addressed in the section on National Guidelines and GP management of Type 
2 diabetes (2016–18). 
There is recognition of the importance of a personalised approach to management of preDM 
and T2DM for older individuals – particularly to avoid hypoglycaemic episodes or a prolonged 
hyperglycaemic state (Dankner et al., 2015, Halter et al., 2014). 
 The total cost of finding a case should be economically balanced in 
relation to medical expenditure as a whole 
The NHMRC National Evidence Based Guideline for Case Detection and Diagnosis of Type 
2 Diabetes (Colagiuri et al., 2009b) provided the rationale and evidence for identifying T2DM 
(benefits and cost) based on “modelling” of a national diabetes screening and prevention 
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program among Australians aged 45–74 years (Colagiuri et al., 2008). The Australian 
Diabetes Cost-Benefit Model compared baseline and scenario outcomes from 2000 to 2010. 
Individuals newly diagnosed with T2DM in year 2000 were “modelled” to receive intensive 
care which would result in reducing rates of complications. In addition, people at high risk of 
developing diabetes (IGT or IFG) were “offered” lifestyle intervention, reducing the numbers 
developing T2DM. Among those at HR, 53,000 individuals were predicted to avoid 
developing diabetes by 2010. Average yearly intervention and incremental treatment cost 
was estimated as AU$179 million, with a cost per disability-adjusted life-year (DALY) of 
AU$50,000. 
However, the Guidelines (Colagiuri et al., 2009c) reported that in general, mass screening 
programs are not recommended, whereas screening for T2DM using targeted opportunistic 
screening in HR populations had been found to be cost effective (Borch-Johnsen et al., 2003, 
Wareham et al., 2001). 
In 2015, Gillett et al (Gillett et al., 2015) conducted a modelling study within the NHS Health 
Check program to compare the cost-effectiveness of screening for T2DM using an HbA1c 
test versus a FPG test. In addition, the study compared the use of a random capillary 
glucose (RCG) test versus a non-invasive risk score to prioritise individuals who should 
undertake an HbA1c or FPG test. The study utilised results from the multiethnic population 
currently attending NHS Health Checks. According to Gillett et al (Gillett et al., 2015) it was 
more cost-effective to screen for T2DM using a HbA1c test than using a FPG test. Use of a 
Risk Assessment Test was considered to be more cost-effective than a random plasma 
glucose test for pre-screening to determine those at high risk (Edelstein et al., 2005). 
Australian GPs implement opportunistic screening to identify individuals they (GPs) consider 
to be at HR. Although the Guidelines recommend the AUSDRISK be used to first identify HR 
prior to blood glucose testing, this is rarely done (Lee & Colagiuri, 2016) . Evidence for 
community screening is not strong and the consensus is that population screening is 
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expensive with low outcomes, and a belief that, where opportunistic screening is considered 
effective, that screening process should continue (Shaw 2017). 
A more comprehensive assessment of each individual’s pattern of dysfunction would be to 
implement a full fasting blood test, however it was considered unlikely to be cost-effective nor 
acceptable to individuals as a first step in a targeted screening process (Colagiuri, 2012, Lee 
et al., 2013, Lee et al., 2016). The most recent comment by Australian researchers was that 
T2DM screening was a balance between maximum identification of those individuals with 
undiagnosed T2DM or at HR, and the cost to achieve this. (Lee et al., 2018). Their research 
utilised data from the Australian Diabetes Obesity and Lifestyle Study (AusDiab) baseline 
and first follow-up study (AusDiab-2) as the basis for determining which of three screening 
scenarios was the most effective and cost effective for community diabetes screen and 
prevent T2DM. The recommended screening protocol for a local community-based diabetes 
prevention program was to combine an AUSDRISK assessment with a score ³15 followed by 
blood glucose testing with either FPG or HbA1c. This combination was the most cost 
effective and the HbA1c test was the most convenient (and acceptable) test as it does not 
require a fasting blood sample, but it was acknowledged to be a less sensitive approach and 
may miss some individuals with T2DM/preDM. This recommended approach is essentially an 
opportunistic screening approach based within a community setting rather than a clinical 
setting. 
 Case-finding should be a continuous process, not just a “once and for all” 
project 
The NHMRC Guidelines for the Case Detection and Diagnosis of Type 2 Diabetes 
recommend that opportunistic screening be undertaken every 3 years for those individuals 
whose last test showed them to be normoglycaemic. Individuals found to have elevated 
blood glucose levels/preDM should be re-tested annually and have lifestyle and or 
medication management implemented. However, as discussed previously in this chapter 
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there is no national system, recording of results or funding to ensure that this screening and 
case finding occurs on a regular basis. 
Results in the Finnish Diabetes Prevention Study (Tuomilehto et al., 2001) and the US 
Diabetes Prevention Program (Edelstein et al., 2005) have shown that screening and early 
management/treatment during the asymptomatic stage improves the long-term outcome for 
those identified as having elevated blood glucose levels (Simmons et al., 2012). These 
intensive Diabetes Prevention Programs have shown a reduction for the risk of T2DM by 
58.0% in adults with Abnormal Glucose metabolism (AGM) as shown by lifestyle changes 
and weight reduction, with/without medication. However there is still some ambivalence 
regarding the effectiveness of population-based T2DM screening in reducing mortality and 
morbidity (Waugh et al., 2013). There is general support for the cost-effectiveness of 
targeted screening to prevent/delaying the onset of T2DM. Australian research by Colagiuri 
provided evidence that although the cost to individuals and government, for the management 
of T2DM with/without complications was substantial, it could be significantly reduced by 
preventing initial development of T2DM and its complications (Colagiuri, 2012). For older 
individuals, this preventive approach has the potential for improving their quality of life. 
 Identification and case detection T2DM and preDM in Australia 
There are no specific signs and symptoms to identify the ongoing and progressive nature of 
glycaemic dysfunction in the early stages of pre-DM/T2DM, thus individuals are not alerted to 
their increasing risk factor burden for developing pre-DM/T2D by experiencing early 
symptomatology (Waugh et al., 2013). 
As stated earlier in this review, there are established Australian guidelines and procedures 
for identification and case detection of T2DM (Colagiuri et al., 2009a, Colagiuri et al., 2009b, 
Royal Australian College of General Practitioners and Diabetes Australia, 2016-18). 
However, in practice, diabetes risk assessment has not been systematically implemented by 
GPs (Wong et al., 2011) with most GPs using a patient’s clinic presentation (for a related or 
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unrelated condition) to opportunistically implement a biomedical assessment of a patient’s 
glycaemic status (Shaw, 2017). 
Prior to 2014, GPs would most likely advise a fasting blood sample to be tested for plasma 
glucose (FPG), cholesterol levels (LDL, HDL, triglycerides) with or without liver function tests 
for individuals presenting with obesity and hypertension. 
In 2014, the Australian government introduced a specific Medicare payment code for one 
annual HbA1c test (Medicare item 66841) for individuals, not previously diagnosed as having 
T2DM, but assessed by their GP as being at HR for T2DM, or assessed as HR on 
completion of the AUSDRISK. 
Other recommended strategies for the entry step in T2DM screening such as point-of-care 
testing with a non-fasting HbA1c test have been utilised in regional and remote Australian 
populations (Colagiuri, 2015, Degeling et al., 2012, Marley et al., 2015) and would warrant 
investigation to determine if this approach was/were more effective, efficient and acceptable 
to the older age cohort (Thompson et al., 2016), for identifying those with pre-DM/T2DM. 
 Opportunistic screening 
A recent commentary by Shaw (Shaw, 2017) stated there was little evidence of benefit 
related to a population screening program for T2DM. This was due to the effectiveness of 
high levels of opportunistic screening in the general population where the outcome of the 
initial opportunistic screening procedure was followed by regular follow-up assessments. 
However, without systematic follow-up screening, the individual opportunistic approach for 
identifying those adults with or at high risk of T2DM does not identify an ongoing pattern of 
potentially increasing hyperglycaemia, nor does it establish a consistent system for regular 
testing and recording results for incident T2DM/preDM. 
In the Australian primary health system, patients are not registered with a particular GP or 
group general practice. Although patients are encouraged to attend one GP/GP practice to 
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maintain consistency with healthcare, there is no regulation to do so and for a variety of 
reasons, patients (with or without their medical records) move between GP providers. The 
National Diabetes Services Scheme (NDSS) database (Australian Government Department 
of Health, 2016) maintains records (with annual updating) of those individuals newly 
diagnosed with diabetes (if registered on the NDSS by their GP), and total annual numbers 
of those with diabetes (all types) by gender and age-range, but does not include those with 
non-diabetic hyperglycaemia – Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance 
and elevated HbA1c (higher than normal but not reaching the T2DM diagnostic point). 
The NDSS database is accurate for people with type 1 diabetes as they access the NDSS for 
insulin supplies and services. However, there is less accuracy for T2DM particularly those 
not requiring insulin supplies and services, as recording is not mandatory. A recent survey by 
the non-government organisation Diabetes Tasmania reports that 48% of GPs in Tasmania 
did not complete NDSS registration for their patients with diabetes (2017 personal 
communication). 
In comparison, healthcare services in the UK, US and European countries have established 
primary healthcare systems in their public health (UK, many European countries) or private 
health (as is the case with the Private Health Insurance companies in the US). These primary 
healthcare systems utilise patient and GP identifiers; patients are allocated/attached to 
particular primary health practices, and the frequency and results of medical tests are 
recorded as part of quality assurance. At a national level for each country/province, primary 
healthcare results are recorded and utilised for policy decisions and changes in direction to 
address documented health needs as evidenced by the development and subsequent review 
of the NHS Health Check program (Martin et al., 2018, Robson et al., 2016). 
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 T2DM screening initiatives within time-limited type 2 diabetes 
prevention programs in Australia 
In many Australian states (NSW, Vic, QLD, WA) but not Tasmania, the AUSDRISK is used to 
identify HR individuals to participate in time-limited initiatives and programs for T2DM 
prevention (Dunbar, 2017, Johnson et al., 2015, Malo et al., 2015, Vita et al., 2016). These 
programs mainly address the modifiable lifestyle risk factors for T2DM – overweight/obesity; 
insufficient physical activity; increased sedentary behaviour; and poor/over nutrition 
(Colagiuri et al., 2009c, Dunstan et al., 2004, Halter et al., 2014, Kalyani et al., 2013). 
Community pharmacies in Australia have also conducted T2DM screening initiatives using 
AUSDRISK to identify those at HR and advise them to attend their GP for a biomedical 
assessment. Eligible participants were adults without diabetes, 18–74 years (Kilkenny et al., 
2014, Krass et al., 2017, Krass et al., 2007). Similarly, the NGO Diabetes Australia and its 
state-based organisations provide access via their websites to the AUSDRISK for individual 
self-assessment of T2DM risk but there is no component to check HR individual follow-up, to 
attend a GP for biomedical assessment. 
There appears to be an ambivalent attitude in Australia to screening for earlier detection of 
chronic conditions. With limited financial support or no additional support for additional work 
required for screening, some governments and health management systems have difficulties 
justifying long term benefit against significant short-term cost for additional screening and 
consider that funding is better utilised for management of those with diagnosed T2DM 
(Shaw, 2017). 
 International type 2 diabetes screening programs 
Review of the literature on screening for T2DM internationally shows that there is still not 
consensus that population screening for T2DM, even within a specified age range, is 
effective and efficient, as the expense and coordination is out of the reach of many 
Governments/countries (Shaw, 2017, Simmons et al., 2017, Simmons et al., 2012). 
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Most developed countries conduct 2–3 step T2DM screening procedures, by first 
implementing an initial risk assessment tool /test to identify those individuals at HR, prior to 
implementing a biomedical assessment. Many countries have developed their own Diabetes 
Risk Assessment tool based on findings from their own population prevalence studies (Aujla 
et al., 2013). 
International T2DM screening/identification/prevention programs are most frequently targeted 
to individuals in the 45–60 years age group with some increasing the upper age level to 75 
years ((Bergmann et al., 2007, Escobar et al., 2015, Hauner et al., 2008, Martin et al., 2011, 
Rathmann et al., 2005, Rey et al., 2012, Van Den Donk et al., 2011) for individuals exhibiting 
known risk factors for T2DM – overweight/obesity; family history; hypertension and abnormal 
lipid levels. New Zealand has diabetes and prediabetes screening as part of cardiovascular 
risk assessment which begins prior to 45 years in high risk groups (e.g. Maori, Pacific, 
obese) and extends beyond 60 years. See -
https://www.health.govt.nz/publication/cardiovascular-disease-riskassessment- 
and-management-primary-care. Some studies have used Risk Assessment Tools, with 
varying success and others have used direct implementation of blood testing. 
 Real world national screening programs 
In the UK the NHS Health Check (Robson et al., 2016) is a national preventive program to 
reduce cardiovascular morbidity in individuals aged 40–74 years. It has been conducted from 
selected medical practices and pharmacies since 2009. Although experiencing initial 
difficulties in establishment, it has shown year-on-year improvement.	A systematic review by 
Harte E et al 2017, found that the reasons for not attending included lack of awareness or 
knowledge, misunderstanding the purpose of the NHS Health Check, aversion to preventive 
medicine, time constraints, difficulties with access to general practices, and doubts regarding 
pharmacies as appropriate settings. The findings particularly highlighted the need for 
improved communication and publicity around the purpose of the NHS Health Check 
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programme and the personal health benefits of risk factor detection. The NHS Health Check 
is now a well-established system with results showing the effectiveness of combined 
screening of cardiovascular and T2DM (introduced in 2016). Among the attendees, new 
cases of hypertension (38/1000 checks); new cases T2DM (9/1000 checks); chronic kidney 
disease (4/1000) were found. Of those found to be at high CVD risk 19.3% were newly 
prescribed with statins and 8.8% newly prescribed with antihypertensive therapy. Those 
identified with T2DM were referred for medication and/or lifestyle management. However, a 
recent retrospective evaluation of the performance of the NHS Health Check program was 
critical of its ability to identify people at high risk of developing T2DM with results showing a 
failure to identify a third of people at HR of having or developing T2DM (Martin et al., 2018). 
In the US, T2DM screening-to-treat programs are well-established for those individuals with 
health insurance whereas those without health insurance are not well covered (Diabetes 
Prevention Program Research Group 2019). Community based and faith-based programs 
have been implemented in Europe and UK for under-privileged and non-insured individuals 
and families (Wareham et al., 2011) (Chang et al., 2016, Robson et al., 2016) (Aujla et al., 
2013, Groenenberg et al., 2015, Van Den Donk et al., 2011). 
Apart from formal screening-to-treat programs (Aujla et al., 2013), opportunistic screening is 
utilised in primary health care and acute care – medical GP practices, blood banks, and 
allied health – optometry, pharmacy, dental clinics (Anghebem-Oliveira et al., 2017, Charfen 
et al., 2009, Cogneau et al., 2006, Holm et al., 2016, Howse et al., 2011, Klein Woolthuis et 
al., 2009, Krass et al., 2007). Opportunistic screening utilises a 2–3 step approach by using 
risk factor assessment questionnaires as the first step. Although many countries/populations 
have their own risk factor questionnaire, the use of FINDRISC (Finnish Diabetes Risk 
Assessment tool) or the simplified FINDRISC has been found to be the “most generic” of the 
European T2D risk assessment tools (Tuomilehto et al., 2001). However, this approach has 
not been universally successful (Bergmann et al., 2007). The FINDRISC, developed in 2003, 
was the first non-invasive Risk Assessment tool for identifying individuals with or at HR for 
T2DM and has been the “proforma” for all subsequent T2DM risk assessment tools. In 2012, 
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Hellgren et al (Hellgren et al., 2012) evaluated the performance of the FINDRISC 
questionnaire to identify individuals with IGT in Swedish primary care. Results showed that 
the FINDRISC questionnaire was a useful instrument for identification of individuals with 
impaired glucose metabolism (HR) but seemed less effective for detection of individuals with 
impaired glucose tolerance (very high risk/prediabetes). The researchers (Hellgren et al) 
concluded that methods other than FINDRISC were needed to identify IGT patients for 
implementation of lifestyle changes. 
A systematic review conducted in the UK by Khunti et al (Khunti et al., 2015) found that using 
3–4 steps in the process to increase the participation rate and confirm high risk, prior to 
implementing an OGTT, was the most effective and cost-effective procedure for identifying 
individuals with different levels of glycaemic dysfunction (Khunti et al., 2015). There are a 
smaller number of studies for screening for T2DM in adults older than 60 years. Studies by 
Dankner et al (Dankner et al., 2009, Dankner et al., 2015) have recommended a 
“personalised approach” for detecting preDM and T2DM with direct biomedical assessment 
rather than implementing a preceding risk assessment test. Similarly Escobar et al (Escobar 
et al., 2015), found that conducting a direct biomedical assessment study (without an initial 
risk assessment procedure) was effective in identifying the prevalence of unknown impaired 
glucose metabolism (prediabetes) and unknown (undiagnosed) T2DM in apparently healthy 
Swiss senior citizens. 
International studies have found that the major facilitating components to achieve effective 
screening procedures are well-established health systems and e-records – in GP practices, 
in UK; Europe (Klein Woolthuis et al., 2007, Schwarz et al., 2008); and in the US for those 
with private health insurance (Diabetes Prevention Program Research Group 2019). 
Participation in screening for T2DM is also facilitated by first raising health awareness in the 
whole population, for example in the US Diabetes Prevention Programs and the Finnish 
screening and prevention programs, prior to implementing a screening program (Guess et 
al., 2015, Schwarz et al., 2008). 
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Additionally, raising awareness of T2DM and preDM in specific high-risk cohorts, such as the 
older age cohort, has been found to be effective in promoting participation in ongoing 
screening. This was shown in the Swedish screening program for identifying abnormal 
glucose levels in healthy older adults (Escobar et al., 2015). 
Generally, the initial use of Risk Assessment tools to identify those at HR prior to blood 
glucose assessment is promoted as being cost effective (Colagiuri, 2012, Lee et al., 2013) 
However, studies and systematic reviews by Noble and others (Abbasi et al., 2012, Noble et 
al., 2011), found that most basic T2DM risk factor screening questionnaires could identify 
people at HR for developing T2DM in a 5-10 year time frame. But at the time of 
implementation, most screening questionnaires over-estimated the actual risk of T2DM and 
did not clearly indicate the HR participants’ glycaemic status, nor whether there was a 
requirement, or not, for blood glucose assessment. Risk Assessment Tools (RATs) have 
been developed using findings from prevalence studies of T2DM in a particular population 
and therefore are not as applicable when being used as a contemporaneous screening tool. 
Nevertheless the NHMRC Guidelines for Case Detection and Diagnosis of Type 2 Diabetes 
and Primary Prevention of Type 2 Diabetes (Colagiuri et al., 2009a, Colagiuri et al., 2009b, 
Royal Australian College of General Practitioners and Diabetes Australia, 2016-18) 
recommend use of the AUSDRISK as the first step in a T2DM screening process to first 
identify individuals at HR. Results from Dunbar et al. and Malo et al. (Dunbar et al., 2015) 
(Malo et al., 2015) in a middle-aged cohort are suggestive that AUSDRISK may also 
overestimate actual risk. However, it may not be an inaccuracy in screening results, but 
rather that a risk assessment tool, designed to estimate future risk, is not very accurate when 
used as a contemporaneous screening tool. 
 Barriers to T2DM screening – national and international 
Patient acceptability is critical to the effectiveness of a screening program. Patient 
acceptability was investigated as part of the MY-WAIST STUDY for T2DM screening (Aujla 
et al., 2013) conducted in UK Primary Health care (GP Practices). Low recruitment (8.6%) 
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was influenced by participants’ beliefs regarding likelihood of developing T2DM with those 
attending showing greater perceived susceptibility, whereas lack of perceived severity of 
T2DM was more common in those who did not attend. Many participants indicated their 
belief that early identification of T2DM was considered to be less necessary than for 
conditions involving cancer. 
Practical aspects about this screening strategy such as having to complete an OGTT – 
lengthy appointment; 2-hour wait; having to undergo overnight fast; dislike of a highly 
sweetened drink were barriers to those who did not attend. Other findings were that older 
people and those with a family history were more likely to attend, as were the “worried well”, 
but those who did not attend the GP practice on a regular basis were less likely to attend. 
There were procedural difficulties in that clinicians did not respond uniformly according to 
Guidelines, with regard to the blood test ordered and presentation of a screening 
assessment result. In addition, many practice staff considered implementing this study made 
additional work or disruption to the usual work routine and imposed additional stressors 
(Mainous 3rd et al., 2016b). Screening studies conducted subsequent to the MY-WAIST 
study (Aujla et al 2013) have found similar logistical barriers mainly due to the lack of 
familiarity with the process or lack of a regular well established and funded system. 
In a systematic review Dhippayon et al (Dhippayon et al., 2014) reviewed 24 studies which 
had implemented Risk Assessment Tools, and noted barriers reported by health care 
professionals and participants in completing the Risk Assessment Tools. Health care 
professionals were concerned with the increased time and lack of remuneration whereas 
individuals expressed a range of attitudes, from concern about the severity of T2DM to 
considering it not as severe as other chronic conditions. Only five of the 24 studies included 
a follow-up blood glucose test component, which participants could either complete or not. In 
this systematic review (Dhippayon et al., 2014), the only Australian study included had been 
conducted by Wong et al (Wong et al., 2011). This study comprised a survey of 78 GPs to 
67 
determine their knowledge and use of AUSDRISK. The findings revealed that the knowledge 
and application of  AUSDRISK to be low. 
In a series of studies Godino et al (Godino et al., 2014a), reported that GPs offered only 
limited reinforcement of the importance and benefit of lifestyle changes and 1-3-year re-test 
of blood glucose as part of a T2DM screening initiative. This lack of emphasis appeared to 
inadvertently reduce the HR individuals’ perception of their T2DM risk (Godino et al., 2012, 
Godino et al., 2016). 
GPs appeared to be responding to a current normoglycaemic status of the older individual 
rather than their ongoing HR status – a missed opportunity to explain the complexity of 
interpreting and communicating HR status to patients and further reinforcing effective 
behaviour change to decrease/stabilise their risk for preDM/T2DM (Mainous 3rd et al., 
2016a). 
 Health literacy/knowledge of type 2 diabetes 
The general public’s knowledge of T2DM appears to be that lifestyle factors alone increase 
or decrease the risk of T2DM whereas the research findings emphasise the complexity of the 
interactions between modifiable and unmodifiable risk factors for T2DM. Information 
available on Australian Government and non-government health websites such as the 
Diabetes Australia Fact Sheets (Diabetes Australia, 2017a, Diabetes Australia, 2017b) 
provide general information in relation to types of diabetes, risk factors and complications: 
“It is a progressive condition in which the body becomes resistant to the normal 
effects of insulin and/or gradually loses the capacity to produce enough insulin in the 
pancreas. We do not know what causes type 2 diabetes. Type 2 diabetes is 
associated with modifiable lifestyle risk factors. Type 2 diabetes also has a strong 
genetic and family-related risk factors”(Diabetes Australia, 2017b). 
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Although this information may hint at the complexity of the condition, the fact that “initially it 
can often be managed with healthy eating and regular physical activity and losing weight” 
tends to simplify the message and push the responsibility for success or failure solely on the 
individual. 
Reviewing the research literature provides a picture of a very complex disease with many 
factors and interactions yet to be identified and accurately documented. In 2017, researchers 
Skyler et al (Skyler et al., 2017) reported on the outcomes of a research symposium 
conducted in October 2015 by the American Diabetes Association (ADA), the Juvenile 
Diabetes research Foundation (JDRF), the European Association for the Study of Diabetes 
(EASD), and the American Association of Clinical Endocrinologists (AACE) to address the 
genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, 
as well as complications. The purpose was to acknowledge the heterogeneity and complexity 
of diabetes and to determine appropriate therapeutic approaches based on disease 
pathophysiology and stage. The outcome was that personalised medicine was still very much 
a “work-in-progress” with the future direction being to address the gaps in knowledge on the 
phenotypes and genotypes of the subtypes of diabetes. This essential research needed to be 
integrated with other research promoting early identification of T2DM risk, and regular T2DM 
screening to avert or reduce the impact of this complex condition. 
A series of studies published in Germany by Genz et al in 2010–2014 (Genz et al., 2010, 
Genz et al., 2012, Genz et al., 2014) found that providing information about T2DM and 
preDM improved recipients knowledge, but had little impact in T2DM screening participation. 
In the Netherlands, Groenenberg et al (2015) found that there was little difference in the 
method of approach for screening (face-to-face or mailout) but the greatest improvement in 
screening attendance was follow-up contact by mail or telephone to remind individuals to 
attend. Finally, those who had not responded were contacted directly by their GP. Using this 
approach achieved a 70 per cent participation rate in completion of a risk assessment test, 
but in this study, there was no follow-up biomedical assessment. 
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 Health risk and perceived health risk and readiness to change 
People with undiagnosed T2DM or preDM considerably underestimate their probability of 
having or developing diabetes. Contrary to associations with actual diabetes risk, perceived 
diabetes risk was lower in men (Davey et al., 2015), in lower educated and in older persons. 
In a study conducted in the Netherlands by Adriaanse et al (Adriaanse et al., 2008), both low 
risk and high risk profile subjects perceived diabetes as a serious disease. Perceived risk of 
having diabetes was slightly lower for the low risk compared with the high-risk profile 
subjects. However, even among those with a high-risk profile for T2DM, almost half 
appeared not to know their risk. In addition, this study found that perceived risk decreased 
with increasing age, whereas actual risk increases with increasing age. 
Anderson-Lister and Treharne (Anderson-Lister et al., 2014) identified four themes that 
influenced an individual’s participation in screening for T2DM: knowledge of diabetes, power 
to influence diabetes, limitations of responsibility or blame for diabetes and feelings about 
individuals with diabetes. Studies by Grzywacz et al (Grzywacz et al., 2011, Grzywacz et al., 
2014) found that beliefs about diabetes could be organised into a discrete number of belief 
domains, such as “causes” and “consequences”. Across individuals there is heterogeneity in 
the beliefs about cause and consequence, however at an individual level, there is remarkable 
consistency in beliefs about diabetes, both in content and over time. Personal experiences 
are a strong force in creating and maintaining beliefs about disease – with reference to 
causes and management. These responses towards diabetes management are likely to be 
shown in screening and the decision whether to participate in screening. Furthermore 
patterns and stability of beliefs are more stable in older adults and less likely to change 
(Bouchard et al., 2012). 
The impact of poor or limited health literacy in Australia is well documented by the National 
Statement on Health Literacy – Time to Take Action (Australian Commission on Safety and 
Quality in Health Care, 2014) and research by Jayasinghe (Jayasinghe et al., 2016) on the 
impact of health literacy and life style risk factors on health-related quality of life of Australian 
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patients. In addition, stigma towards those with diagnosed T2DM as having been responsible 
for the condition, by poor health behaviour, has been reported in the recent MILES-2 study in 
Australia (Ventura Ad et al., 2016). This attitude along with poor health literacy has been 
noted in studies internationally (Hivert et al., 2009, Vassy, 2013). 
Behavioural responses to actual risk, both positive and negative, impact on participation in 
screening initiatives. Experience of risk as “measured vulnerability” is well-known in the 
disinclination of HR male participants with an increased perceived health threat leading to 
decreased attendance to follow through to diagnosis (Ajzen, 1991, Davey et al., 2015, 
Godino et al., 2014a), and would be an issue to be addressed with males being at greater 
risk for T2DM than females (Australian Bureau of Statistics, 2011-12, Dunstan et al., 2002b). 
The ADDITION-Cambridge study (Echouffo-Tcheugui et al., 2015, Paddison et al., 2009) 
reported that negative screening results did not lead to positive or negative lifestyle 
modification over a 7-year follow-up. Overall, this lack of behavioural change would suggest 
that in order for T2DM prevention, screening and management to be effective, it would need 
to be embedded in strong systems methodology, as recently recommended in the evaluation 
of the National Health Service Health Check on Cardiovascular Disease Risk (Chang et al., 
2016). This would be of specific importance for those groups known to be at HR for T2DM 
such as older age individuals, many of whom have mainly non-modifiable risk factors specific 
to their age. 
 Issues for T2DM screening in Australia 
Effectiveness of screening strategies need to be determined by a balance between sensitivity 
and specificity of the population requiring further testing; the convenience and acceptability of 
screening by the participants, and the cost of screening. Cost is of particular concern to 
health providers as the cost of delivering health care continues to escalate (Colagiuri, 2012). 
In Australia opportunistic screening via general practice is not supported by strong systems 
for recording and reviewing patient outcomes. Continuing this practice as the main strategy 
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for identifying individuals with or at high risk for T2DM, without it being embedded in strong 
systems methodology, needs careful review. GPs appear to respond to the current health 
status of older individuals rather than their potential HR status due to increasing age. This 
appears to be a missed opportunity by GPs to educate older patients to the benefits of 
effective lifestyle approaches for a wide range of conditions and the importance of annual or 
bi-annual screening for T2DM. Unfortunately, it is likely that the time limits under which GPs 
work in Australia are restricting the possibility for implementing a consultative approach to 
chronic disease prevention and self-management. The length of time for a standard GP 
appointment is 10-15 minutes (www.betterhealth.vic.gov.au). 
Although the AUSDRISK risk assessment tool has been available since 2008, it has rarely 
been utilised by GPs and other healthcare practitioners as part of an opportunistic screening 
process for identifying those individuals with or at high risk for T2DM. The AUSDRISK 
highlights the range of factors that influence risk for T2DM. The lack of AUSDRISK use is a 
further missed opportunity to educate individuals on the wide range of risks for developing 
T2DM and they remain generally unaware of the impact of older age on the risk for T2DM 
(Johnson et al., 2015, Laws et al., 2012, Vita et al., 2016). 
With regard to the estimated 5–10-year latent period in the development of T2DM from 
preDM, consideration of preDM/T2DM screening on a routine basis for older age adults from 
age 60 years onward would be warranted. This timeframe for T2DM screening could be 
similar to the 5-yearly Australian bowel cancer screening (55–70 years) and bi-annual breast 
cancer screening (50–74 years) (Australian Government). 
 Conclusion 
To my knowledge, the AUSDRISK has not been used in Australia in a systematic manner as 
the first step in a targeted community-based screening procedure in a cohort of older 
individuals, and to follow them through to biomedical assessment. The aim of this study is to 
determine the feasibility (distribution), acceptability (uptake) and effectiveness (finding HR 
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and T2DM) of implementing the AUSDRISK specifically to this high risk group of community-
living adults aged 60 years and older, with follow-up biomedical assessment if 
recommended, in a real world T2DM screening scenario (Wareham et al., 2011) for older 
age individuals in Tasmania. 
 Implementation project 
• The AUSDRISK was implemented as recommended by NHMRC National 
Evidence based Guideline for Case Detection and Diagnosis of Type 2 Diabetes 
for T2DM screening in the young-old adult cohort (60 years and older) in 
Tasmania, Australia  
• Determined the feasibility and acceptability (distribution and uptake) of 
implementing the AUSDRISK in a real world setting of older adults   
• Determined the effectiveness of the AUSDRISK for identifying older adults with or 
at HR for developing T2DM 
• Documented the follow-up the actions of those assessed as HR and the actions 
of their GPs in implementing a biomedical assessment of those older individual 
assessed as High Risk on the AUSDRISK 
• Documented the facilitators and barriers to community-based screening of older 
adults by following the National Evidence based Guideline for Case Detection 
and Diagnosis of Type 2 Diabetes for older adults with or at High risk for type 2 
diabetes 
 Project methodology 
This study had two main phases. Phase 1 comprised the recruitment and completion of 
AUSDRISK by older individuals via either a Direct approach (health services) or an Indirect 
(mail-out) approach, with an invitation for participants to voluntarily self-assess their risk for 
T2DM by completing the AUSDRISK and to follow the AUSDRISK recommendations for their 
assessed level of T2DM risk. Phase 2 comprised documentation via a survey and recording 
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via semi structured interviews, focusing on the follow-up actions of the participants assessed 
as HR; their GP actions; and the HR participants’ biomedical assessment results (Diagnostic 
category only: Normal; EBG;T2DM). 
 Eligibility 
The primary eligibility requirement for participants recruited for this study was to be aged 60 
years or over. Exclusion criteria for Direct recruitment of individuals via the health service 
settings included previous diagnosis of diabetes, cardiovascular diseases or neurologic 
diseases that could compromise an individual’s ability to participate in the study; any 
admissions for community palliative care treatment at home; or an inability to reliably 
understand the English language, even with assistance. The only exclusion criteria for those 
recruited via SC mailout was a diagnosis with any form of diabetes. 
 Recruitment 
This AUSDRISK screening study was conducted over a 6-month period. It utilised a cross 
sectional survey of older general community members using the AUSDRISK questionnaire 
with a follow-up survey of those assessed as HR to document their actions (re biomedical 
assessment) on being advised of their HR status. There were two methods of recruitment. 
Direct recruitment (face-to-face) with screening being conducted in two health care settings 
in Southern Tasmania over a 6 week period (within the 6-month period): a community health 
centre (public health) servicing a low socio-economic status (SES) outer metropolitan 
community and two metropolitan optometry practices (private health). Indirect recruitment 
(mail out) and screening utilised three State Government statewide Seniors Card (SC) mail-
outs to access older individuals aged 60 years and over. At the time the project was 
conducted (2014–15) there were over 96,000 older Tasmanians recorded on the SC 
database with 450–500 new/renewed cards mailed out every 4-6 weeks.  
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 Direct recruitment 
Direct recruitment was achieved via, health professionals or clinical admission staff inviting 
individual adult outpatients to complete an AUSDRISK as an assessment of their risk for 
T2DM not a diagnosis of T2DM (diagnosis only via blood test ordered by a GP. Participation 
was voluntary. Informed consent was obtained. The process for completing the AUSDRISK 
was explained and assistance offered for waist measurement. Those who scored HR (12 
points or more) were invited to complete a follow-up survey (by phone or email) in 5-6 weeks 
to advise what measures they had taken towards having a biomedical assessment of their 
blood glucose level. Completing a follow-up survey was voluntary. If agreeing, participants 
provided their preferred contact details. 
 Indirect recruitment 
Indirect recruitment was achieved via three Seniors Card mail-outs over a 6-month period. 
Permission was granted to utilise only three mail-outs.  With each mail out, in addition to the 
SC, the recipients received an AUSDRISK, an information/instruction/consent form, an 
invitation to self-assess their diabetes risk status and a reply-paid envelope to return 
documents. The documentation also included an invitation specifically for those who self-
scored HR on the AUSDRISK to participate in a short follow-up survey and, if agreeing, to 
provide additional written consent, contact details and a request to return all documentation 
in the reply-paid envelope. 
 HR follow-up survey 
A short follow-up survey offered to those who scored HR was conducted 5-6 weeks after 
completion of the AUSDRISK, by phone or email. The survey comprised 8 questions relating 
to the HR participants’ follow-up actions after completion of the AUSDRISK including their 
attendance/non-attendance at a GP practice for biomedical assessment and if attending, 
their GP’s actions and recommendations and blood test results indicating their current 
glycaemic status. As part of the follow-up survey, HR participants were invited to comment 
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on their prior awareness of AUSDRISK and on the questions contained in the AUSDRISK 
risk assessment questionnaire. 
 Data recording 
De-identified quantitative data was recorded on Excel spreadsheets from the 
information/consent forms and online survey forms. De-identified qualitative data was 
compiled from paper-based standardised records of the interview for the follow-up survey 
and from paper-based records of the participating health professional and administrative staff 
and recorded on Excel spreadsheets. All data was kept securely as per requirements in the 
Tasmanian Health and Medical Human Research Ethics Committee documentation for data 
storage. The data  was kept in locked cupboards/filing cabinets with access only via a key 
held by one designated person at each site and by researcher, Elizabeth Bingham. 




In this chapter, the philosophical viewpoint, theoretical underpinning, ethical considerations 
and the rationale for the methods utilised in this research will be addressed. In addition, the 
methods utilised in developing the Literature Review and the AUSDRISK research project 
will be discussed. 
The AUSDRISK Assessment Tool has been available since 2010, and is recommended by 
Australian Medical Guidelines to be used as the first step to identify those at HR when 
screening for T2DM. The AUSDRISK has had limited use by GPs (Wong et al., 2011) or in 
health promotion (Diabetes Australia, 2017a). This study aimed to take a pragmatic real-
world approach (Glasgow et al., 2013 ) to disseminating the AUSDRISK within the older age 
cohort in Tasmania, Australia. In addition, the study was designed to identify any stakeholder 
issues that may be negatively impacting on the use of AUSDRISK as the first step in T2DM 
screening as recommended by the NHMRC Guidelines for the Case Detection and 
Identification of Type 2 Diabetes (Colagiuri et al., 2009c). By taking a comprehensive 
approach, information may become available to drive quality improvement (Glasgow et al., 
2013 ) in screening for T2DM, particularly in the older age group. 
 Epistemology 
In scientific research there are two major paradigms used to determine what is knowledge 
and how it may be established, investigated, ratified and viewed. The two paradigms – 
empiricism and constructionism are different in perspective. 
From the perspective of empiricism, which is the foundation of positivism – reality/knowledge 
is viewed as universal, objective, quantifiable and replicable. Therefore, from this standpoint 
it is argued that reality is the same for everyone and via the application of science, that 
shared reality can be identified. Research based on a positivism paradigm may utilise a 
quantitative approach. 
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As opposed to positivism, the basic premise of the constructionist approach is that reality is 
socially constructed by and between the persons who experience it (Gergen, 2015). 
The constructionist view is that reality is a consequence of the context in which the action 
occurs and is shaped by the cultural, historical, political and social norms that operate within 
that context and time. As such, reality can be experienced quite differently for each 
individual. 
The constructionist approach views the individual as a “sense maker”, in that each individual 
seeks to understand or make sense of the world from their own experience. Social 
constructionism (Gergen, 2015) provides a different perspective from which to view the world 
that allows for the unique differences of individuals to influence their perception of reality, 
whilst at the same time, permitting the essential “sameness” that unites human beings to be 
identified (Andrews, 2012). Research based on a constructionist paradigm may utilise a 
qualitative approach. 
A methodological movement – Pragmatism – which addresses elements of both the 
positivism and constructionism approaches has emerged to overcome the quantitative-
qualitative dichotomy and reduce the tensions between these different paradigms (Glasgow 
et al., 2013 , Teddlie et al., 2010). Multimethod research is a pragmatic comprehensive 
approach which is utilised frequently in health science research to gain a greater 
understanding of the complexities within health science and address questions that may 
have not been fully answered by either quantitative or qualitative approaches implemented 
alone. A multimethod research design may be quantitatively or qualitatively driven with the 
alternate approach providing the supplementary material. 
 Multimethod research 
The multimethod research used in this study was a quantitatively-driven approach/design 
with qualitative data added to supplement and improve comprehension of the quantitative 
results. A key characteristic of the multimethod approach is the capacity for integration at all 
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levels of the research study from design level through to the methods level and finally 
integrating interpretation and reporting of results. 
In 2010, Tashakkori & Teddlie (Teddlie et al., 2010) identified seven reasons often given for 
using a multimethodology approach. 
1. Complementarity – to integrate two different but connected answers to a research 
question: one reached via a quantitative approach and the other by means of a 
qualitative one. 
2. Completeness – to gain a greater understanding of the phenomenon under 
investigation by merging qualitative and quantitative findings. 
3. Development – to use the first phase of the study to obtain research questions, 
data sources or sampling frameworks for the second phase of the study. 
4. Expansion – as in “development” but with the aim of elaborating on the information 
obtained in the first phase of the study. 
5. Confirmation – to determine the integrity of the inferences attained from the study 
by means of integrated methods. 
6. Compensation – to compensate for the weaknesses of one method via the 
strengths of the other. 
7. Diversity – to compare and contrast divergent representations of the same 
phenomenon. 
The choice of the multimethod approach in this research was triggered by aiming to achieve 
complementarity, completeness, development, expansion and confirmation in relation to 
implementing the Type 2 Diabetes Risk Assessment Tool (AUSDRISK) (Chen et al., 2010) 
for community-based screening to identify older age individuals with undiagnosed T2DM or 
being at High Risk of T2DM. The multi-method approach as described by Fetters et al., 
(2013). 
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The multimethodology structure for this study was explanatory sequential at the design level, 
then via multi-stage inputs from each of the recruitment settings. Quantitative analysis of the 
first stage (Phase 1) will allow for identification of the number of older individuals who scored 
High Risk (HR cohort) on the AUSDRISK. In the second stage (Phase 2), this HR cohort will 
then form/build the next database to complete a follow-up survey which will expand the 
quantitative data collected in Phase 1, and document additional qualitative data on beliefs 
and attitudes towards screening for T2DM risk. The quantitative data and qualitative data will be 
integrated at the interpretation and reporting levels. A narrative approach will be used at the final stage 
of the interpretation and reporting level (Fetters et al., 2013)..  
 
3.1.2 Cross-sectional survey. 
A cross-sectional study design Busk (Busk, 2014) was chosen for a number of reasons. This 
research study was a population-based survey to gain a snapshot of a range of older 
persons aged 60 years and over (excluding those with diagnosed diabetes) with respect to 
their risk for T2DM as assessed by their results on the AUSDRISK. The survey was a 
community-based one-off presentation/exposure of AUSDRISK. Further implementation of 
AUSDRISK in this cohort was dependent on the success of finding those with or at HR for 
T2DM (outcome). As such it was a pilot study by solely using an older-age cohort, the two methods 
of distribution, and the resultant uptake and completion of the AUSDRISK. The findings of which could 
be used in future public health screening for T2DM in older age individuals and developing T2DM 
prevention activities relevant to the older-age group. Following the distribution of AUSDRISK, the 
actions of those older individuals at HR towards determining their current glycaemic status were 
recorded via the follow-up survey questions (on line or via phone).  
3.1.3 Quantitative and qualitative components of the multimethod design 
The quantitative component of the multimethod design included: the initial participation rate 
of older individuals invited to assess their risk for T2DM by completing the AUSDRISK; the 
number who scored HR, and the number at HR who completed the full screening process to 
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biomedical assessment. In order to sample a wide range of community-dwelling older adults, 
three different settings were utilised to access and recruit older-age individuals. Due to Ethics 
commitments the study was required to additionally offer completion of the AUSDRISK to 
adults aged 50 years and above in the health service settings. The first setting was a public 
health integrated community health centre providing individual or multiple allied health 
services for community members of all ages for a short period to improve their functionality. 
The second setting comprised two private optometry practices used by the older community 
for maintenance of health and well-being (e.g. review of eye health status and prescription of 
lens to improve visual acuity). The third setting was an age-related statewide mail-out service 
for the Seniors Card (Australian Government, 2019b) available to all individuals 60 years and 
over who are not employed for more than 20 hours per week. This mailout service was 
chosen to achieve statewide distribution of the AUSDRISK which had the potential to reach 
those individuals who were not regularly accessing medical/health services. 
The qualitative component of the multimethod research design complemented the 
quantitative component, by utilizing multiple choice sections in the survey, and a semi 
structured interview utilizing the survey questions, via phone.  These methods, and 
particularly the latter, elucidated the HR individuals’ experience in participation (voluntary) in 
a community-based T2DM screening initiative; their knowledge of T2DM and its risk factors; 
their knowledge of the AUSDRISK as a risk assessment tool for predicting T2DM risk, and 
their knowledge of the subsequent steps, that must be completed for those identified at HR 
to have their glycaemic status biomedically assessed by a general practitioner (GP). 
3.1.4 AUSDRISK assessment tool 
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) was developed in 2008 
by the Baker IDI Heart and Diabetes Institute on behalf of the Australian, state and territory 
governments, as a screening tool to identify those at high risk of developing T2DM (Chen et 
al., 2010). It was based on the findings nationally from approximately 6,000 adults who had 
participated in both the original Australian Diabetes Obesity and Lifestyle study in 1999-2000 
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– AUSDIAB (2000) (Dunstan et al., 2002a) and the 5-year follow-up AUSDIAB-2 (2005) 
(Chen et al., 2011) study. In development of the AUSDRISK, a range of factors was 
considered for inclusion, including alcohol, smoking and obesity, but only the risk factors that 
were the best predictors of the development of T2DM were included in the score. The risk 
factors are age, gender (male), nationality (where born); family history of diabetes; being 
diagnosed with high blood glucose (including gestational diabetes mellitus); taking 
medication for high blood pressure; smoking; not eating vegetables or fruit daily; less than 
2.5 hours of physical activity per week; waist measurement (cm) (score adjusted for gender 
and height). Each factor is allocated a score (depending on its impact on risk for T2DM) and 
the Total Score is the sum of the scores of the individual risk factors. The AUSDRISK has 
been validated in three other Australian studies ((Dunbar et al., 2015, Dunbar et al., 2014, 
Malo et al., 2015) as a predictor of diabetes risk at 5-year follow-up and has been 
acknowledged internationally as a valid and reliable pre-screening test to identify people at 
HR for developing T2DM within a 5-year period (Kegne et al., 2014, Noble et al., 2011). 
 Methods 
 Literature search 
In consultation with a University of Tasmania (UTAS) research librarian, a series of literature 
searches were conducted using a systematic and comprehensive search strategy. These 
were completed and then updated first in 2017 and again in 2019. 
With the epistemological foundation of the research design in mind a detailed literature 
search covering both quantitative and qualitative elements in relation to T2DM screening 
processes, nationally and internationally, was undertaken to review the rationale, risk 
assessment procedures, the facilitators, and barriers to the uptake of health screening for 




 MeSH search terms 
Table 3.1 MeSH search terms 
MEDLINE CINAHL SCOPUS 
MeSH TERMS. 
Diabetes Mellitus, type 2 OR. 
Prediabetic state OR. 
Hyperglycaemia OR. 
Title/Abstract: 
Pre-diabetes OR type 2 
diabetes OR prediabetic OR 
prediabetes OR 
hyperglycaemia OR 






Risk factors OR. 
Precipitating factors OR. 
Title/Abstract: 











MeSH: no exp. 
Surveys and questionnaires 
OR. 
health status indicators OR. 
MeSH Terms: 
risk assessment OR. 
Title/Abstract: 
Screening OR. 





MeSH: no export. 
Aged OR. 
Title/Abstract: 
Older adults OR. 
Older age OR. 
Older individuals OR. 
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Concept 1: 
• Diabetes Mellitus, 
Type 2. 










• Health Screening. 
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 Search strategy 
The online databases US National Library of Medicine (PubMed), the Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), and Elsevier’s Abstract and Citation database 
(SCOPUS) were searched through the UTAS library database search function. Five concepts 
(groups of terms relating to each concept) were established using the Medical Subject 
Headings (MeSH) and key words – Diabetes Mellitus, type 2: prediabetic state: 
hyperglycaemia AND risk factors: precipitating factors AND asymptomatic: undiagnosed 
AND surveys and questionnaires: health status indicators: risk assessment: screening; risk 
assessment tool AND aged: older adults: people over 60 years: young-old: seniors. 
The search retrieved information for 1235 articles. After title scanning, 671 articles were 
selected as potentially relevant (subsequent titles to be added for updating the literature). 
Additionally, papers were identified through ancestral searches of bibliographies and cited 
research articles. Additional searches comprised hand searches and snowballing from 
references in articles already in hand, and via grey literature from government, non-
government sources and policy documents relating to risk factors, screening and prevention 
and management of T2DM and precursor preDM. 
 Inclusion/exclusion criteria 
Articles were included if they related to one of the following topics: 
• Type 2 diabetes and prediabetes 
o Pathophysiology – all ages; specifically, in the older age group 
o Prevalence – all ages; specifically, in the older age group 
o Complications and increased risk for other medical conditions 
• Screening Guidelines and policies 
o Screening interventions 
o Screening via medical practitioners 
o Screening via other health practitioners 
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o Non-medical/non-health screening interventions 
o Screening type – opportunistic, targeted, population 
o Screening – specifically older age cohort 
• Risk Assessment 
o Risk assessment tool prior to biomedical assessment 
o Assessment of known risks – biomedical 
• Qualitative impacts on participation and outcome of screening 
o Socioeconomic 
o Perception of diabetes risk 
o Diabetes awareness, Health literacy 
• Economic 
o Cost of screening 
o Cost of type 2 diabetes/prediabetes 
Articles were excluded if they: 
• pertained to non-multicultural populations 
• were in a non-English language 
• did not include risk assessment for the 60 -74-year age range 
• had a participant mean age of less than 65 years 
• pertained only to Type 1 diabetes, Gestational Diabetes Mellitus, LADA 
• examined genetic factors only. 
 Article selection 
The titles and key words section of the articles identified by the searches were examined, 
and those not on the topics for consideration were excluded. The abstracts of the remaining 
articles were read. Articles not based on the major inclusion criteria were excluded and any 
articles, which appeared potentially relevant, were kept for further examination. 
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The remaining articles were then examined fully (the whole text) for the specific topic 
relevance for which they would be used. The principles of PRISMA (Preferred Reporting 
Items for Systematic Review and Meta-Analysis) were used in determining the final content 
of the Literature Review. The PRISMA Flow Diagram (Figure 1) provides the visual 
representation of the decision-making procedure used to determine inclusion/exclusion of 
articles in this thesis. 
 Endnote compilation 
Once the combined search was complete for each database the references were saved in a 
single master folder in Endnote. 
Abstracts were further categorised within EndNote subheadings according to topic 
contribution for the Literature Review. 
 EndNote Keep Abstracts sub-categories 
1. Pathophysiology of T2DM 
2. T2DM prevalence 
3. Models of T2DM 
4. T2DM risk 
5. Guidelines/policies for T2DM screening 
6. T2DM risk assessment tools 
7. T2DM medical screening 
8. Screening in non-medical settings 
9. Prevention T2DM via screening 
10. T2DM screening for older individuals 
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11. Prevention preT2DM in older individuals 
12. Qualitative elements in T2DM screening 
13. T2DM awareness 
14. T2DM risk perception 
15. Socioeconomic impacts on screening 
16. Cost of diabetes 
17. Cost of screening 
18. Other screening models 
19. T2DM complications in older people 
20. Multicultural community cohorts. 
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 PRISMA flow diagram 
Figure 3.1 PRISMA Flow Diagram. 
 Data collection and analysis of results 
 AUSDRISK Assessment Tool (for information/instruction forms see 
appendices) 
The AUSDRISK is a 10-item, validated questionnaire that estimates an individual’s risk of 
progression to T2DM over a 5-year period (Appendix 1). The AUSDRISK comprises 
questions related to risk of developing T2DM based on age, gender, ethnicity, family history 
of diabetes, history of abnormal glucose metabolism, current hypertensive treatment, 
smoking status, physical activity, fruit and vegetable consumption and waist circumference. 
Each risk factor is apportioned a numerical score based on its impact on T2DM risk. The 
individual risk factor scores are added together to reach a total score. A total score of 12 
points or more indicates the individual is at High Risk (HR). Within the HR category there are 
Records identified through 
database searching 
PubMed (n = 158) 
CINAHL (n=45) 
Scopus (n=564) 
TOTAL = 767 
 
Additional records identified through 
other sources 
(n = 553) 
Records after duplicates removed 
(n =1320) 
Records screened 
(n = 1320) 
Records excluded 
(n = 571) 
Studies included in 
Literature Review 
(n = 749) 
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3 levels progressing from HR1 (12-15 points) = approximately one person in every 14 will 
develop T2DM in 5 years; HR2 (16-19 points) = approximately one person in every 7 will 
develop T2DM in 5 years; HR3 (20 points or more) = approximately one person in every 3 
will develop T2DM in 5 years. The AUSDRISK assessment tool provides an estimate of risk, 
not a diagnosis of T2DM. The purpose for using the AUSDRISK as the first step in a T2DM 
screening process, is for the AUSDRISK total score to first identify those individuals 
estimated to be at HR prior to implementing a biomedical assessment for confirmation/not of 
T2DM diagnosis or raised blood glucose levels but not at the level designated for T2DM. As 
such the AUSDRISK acts as a filter, to reduce the number of unnecessary blood tests 
(biomedical assessment) and target those individuals who, by their total AUSDRISK score, 
have shown there is a need for a biomedical assessment. This is particularly important as 
T2DM is a condition that has few specific symptoms to indicate a person’s blood glucose 
level. 
The AUSDRISK not only presents risk items with their risk score but also includes 
information (at the base of the pamphlet) regarding the individual’s estimated level of risk and 
advice on the follow-up actions that the individual is recommended to complete. Those 
individuals scoring in the HR category are advised to see their doctor about having a fasting 
blood glucose test. 
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Figure 3.2 Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK). 
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 AUSDRISK screening study introduction 
This AUSDRISK screening study was conducted during a 6-month period from May to 
November 2014 in Tasmania, Australia. 
Three settings were chosen to reflect a range of non-medical community settings in which 
the AUSDRISK might be implemented and outcomes assessed. Two settings were health-
related and comprised the Direct recruitment component of the study – a public health 
community integrated care centre and 2 optometry clinics within a private health optometry 
practice. The other setting was non-health-related mail out specifically for individuals over the 
age of 60 years who were eligible for a Seniors Card (SC) (Australian Government, 2019b). 
Individuals may apply for a SC if they are aged over 60 years, are retired or working for less 
than 20 hours per week. It is not related to the aged pension. At the time of the study over 
96,000 older Tasmanians had a SC. This number has increased to 106,000 in 2018–19 
(Australian Government, 2019b). New and renewed SCs are mailed to the recipients. 
Mailouts to 500 individuals occur every 6 weeks. Three SC mailouts covered the Indirect 
recruitment component of this study. Details of the settings are provided in section 3.3.1.4 
Phase 1 recruitment, settings and eligibility criteria. 
 Participating organisations – formal agreements 
The AUSDRISK trial received approval from the organisations (see Appendix 2,) in which the 
trial was implemented. There were limitations imposed by each of the sites. All prospective 
participants were to be advised that participation was voluntary and their details and all 
details were kept confidential. Implementation of the AUSDRISK was required to be within 
the normal duties of the staff of the health services and therefore may not be possible during 
very busy times. The manager of the community healthcare centre gave permission for the 
AUSDRISK to be implemented for all new adult out-patients (18 years and over) as part of a 
new patient assessment over a 2- month period only. New patients under the age of 50 years 
were advised that they were welcome to complete an AUSDRISK  but their scores would not 
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be used as part of the project. Similarly, the directors of the two optometry clinics agreed to a 
2-month implementation of the AUSDRISK only if all adult clients (18 years and over) who 
were having a full vision assessment (1-hour with pupil dilatation) could be invited to 
participate. Those who were under the age of 50 were advised that their results would not be 
used in the project. Participation was voluntary. The manager of the Tasmanian State 
Government Seniors Bureau gave permission to include the AUSDRISK project 
documentation in 3 mail-outs (500 per mailout) of new or renewed SCs over a 6-month 
period (See Appendix 2 for project documentation). 
 Staff training 
In the Community Health Centre (CHC) setting, Community Service Officers (CSOs) manage 
all the new patient admissions for the CHC. The CSO Team leader was designated and 
trained (training schedule see Appendix 2) to be the clinical/administrative coordinator of the 
AUSDRISK project. All CSOs were trained to introduce the AUSDRISK. On completion of the 
admission procedures and the AUSDRISK, the new patient progressed to their first treatment 
session. At a convenient point in the treatment session, the Allied Health Professional (AHP) 
reinforced the importance of knowing your diabetes risk status. If the patient had been 
assessed as HR, the AHP would briefly reinforce the importance of the patient attending their 
GP for biomedical assessment (Appendix 2). 
In the optometry practices, the optometrists were trained to introduce the AUSDRISK as they 
considered it opportune to discuss the importance of patients knowing their T2DM risk in 
relation to eye health. The optometrists introduced the AUSDRISK at a time deemed suitable 
in the full eye assessment consultation (Appendix 2), and then followed the same process, 
as described for the CHC, for those assessed as HR. The optometrists explained that 
optometry assistants’ duties did not include providing information in regard to eye health, and 
therefore it was not appropriate for them to be involved in the presentation of AUSDRISK. 
Recruitment and data collection protocols (Appendix 3). 
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 Phase 1 recruitment, settings and eligibility criteria 
In all settings, participation was voluntary. There were 2 methods of recruitment. Direct 
recruitment (face-to-face) of 217 participants was conducted in two health care settings in 
Southern Tasmania: a community healthcare centre (public health) and two metropolitan 
optometry practices (private health). Indirect recruitment via 3 state-wide mailouts (500 per 
mail out) to 1500 older adults was achieved by utilizing the State Government statewide 
Seniors Card (SC) mail-out services. 
Exclusion criteria for Direct recruitment of adult individuals via the health service settings 
were: 
• a previous diagnosis of diabetes (all forms) 
• cardiovascular diseases or neurologic diseases that would compromise the 
person’s ability to participate in the study 
• any admissions for community palliative care treatment at home and 
• inability to reliably understand the English language, even with assistance. 
Individuals aged under 50 years were invited to complete the AUSDRISK (as per service 
agreements with health services) but were advised that their results would not be included in 
the research project. The only exclusion criteria for those recruited via mailout was a 
diagnosis of any form of diabetes. 
 Direct recruitment process 
Clinical admission staff introduced the AUSDRISK to new patients as an assessment of their 
risk for T2DM, not a diagnosis of T2DM. Advice was provided on the importance and 
advantages of being aware of their risk status for T2DM. Each patient was advised that 
completion of the AUSDRISK was part of a research study by the University of Tasmania 
and as such, participation was voluntary. The need for consent was explained prior to 
commencement of the AUSDRISK. The process for completing the AUSDRISK was 
explained and assistance was offered for completion (not content). Those who scored HR 
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were reminded that the score indicated their risk for T2DM (not diagnosis) and that the 
recommendation on the AUSDRISK was that they attend their GP for a biomedical 
assessment (blood test) to check their blood glucose (sugar) level. 
Due to agreements with the health services, some new patients in the health services who 
completed an AUSDRISK were younger than 50 years. Health service staff advised these 
patients they would not be included in this study but should note the recommendations for 
their AUSDRISK score. 
 Indirect recruitment process via three Seniors Card mail-outs 
With each mail-out, in addition to the SC, the recipients received an invitation (see Appendix 
2) to self-assess their diabetes risk status; an AUSDRISK; an information/instruction/consent 
form providing written directions on completing the AUSDRISK (Appendix 2); and a reply-
paid envelope to return documentation. 
 Phase 2 – high risk follow-up survey 
High risk participants (from all recruitment settings) were invited to participate in a follow-up 
survey (by phone or email which ever they preferred) in 5-6 weeks to advise the researcher 
on the measures they had taken with reference to establishing their current blood glucose 
level. The 5-6 week timeline was chosen as being sufficient time for participants scoring HR 
to contact/not contact their GP (as per instruction on AUSDRISK Assessment Tool) for a 
biomedical assessment. Participation was voluntary and, if agreeing to participate in the 
follow-up survey, those at HR provided additional written consent, preferred contact details 
and returned all documentation in the reply-paid envelope. The survey comprised eight 
questions (in Appendix 3) relating to the HR participants’ follow-up actions after completion of 
the AUSDRISK including their attendance/non-attendance for biomedical assessment; if 
attending, their general practitioner’s actions and recommendations, and blood test results 
indicating their current glycaemic status. Those HR participants who chose to complete the 
survey online received an email with a direct link to the Survey Monkey format of the survey 
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(Appendix 3). Those who chose to complete the survey via a phone call had their responses 
recorded by the researcher who then transcribed the responses into the Survey Monkey 
format. 
All responses were analysed via the Survey Monkey format. As part of the follow-up survey 
there was an opportunity for HR participants who chose to complete the follow-up survey by 
phone to comment on their prior awareness of AUSDRISK, and on the questions and related 
points score contained in the AUSDRISK. 
 High risk follow-up survey 




Q1 Have you seen your GP about your HR AUSDRISK result? (Yes/No) 
If No, go to Q8 
Q2 When you saw your GP, did you have blood tests to check if you had T2DM? (Y/N) 
If no   go to Q6 
Q3 If you had blood tests, did the results show you had T2DM? (Y/N) If No, go to Q5 
Q4 If you were found to have T2DM on your blood tests, did the GP prescribe tablets to 
manage your T2DM? (Y/N) 
Q5 Did the GP advise changes to your lifestyle? (Y/N) 
Q6 If your blood tests showed no T2DM, did the results show pre-diabetes or high blood 
sugar? (Y; N; DK)  
Q7 Did your GP discuss lifestyle changes to reduce your risk for developing T2DM in the 
future? (Y/N) End 
Q8 Will you go and see your GP about your HR AUSDRISK result? (Y/N) End 
. 
 Data collection 
De-identified quantitative data were recorded from the information/consent forms and online 
survey forms (examples attached). De-identified qualitative data were compiled from paper-
based standardised records of interview for the follow-up survey, and from paper-based 
records of the participating health professional and administrative staff. 
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The follow-up survey was presented in Survey Monkey format to HR participants who 
requested email as their preferred option for receiving the follow-up survey. The follow-up 
survey information collected from HR participants over the telephone was transcribed into the 
Survey Monkey format for analysis of all information received via the follow-up survey. 
 Statistical analysis 
Descriptive data were entered into the STATA 12 (StataCorp. 2011. Stata Statistical 
Software: Release 12. College Station, TX: StataCorp LP), a data analysis and statistical 
software package and collated. For comparisons of groups, t-tests were used to compare 
continuous outcomes, and chi-squared tests for categorical outcomes. A P value of less than 
0.05 was considered statistically significant. Interactions, such as those between gender/high 
risk category/GP attendance, were tested by using log-binomial regression (Poisson 
regression model) and included cross-product terms in the model. 
The feasibility of implementing the AUSDRISK was assessed in Phase 1 by the uptake of the 
AUSDRISK achieved via the two recruitment methods (Direct/Indirect), and initial completion 
of the AUSDRISK, and in Phase 2, by comparing those assessed as High Risk who 
participated in the follow-up procedures, in comparison to those who did not. 
The effectiveness of the AUSDRISK was determined by the predictive value of the HR 
scores on AUSDRISK for identifying participants with a T2DM result on biomedical 
assessment and will be covered in the following chapters. 
 Ethics 
This study was supported and approved by all participating organisations and received 
Ethics Approval (H0013490) from the Human Research Ethics Committee (Tasmania) 
Network (Appendix 4). The Study received approval and funding from the virtual Tasmanian 
Academic Health Precinct Study (Appendix 5). 
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 Results Phase 1 
 Phase 1. Distribution and uptake of the AUSDRISK by older adults 
in 3 different community settings 
 Introduction 
In the previous chapter the methodology and methods for this study were covered in detail. 
This chapter describes Phase 1 of the study which includes distribution of the AUSDRISK in 
three different community settings and uptake of AUSDRISK by older individuals residing in 
the community. The purpose of this part of the study was to identify older individuals at High 
Risk (HR) for T2DM and examine any differences in the AUSDRISK uptake between the 
settings and participants. First, it was essential to establish the baseline characteristics of 
each setting, the method of AUSDRISK distribution and the age-range, number and gender 
of individuals participating. 
The AUSDRISK and the information/instruction/consent form was distributed in two health 
service settings over a 6-week period between May and November 2014 to new adult out-
patients at the Clarence Integrated Care Centre (public health), and to adults over the age of 
50 years having a full vision assessment at two optometry practices (private health). During 
the same period six-month period (May–November 2014) an AUSDRISK plus the 
information/instruction/consent form and a letter of invitation to participate in assessing their 
risk for T2DM was distributed to 1500 older adults aged 60 years and over, via three state-
wide Seniors Card mail-outs (500 per mail-out). The Tasmanian Seniors Card Program is 
part of a State Government initiative, conducted by the Tasmanian Government Seniors 
Card Bureau, and jointly supported by private enterprise. Currently in Tasmania there are 
over 109,000 registered Seniors Card holders, supported by more than 600 businesses that 
offer a diverse range of discounts on products and services. It is available to all older 
individuals 60 years and over who are either not working more than 20 hours per week or 
retired. The older adults who completed an AUSDRISK in the healthcare settings formed the 
Direct Recruitment cohort. Those older adults who responded to the Seniors Card mail-out 
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by completing the AUSDRISK and returning the information/instruction/consent form to the 
researcher, formed the Indirect Recruitment cohort. All older participants who scored HR on 
the AUSDRISK were invited to take part in a follow-up survey (by phone or email according 
to their preference) to report their actions to the recommendation (for further action) that was 
linked to their HR score on the AUSDRISK. At the time of the research there were many older 
adults in Tasmania who did not have access to the internet. Providing them with 2 options was utilized 
to mitigate large participation bias of only having replies from those who had internet access.  
The Phase 2 follow-up data is reported in Chapter 5. 
 Objectives 
The objectives of this phase were to document: the findings on distribution, participation, and 
completion of the AUSDRISK tool across 3 community-based settings; the demographics of 
the older age cohort and their initial responses to participating in self-assessment of their 
T2DM risk by completing an AUSDRISK, and the number and gender of participants who 
scored HR on the AUSDRISK by their HR level (HR1, HR2, HR3) and recruitment method 
(Direct or Indirect). 
 Methods 
Descriptive data were entered into the STATA 12 (StataCorp. 2011. Stata Statistical 
Software: Release 12. College Station, TX: StataCorp LP), a data analysis and statistical 
software package and collated. For comparisons of groups, a t-test was used to compare 
continuous outcomes, and a chi-squared test for categorical outcomes. A P value of less 
than 0.05 was considered statistically significant. 
The feasibility of implementing the AUSDRISK was assessed in Phase 1 by first, the 
distribution of the AUSDRISK achieved via the two distribution methods, and secondly, the 
initial completion of the AUSDRISK. 
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 Results 
 Settings and AUSDRISK distribution 
During the trial period May–November 2014, the AUSDRISK, along with an 
instruction/information/ consent form, was distributed to 1717 older adults residing in the 
community. As per agreement with the health service recruitment centres (CICC and 
optometry), the research project was required to offer the AUSDRISK to all adults 
irrespective of age if they met all other requirements of the study. 
At the Clarence Integrated Care Centre (CICC), 177 new adult out-patients were approached 
to participate in the study. Of those, 28 individuals had diabetes (type 1 or type 2) and were 
ineligible to participate in the study, 54 individuals declined participation, leaving 95 potential 
participants. Of these, 81 participants successfully completed the AUSDRISK and 14 
participants/individuals commenced the AUSDRISK but did not successfully complete and 
were excluded from the study. There were 5 adults who successfully completed the 
AUSDRISK and scored HR who were aged under 50 years (2 x 40-50 years; 2x 30-40; 1x < 
30). The initial participants who scored HR but were aged under 50 years were excluded 
from the HR analysis as they did not meet the age requirements of the study. This left 76 
eligible participants from the CICC. 
At the optometry practices, 40 adults were approached to participate in the study, and none 
refused participation. Thirteen of those approached had diabetes (type 2) and were ineligible 
to participate in the study, and of the remaining 27 individuals, 26 successfully completed the 
AUSDRISK and 1 commenced but did not complete the AUSDRISK. Within the group who 
successfully completed the AUSDRISK there were 2 adults (aged 49, 45 years) who scored 
HR but did not meet the age requirements of the study and were excluded from the HR 
analysis. This left 24 eligible participants from the optometry practices. 
Three Seniors Card mail-outs were utilised to invite 1500 individuals aged 60 years and over 
to participate in the AUSDRISK study. The mail-out initiative achieved a balanced statewide 
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distribution – 51% South; 45 % North/North West; 4% East Coast which is broadly 
representative of the state’s population. There were 293 responses received. Of these, 24 
individuals reported diagnosed diabetes and were ineligible to participate in the study and 67 
individuals declined participation.  No participant failed to successfully complete the 
AUSDRISK. Thus 202 potential participants were Indirectly recruited. 
After removal of ineligible participants, the number of potential participants was reduced to 
1645 with 169 in the Direct Recruitment cohort and 1476 in the Indirect Recruitment cohort. 
Of those remaining, 121 individuals declined to complete the AUSDRISK (54 individuals in 
the Direct recruitment group and 67 in the Indirect mailout group) and there was no response 
from a total of 1207 individuals from the Seniors Card mail-out. The AUSDRISK was 
attempted by 317 eligible participants, however 15 directly recruited participants commenced 
the AUSDRISK but did not satisfactorily complete. Thus, leaving a final total of 302 
AUSDRISK forms satisfactorily completed (Table 4.1). 
Table 4.1 Participant recruitment by Settings by AUSDRISK completion 
 Direct. 




Potential participants 217  1500  1717 
Invitees diagnosed with 
diabetes 
41  24  65 
Ineligible due to age 7 0 7 
Declined participation 54  67  121 
No active response to 
invitation  
0 1207 1207 
Eligible participants who 
attempted AUSDRISK  
115 202 317 
Incomplete AUSDRISK 15 0 15 
Final AUSDRISK completion 100  202 302  
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 AUSDRISK results by recruitment settings 
A final total of 302 (17.6%) participants formed the study group having completed an 
AUSDRISK with 100 (5.8%) directly recruited and 202 (11.8%) indirectly recruited. 
The AUSDRISK results indicated that 136 individuals had scored in the High Risk category 
(12 points or more); 154 individuals scored in the Intermediate Risk category (6-11 points) 
and 12 adults scored in the Low Risk range category (5 points and under). Those who 
scored in the Intermediate Risk or Low Risk categories were not included in the remainder of 
this study which addressed only those who scored in the High Risk category. The final High 
Risk group of 136 individuals comprised 37/136 (27.2%) individuals directly recruited and 
99/136 (72.8%) individuals indirectly recruited and formed the Study Group (Table 4.2). 
Table 4.2 AUSDRISK results by Recruitment settings 
 DIRECT INDIRECT TOTAL 
AUSDRISK completion  100  202  302  
Study Group    
High Risk (HR) (≥12 points) 37 99  136 
Intermediate Risk (IR) (6-11 points) 51  103  154  
Low Risk (LR) (5 points or less) 12  0 12  
 
 HR participants by age range 
The ages of the 136 HR participants ranged from 50–85 years with a mean age of 65.4 years 
and a standard deviation of 6.9. The age range for HR participants directly recruited was 50–
85 years with a mean of 65.0 years. For those HR participants indirectly recruited the age 
range was 60–82 years with a mean of 65.5 years. 
Increasing age is a major non-modifiable risk factor for T2DM. This is reflected on the 
AUSDRISK by the AUSDRISK points score for age increasing by 2 points for each age 
group, commencing at 0 points (under 35 years); 2 points (35–44 years); 4 points (45–54 
years); 6 points (55–64 years) and 8 points (65 years or over). As the commencing age for 
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our older age cohort was fifty years, the first age range score was 4 points (50–54 years). 
The distribution of age ranges in the 136 participants who scored High Risk were; 4 
participants (50–54 years); 59 participants (55–64 years) and 73 participants (65 years or 
over) (Table 4.3). 
Table 4.3 Age-related (AUSDRISK points) by HR participants  
Age related (AUSDRISK points) HR participants  
50–54 years (4 points) 4  
55–64 years (6 points) 59  
65 years or over (8 points) 73  
TOTAL 136 
 
Within the Direct recruitment group of 37 HR, 11 were aged 50-60 years, and 26 were aged 
60+ years. Of the 11 aged 50-60 years, there were 4 x HR1; 4x HR2 and 3 x HR3. Within the 
full HR group of 136 (Direct and Indirect), 8.0% were aged between 50-59 years, and 92.0% 
were aged 60 years and over. Distribution of HR scores was 64 x HR1; 48 x HR2; 24 x HR3. 
 Distribution of high risk score 
The distribution of individual HR scores for older adults in this study ranged from 12 to 31 
points, with a mean of 16.2 points and standard deviation 3.7 points. The HR scores for the 
37 directly recruited participants ranged from 12–24 points; mean = 16.7. For the 99 
indirectly recruited participants the range was 12–31 points; mean = 16.0 points. For the total 
HR cohort, the mean score was 16.2 points. 
 Family history of diabetes 
A family history of all forms of diabetes, that is an immediate family member or first/second 
degree blood relative (grandparent, parent, sibling) with diabetes, is another major non-
modifiable risk factor in increasing an individual’s risk for T2DM. In this study of 302 
participants who completed the AUSDRISK, 56 individuals (across all settings) reported 
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having a family history of diabetes. Within the group scoring High Risk, 54 HR participants 
(across all settings) reported having a parent or sibling with diagnosed diabetes (Table 4.4). 
Table 4.4 Family History by Participant and HR participant by recruitment setting 

















 Participants scoring high-risk were distributed across all settings 
Across all recruitment settings the distribution of AUSDRISK HR score levels (HR1–HR3) 
was consistent, that is in all settings the highest number of participants scored in the lowest 
HR level (HR1 12–15 points), and the smallest number of participants scored in the highest 
HR level (HR3 20 points and more). 
The gender distribution between the Indirect and Direct recruited groups showed there were 
more HR males than HR females in the Indirect recruitment (SC) at all High Risk levels. 
Whereas in the Direct recruitment (CICC & OPTOM) HR group, the gender balance was the 
reverse, with more HR females than HR males at each HR level. However, when the results 
of the two distribution methods were combined there were more males and females at each 
of the HR score levels and final total (Table 4.5). 
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Table 4.5 HR participants by HR Levels by Gender by Recruitment settings 




HR3 20pts+ TOTAL 
Direct Clarence Integrated 
Care Centre 
9 11 7 27 
 Gender 3M:6F 4M:7F 4M:3F 11M:16F 
 Optometry practices 8 1 1 10 
 Gender 1M:7F 1F 1F 1M:9F 
Direct 
Combined 
Combined CICC + 
Optom 
17 12 8 37 
 Gender 4M:13F 4M:8F 4M:4F 12M:25F 
Indirect Seniors' Card mail out 47 36 16 99 
 Gender 32M:15F 22M:14F 10M:6F 64M:35F 
TOTAL  64. 
36M:28F. 
M = 56.3% 
48. 
26M:22F. 
M = 54.2% 
24. 
14M:10F. 
M = 58.3% 
136. 
76M:60F. 
M = 55.9% 
 
 
 High-risk by gender by recruitment setting (Direct vs Indirect) 
A total of 37 HR participants (12 male and 25 female) were directly recruited from either 
Clarence Integrated Care Centre or the two optometry practices. There were 99 HR 
participants (64 males: 35 female) indirectly recruited via the Seniors’ Card mail-out. The 
Direct recruitment strategy achieved 100 of 169 (59.2%) of its potentially eligible participants 
successfully completing an AUSDRISK. In comparison the Indirect recruitment strategy 
achieved only 202 of 1476 (13.7%) of its potential participants successfully completing an 
AUSDRISK. However, in terms of numbers of participants who scored HR, the Indirect 
recruitment strategy with 99 HR participants surpassed the Direct recruitment strategy which 
had recruited 37 HR participants.(Table 4.6) 
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Table 4.6 Direct vs Indirect Recruitment of HR participants by gender 
Setting Male (%) Female (%) Total (%) 
Direct CICC and OPTOM 12 (32.4%) 25 (67.6%) 37 (27.2%) 
Indirect SENIORS’ CARD 64 (64.6%) 35 (35.4%)  99 (72.8%) 
Total 76 (55.9%) 60 (44.1%)  136 
 
Analysis of results from settings x gender distribution showed the gender distribution/balance 
in the Direct vs Indirect recruitment cohort was significantly different. Chi squared statistic is 
10.258 P value = 0.00014. However, interpretation of these data is difficult as the gender 
ratio of those who declined to participate was unknown. In total 136 older individuals scored 
High Risk. Of those, 108/136 provided written consent to be contacted in 5-6 weeks to 
complete a follow-up survey to record their actions to seek a biomedical assessment to 
confirm their current blood glucose level (Appendix 3). 
 Summary of findings 
Completion of Phase 1 showed both methods of distribution were feasible but uptake of the 
AUSDRISK was limited in health and non-health community settings. Of the 302 participants 
who completed the AUSDRISK, 136 (45.0 %) participants scored High Risk; 154 (51.0 %) 
participants scored Intermediate Risk, and 12 (4.0 %) participants scored as Low Risk. 
The initial percentage uptake of AUSDRISK (response rate) in the Direct recruitment group 
(59.2%) was greater than the response rate in the Indirect recruitment Seniors’ Card group 
(13.7%). This response differential is likely due to the method of initial recruitment with the 
Direct recruitment group who received a face-to-face presentation of the AUSDRISK by 
health service personnel. In addition, they were able to discuss any queries they had about 
the AUSDRISK and the benefit of knowing your diabetes risk. However, the face-to-face 
approach appeared not to have the same positive impact in recruitment via the optometry 
practices which provided the least number of participating clients in the recruitment phase. 
However, on completion of the AUSDRISK the Indirect recruitment via the Seniors’ Card 
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mailout generated 99/136 (72.8%) HR participants in comparison with the Direct recruitment 
via health services which generated 37/136 (27.2%) HR participants. Potential reasons for 
these different response patterns will be considered in Chapter 6 Discussion. 
Participants who scored High Risk were identified in all three recruitment settings. The 
distribution of AUSDRISK scores was consistent through all HR levels with the greatest 
number of participants scoring in the lowest HR level (HR1 = 12–15 points) and the least 
number scoring in the highest High Risk level (HR3 = 20 points or more). This result was 
consistent across all settings. 
In the total Indirect recruited cohort, there were equal numbers of females and males (101 
males and 101 females) who were eligible to participate. In the total Direct recruited cohort, 
there were twice as many females as males (68 females and 32 males) who were eligible to 
participate. However, in the HR cohort there were more males than females in total and at 
each of the HR levels (76 males and 60 females). The potential reasons for these differences 
will be discussed in the Chapter 6. 
Participants with a family history of diabetes were identified in all settings. In the full study 
cohort, 18.2 per cent had a family history of diabetes. In the HR cohort, the percentage of 
those with a family history was 39.7 percent. 
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Figure 4.1 AUSDRISK Distribution, participation and T2DM risk profiles. 
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 Results Phase 2 
 Major finding 
AUSDRISK had zero predictive validity for T2DM in HR older age cohort. 
The major finding in this study of screening for T2DM in older-age participants was that the 
AUSDRISK HR scores had no predictive value for T2DM (positive predictive value = 0). 
Elevated blood glucose (EBG) levels were found across all HR levels (HR1 = 10.0% (2/20), 
HR2 = 17.6% (3/18), and HR3 16.7% (2/12). There was no association between the older-
age participants’ HR score levels on the AUSDRISK and the diagnosis of EBG. Those who 
were biomedically assessed as having EBG had a risk score that was, on average, only 0.95 
units higher (P=0.50) than those at HR who were biomedically assessed as normoglycaemic. 
This major finding begs the question that if the AUSDRISK is not effective in identifying 
T2DM in older individuals, what is the purpose of addressing whether it is feasible to 
distribute and acceptable to complete an AUSDRISK for the purpose of case finding for 
T2DM. However, there were additional findings that influenced participation which are 
applicable for promoting T2DM literacy, health promotion and participation in future T2DM 
screening for the older age cohort. These findings will be addressed via the stated objectives 
of the study. 
 Introduction to Chapter 5 
The primary purpose of this component of the study was to discover if the AUSDRISK 
predicted whether older individuals, assessed as HR, had T2DM or preDM. In order to 
determine this outcome, the older HR individual needed to attend their GP regarding their HR 
score and for the GP to order a blood test to check their glycaemic status. This chapter 
covers the results of those participants assessed as High Risk (HR) for T2DM on the 
AUSDRISK who completed a follow-up survey reporting on whether they did or did not attend 
their GP for a blood test to confirm their blood glucose status (Refer Chapter 3 Methodology) 
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 Section 3.3.1.7 Phase 2 – high risk follow-up survey). The study also aimed to discover the 
actions of their GPs in determining the individuals’ blood glucose status. For those HR 
participants who attended their GP, the information in this chapter includes their GP’s actions 
in determining the individual’s current glycaemic status; each HR participant’s blood test 
result and the GPs’ directions to the HR participants subsequent to the blood test result – all 
this information was reported by the HR participant. In addition, the HR participants who 
completed the survey over the phone, had the opportunity (if they wished) to comment on 
their experience of completing an AUSDRISK, including the AUSDRISK questions, and 
provide their reaction to participating in this T2DM screening study generally. All analyses in 
Phase 1 and Phase 2 were pre-specified. 
 Objectives (in sequence of occurrence) 
The first objective of Phase 2 was to record and compare the number and details of HR 
participants who completed the follow-up survey, with those who did not. 
The second objective was to record the number and details of HR participants who 
completed the full screening sequence and compare these findings with those HR 
participants who did not. 
The third objective was to record the results of the blood test (as reported by the HR 
participants) and determine the predictive value of the AUSDRISK HR score level in relation 
to the HR participants’ glycaemic results. 
The fourth objective was to record the GPs’ actions on being advised by the participants of 
their HR AUSDRISK score (Did the GP order a blood test, or not?) and to record the GPs’ 
directions (as reported by HR participants) to the HR participants following their blood test 
results. 
The fifth objective was to record the free-text information provided by the HR participants via 
the follow up survey and a semi structured interview (using the follow-up survey format) for 
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those who completed the survey via phone.  HR participants were invited to report their 
knowledge of the AUSDRISK, their knowledge, attitudes and beliefs towardsT2DM and risk 
for T2DM, and their response to receiving their blood test results. This qualitative information 
was sought to complement/enhance the quantitative results and provide comprehensive 
direction for planning future studies on T2DM screening for older adults. 
 Methods 
The follow-up survey (available 3.3.1.8 High risk follow-up survey) provided single word 
responses (Yes, No, Don’t Know) to the survey questions which included GPs’ actions in 
response to participants’ AUSDRISK HR score and recommendation for a biomedical 
assessment of their current glycaemic status; blood test results and GP recommendations 
following the blood test result was available. The follow-up survey was presented online in 
Survey Monkey format. An email containing a link to the survey was sent to HR participants 
who requested email as their preferred option for completing the follow-up survey. The 
follow-up survey information collected from HR participants whose preferred option for 
completion of the survey was via telephone, was written (by the researcher) on the paper 
form of the survey and transcribed into the Survey Monkey format for analysis of all 
quantitative information received. 
The qualitative data on HR participants’ knowledge and beliefs about T2DM and their 
reaction to being advised of their biomedical assessment results was collected from those 
HR participants who completed the survey via telephone. Their responses were recorded on 
paper survey forms and transferred to an Excel spreadsheet. 
 Statistical analysis 
Descriptive data (quantitative) were entered the STATA 12, a data analysis and statistical 
software package and collated. For comparisons of groups, t-tests were used to compare 
continuous outcomes, and chi-square test for categorical outcomes. A P value of less than 
0.05 was considered statistically significant. Interactions, such as those between gender/high 
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risk level/GP attendance, were tested by using log-binomial regression (Poisson regression 
model) and included cross-product terms in the model. 
The feasibility of implementing the AUSDRISK was assessed in Phase 2, by comparing 
those assessed as High Risk who participated in the follow-up procedures, in comparison to 
those who did not. The effectiveness of the AUSDRISK was determined by the predictive 
value of the HR scores on AUSDRISK for identifying participants with a T2DM result on 
biomedical assessment. 
Due to the small number of free-text comments, no attempt at formal analysis of these was 
made, but a narrative approach was employed as per the methods of Fetters et al.(2013), 
allowing patterns to emerge from certain groups. These are elucidated in section 5.10. 
 Results of follow-up study 
 Phase 2 follow-up survey 
The screening results of this older age cohort (mean age 65.5 years) showed that 136 
individuals (76 males and 60 females) scored High Risk. Of those HR individuals, 79.4% 
(108/136) being 66 males and 42 females provided written consent to complete a follow-up 
survey in 5-6 weeks following completion of the AUSDRISK. When the 108 HR participants 
who had agreed were contacted by either email or phone (by the researcher) only 92 actually 
agreed to complete the survey. Overall, 92 of the 136 HR participants (56 males and 36 
females) completed the follow-up survey, and 44 (20 males and 24 females) did not. 
 Details of HR participants who completed/not completed the follow-up 
survey 
Of the 92 HR participants who completed the follow-up survey there were 11 HR participants 
(3 males and 8 females) directly recruited (CICC and optometry clinics), and 81 HR 
participants (53 males and 28 females) were indirectly recruited (Seniors Card mailout). 
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Within the Direct recruited group there were 3 HR participants (1 male:2 female) recruited via 
optometry clinics and 8 HR participants recruited via CICC (2 males:6 female). 
The distribution of HR score levels for the 92 HR participants who completed the follow-up 
survey was 42 HR1 (45.6%) participants (25 males:17 female); 32 HR2 (34.8%) participants 
(20 males: 12 female) and 18 HR3 (19.6%) participants (11 males :7 female). In this group of 
92 HR participants 44.6% (25 males:16 female) had a family history of diabetes and 55.4% 
(31 males:20 female) did not. (Table 5.1). 
Table 5.1 Details of HR participants who completed the Follow-up survey 
 Male Female Total 
Total 56  36  92 
Recruitment    
Direct 3  8 11 
Indirect 53  28  81 
High Risk Levels    
 HR1 12-15 25  17 42  
 HR2 16-19 20  12  32  
 HR3 >=20 11  7  18  
Family History    
No 31  20  51  
Yes 25  16  41  
 
 Analysis of completed follow-up study 
Comparisons between the HR participants who completed or did not complete the follow-up 
survey were analysed with relation to participants’ recruitment setting; age; gender; HR level; 
and family history. 
 Completion/non-completion follow-up survey by recruitment setting 
The follow-up survey was completed by 92 participants who scored HR. Of the 44 HR 
participants who declined to participate in the follow-up survey 26 HR participants had been 
directly recruited, and 18 HR participants had been indirectly recruited. There were 
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significant differences between the Direct and Indirect recruitment in terms of proportion of 
HR participants completing/not completing the follow-up survey. c2= 33.4, P = <.00001. 
(Table 5.2), with those in the Indirect recruitment group more likely to complete the follow-up 
survey. 
 Completion/non-completion follow-up survey by age 
The 92 HR participants (56 males: 36 female) who completed the follow-up survey had a 
mean age of 65.5 years (SD 6.1). The 44 HR (20 males: 24 female) who did not complete 
the follow-up survey had a mean age 65.1 years (SD 8.5). There was no significant 
difference in age between the two groups = 0.62 (t-test) n.s (Table 5.2). 
 Completion/non-completion follow-up survey by gender 
There were no significant differences in male/female gender distribution of 56 males and 36 
females who completed in the follow-up survey, compared to the 20 males and 24 females 
who did not complete the follow-up survey c2= 2.87. P=0.09 n.s (Table 5.2). 
 Completion/non-completion follow-up survey by HR levels 
The range of HR score levels of the 92 HR participants who completed the follow-up survey 
comprised 42 HR1; 32 HR2 and 18 HR3. The range of HR score levels of the 44 who did not 
complete the follow-up survey comprised 20 HR1, 18 HR2 and 6 HR3. 
There was no significant difference between the distribution of High Risk score levels in 








Completed survey Yes (%) Total  
 44 (32.4%) 92 (67.6%) 136  




 Male 20 (26.3%) 56 (73.7%) 76  
 Female 24 (40.0%) 36 (60.0%) 60  
Age     
Mean (SD) 65.1 (8.5) 65.5 (6.1) 65.4 (6.9) P= 0.62 
(t-test) 
n.s 




Direct 26 (70.3%) 11 (29.7%) 37  
Indirect 18 (18.2%) 81 (81.8%) 99  
High Risk 
Category 
   c2= 0.59 
n.s 
 HR1 12-1 20 (32.3%) 42 (67.7%) 62  
 HR2 16-19 18 (36.0%) 32 (64.0%) 50  
 HR3 >=20 6 (25.0%) 18 (75.0%) 24  
 Completion/non-completion follow-up survey by family history 
Information regarding a family history of diabetes was reported by 134/136 HR participants in 
Phase 1. Of the 92 HR individuals who completed the follow-up survey, 41 HR participants 
reported having a family history of diabetes and 51 HR participants either did not (49) or had 
not reported (2) having a family history. Of the 44 HR participants who did not complete the 
follow-up survey, 13 reported having a family history, and 31 did not have a family history. 
There was no significant difference (P=0.09) between completion/non-completion of the 
follow-up survey and the presence or absence of a family history of diabetes. (Table 5.3). 
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Table 5.3 Completed Follow-up survey by Family History 




Total c2 = 0.09 n.s 
No 31 51 82  
Yes 13 41 54  
 
 Results of GP attendance/non-attendance by HR participants 
Individuals who score High Risk on the AUSDRISK tool, that is, score 12 points or more, are 
advised, via the AUSDRISK, “to attend their GP for a fasting blood glucose test as they may 
have undiagnosed type 2 diabetes or be at high risk of developing the disease” (as per quote 
on the AUSDRISK). 
 GP attendance 
Of the 92 HR participants who completed the Phase 2 follow-up survey, 54.3% (50/92, 27 
males and 23 females) subsequently attended their GP for a blood test of their glycaemic 
status and 45.7% (42/92 29 males and 13 females) had not seen their GP by the time the 
follow-up survey was conducted 5-6 weeks after their completion of the AUSDRISK. Of those 
who had not attended their GP for a biomedical assessment, 19.6% (18/92) stated they 
planned to request blood tests when they had their regular annual or bi-annual appointment 
with their GP. Therefore, at the time of the follow-up survey 73.9% (68/92) HR participants 
had attended, or had stated an intention to attend their GP, and the remaining 26.1% (42/92) 
had not indicated an intention to see their GP about their HR score. 
 Attended GP by age 
Of the 92 HR individuals who completed the follow-up survey, 50/92 HR (27male: 23 female) 
with a mean age of 65.1 years (SD 6.0) had attended their GP, and 42/92HR (29 male: 13 
female) mean age 65.9 years (SD 6.2) had not attended their GP within a 5-6-week period 
when the follow-up survey was implemented. There was no significant difference in age 
between the attenders/non-attenders P=0.54 (t-test)n.s (Table 5.4). 
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 Attended GP by gender 
Of the 92 HR individuals who completed the follow-up survey, 54.3% (50/92) 27 males and 
23 females had attended their GP, and 45.7% (42/92) 29 males and 13 females, had not 
attended. There was no significant difference in male/female attendance or non-attendance 
at GP (P=0.14) indicating that gender did not have a significant impact on the frequency of 
GP attendances or non-attendances for a biomedical assessment of HR participants’ 
glycaemic status. c2 = 0.14 n.s (Table 5.4). 
 Attended GP by high risk level 
The distribution of HR levels of the 50 HR individuals who attended their GP comprised 20 
HR1 (13 males and 7 females); 18 HR2 (9 males and 9 females) and 12 HR3 (5 males and 7 
females). The distribution of HR levels of the 44 who did not complete the follow-up survey 
comprised 22 HR1 (12 males and 10 females); 14 HR2 (11 males and 3 females); 6 HR3 (6 
males and 0 females). 
The participants’ HR level did not influence attendance or non-attendance at the GP  
c2 = 0.38 n.s (Table 5.4). 
 Attended GP by family history 
Of the 50 HR who had attended their GP, 25 HR individuals reported having a family history 
of diabetes and 25 individuals did not or had not reported it. Of the 42 HR who had not 
attended their GP, 16/42 reported having a family history whereas 26/42 did not have a 
family history. There was no significant difference in presence or absence of a family history 
in attending a GP for a biomedical assessment c2 = 0.18 n.s (Table 5.4). 
 Attended GP by Direct/Indirect recruitment 
Of the 92 HR participants who completed the follow-up survey, there were 11 HR (3 males 
and 8 females) directly recruited via health services (CICC and optometry) and 81 HR (53 
males and 28 females) indirectly recruited via Seniors Card mail out. Of the 11 HR directly 
116 
recruited, 7 HR participants (7 x CICC: 0 x optometry) had attended their GP and 4 HR 
participants had not. Of the 81 HR participants indirectly recruited, 43 HR had attended their 
GP and 38 HR had not attended. There was no significant difference in percentage of 
attenders vs non-attenders within each Direct and Indirect recruitment setting c2 = 0.51 n.s 
and no significant difference within each of the three recruitment settings and GP attendance 
c2 = 0.33 n.s (Table 5.4). 
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Total 42  50  92  
Age     
Mean (SD) 65.9 (6.2) 65.1 (6.0) 65.5 (6.1) P=0.54 (t-test)n.s 
Gender    c2 = 0.14 n.s 
Male 29  27  56   
Female 13 23  36   
High Risk Category    c2 = 0.38 n.s 
HR1 12-15 22 20  42   
 HR2 16-19 14  18  32   
 HR3 >=20 6  12  18   
Family History    c2 = 0.18 n.s 
No 26  25  51  
Yes 16 25  41  
Recruitment    c2 = 0.51 n.s 
Direct 4  7  11  
Indirect 38  43  81  
Recruitment settings    c2 = 0.33 n.s 
CICC 3  7  10   
OPSM 1 0 1   
Seniors Card 38  43  81  
 
 GP attendance by gender by high risk score level 
There was a significant interaction between gender, HR score and GP attendance (test for 
interaction P=0.03). All interactions were determined by the Poisson regression method. The 
HR score level did not influence the behaviour of males to see their GPs (P=0.67), whereas 
for females, those with higher scores were more likely to attend their GP (test for trend 
P=0.002) with 100% GP attendance of females with a HR3 score level. (Table 5.5, Table 
5.6). 
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 GP attendance by HR males 
Analysis of the association between males in different HR levels attending their GP 
demonstrated that the HR risk score level for males was not associated with whether they 
attended their GP (P= 0.727) (Table 5.5). 
Table 5.5 GP attendance by male HR participants by HR score level 




Total P-value  
Total 29 27 56  
High Risk Category     
 HR1 12-15 12 13 25 reference 
 HR2 16-19 11 9 20 0.647 
 HR3 >=20 6 5 11 0.727 
 
 GP attendance by HR females 
Analysis of the association between females in different HR levels attending their GP 
demonstrated that there was a significant difference (P=0.002) between females in the HR3 
level who were significantly more likely to attend their GP compared to females in the HR1 
level. There was no significant difference between females in HR2 and HR1 levels (Table 
5.6). 
Table 5.6 GP attendance by female HR participants by HR level 




Total P-value  
Total 13 23 36  
High Risk Category     
 HR1 12-15 10 8 18 reference 
 HR2 16-19 3 8 11 0.131 
 HR3 >=20 0 7 7 0.002 
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 Conclusions from HR participant biomedical assessment results 
In 98% cases (49/50) of HR individuals presenting for biomedical assessment, the GP 
ordered a blood test (unspecified by most respondents) and in 70% cases the GP also 
provided lifestyle change advice (improved nutrition and increased exercise). One male 
participant (HR1) did not receive a blood glucose test, but did receive lifestyle modification 
advice. 
Results of biomedical assessment showed that no individuals assessed as HR on the 
AUSDRISK tool were diagnosed with T2DM; 14.3% HR individuals (7/49) were advised by 
their GP that their blood glucose level was elevated (elevated blood glucose, EBG) (5.5-6.9 
mmol/L) above the normal range, but not in the diabetic range (7 or above mmol/L) and 
85.7% HR individuals (42/49) were advised that their blood glucose level was in the normal 
range (below 5.5 mmol/L), i.e. normoglycaemic (NG) at time of testing (Table 5.7). 
There was no association between the HR score level on the AUSDRISK and the diagnosis 
of EBG c2 = 0.52 P = 0.77 n.s. Those HR participants who were biomedically assessed as 
having EBG had a risk score that was on average only 0.95 units higher (P=0.50) than those 
at HR who were biomedically assessed as normoglycaemic. 
The AUSDRISK risk scores of the 7 HR individuals diagnosed with EBG, were distributed 
across all HR levels– 2 x HR1; 3 x HR2 and 2 x HR3 (Table 5.7). There was no interaction 
between risk score level, gender and EBG result (P=0.48). There was no statistical 
association between type of screening recruitment (Direct/Indirect), and risk score level 
(P=0.37). There was no statistical association between HR score levels (HR1:HR2:HR3) and 
the resultant glycaemic status on biomedical assessment (P=0.77). However, with small 
numbers of participants, the ability to draw specific statistical inferences is reduced. 
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Table 5.7 HR participant biomedical assessment results (49/50*) 
 Gender Biomedical assessment results (%) x gender 
Glycaemic status Male Female EBG NBG EBG 
















HR = 49 
(27M: 22F) 






Note – No optometry participants attended for biomedical assessment. 
Note – *GP chose not to order blood test for one male (HR1). 
EBG = Elevated Blood Glucose (pre-diabetes). 
NBG = Normal Blood Glucose levels (normoglycaemia). 
HR1 – 2 EBG = 1 Male 63 years; 1 Female 75 years. 
HR2 – 3 EBG = 1 Male 67 years, 1 Male 76 years; 1 Female 60 years. 
HR3 – 2 EBG = 1 Female 60 years; 1 Female 70 years. 
 HR participants’ reports of GP advice following blood test results 
Seven (7) HR individuals reported that their GP had advised them that they had elevated 
blood glucose but not in the diabetes range. However, as their blood glucose level was 
above the normal range, their blood glucose levels would be regularly monitored. They were 
also advised to make lifestyle changes (increase physical activity, eat a healthy diet and, if 
necessary, lose weight) to reduce their elevated blood glucose levels and reduce their risk 
for T2DM. No medication to facilitate reduction in blood glucose level was prescribed by their 
GPs for any individual having an EBG level. The 42 HR participants assessed as 
normoglycaemic were advised of this result. When asked by the researcher if they were 
advised to have regular blood glucose tests, all individually reported that their GP had not 
advised them that they should continue to have regular blood glucose testing. That is not to 
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say that GPs did not advise regular blood glucose monitoring but rather that the HR 
participants had no recollection of this. Of those assessed as normoglycaemic, 70.0% 
reported they were given lifestyle advice (improved nutrition and increase physical activity). 
It is acknowledged that the information gathered regarding GP behaviour was necessarily 
second hand, and therefore, subject to inaccuracies. However, the information reflected the 
HR participants’ comprehension of the GP information and directions presented. 
 HR participants comments and responses within the follow-up 
survey 
As part of the follow-up survey, HR participants who completed the survey via phone were 
given the opportunity to provide comments on the AUSDRISK and its questions in addition to 
providing responses (Yes, No or Don’t Know) to the specific questions on the follow-up 
survey. A total of 92 participants completed the follow-up survey. Of that total, 49 HR 
participants provided comment additional to their follow-up survey responses. By the time the 
follow-up survey was implemented 50 (50/92) HR participants had attended their GP. Of 
those 22 provided additional comments relating to the GP attendance and biomedical 
assessment. Additional comments were also received from 10 HR participants who had not 
seen their GP within the 5-6 week timeframe after AUSDRISK completion but reported at that 
time they intended to do so. In addition, 17 HR participants who chose not to attend their GP 
provided additional comment for their decision. There were 43 HR participants who indicated 
their actions for GP attendance/nonattendance by completing the follow-up survey but did 
not provide additional comment. Of those, 23 had attended their GP; 9 reported that they 
planned to attend their GP; 6 had chosen not to attend their GP and 5 HR participants did not 
respond (Table 5.8). 
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Table 5.8 HR participant responses/no responses within follow-up survey 
 Comments - Yes Comments - No Total 
Attended GP 22 23 45 
Intention to attend GP 10 9 19 
No intention to attend GP 17 6 23 
No response  5 5 
TOTAL 49 43 92 
 
Due to the small number of free-text comments, no attempt at formal analysis of these was 
made, but a narrative inquiry was employed as a tool for allowing patterns to emerge from 
certain groups as per the methods of Fetters et al., (2013). 
5.10.1 Comments made by HR participants who assessed as elevated blood 
glucose (EBG)  
The seven HR participants who were biomedically assessed as having elevated blood 
glucose levels provided comments in relation to being advised of their current blood glucose 
status. 
Comments from 2 male HR participants (Table 5.9) with EBG indicated that they and their 
GP were aware of their high risk status prior to completing the AUSDRISK and both HR 
participants had already made lifestyle changes, but remained at high risk. Comments from 
four of the other participants with EBG appeared to indicate that their AUSDRISK score 
triggered the first occasion their GP had ordered a blood glucose test and they were 
recommended to implement lifestyle changes (increase physical activity; follow a healthy diet 
and weight reduction if required) to reduce their risk for T2DM. None of these HR participants 
provided detail as to the implementation methods to achieve these goals. The female HR 
participant with rheumatoid arthritis voiced her concern at being unable to increase her 
physical activity. One female participant aged 75 years who scored HR1 reported that her 
GP had ordered an Oral Glucose Tolerance Test (OGTT). This may suggest that she had 
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had an FPG or HbA1c test initially (which she did not report) which was inconclusive, and the 
GP subsequently ordered an OGTT as a confirmatory test (Table 5.9). All HR participants 
with an EBG result were advised that their GPs would ensure they had regular blood glucose 
tests. No HR participant with EBG was referred to a diabetes prevention program nor to a 
Credentialed Diabetes Educator for diabetes education. 




Male, 63 years, score HR1 "My GP said my blood sugar was up a bit. He'd keep an eye on it. I 
have to exercise more and be careful what I eat" 
Female, 75 years, score HR1 "My GP said my blood sugar was up a bit. He ordered a test where 
you must drink a horrible sugary drink and then sit around for ages 
and they keep taking more blood tests. He said he would keep an 
eye on the situation". 
Male, 76 years, score HR2 "Some time ago my blood sugar was a bit highish. My GP put me on 
Metformin. I lost 10 kg weight. So, the GP stopped Metformin. My 
blood sugars are now OK. I eat healthy things now". 
Male, 67 years, score HR2 "I have borderline diabetes. My GP is aware of this and I have 
regular blood tests. Some of my family have diabetes". 
Female, 60 years, score HR2 "I'm not surprised that my blood sugar is up a bit. I need to lose 
weight" (notes on the data collection form indicated no FH; age 6 
points; therefore 12 points from other risk factors). 
Female, 70 years, score HR3 "I have rheumatoid arthritis. My GP said my blood sugar was high. 
He said I should eat healthily and get more exercise. That's difficult 
with rheumatoid arthritis. He didn't give me any medication for the 
high blood sugar". 
Female, 60 years, score HR3 " My GP recommended lifestyle changes – increase physical activity, 
improve nutrition and lose weight". 
 
 Comments from HR3 participants who were assessed as normoglycaemic 
Of the 12 HR3 participants who had a biomedical assessment, 2 were assessed as having 
EBG and 10 were assessed as normoglycaemic. Examples of comments from those 
assessed as normoglycaemic would suggest that their GP had already recognised their high 
risk for T2DM prior to completion of an AUSDRISK. Two male HR3 participants* indicated 
they had implemented lifestyle changes or already lead a physically active lifestyle, but their 
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risk remained high (HR3) for T2DM. Five HR3 participants had a family history of diabetes 
and by their comments acknowledged the impact this (FH) would have on their overall risk 
for T2DM (Table 5.10).  
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Table 5.10 HR3 Participants who were assessed as normoglycaemic 




*Male, 63 years, score 20 " I have regular blood tests because members of my family have type 
2 diabetes. I walk for 30 minutes every day. I do a lot of gardening. 
It's on a steep slope. I don't eat junk food. I take tablets for 
depression and helping me to sleep" 
Male, 66 years, score 21 "I'm not surprised that I scored high risk because my 2 brothers have 
type 2 diabetes". 
Female, 73 years, score 22 " I have blood tests every 6 months to monitor cancer and high blood 
sugar levels. My sister has insulin for her diabetes”. 
Female, 60 years, Score 22 "Some of my family have diabetes. I saw the GP, but he didn't say 
anything about changing my lifestyle". 
Male, 61 years, score 23 "I have had regular blood sugar tests since 1995. The test results 
have always been negative". 
*Male, 65 years, score 23 "I'm surprised at my HR score. I'm very active and do lots of house 
renovations and heavy work". 
Female, 65 years, score 23 Wrote on form – "score 23 but 8 for age" – “Some members of my 
family have diabetes”. 
5.10.3 Comments from HR participants who had not attended their GP  
Within the HR group who completed the follow-up survey there were 23 HR participants (6 
females: 17 males) who indicated that they would not make a specific appointment with their 
GP for a blood test based on their AUSDRISK HR score because they had regular/semi-
regular GP appointments and would mention their AUSDRISK score at their next 
appointment. 
Comments from 10 of these participants (3 female: 7 males) indicated they were already 
attending their GP either on a scheduled basis for monitoring of risk factors (high blood 
glucose, overweight) (Table 5.11) or were regularly seeing their GP for other health 
conditions (3 female: 10 male) (Table 5.12). Two male HR participants (scores HR1 and 
HR2)* chose not to attend their GP immediately as they considered they had already 
successfully implemented lifestyle changes (Table 5.11).  
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Table 5.11 HR participants who regularly attend GP for blood tests for T2DM risk will delay GP 
attendance to verify glycaemic status post AUSDRISK completion 
HR participant/score 
Regular GP attendance 
for blood tests for T2DM 
risk 
 
Comment on delay to attend GP to verify glycaemic status 
Male, 65 years, HR1 "I have regular appointments with my GP to manage my high blood 
pressure. I'll mention the AUSDRISK result when I see him next. Thank 
you for reminding me" 
Male, 60 years, HR1 "I have annual blood tests and they're due in 3 months, so I'll wait until 
then." 
Female, 60 years, HR1 "I've had tests for diabetes previously and they've always been OK. I 
have a few other problems. Recently I've put on weight so I'm trying to 
do regular walking" 
Male, 66 years, HR1 "My GP has already given me blood tests for diabetes. I've never heard 
about the AUSDRISK but I’ll mention it to the GP". 
Male, 61 years, HR2 "I see my GP regularly for blood pressure check. I remember filling in the 
"brochure”, so I'll speak to GP about it." 
Female, 65 years, HR2 "I have regular blood tests because both my parents have type 2 
diabetes" 
Female, 56 years, HR2 "My GP said my vitamin D levels were low, so he's put me on vitamin D 
capsules. When my vitamin D levels get back to normal, he'll re-test my 
blood sugar. My husband has type 2 diabetes, so I know the importance 
of a healthy diet and regular exercise". 
Male, 66 years, HR2 "I'm not going to see my GP straight away because I have annual blood 
tests in 3 months’ time." 
*Male, 71 years, HR2 "I have a blood test every 6 months. I had a heart attack 2 years ago. 
Since then I've lost 20kg by eating better and exercising." 
Male, 61 years, HR3 "I have had regular blood sugar tests since 1995. The test results have 
always been negative." 
 
Within the group of HR participants who had not attended their GP for a biomedical 
assessment prior to the follow-up survey but intended to do so, there were 10 HR 
participants who provided comment to explain the delay – four HR participants had forgotten 
to make an appointment and were pleased to receive a reminder, and the other six had 
regular GP appointments and planned to discuss their AUSDRISK result with their GP at the 
next scheduled appointment (Table 5.12). However, within this latter group of six persons, 
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two had seen their GP in the interim 5-6 week period but had forgotten/omitted to mention 
the AUSDRISK result to their GP.  
Table 5.12 HR participants who regularly attend GP for other health conditions will delay/not attend GP 
to verify glycaemic status post AUSDRISK completion 
HR participant/score 
Regular GP attendance 
for other health 
problems 
 
Comment on delay to attend GP to verify glycaemic status 
Female, 72 years, HR1 "I see my GP every week for injections for rheumatoid arthritis. I’d 
forgotten I completed the AUSDRISK. I'm seeing my GP next week, so 
I'll ask about testing for diabetes". 
Male, 77 years, HR1 "I see my GP regularly because I have back problems. I didn't think 
about the AUSDRISK score, but I'll mention it at my next visit". 
Female, 66 years, HR1 "I've just come out of hospital. I have blood tests every 3 weeks. I have 
asthma, epilepsy, atrial fibrillation. I'm trying to give up smoking, but I've 
been smoking for 46 years. My GP says diabetes is the least of my 
worries.” 
Male, 76 years, HR1 "I'm not going to see my GP about the AUSDRISK result. I have regular 
blood tests because I have cirrhosis of the liver." 
Male, 65 score, HR1 "I see my GP regularly, so I don't plan to follow this up immediately." 
*Male, 64 years, HR1 "No, I'm not going to see my GP. I had major surgery due to a helicopter 
crash. I feel much better since the operation. I'm physically fit and eat 
really well." 
Female, 61 years, HR2 " I haven't seen the GP yet. I've been busy with all the Xmas 
preparations. But I will go to the GP for a test". 
Male, 67 years, HR2 "I see my GP regularly about other health issues, but I haven't seen him 
about the AUSDRISK result.” 
Male, 60 years, HR2 "I had blood tests before I had an operation 4 months ago and 
everything was OK then. So, I won't go to see my GP.” 
Male, 72 years, HR2 "I have a regular appointment with the GP every 3 months " 
 
Male, 65 years, HR2 “I have a regular appointment with the GP every 3 months.” 
 
Male, 70 years, HR3 “Regular GP appt. Wife says he has every other ailment. Doesn't know 
whether checked for T2DM. Will ask at next GP appt” 
Male, 60 years, HR3 "I didn't realise I had to see a GP for a blood test, but I'll mention it the 
next time I go to the doctor." 
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 HR participants’ knowledge of risk factors for T2DM 
The 49 HR participants who provided comments were aware of the modifiable risk factors for 
T2DM such as overweight and obesity, poor diet, such as “eating too much sugar, and not 
getting enough exercise” (as per quote) a variation on a healthy lifestyle message as 
promoted by many government and non-government health organisations. Two HR 
participants commented they were restricted in the amount of exercise they could do 
because of rheumatoid arthritis and had not been advised of any medication that might assist 
them. Those with a family history of diabetes acknowledged they probably had a risk for 
developing diabetes, but that belief appeared to be based on personal experience, as per 
quote from one HR participants “although not everyone in my family has had diabetes”, 
rather than knowledge of the genetic-environmental complexity underscoring T2DM. Another 
HR participant who had experienced a family member with diabetes commented, as per 
quote “I hope I don’t get it as it was terrible” and then proceeded to provide details of 
amputation, blindness and kidney failure. 
When asked by the researcher, no HR participant reported knowing that ageing was a major 
risk factor for T2DM. 
Of those HR participants who provided additional comments, none could understand the 
AUSDRISK rating score for older age groups, which many expressed as “seeming unfair” 
because “you can’t change your age”. Two HR males were particularly dismissive, as 
evidenced by the following quote from a male aged 81 years – “So just because I’m a man, I 
only need 1 more point and I’ll be at high risk and there’s nothing I can do about it” (as per 
quote). The basis for his comment was the score for his age over 65 years (8 points) plus 
male gender (3 points) and one more point (e.g. not eating fruit and vegetables every day) 
would bring the total to 12 points (HR1). Another male HR participant questioned the validity 
of the AUSDRISK scoring for age and gender and refused to engage any further in the 
screening process, “So, according to AUSDRISK all old guys are going to get diabetes. 
That’s rubbish.” (as per quote). 
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 Summary of findings by objectives 
The first objective was recording the number and details of HR participants who did/did not 
complete the follow-up survey, in this way this study was able to demonstrate that the drop in 
participation at each step of the screening process, which had been noted in the earlier 
stages, continued during the follow-up survey and GP attendance. There were 136 
participants who scored HR; 108/136 consented to complete a follow-up survey; and 92/108 
completed the follow-up survey. 
Analysis of participation numbers and rates in the follow-up survey showed the numbers and 
rate of those recruited indirectly through the mail out was significantly greater than those 
directly recruited in health service settings.  However, there were no significant differences in 
age, gender, HR score level and family history between those who completed or did not 
complete a follow-up survey. 
The second objective was to record and compare the number and details of HR participants 
who completed the full screening sequence and compare these findings with the details of 
those HR participants who did not complete the full screening. There were no significant 
differences between those who attended or did not attend a GP for biomedical assessment 
by HR score levels (P=0.44), age (P=0.54) gender (P=0.14) or recruitment type (P=0.52: 
P=0.33). There was no significant difference in GP attendance by males who scored at 
different HR levels. Analysis of GP attendance by gender showed that HR score levels did 
not influence males’ behaviour to attend their GP. Analysis of GP attendance by females in 
different HR levels showed there was a significant difference between females in the HR3 
level who were significantly more likely to attend their GP compared to females in the HR1 
level. There was no significant difference in GP attendance between females in HR2 and 
HR1 levels. Overall the difference in pattern for GP attendance between HR males and HR 
females was statistically significant, with females more likely to attend their GP for biomedical 
assessment than males. 
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The third objective was to record the results of the blood test (as reported by the HR 
participants) and determine the predictive value of the AUSDRISK HR score level in relation 
to the older age HR participants’ glycaemic results. GPs ordered blood tests for 49/50 older-
age HR participants. The blood test results of the 49 HR participants showed that 42/49 
(85.7%) were normoglycaemic; and 14.3% (7/49) had EBG. No older-age HR participant was 
assessed as having T2DM. Therefore, the AUSDRISK HR scores in this study of older-age 
participants had a positive predictive value of zero for T2DM. Elevated blood glucose (EBG) 
levels were found across all HR levels (HR1 = 10.0% (2/20), HR2 = 17.6% (3/18), and HR3 
16.7% (2/12). There was no association between the older-age participants’ HR score levels 
on the AUSDRISK and the diagnosis of EBG. Those who were biomedically assessed as 
having EBG had a risk score that was on average only 0.95 units higher (p=0.50) than those 
at HR who were biomedically assessed as normoglycaemic. 
In summary, from a total of 136 HR older-age participants, 36.8% (49/136) completed the full 
screening process with no HR participant found to have T2DM,14.3% (7 HR participants) had 
EBG/preDM, and 85.7% (42/49) had a normal blood glucose level. Furthermore, there was 
no significant difference in HR score levels for those at HR who were biomedically assessed 
as having EBG/preDM, and those at HR who were biomedically assessed as having blood 
glucose levels in the normal range.   
The fourth objective was to record the GPs’ actions (as reported by the HR participants) on 
being advised of the participants’ HR AUSDRISK score, and note the GP directions to the 
HR participants based on their blood test results. Those with EBG were advised by their GPs 
that in future they would have regular blood glucose monitoring and needed to make lifestyle 
changes to reduce their risk for T2DM. No HR participant with EBG was prescribed 
medications to reduce blood glucose. Of the HR participants found to be normoglycaemic, 
70% were advised by their GP to make lifestyle changes. None of the HR participants 
assessed as normoglycaemic recalled being advised they should continue to have regular 
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blood glucose tests. This is not to say that some/all were not informed of this by their GP but 
rather they had no recollection of this. 
The fifth objective was to record the free text information provided by HR participants on their 
knowledge, beliefs and attitudes regarding the AUSDRISK, T2DM and risk for T2DM, 
including their response to their blood test results. A main finding related to this objective was 
that none of the HR participants was aware that older age was a major risk factor for T2DM. 
Secondly, approximately 90% had never heard of the AUSDRISK. Review of comments from 
HR participants who completed the follow-up survey and attended or did not attend for a 
biomedical assessment showed that close to 100% were already attending their GP on a 
regular basis, ranging from annual attendance (for a general health check) to fortnightly 
depending on need. Of those who provided comments 50.0% specified they had other 
illnesses for which they were attending their GP, and 50.0% had regular comprehensive 
blood tests which included assessment of blood glucose. The comments provided by 49/92 
HR participants indicated they had an established relationship with their GP and were guided 
by the GPs recommendations and directions. The close relationship between older adults 
and their GPs with regard to their health and in particular T2DM screening, prevention and 
management would suggest that participation in screening for T2DM and its precursor 
preDM would be best achieved through this established system. 
In addition, this study found  that older-age participants were not familiar/very unaware of the 
AUSDRISK tool. This made it difficult to estimate the impact  of this lack of knowledge of the 
AUSDRISK on the initial participation rate, and the follow through to complete the T2DM 
screening process. Earlier research (Lavielle et al 2014; Davey et al 2015) had shown that a 
HR score had the risk averse effect for those scoring HR by their not following through to a 
biomedical assessment.  
Using the AUSDRISK as the first step in T2DM screening in an older cohort was not an 
efficient process, in that many older individuals chose not to participate initially, and of those 
who scored HR, many chose to delay obtaining a blood test to verify their glycaemic status 
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until attending a pre-booked GP appointment sometime in the future. As the AUSDRISK was 
unfamiliar to most older participants, and preDM/T2DM have very few symptoms in the early 
stages,  they may well forget/or not consider necessary to mention their HR score to their 
GP.  
Overall, this study showed that older individuals’ knowledge of risks for T2DM is markedly 
lacking. As they are in a high risk group for preDM/T2DM due to their age, they would benefit 
from age-specific health information and health promotion aimed at having their risk for 




The research described in this thesis was undertaken, in 2014–15. At that time there had 
been no systematic implementation of the AUSDRISK as the first step in a T2DM screening 
program for identifying older individuals with or at HR for T2DM. Both the Australian National 
Health & Medical Research Council (NHMRC) Evidence-based Guideline for Case Detection 
and Diagnosis of Type 2 Diabetes (Colagiuri et al., 2009c) and the Royal Australian College 
of General Practitioners (RACGP) Guidelines for Preventive Activity in General Practice 
(Royal Australian College of General Practitioners, 2014) had recommended completing the 
AUSDRISK every 3 years as the first step in screening adults ≥ 45 years considered to be at 
risk (by their GP) for undiagnosed T2DM prior to biomedical assessment. However, a study 
by Wong et al., (Wong et al., 2011) found it was rarely used by GPs in Australia. As at 2019 
the guideline recommendations remain the same (Royal Australian College of General 
Practitioners, 2018) and the AUSDRISK is still rarely used by GPs. The AUSDRISK is 
available in print and on-line but not regularly publicised. The AUSDRISK is promoted for 
self- assessment annually in health promotion events such as Diabetes Week or World 
Diabetes Day by the non-government organisation Diabetes Australia and its state-based 
organisations. The AUSDRISK score has been used as a basis for identifying HR 
participants for short term state-based T2DM prevention programs for individuals in the 45-
74 year age range; mean 57 (9.6) years (Aguiar et al., 2015, Dunbar et al., 2015, Johnson et 
al., 2015, Malo et al., 2015) but no similar programs had, or subsequently have been 
conducted in Tasmania. 
Tasmania has the oldest population of any state/territory in Australia. As with many chronic 
health conditions the risk for, and occurrence of, T2DM increases with age. In 2014-15, 
Diabetes Tasmania reported that 26.9% of individuals newly diagnosed with T2DM were 
aged 70 years and over. The primary aim of this research was to determine the 
effectiveness, acceptability and feasibility, of implementing the AUSDRISK, in community-
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based non-medical healthcare and non-healthcare settings in Tasmania to screen older 
individuals aged 50 years and over for T2DM and identify those with undiagnosed T2DM or 
at HR for developing T2DM at an earlier age than was currently occurring. 
A real-world multi-methods strategy (Fetters et al., 2013) was chosen to capture the range of 
influences, both positive and negative, impacting on this AUSDRISK screening strategy 
particularly with reference to the older age cohort. In order to evaluate this complex primary 
aim, a series of linked objectives were implemented to reflect the sequential steps taken in 
this T2DM screening initiative. These objectives were, in sequence, to determine the 
uptake/initial interest shown by this age-specific cohort in assessing their risk for T2DM by 
completing an AUSDRISK. Next, to determine if those older individuals assessed at HR, 
continued in the screening process to attend their GP for a biomedical assessment, and, for 
those HR older individuals who did attend their GP, to assess the positive predictive value of 
the AUSDRISK HR scores, by comparing the participants’ HR score levels with their blood 
test levels (normal glucose level; elevated blood glucose; T2DM). Finally, to identify systemic 
(medical and non-medical) and personal factors which act as facilitators or barriers to 
implementing a community based T2DM screening process for older adults. 
However, as the major finding in this research was that AUSDRISK HR scores had zero 
positive predictive value for identifying T2DM in an older age cohort, this finding will lead the 
Discussion chapter. 
 Overall findings 
 Effectiveness of AUSDRISK 
The major finding in this T2DM screening research project, showed that no older age 
individual (mean age 65.5 years) assessed as HR on the AUSDRISK, was identified as 
having T2DM on blood glucose testing, 14.3% HR were identified as having elevated blood 
glucose (EBG) and 85.7% HR had a normal blood glucose level. There was no association 
between the actual HR score level (HR1; HR2; HR3) on the AUSDRISK, and the diagnosis of 
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EBG. Those who were biomedically assessed as having EBG had a risk score that was on 
average only 0.95 units higher (P = 0.50) than those assessed as HR who subsequently 
were identified as being normoglycaemic, on blood glucose testing. Older participants with 
Elevated Blood Glucose (EBG) levels were found at all HR levels from HR1 to HR3 and not 
just HR2 and HR3 as predicted by some Australian diabetes prevention studies using 
AUSDRISK HR cut-off points as the entry level for diabetes prevention programs (Dunbar, 
2017, Dunbar et al., 2015, Lee et al., 2018, Malo et al., 2015). At the time this research was 
conducted, this lack of association between HR score levels and blood glucose test results, 
was not expected. 
The AUSDRISK screening project was conducted according to the NHMRC Guidelines for 
the Case Detection and Identification of Type 2 Diabetes, with completion of an AUSDRISK 
as the first step in the screening process to identify those at HR prior to implementing a blood 
glucose test (Colagiuri et al., 2009c). To reiterate, the purpose of completing an AUSDRISK, 
as the first step in T2DM screening, is to first identify those at HR, prior to a GP determining 
to initiate blood glucose testing. This is considered an efficiency measure to overcome the 
expense of implementing a FPG or HbA1c blood test for all individuals over the age of 45 
years, who show evidence of being at HR for T2DM (Lee et al., 2018). 
In this research 44.2% older adults (mean age 65.5 years), were identified as being at HR, 
that is, scoring 12 points or more. This percentage of older individuals at HR was two-fold 
higher than the predicted percentage at HR (21.1%) when the AUSDRISK HR2³15 minimum 
score alone was used to classify the HR category in a modelled study by Lee et al (Lee et al., 
2018) based on participants aged 45–74 years with a mean age for men of 58.2 (9.5) years 
and for women 56.9 (9.5) years. 
Despite the higher percentage of individuals at HR (by AUSDRISK) in this study of older 
individuals, the resultant percentage of HR individuals shown to have EBG levels on 
biomedical assessment was consistent with results from other Australian T2DM screen and 
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prevention programs which, after eliminating individuals with diagnosed diabetes (all types), 
used the AUSDRISK to identify HR individuals (age range 45–74 years) for admission to 
T2DM prevention programs, (Dunbar et al., 2015, Malo et al., 2015). Those studies were the 
Melbourne (Victoria) Diabetes Prevention Study (Dunbar et al., 2012, Dunbar et al., 2015) 
and the Greater Green Triangle study in Victoria (Dunbar et al., 2014) where 84.8% of HR 
participants were found to be normoglycaemic and 15.2% had EBG on biomedical 
assessment. 
The decision to make a HR2 score 15/16-19 on the AUSDRISK (prediction of 1 person in 7 
HR developing T2DM within 5 years) as the minimum entry level to T2DM prevention 
programs was on a cost-efficient basis. The previous researchers did acknowledge that 
some individuals scoring HR1 may be missed (HR 1 = 12–15; with a prediction of 1 in 14 
developing T2DM within 5 years). However, my study found there was no association 
between the older-age participants’ HR score levels on the AUSDRISK and the diagnosis of 
EBG. Therefore, according to my findings of EBG/preDM at all levels of HR, to determine 
that those who scored HR2 and HR3 were likely to be at greater risk than an individual 
scoring HR1, may need to be reconsidered in relation to older adults. 
As stated in the introduction to Chapter 5, as the AUSDRISK had been found not to be 
effective in an older age cohort, there may be little point to continuing with the feasibility and 
acceptability of AUSDRISK in T2DM screening in older individuals. However, the findings in 
relation to these two essential components of screening are equally applicable to other 
T2DM screening practices. The benefit of taking a multi-method approach to this screening 
study has been the opportunity to evaluate the quantitative results in relation to the 
qualitative/subjective comments provided by the older HR individuals who completed the 
follow-up survey. Their comments provided valuable insight and clarification for the older age 
participants’ responses, attitudes and observed behaviour towards T2DM screening. 
Therefore, in order to examine the inter-related aspects of this research, the ongoing 
discussion will be presented in sections relating to each of the study’s objectives. Finally, a 
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discussion on the implications of this study’s findings for future policy and practice for T2DM 
screening, with or without utilizing AUSDRISK, for those in the young-old cohort, will 
complete the chapter. 
 Feasibility of distribution of AUSDRISK 
 Distribution 
This study found that the actual distribution of the AUSDRISK plus information/instruction/ 
consent form was feasible via direct distribution by local healthcare services and indirectly 
via a non-healthcare Seniors Card mailout. The direct healthcare service face-to-face 
presentation was more effective in initially recruiting older age individuals to complete an 
AUSDRISK than the Indirect method. In both the Direct and Indirect recruitment participation 
was voluntary. The high level of initial recruitment via direct AUSDRISK presentation in 
health services appeared to be due to the health service setting, with the opportunity for 
health service staff (if asked) to verify the purpose of the AUSDRISK and help with waist 
measurement (if requested). This direct interaction with a health service staff member was in 
addition to the printed material provided which explained the purpose and rationale for 
completing an AUSDRISK. The recipients of the AUSDRISK via mailout had the same 
printed information but not the verbal interaction face-to face with health service staff. In the 
planning stage this potential difference was acknowledged, as the study wished to determine 
if there were any differences in uptake of the AUSDRISK by the way it was presented to the 
potential participant. One reason for choosing the Seniors Card (SC) mailout service, apart 
from convenience and cost effectiveness, was that the SC mailout was an acknowledged 
and reputable service specifically for older age individuals and had been used previously for 
health promotion material such as Falls Prevention information. 
The initial participation numbers of individuals recruited through mailout to complete an 
AUSDRISK clearly indicated that, in future age-specific information about T2DM, age related 
risks for T2DM, explanation of “risk” as opposed to a diagnosis, and the benefit of knowing 
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your T2DM risk, would be needed to promote/encourage more participation of older 
individuals indirectly recruited. Recent articles by Harte et al, and Usher-Smith et al (Harte et 
al., 2017, Usher-Smith et al., 2017) on reasons why people do not attend the NHS Health 
Check programme and patient experiences of the NHS Health Check programme found 
there was insufficient communication targeted to the expected recipients, on the potential 
benefits for prevention and early detection of CVD/T2DM, along with the knowledge of 
purpose of the risk assessment tool/protocol, in order for screening to be effective. 
 Staffing issues for direct AUSDRISK distribution 
On completion of the research study, health care professionals in the Integrated Care Centre 
and in the two optometry practices who participated in implementing the AUSDRISK, were 
interviewed. In this post-research interview, the healthcare professionals expressed concern 
about the time taken for the AUSDRISK introduction and completion which reduced the time 
available for addressing the patient’s clinical needs for which they had attended the service, 
thus creating stress and inconvenience for both clinicians and patients. The time to complete 
an AUSDRISK and other risk assessment tools (Aujla et al., 2013, Stone et al., 2014) has 
been documented as a potential limiting factor in national and international T2DM prevention 
initiatives (Dunbar et al., 2015, Krass et al., 2007, Malo et al., 2015). 
During the planning phase of this study, time to introduce and complete AUSDRISK was 
discussed with the health professionals who appreciated the benefit of implementing the 
AUSDRISK and considered that there would be sufficient time and staff to introduce and 
have the AUSDRISK completed. In reality, this proved not to be the case. The administrative 
(in-take) staff in the Integrated Care Centre were found to be best suited to present the 
AUSDRISK within their usual new patient admission duties. The duty roles of the 
administrative staff in the two optometry practices did not allow their participation in 
presenting the AUSDRISK as this initiative came under the description of providing health 
services and, as such, was not allowed. This had not been anticipated as a difficulty during 
initial planning. Older-age participants took longer time to complete the AUSDRISK than 
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optometrists expected due to lack of familiarity with the AUSDRISK, which potentially 
impacted on the provision of optometry services. 
In terms of overall numbers of individuals approached to participate, there was only a small 
impact/reach via those attending the particular health services whether that be the Integrated 
Care Centre or the optometry practices. The ‘reach’ could be extended and standardised as 
part of a new patient assessment for all services in an Integrated Care Centre, but this would 
require a considerable systems management change and still remain vulnerable to local 
implementation issues. Most older participants recruited via optometry practices did not 
perceive optometry services as having a role in T2DM screening and identification, although 
optometrists are often the first health professional to note changes in the eye-health status 
indicative of prediabetes (personal communication with participating optometrist). Optometry 
services were considered by most clients as health improvement services for individuals in 
good general health. As an aside, people with T2DM are allocated with free Medicare-funded 
optometry services to ensure good eye health. It would appear that the general public is not 
aware of this service. The optometry settings had the lowest participatory rate of all the direct 
settings and this lack of knowledge regarding the role of optometry in T2DM prevention and 
management may account for the lack of interest in participation. 
The three Seniors Card mail-outs to 1500 (3 x 500) older adults was superior (to the direct 
healthcare implementation) in its equitable ‘reach’ statewide. Use of an established and 
regular mail-out system with specific access to the older age community had the potential to 
make the AUSDRISK available to a wide range of older adults, including those so-called 
‘hard-to-reach’ clients who may not be regularly accessing medical/health services. 
Unfortunately, this proved not to be the case, as will be discussed later in this chapter. The 
mail-out also had the advantage of being independent of demands on the staff and staff time, 
in health services. Furthermore, the mail-out had the potential to be linked to initial 
recruitment with other established Australian national health-screening mail-outs to older age 
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individuals, such as those for colorectal cancer(Cenin et al., 2014) and breast cancer 
screening,(Hersch et al., 2011). 
In Australia, the breast cancer screening and colorectal cancer screening programs use mail 
out notification and decision aids (Hersch et al., 2014, Hersch et al., 2011) to great effect, 
both to facilitate initial participation, and also as a reminder to those individuals who had not 
responded within a pre-set time. This approach is used in UK, US and European cancer 
screening and T2DM screening programs (Alberti et al., 2015, Essink-Bot et al., 2016, 
Wardle et al., 2016) (Khunti et al., 2015). However, the recipients of the AUSDRISK via mail 
out in this research did not have the opportunity to be reminded or encouraged to participate. 
Unfortunately, in order for this study to gain permission from the Tasmanian State 
Government to utilise three Seniors Card mail-outs for statewide distribution of AUSDRISK, 
the researcher was not permitted to know the names/addresses of recipients. The role of the 
Seniors Card bureau was to arrange the three mailouts and provide information on the 
geographic distribution of AUSDRISK across the state. Follow-up of recipients of the 
AUSDRISK was not part of the Seniors Bureau agreement. Under that agreement a reminder 
system could not be used to facilitate an increase in initial participation. Recruitment of 
participants in future studies would benefit from ensuring a reminder facility is allowed and 
included. In this research, subsequent contact could only be made with those HR participants 
who provided a separate signed agreement and contact details to participate in the follow-up 
survey, which followed the initial AUSDRISK completion. 
 AUSDRISK uptake/interest 
This study found that although the AUSDRISK was effectively distributed, the interest and 
initial response rate of this older age group to being invited to assess their risk for T2DM was 
limited. The overall uptake (Direct and Indirect) of the AUSDRISK in this study was 17.6 per 
cent. Although this may appear to be low, it was greater than the 8.6% response rate of the 
first MY-WAIST UK T2DM mailout study (Aujla et al., 2013) and comparable to the uptake of 
first mailout recruitment for the NHS Health Check program in 2009 (Gidlow et al., 2015, 
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Robson et al., 2016). The uptake was also comparable to the initial 18% uptake of the large 
baseline survey for The 45 and up Study in Australia in 2015 (Bauman et al., 2016). A low 
response rate to new initiatives when first presented has been noted in other international 
T2DM and CVD screening programs (Aujla et al., 2013, Eborall et al., 2012, Groenenberg et 
al., 2016, Groenenberg et al., 2015) and T2DM screening/prevention studies in Australia 
(Dunbar et al., 2015), and therefore it was not a surprising finding in this study. 
The impact of the difference in recruitment rates between the Direct and Indirect groups was 
somewhat reduced at a later stage in the screening process, when information became 
available from the HR follow-up survey and GP attendance. The results from those sources 
revealed that 37.0% HR responders recruited via the Seniors’ Card mailout had completed 
the follow-up survey and GP attendance, whereas only 15.9% of the HR participants invited 
via a health service completed the full follow-up to completion of survey and decision to 
attend/not attend for biomedical assessment. This latter finding would suggest that once the 
participants, recruited directly via face-to-face by healthcare staff, were removed from the 
personal connection, they reverted to more usual behaviour. The concept of social 
desirability bias, that is “to do the right thing”, may have been in evidence in the initial 
completion of an AUSDRISK when it was presented directly. If the participants’ health 
literacy was poor, the default position would likely be to cease any further involvement with 
follow-up. This pattern of behaviour has also been noted in the NHS Health Check 
programme (Usher-Smith et al., 2017). Whereas those indirectly recruited via mailout had 
voluntarily made their choice to participate in the screening program, and they showed a 
greater preparedness to follow-through to GP attendance than those directly recruited. 
Comments made during the follow-up survey by HR participants recruited through the 
Seniors Card, also indicated that they were familiar with the GP/primary healthcare system. 
This familiar relationship was also likely to have facilitated their ongoing participation. 
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The level of health literacy of older Tasmanians was difficult to determine. In 2014 the 
Facing the Future Report compiled by the Tasmanian Council on the Ageing 2014 
(Council on the Ageing Tasmania, 2014) reported that many older Tasmanians 
had poor health literacy. The Australian Commission on Safety and Quality 
released the National Statement on Health Literacy- taking action to improve 
safety and quality (Australian Commission on Safety and Quality in Health Care, 
2014) in recognition of the need to improve health literacy. However the 
Tasmanian Population Health survey 2016 (Tasmanian Department of Health and 
Human Services, 2016) reported that close to 90 per cent of older individuals 
indicated that they had no difficulties communicating with their doctor and 
understood medical information and instructions. It would appear unlikely that 
there had been a dramatic improvement in health literacy over a two-year period. 
Rather, that older individuals could follow instructions provided by their GP, as 
opposed to comprehending the nature of a chronic health condition. 
Overall the findings suggest that there was not sufficient information relevant to older age 
and T2DM risk in the AUSDRISK, and on the instruction/consent sheet to facilitate older age 
participation in self-assessment of T2DM risk. This lack of knowledge appears likely to have 
been reflected in the limited initial uptake, and a reduction in numbers of HR individuals 
following-up at subsequent steps in the screening-to-biomedical assessment process. That 
being the case, added age-related information regarding the benefit of ‘knowing your risk’ 
may prove to be an essential factor to encourage participation via both health service and 
mail-out recruitment, as has been found in the US, UK (Usher-Smith et al., 2017) and in 
European countries, and in Australia, in bowel cancer (Duncan et al., 2013, Flitcroft et al., 
2010) and breast cancer screening programs (Hersch et al., 2014, Hersch et al., 2011). In 
addition, these cancer screening initiatives have an established and well-promoted regular 
screening system, which in addition to the actual screening process, recognises the need for 
promoting awareness and facilitating engagement in screening for early identification 
(Rockliffe et al., 2018). The follow-up research of the large Australian 45 and up Study was 
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designed to determine effective strategies for maximizing response rates. It found that 
mailing advance notice postcards to prospective participants followed by reminder notices 
(for those who had not responded) increased the response rate from 18% to 61.6% (Bauman 
et al., 2016). 
As noted in the previous chapter, at the time of initial recruitment for the AUSDRISK study, 
there was no way of accurately determining older individuals’ knowledge of T2DM, including 
knowledge of the purpose and value of screening for T2DM, the use of AUSDRISK, and the 
modifiable and non-modifiable risk factors for T2DM. However, the purpose of implementing  
a real-world approach was to present the intervention in a manner recommended in the 
National Evidence Based Guideline for Case Detection and Diagnosis of Type 2 Diabetes 
(Colagiuri et al., 2009c), which in this case was to use AUSDRISK as the first step in 
screening for T2DM in a targeted intervention for a HR group. By implementing the 
AUSDRISK in the prescribed manner, the issues that would impact positively or negatively 
on participation in a T2DM screening study using AUSDRISK for older individuals would 
become apparent. The comments of those HR participants who subsequently completed the 
follow-up survey showed evidence of a low level of diabetes-specific health literacy (i.e. 
functional literacy) in older individuals in both the Direct and the Indirect recruited groups in 
this study. 
When all the factors involved in the distribution and uptake of AUSDRISK were considered, it 
would appear that a mailout such as the Seniors’ Card mail-out with greater reach for a 
targeted older-age population would be the preferred approach. The potential for increased 
uptake if reminder notices, and targeted information on the benefit of T2DM screening for 
older individuals were implemented, could be explored, to determine if increased initial and 
follow-up participation occurred (Bauman et al., 2016). However, in view of the lack of 
effectiveness of AUSDRISK, perhaps an initial postcard alerting older-age individuals to the 
age-related risk of T2DM, followed by a notice to attend for a direct biomedical assessment 
such as an HbA1c test, might be considered. 
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Despite the limitations associated with recruitment, HR individuals were identified in all 
recruitment settings. The pattern of AUSDRISK scores was consistent through all HR levels 
with the greatest number of HR participants scoring in the lowest HR1 level, and the least 
number scoring in the highest HR3 level. This result was present across all recruitment 
settings which would indicate comparable levels of T2DM risk across individuals recruited via 
different settings. However, there was a noticeable difference in gender balance between 
those initially recruited via Direct and Indirect settings. In the initial Indirect recruited cohort, 
there were equal numbers of males and females recruited (101 males and 101 females). In 
the initial Direct recruited cohort, there were twice as many females as males (32 males and 
68 females). Without knowing the gender distribution of all individuals who received an 
invitation to take part in this research, it is not possible to determine the significance of this 
finding. The reason for the greater female to male participation in the Direct recruitment 
setting appears likely to be that females are known to access health services more frequently 
and in greater numbers than males, as noted in the ADDITION-Leicester study (Bodicoat et 
al., 2017, Davey et al., 2015, Dunkley et al., 2014). However, in the total HR cohort in this 
research, there were more males than females, and this pattern was also reflected at each of 
the HR levels. Again, this finding seems more likely to have been related to the AUSDRISK 
scoring which has an additional 3 points for being male gender to reflect the prevalence of 
T2DM being significantly greater for males than females. 
 Impact of the hard copy AUSDRISK 
The AUSDRISK is now available in two formats (printed and e-copy), although at the time of 
this research it was only available in printed copy. An on-line electronic copy may be 
accessed via the Diabetes Australia website (Diabetes Australia, 2015) (and its state-based 
organisations) and government health sites (Australian Government Department of Health 
and Ageing, 2008). For this research, the hard copy of AUSDRISK was used, which has the 
points score placed against each risk factor. Whereas in the electronic copy, scores are not 
placed against risk factors, and the overall test result/score is presented on completion of all 
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the risk factor questions. Comments provided by HR participants in this research indicated 
that the availability of each risk factor score caused confusion, and for at least one potential 
participant caused him to dispute the validity of the AUSDRISK and refuse to engage any 
further in the screening process. 
The scoring points for age group and gender (as printed on the AUSDRISK) that reportedly 
caused the most disquiet for participants were: 
Table 6.1 AUSDRISK Scoring system for risk 
Your age group  
Under 35 years  0 points 
35–44 years  2 points 
45–54 years  4 points 
55–64 years  6 points 
65 years or over  8 points 
Your gender  
Female 0 points 
Male 3 points 
 
Of those HR participants who provided additional comments, none could understand the 
AUSDRISK rating score for older age groups, which many expressed as “seeming unfair” 
because “you can’t change your age”. Some HR participants were dismissive particularly in 
regard to the scores apportioned for age and gender. For others, the confusion was 
associated with the age ranges, which is the first item on the AUSDRISK, where some 
participants considered the age group printed on the AUSDRISK was there to reflect their 
biological age range, rather than the number allocated to each age-range indicating the 
predicted risk for T2DM associated with that age group, and one participant actually reduced 
the final score by subtracting the number apportioned for age. Had an electronic version of 
the AUSDRISK been utilised, the participants would not necessarily have been so aware of 
the individual risk scores, particularly those linked to the non-modifiable risks. Whilst this may 
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have reduced their concern during the completion of the AUSDRISK, it would not have 
highlighted the distribution of their risk whether that be due to modifiable or non-modifiable 
risk factors. 
 HR participants’ follow-up actions 
 Follow-up Survey – actions of HR participants 
As indicated in the preceding chapters, the AUSDRISK is a Risk Assessment Test (RAT) and 
does not provide a diagnosis of T2DM. Therefore, in order to complete the screening 
process, an individual assessed as HR on the AUSDRISK is advised, by information on the 
AUSDRISK form, to attend their GP for a Fasting Blood Glucose Test (biomedical 
assessment) as they may have type 2 diabetes. 
By recording the number and details of HR participants who did/did not complete the follow-
up survey, this study was able to show that the decrease in participation occurred at each 
step of the screening process, from the early stages of the screening process, through to the 
follow-up survey and GP attendance. This response pattern has been noted in international 
studies (Davey et al., 2015, Echouffo-Tcheugui et al., 2009, Hanoch et al., 2016). 
There was no significant difference in risk score levels between those who attended or did 
not attend for a biomedical assessment. The proportion of HR individuals attending their GP 
for assessment of their glycaemic status increased as the level of risk increased from lowest 
HR1 level to the highest HR3 level, which would suggest that participants had “self-
assessed” their risk and determined their need to see their GP according to the AUSDRISK’s 
total risk score prediction for developing T2DM within a 5-year period, that is: HR1 = one 
person in fourteen; HR2 = one person in seven; and HR3 = one person in three. This self-
assessment has been noted in T2DM screening initiatives internationally (Hanoch et al., 
2016). 
147 
Although there was an increase in overall attendance to non-attendance for biomedical 
assessment as the level of High Risk increased from HR1 to HR2 and HR3, this was not 
observed for both males and females. There was a significant interaction between HR 
participant’s gender, risk level and GP attendance or non-attendance. The response pattern 
of HR males for attending/non-attending GPs for a biomedical assessment was not 
influenced by their level of HR. Whereas HR females showed the highest level of GP 
attendance when their level of HR was greatest (HR3) and lowest attendance associated 
with lowest risk (HR1). This gender difference in GP attendance is well known, with males 
being known to have lower health knowledge and attention to disease prevention than 
females (Davey et al., 2015). As males have a higher prevalence and incidence of T2DM, the 
male response pattern of not increasing engagement with perceived increased personal 
health risk (Davey et al., 2015), would be an additional challenge to address for any T2DM 
screening program. However, for this study it must be acknowledged that the numbers of HR 
participants-by-gender are small and may lack sufficient power to support a conclusion on 
this occasion. 
The major finding of the reduction in numbers of participants at each “next stage” of the 
screening process is not an unusual finding in the Australian Health system, in that in a multi-
stage screening process which involves different sectors in the health system, there is a loss 
of participants between stages for a variety of reasons including personal cost, time, and 
personal estimate of need to continue with the assessment process or not. These same 
factors had been noted in international screening initiatives (Harte et al., 2017, Usher-Smith 
et al., 2017). In Australia individuals are not registered with particular GPs or GP practice, so 
for many individuals/families there is no appreciation of the benefit of a long-term record to 
systematically follow a sequence of prevention and management initiatives to address 
recognised risks for developing chronic conditions such as T2DM. 
The Australian Government is attempting to overcome the lack of integration of personal 
health data by the introduction of the new MyHealth record which is expected to provide a 
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long-term electronic record of all health-related interventions at an individual level across 
primary and secondary health care. Unfortunately, there has been an initial rejection for 
immediate implementation (December 2018). Whilst opt-out reasons for the MyHealth record 
are complex, the people who opt out are at least saying that they do not see the benefit of an 
enduring health record as outweighing their other concerns (be they privacy or whatever). 
Nevertheless, reminder notices implemented within an established system to encourage 
greater initial and follow-up participation in pre-DM/T2DM screening, have been effective in 
increasing numbers of participants in T2DM screening in UK and Europe (Groenenberg et 
al., 2016, Groenenberg et al., 2015, Sussman et al., 2015, Van Den Donk et al., 2011). 
 Actions of GPs in response to HR participants’ attendance 
For those HR participants who were determined to learn their glycaemic status by taking their 
completed AUSDRISK to their GP, most general practitioners responded as recommended 
(Colagiuri et al., 2009c, Royal Australian College of General Practitioners, 2014) by ordering 
blood glucose tests and providing lifestyle modification advice. The HR clients biomedically 
assessed as currently normoglycaemic reported that GPs had discussed potential lifestyle 
modification in general terms, rather than in a specific and personalised manner suited to the 
needs of each HR participant. Ongoing regular monitoring was only recommended to those 
assessed as having elevated blood glucose (EBG). The GP response (reported by HR 
participants) of “keeping an eye on the situation” was given to those assessed as having 
elevated blood glucose. This appeared to be done to alleviate the participants’ concerns. 
However, whilst acknowledging the known variability of blood glucose levels, the HR 
participants with EBG reported that their GP did not suggest implementing a confirmatory 
blood glucose test immediately, or in the near future. 
The HR individuals who were found to be normoglycaemic on biomedical assessment 
reported that the GP had not stated that they would be tested again in 1-3 years (as 
recommended by NHMRC Guidelines). This is not to say that the GP would not implement 
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regular testing, but rather that the HR individuals were given no expectation of this. GPs 
appeared to be responding to their patients’ current normoglycaemic status rather than their 
potential ongoing risk associated with increasing age, with or without additional lifestyle or 
other biomedical risks. This limited reinforcement appeared to inadvertently reduce the HR 
individuals’ perception of their ongoing T2DM risk due to ageing. 
The impact of similar patient/doctor interactions and resultant perceived risk reduction on the 
part of the patient has been noted in UK and US screening studies (Godino et al., 2014b, 
Mainous 3rd et al., 2016b). In addition, this would appear to be a missed opportunity on the 
part of the GP to educate HR individuals about the progressive nature of T2DM and what 
“High Risk” means; the rationale for regular monitoring of blood glucose status, and the 
benefit of effective lifestyle behaviour change as a protective measure to reduce or stabilise 
their risk for preDM/T2DM. The issue of missed opportunity in this educative component has 
also been noted in international T2DM screening in primary health care (Mainous 3rd et al., 
2016b). 
A survey by Tseng E et al (Tseng et al., 2017) reported that many US primary care 
physicians lacked knowledge of risk factors, diagnostic criteria and management and 
prevention of prediabetes.  However, in the Australian primary healthcare context, the limited 
educative component may be due in part to the short time-limited Medicare funding for GP 
consultations.  Overall, however, the reported GP responses suggested a hierarchical 
management on the part of the GPs, rather than a collaborative approach including the 
patient/participant. For most older age HR participants, relying on the GP for guidance and 
direction was acceptable as usual practice (Mainous 3rd et al., 2016a, Mainous 3rd et al., 
2016b). 
In collating the comments received from HR participants, irrespective of whether they had 
scored EBG; scored HR3; chose not to attend their GP, or planned to attend GP for 
biomedical assessment, it was clear that all participants had regular (weekly to yearly) 
contact with their GP for a variety of reasons. There may have been some hard-to-reach 
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individuals recruited, however if they were initially recruited, they did not complete the full 
assessment. This was disappointing as the Seniors Card mailout was used in an attempt to 
access older individuals who may not be attending, or being financially or geographically 
unable to attend, their GP on a regular basis. Perhaps this was somewhat ingenuous 
considering that most of the information that would encourage older age individuals to 
participate in T2DM screening would be received via GP contact. (Royal Australian College 
of General Practitioners and Diabetes Australia, 2016-18). 
 HR individuals’ T2DM knowledge and response 
When the resultant outcomes of the screening process were considered in the light of 
comments from those who scored High Risk, it showed that less than one third of those 
individuals assessed as HR (30.6%) actually completed all the follow-up actions and 
attended their GP for a biomedical assessment. The researcher specifically asked those 
participants who completed the follow-up survey by phone, whether they were aware that 
older age was a risk factor for T2DM. No participant was aware of this fact. Ninety per cent of 
the survey respondents stated that they had never heard of the AUSDRISK, despite its being 
available in print and on-line since 2010. This unfamiliarity with the questionnaire and its 
purpose, together with their lack of knowledge that increasing age was an independent risk 
factor for developing preDM/T2DM, appeared to have adversely influenced initial and follow-
up participation (Rockliffe et al., 2018). Poor health literacy has been implicated as a barrier 
to initial participation and completion to biomedical assessment in other international T2DM 
screening studies (Aujla et al., 2013, Godino et al., 2014b, Kalyani et al., 2013, Lavielle et al., 
2014). 
Many survey respondents stated they found the scoring for older age participants to be unfair 
and “ageist” as it was a non-modifiable risk. This study did not have the capacity to 
determine the extent to which this attitude, associated with a lack of knowledge regarding 
modifiable and non-modifiable risk factors, may have contributed to older adults declining to 
participate in the AUSDRISK screening program, either initially, by not undertaking the 
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survey, or after completing the AUSDRISK and scoring HR, by not attending for biomedical 
assessment. The majority of those assessed as HR indicated some concern regarding their 
level of risk for T2DM. In addition, there were those who stated they were very active and fit, 
and therefore could not understand why they were assessed as HR. Research by Grzywacz 
et al (Grzywacz et al., 2014) noted that belief patterns varied by the extent to which popular 
beliefs on T2DM formed the basis of knowledge rather than biomedical information. Those 
who had a biomedical assessment, and were found to be normoglycaemic, reported being 
very relieved and considered themselves to be no longer at risk for T2DM, which suggests 
they considered the AUSDRISK results to be diagnostic rather than an estimate of ongoing 
risk for T2DM. This belief was consistent with recent findings internationally (Mainous 3rd et 
al., 2019). This HR participant attitude persisted despite the fact that their GPs had provided 
them with general lifestyle modification advice to reduce their T2DM risk. A similar response 
and lack of understanding of risk was reported by the ADDITION - Cambridge study 
(Paddison et al., 2009) which found that negative biomedical screening results (i.e. 
normoglycaemia) did not lead to either positive or negative lifestyle modification over a 7-
year follow-up. 
From a health promotion viewpoint, the participants’ responses indicated limited health 
literacy in understanding the concept of risk and ongoing risk. However, their responses in 
regard to their unawareness of increasing age being a major risk factor for T2DM most likely 
reflected the emphasis that continues to be taken by health professionals and Diabetes 
Australia on promoting adverse lifestyle risk factors such as overweight/obesity; insufficient 
physical activity and poor nutrition as the major risks and reasons for developing T2DM 
(Diabetes Australia, 2015). With a rapidly ageing population, these attitudinal responses and 
limited functional literacy regarding T2DM, indicate a need for a more nuanced approach to 
health promotion and risk reduction of T2DM in older adults. 
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 Effectiveness of the AUSDRISK 
The unexpected finding of lack of association between AUSDRISK HR score levels and 
biomedically assessed glycaemic levels in older individuals assessed as HR, may be 
accounted for in part by research findings over the past eight years. 
Screening studies for T2DM risk in older individuals by Noble et al (Noble et al., 2011) and 
Kalyani et al (Kalyani et al., 2013), have shown that risk assessment tools and risk 
assessment algorithms such as the AUSDRISK performed less well in older adult cohorts 
than for younger and mid-age adult cohorts (Gray et al., 2015, Kalyani et al., 2013, Kegne et 
al., 2014, Noble et al., 2011). However, at the time of my research the effectiveness of the 
AUSDRISK for T2DM risk assessment in older individuals had not been tested. 
The results may also indicate that the combination of risk factors predictive for pre-DM/T2DM 
in older adults differs from those in middle-aged adults (Ding et al., 2015a, Kalyani et al., 
2013), particularly in older age women with a low muscle mass (Caspersen et al., 2015, 
Kalyani et al., 2014) and these risk factors are either not addressed by the AUSDRISK, or 
the score of AUSDRISK risk elements does not reflect the inter-related components of T2DM 
risk in an older-age cohort (Ding et al., 2015b, Ding et al., 2014). 
As a possible correlate of the notion that biochemical markers of T2DM might differ between 
ages, a recent study by Alva et al (Alva et al., 2017) compared the performance of 4 simple 
Risk Assessment Tests, against enhanced equations using the 4 Risk assessment tests plus 
biomedical assessment across 3 different age cohorts – young (18–40 years), middle-aged 
(45–64 years), and older (65 years and older) US adults to predict T2DM risk. The 
biomedical tests comprised Fasting Plasma Glucose (FPG); High Density Lipoprotein 
cholesterol (HDL-C) and Triglyceride levels. They found that the predictive capacity of all 4 
risk assessment tests alone was better in middle-aged (45-60 years) than in younger (18-40 
years) and older cohorts (65 years plus). Biomarkers were more reliable and important in 
older age populations than younger (populations) for accurate identification of T2DM risk. As 
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a result of their findings, Alva et al (Alva et al., 2017) recommended the development and 
use of age-specific equations for practical tools for T2DM risk stratification. 
 Conclusion 
Individuals in the older age group are living longer than any previous generation and the 
healthcare emphasis should be on ensuring they retain a good quality of life and effectively 
manage age-related conditions (Corriere et al., 2013, Kalyani et al., 2017, Schneider et al., 
2016). Routine T2DM screening, particularly for those in the young-old age group, with 
follow-up biomedical assessment for those at HR, and implementation of lifestyle changes 
and/or medication management for those with established preDM/T2DM, would offer the 
opportunity to achieve immediate benefits to their quality of life, and reduce the risk of having 
an undiagnosed hyperglycaemic condition with microvascular, macrovascular complications 
(Halter et al., 2014), disability (Bianchi et al., 2016, Koye et al., 2017), hospitalisations 
(Comino et al., 2015), and some cancers (Steele et al., 2015, Twigg et al., 2015). From a 
positive viewpoint routine T2DM screening would reduce mortality risk (Kristensen et al., 
2016, Paprott et al., 2015) from T2DM, and maintain/improve their current lifestyle and 
independence potentially over the next 15–25 years. 
This real-world study implemented and evaluated an innovative community-based T2DM 
screening to biomedical assessment initiative for young-old individuals in Tasmania. As an 
effective screening strategy, recruitment via mail-out followed by completion to biomedical 
assessment was shown to be more successful than Direct recruitment via healthcare 
services. In Australia established national screening initiatives (colon cancer, breast cancer) 
utilise initial mail-outs for recruitment and reminder systems to increase participation in the 
young-old age group. This approach is familiar to older age individuals and potentially could 
be implemented for preDM/T2DM screening in the 60–74 years age group. However, results 
of this study suggest that this (preDM/T2DM screening) may be achieved with greater 
acceptability and be more effective for young-old individuals (60 – 74 years) by the 
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implementation of a screening system utilising direct blood glucose testing via HbA1c on a 
regular and routine basis during these years.  
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 Conclusion, recommendations and future 
directions 
 Introduction 
This chapter considers the major findings of this study in the light of current T2DM 
prevalence figures, research findings and policy directions implemented since this study was 
completed in 2015. This will include proposals and initiatives for T2DM screening in 
Australia, particularly for older individuals. Comparisons will be made between the current 
Australian approach to identifying older adults with undiagnosed T2DM or at HR, and 
screening and management initiatives in other countries. In the UK, US and European 
countries the emphasis has moved from screening for established T2DM to screening for 
early identification and management of elevated blood glucose (EBG) to prevent or slow the 
progression to T2DM (Aroda et al., 2017, Cefalu et al., 2019, Diabetes Prevention Program 
Research Group, 2019). 
Internationally, a personalised medicine approach, using physiological biomarkers, is being 
advocated for diagnosis and management of T2DM particularly in the older age group (Alva 
et al., 2017). Identification of the patho-physiological changes underpinning T2DM, including 
age of T2DM onset, and differences in biomarkers and their rate of progression, is being 
advocated as the most effective approach to diagnosis and management of preDM/T2DM by 
Ahlqvist et al. (Ahlqvist et al., 2018) and Dennis et al (Dennis et al., 2019). This approach is 
also advocated by the German Diabetes Study Group (Zaharia et al., 2019) for the prediction 
and early identification and management of T2DM complications. 
The American Diabetes Association and the European Society of Endocrinology in 
collaboration have recently released clinical practice guidelines to identify and reduce risk for 
both atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (T2DM) in 
individuals at metabolic risk (Rosenzweig et al., 2019). These guidelines emphasise regular 
screening in adults aged 40–75 years for five metabolic risk factors which are known to 
increase risk in ASCVD and T2DM. The risk factors are elevated blood pressure; increased 
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waist circumference; elevated fasting triglycerides; low HDL cholesterol and elevated blood 
glucose. The guidelines are recommending that individuals who have one or two risk factors 
should receive regular routine screening (fasting blood tests) every 3 years. Those with three 
risks or more, are considered to be at metabolic risk, and therefore should be assessed 
annually, or more, if any of the risk factors is increasing. In addition to the active monitoring, 
those at metabolic risk should follow a healthy lifestyle and if available, be referred to 
intensive lifestyle programs. 
To reiterate, the primary aim of my research in 2014-15 was to determine the feasibility, 
effectiveness and acceptability of implementing the AUSDRISK, in community-based non-
medical healthcare and non-healthcare settings in Tasmania to screen older individuals aged 
50 years and over for T2DM and identify those with undiagnosed T2DM or at HR. This 
targeted screening procedure was in accordance with the NHMRC Guidelines for Case 
Detection and Diagnosis of Type 2 Diabetes (Colagiuri et al., 2009c) for identifying 
individuals with or at HR for T2DM. These Guidelines recommend completing the 
AUSDRISK Assessment Tool as the first step in identifying individuals at High Risk for 
T2DM, followed by a blood glucose assessment to determine their glycaemic status. 
The decision to implement a community-based strategy for this study was based on the 
NHMRC Guidelines (Colagiuri et al., 2009c) with regard to the suitability of targeted T2DM 
screening for population groups known to be at HR for T2DM such as the older age group, 
and to increase the availability of the AUSDRISK for self-assessment and health promotion 
of T2DM. At the time of this study, a fasting blood glucose (FBG) test was recommended. 
Later as the HbA1c diagnostic test became a funded Medicare item, it was the first test of 
choice for its higher reliability in that it reflects the integrated blood glucose level over the 
previous 3 months (D’emden et al., 2012) and has higher specificity than FPG and OGTT 
(Vistisen et al., 2019). From the viewpoint of participating individuals, the HbA1c test is more 
convenient as it does not require an 8–12 hours fast prior to testing. 
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Type 2 diabetes is an age-related disorder (Lee et al., 2017) and older adults are at high risk 
for the development of T2DM due to the combined effects of epigenetic, genetic, lifestyle and 
ageing factors. The stimulus for this research was the recognition that the older age cohort is 
the most rapidly increasing in Tasmania and nationally. Tasmanian data from the National 
Diabetes Services Scheme (NDSS) indicated that the number and percentage of individuals 
aged 70 years and above being newly diagnosed with T2DM have increased annually over 
the last 5 years. In Tasmania, 337, or 29.0% of newly diagnosed with T2DM in 2018 were 
aged 70 years or older, while nationally the number was 16,101, or 25.3% (Australian 
Government, 2018). Type 2 diabetes has a long latent period (5–10 years) with fluctuating 
and gradually increasing dysglycaemia prior to the onset of T2DM. If this gradually increasing 
dysglycaemia had either not occurred in previous years, or was occurring but not identified 
prior to the individual entering the older years, then to identify the T2DM risk status in the so-
called “young-old” age period (60–74 years) (Beard et al., 2016a) would offer the opportunity 
to prevent progression to T2DM, or alternatively to effectively and appropriately manage an 
existing but previously undiagnosed T2DM (Ahlqvist et al., 2018, Dennis et al., 2019). 
 Feasibility of distributing AUSDRISK for community-based screening 
The research presented in this thesis has shown it was feasible to distribute the AUSDRISK 
both face-to-face (Direct) in community healthcare settings and via a non-health service mail 
out (Indirect). The initial uptake and completion of AUSDRISK was limited but comparable to 
the initial presentations of screening initiatives internationally (Robson et al., 2016, Stone et 
al., 2014). Although the Direct presentation of AUSDRISK achieved a greater initial 
completion, it had a poor follow-up rate of High Risk (HR) participants presenting to their GP 
for biomedical assessment. The Indirect recruitment via mail out achieved a limited take-up 
rate, but for those assessed as HR, the follow-up rate was higher than for those identified via 
the face-to-face presentation. The Indirect procedure had no complications associated with 
impact on time for service delivery experienced by health professionals in the Direct 
presentation. Overall, a mail-out was superior to invite older age individuals to participate in a 
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T2DM screening strategy and had the potential for increased participation by providing age-
specific T2DM information in invitations, and utilizing reminder notices. This finding is in line 
with screening strategies currently implemented in Australia, breast cancer screening and 
colorectal cancer screening, which use mail-outs for recruitment and reminders to individuals 
in the same age cohort. 
 Effectiveness of AUSDRISK 
However as discussed previously the HR score on the AUSDRISK was found not to 
accurately predict those older age individuals at HR who required a follow-up blood glucose 
assessment to verify their blood glucose status from those older individuals scoring HR who 
did not require follow-up. Therefore, the AUSDRISK did not fulfil its role as an effective first 
step “filter” in a T2DM screening procedure for the older age cohort. In fact, at the time of 
biomedical assessment, the AUSDRISK results appeared to have “over diagnosed” (Bulliard 
et al., 2015) the T2DM risk status of this older-age cohort. The blood glucose test results of 
those at HR (who were subsequently) biomedically assessed, found no HR individual with 
T2DM; 14.3% HR with elevated blood glucose/preDM, while 85.7% HR were 
normoglycaemic. Furthermore, there was no significant difference in the HR scores of those 
with EBG, and those at HR who were found to be normoglycaemic on biomedical 
assessment. The AUSDRISK is based on population level risk predictions for development of 
T2DM within a 5-year period (Dunstan et al., 2002a) and as such is not designed to take into 
consideration the complex interactions of risk factors at an individual level (Ding et al., 
2015a) nor to identify an individual’s precise level of risk and current blood glucose status 
(which is actually what participants want to know). Therefore, to propose using AUSDRISK 
HR results, as a first stage filter to increase efficiency and reduce cost, appears not to be an 
appropriate step prior to blood glucose testing for the older age cohort. An argument may be 
presented that at least the AUSDRISK “delineates” between HR and intermediate risk (IR) for 
T2DM. However as the NHMRC Guidelines for Case Detection and Diagnosis of Type 2 
Diabetes (Colagiuri et al., 2009c) and AUSDRISK do not have recommendations for those 
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scoring in the IR range to receive a blood glucose test, it is not possible to know the accuracy 
of this “delineation”. 
 Acceptability of AUSDRISK for community-based screening 
Overall, the older adults who participated in this study had knowledge of the modifiable 
lifestyle risk factors for T2DM, but little knowledge of the complexity and potential severity of 
risks for T2DM, and no knowledge that older age was a major non-modifiable risk factor. 
These knowledge barriers were comparable with findings in international research (Eborall et 
al., 2012, Heidemann et al., 2019). The older age cohort was dependent on their GP for 
health advice and direction, and were not well-prepared to self-assess their T2DM risk, and 
self-direct the follow-up actions required if found to be at HR. This lack of diabetes literacy 
limited their initial and follow-up participation in a screening program. This appears to be an 
ongoing difficulty. In July 2017, as part of National Diabetes Week (NDW), Diabetes Australia 
news (www.diabetesaustralia.com.au/news/15424?type=articles) reported that recent 
research had found that only 5.0% of Australians aged over 40 years had completed an 
AUSDRISK assessment in the previous 2 years, and only 21.0% in the same age range had 
heard of the AUSDRISK assessment. Clearly the unfamiliarity with the AUSDRISK and lack 
of knowledge that increasing age was a major non-modifiable risk factor for T2DM, did not 
encourage older individuals to investigate their T2DM risk. 
 Findings and comparisons with international studies 
The value of my study was that it showed there were limitations in distribution, acceptability 
and effectiveness of using AUSDRISK at an individual level in an older age cohort. This 
finding aligns with international research which reported that Risk Assessment Tools were 
less effective in predicting T2DM risk in older-age cohorts (Alva et al., 2017, Kegne et al., 
2014, Noble et al., 2011). 
Whilst distribution via mail out was found to be effective, my study did not have the 
opportunity to increase participation via reminders (phone/mail) as Groenenberg et al. 
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(Groenenberg et al., 2016, Groenenberg et al., 2015); Robson et al. (Robson et al., 2016) 
and Bauman et al (Bauman et al., 2016) had found to be essential for maximising numbers of 
participants. In addition, participation in my study is likely to have been limited by personal 
barriers of poor functional diabetes literacy and poor perception of actual risk. This lack of 
knowledge has been reported by many researchers in relation to both the general population 
and the older age cohort Lavielle and Wacher (Lavielle et al., 2014) Godino et al. (Godino et 
al., 2014b) and more recently Robson et al. (Robson et al., 2016) and Harte et al (Harte et 
al., 2017). Poor diabetes literacy and poor perception of T2DM risk had been found 
specifically in the older age cohort by Adriaanse et al: Gallivan et al; and Heidemann et al 
(Adriaanse et al., 2008, Gallivan et al., 2009, Heidemann et al., 2019) and was obvious in the 
responses from HR individuals who participated in the follow-up survey in my study. 
The ongoing concern for health service provision, particularly for older adults, is that the 
older age cohort is living longer and is known to be the cohort at highest risk for T2DM and 
the actual level of risk and presence of T2DM in many individuals is not being identified 
before they reach their older years (Australian Government, 2019c). This is at a time in their 
lives when they are likely to be experiencing a range of illness conditions which make it more 
difficult to achieve effective management of preDM or T2DM. This scenario was evident from 
the comments made by HR participants in this study. The Australian Institute of Health and 
Welfare Diabetes Snapshot (Australian  Institute of Health and Welfare (Aihw), 2018) 
reported there were one million hospitalisations associated with diabetes (principal and/or 
additional diagnosis) in 2015–16. Type 2 diabetes accounted for 63% of 50,000 
hospitalisations with diabetes as a principal diagnosis. There were 1,053,700 hospitalisations 
with diabetes as an additional diagnosis of which 90% were due to T2DM. Hospitalisation 
rates for T2DM (30,055 per 100,000), were highest among males 85 years and over (old-old 
years) and in females aged 75-84 years (19,261 per 100,000) in their mid-old years. There 
were 5,000 lower limb amputations during 2015-16, mainly male with 62% aged 65 years 
and over. 
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 Prevalence of type 2 diabetes in 2017-18 
The recently released statistics from the Australian Bureau of Statistics (ABS) National 
Health Survey (AHS): First Results 2017–18 (Australian Bureau of Statistics, 2018) show that 
4.9% or 1.2 million people over age of 15 years had diabetes (all types). This finding 
indicates that the overall rate of diabetes has remained virtually the same since 2014–15. 
This is the first time in 5 years that the rate of diabetes has stabilised. The prevalence of type 
2 diabetes (T2DM) has also remained steady since 2014–15 at 4.4%, with a further 3.1% 
having impaired fasting plasma glucose (IFG/elevated blood glucose /EBG) which puts them 
at very high risk for developing T2DM. However, this stability in incidence and prevalence of 
T2DM is not the finding for the older age cohort aged 60 years and over. The 2017–18 
Australian Health Survey highlights that: 
the rate for T2DM in those aged 65-74 years has increased from 12.5% in 2001 to 
15.4% in 2017-18 and for those aged 75 years and over from 11.2% in 2001 to 18.7 
% in 2017-18. Males have a higher prevalence than females for T2DM which is 
indicated in the current rate for males being 18.7% in 65-74 years and 20.7% in those 
aged 75 years and over. The current  rate for females aged 75 years and over is 
17.0%. (Australian Bureau of Statistics, 2018). 
So, whilst the overall rate of T2DM has remained steady for individuals up to the age of 
approximately 60 years since 2014, both the prevalence and incidence of T2DM in older-
aged individuals is increasing (Australian  Institute of Health and Welfare (Aihw), 2018). This 
is due in part to those with T2DM living longer but in so doing, the risk for diabetes-related 
complications increases. Information from Diabetes Tasmania (personal communication) 
indicates that 72.0% of current NDSS registrants with T2DM in Tasmania are in the 60 years 
and over age group, of whom 44.0% are aged 70 years and over (Australian Government, 
2018). The older age cohort has a mix of individuals some with established T2DM and others 
with newly diagnosed T2DM. The management of the older age cohort with T2DM and 
preDM is a rapidly growing problem for effective clinical management (Kalyani et al., 2017). 
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However, the prevalence and occurrence of T2DM in the older cohort is not being 
communicated to older individuals and not being effectively addressed as an age-related 
condition by Government and Non-Government organisations. 
 Major research findings subsequent to my research in 2014–15 
For some time a consensus has been emerging in regard to the pathology of T2DM from it 
being considered mainly a lifestyle disease, to T2DM being a complex heterogeneous 
condition involving epigenetic, genetic, ageing and environmental factors (Ahlqvist et al., 
2018, Kalyani et al., 2017). This acknowledgement of the heterogeneity and complexity of 
T2DM and preDM has transformed the recommended approaches for identification and 
management of these dysglycaemic states from a “one-size-fits-all” to an individualised 
approach to identify the combined influence of risk factors at the individual level, followed by 
individualised management, be that lifestyle modification and/or medication, to best address 
the impact of those risk factors, be they modifiable or non-modifiable (Ahlqvist et al., 2018, 
Kalyani et al., 2017).  
In the last five years, research has clearly demonstrated that, in overweight individuals, 
T2DM in early stages can be reversed to normoglycaemia via an initial strict weight loss 
program (initially 800 calories per day for 6-8 weeks) followed by low calorie diet (Taylor et 
al., 2018b, White et al., 2016) (Lean et al., 2018), (Bodicoat et al., 2017, Taylor et al., 2018a). 
Studies by the Diabetes Prevention Program Outcome Studies (Diabetes Prevention 
Program Research Group, 2019) have also shown that early identification of glycaemic 
dysfunction (notably IGT) with early treatment lifestyle, and/or metformin will significantly 
reduce onset of T2DM and in some individuals revert to and maintain normoglycaemic levels 
of blood glucose (Apolzan et al., 2019, Diabetes Prevention Program Research Group, 
2019). These studies are among the first to show that having a blood glucose level in the 
T2DM range is reversible within 2–5 years of diagnosis. Participants included in these trials 
were aged up to 65 years which makes those individuals in the early years of the “young-old” 
cohort suitable for this type of intervention. It also implies that those in the young-old cohort 
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would most likely obtain the best results if they were receiving regular blood glucose testing 
to reveal when they first enter a dysglycaemic state. Research completed by Vistisen, et al. 
(Vistisen et al., 2019) found that within a 5-year period most people with HbA1c-defined 
preDM either remained in that state or progressed to T2DM. In contrast to this, people with 
FPG or 2hr-OGTT-defined preDM frequently reverted from preDM to normoglycaemia. 
However only those whose preDM status was diagnosed via a 2hour OGTT, had a reduction 
in future risk for cardiovascular disease if they reverted to and maintained a normoglycaemic 
state. Initial annual screening (followed by 3- yearly screening), from the date of identification 
of dysglycaemia for at least five years, would most likely identify the trajectory of the 
dysglycaemic condition and facilitate appropriate management of whichever pattern of 
dysglycaemia they were experiencing (Ahlqvist et al., 2018, Dennis et al., 2019, Taylor et al., 
2018a). A study by Zucker et al. 2017 (Zucker et al., 2017) which considered the age at first 
diagnosis of T2DM and mortality, noted that increased risk for mortality was observed at all 
ages including those aged 75 years and older. However, as noted by Kalyani et al. (Kalyani 
et al., 2017) when adults over 65 years are first diagnosed with T2DM it is not immediately 
clear whether the T2DM is “elderly onset” and therefore more likely to have a relatively 
benign progress of their diabetes condition (Ahlqvist et al., 2018) or whether the T2DM has 
been long-standing, but undiagnosed. 
Implementing these research findings at a clinical level is dependent on the recognition of the 
complexity of preDM (by differences in diagnostic criteria) and whether preDM is considered 
a recognised condition to invoke active management or a risk factor for T2DM to be 
monitored. Recent published research by Njeru et al. (Njeru et al., 2019), has found that 
preDM is not fully recognised by clinicians in primary care and that education for clinicians on 
the diagnosis and management of preDM with the aim to revert to normoglycaemia is 
essential to achieve T2DM prevention and avoid cardiovascular disease complications 
associated with preDM. Whilst these latest research findings offer a more positive outcome 
to highlight the benefit of screening and identifying HR for T2DM, the heterogeneity of T2DM 
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and complexity of identification and effective management of risk for T2DM presents an 
increasing demand on clinical management (Gray et al., 2016, Kalyani et al., 2017). 
Australia lacks a national screening program for identifying preDM/T2DM, with GPs following 
current guidelines (Colagiuri et al., 2009c, Royal Australian College of General Practitioners, 
2018) to pursue an opportunistic approach to implementing a blood test to identify individuals 
with or at HR for developing T2DM. The results of this study showed that on presentation of 
a HR score on AUSDRISK, most GPs followed NHMRC and RACGP guidelines (Colagiuri et 
al., 2009c, Royal Australian College of General Practitioners and Diabetes Australia, 2016-
18) and recommended a blood test (most likely FPG in 2014/15) to identify preDM/T2DM. 
The GPs recommended general lifestyle modification measures for those individuals 
identified with preDM, and advice that they would be monitored but no detailed or 
personalised lifestyle program, referral for specialist diabetes education nor medication was 
offered. This would suggest that the impact of preDM and the need and benefit of early 
intervention was not being fully recognised by GPs in Tasmania at the time of my research 
(Njeru et al., 2019). Personal communication with accredited diabetes educators in Tasmania 
would suggest that unfortunately little has changed over recent years.  
 Australian national policy directions relating to T2DM 
The National Diabetes Strategy (NDS) 2016–2020 (Australian Government, 2015) was 
developed by the National Diabetes Strategy Action Group (NDSAG) in 2015 and 
implemented from 2016 (after completion of my field research). 
NDS Goal 1 addressed issues to reduce the number of people developing T2DM – taking a 
whole-of-population approach to encourage and enable healthier lifestyles. 
NDS Goal 2 aimed at promoting earlier detection T1DM and T2DM to facilitate earlier 
diagnosis and earlier treatment for all forms of diabetes. In relation to earlier detection of 
T2DM the following initiatives were recommended (Australian Government, 2015): 
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• Establish a nationally coordinated detection program to identify high-risk 
individuals using the AUSDRISK screening tool. 
• Establish multiple avenues for the dissemination of AUSDRISK, using Primary 
health networks, community health centres, community pharmacies, 
optometrists, dentists and online health services in state and federal health 
departments. 
• Promote increased use of the AUSDRISK screening tool among all age groups – 
with the acknowledgement that this may require calibration of scoring on the 
AUSDRISK tool for different age ranges. 
• Integrate the AUSDRISK screening tool with risk assessment for other chronic 
conditions, including absolute cardiovascular and kidney disease risk, such as 
has been achieved in the UK with the National Health Service (NHS) Health 
Check program (Robson et al., 2016) in primary care. 
• Improve the health literacy of the community with particular reference to risk for 
T2DM – both modifiable risk (lifestyle) and non-modifiable (age and genetic). 
• Educate primary health care practitioners about who should be screened. 
• Review biomedical screening methods (e.g. the use of HbA1c in the screening 
algorithm procedure). 
The goals of the National Diabetes Strategy 2016–2020 are wide ranging and ambitious. 
Four of the initiatives involve utilizing the AUSDRISK. In the light of the findings of this 
research, it would appear appropriate that a National Diabetes Strategy (NDS) specifically for 
older individuals be developed, or at least the current NDS amended to reflect the particular 
issues for older adults, particularly with reference to utilisation of the AUSDRISK in screening 
and instead implement regular direct HbA1c testing for all individuals aged 60 – 74 years 
within a nationally co-ordinated T2DM screening system. 
In relation to the NDS Goal 2, three major clinical initiatives which have the potential to 
impact on the earlier detection and effective management of preDM/T2DM have been 
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introduced, and further initiatives are in the planning phase. All initiatives include and require 
an established regular and replicable screening system supporting the screening/data 
collection initiatives. 
 Clinical initiatives introduced as part of the NDS 2016–2020 
1. a diagnostic HbA1c test for T2DM (Medicare item 66841) which may be performed 
once per year. 
2. the My Health Record – a collated and up-to-date patient record of all services 
received in all health sectors. 
3. Heart Health Check (Medicare item 699) for individuals aged 45 years and over 
considered by their GP to be at risk for CVD events – once per year. 
 HbA1c diagnostic test for T2DM (Medicare item 66841) 
The commencement of a Medicare funded annual diagnostic HbA1c test (Medicare item 
66841) for asymptomatic individuals considered to be at HR for T2DM by their GPs was first 
introduced in November/December 2014 but not widely used at the time of my field research. 
The patient criteria for using the diagnostic HbA1c test are either having (i) a medical 
condition or ethnic background associated with high rates of type 2 diabetes, or (ii) an 
Australian type 2 diabetes risk (AUSDRISK) score of 12 or greater, placing them at increased 
risk of diabetes. Introduction and standardisation of blood glucose testing using HbA1c as 
both a T2DM diagnostic and monitoring test (Medicare items 66551, 66554 or 73840) has 
facilitated ease of blood glucose testing by using a non-fasting test and having rapid results 
which reflect average blood glucose level for the previous 3 months testing. Confirmatory 
testing may then be implemented if the HbA1c test is “borderline”. (Colagiuri, 2015); (Lee et 
al., 2016) This direct blood glucose testing approach overcomes the problem of initially 
assessing the 5-year risk for developing T2DM via the AUSDRISK, which older age adults 
have found very confusing. The potential to access HbA1c diagnostic screening annually 
overcomes the issue of irregular opportunistic screening (Colagiuri, 2015). For example, in 
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older people the annual diagnostic HbA1c test could be initially be implemented every 1–3 
years between 60–74 years for non-diabetic asymptomatic individuals, along the lines of the 
NHS Health Check in UK (Martin et al., 2018, Robson et al., 2016). This would provide an 
opportunity for early detection of dysglycaemia within a system which would become familiar 
to older individuals who would relate to this as a “normal procedure” – an important factor as 
indicated by participants in the NHS Health check program (Usher-Smith et al., 2017). In this 
way all elements of feasibility, effectiveness and acceptability in a screening program would 
be covered. 
 My Health Record 
In December 2018, the Australian Government introduced the My Health Record 
(https://www.myhealthrecord.gov.au). All Australians will be recorded on the digital My Health 
Record system but be able to “opt out” should they wish. Current concerns are in regard to 
individual privacy and accuracy of health service reporting versus the convenience and 
benefits to patients of access by patients, GPs, hospitals, and other health professionals of 
all the patient’s healthcare records and attendances. As at June 2019 close to 90.0% were 
recorded on the My Health Record. Recent media reports suggest that it will take time for this 
initiative to be established. 
Since July 2018, Diabetes Australia has been promoting the benefits to people with diabetes 
(all types) of having their health information recorded on the My Health Record. People with 
diabetes often attend a wide range of health services and there is great benefit in having all 
the information available to all health professionals providing those services. It is unclear 
whether people with elevated blood glucose (EBG), that is at HR, will have this recorded 
annually in order to monitor the increase or reversion to normal levels in their initial elevated 
blood glucose levels. If such a database were developed and found to be cost-effective, re-
test HbA1c reminder notices could be linked to this information in the My Health Record and 
sent annually to those who had previously recorded EBG or had an increased HbA1c result. 
In addition, there would appear to be potential for all individuals aged from 60–74 years (high 
168 
non-modifiable risk) to have a notification generated via the My Health Record to attend their 
GP every 1-3 years for an HbA1c test using the Medicare subsidised diagnostic HbA1c code. 
Potentially, the My Health Record could provide the system for early identification of 
preDM/T2DM and provide systematic monitoring of those older individuals who remain “at 
risk for T2DM” with elevated blood glucose. Irrespective of which health services 
implemented a blood glucose test, the results would be recorded centrally and any pattern of 
increasing blood glucose level moving towards the T2DM range could be identified early. 
Such a database could provide a longitudinal record for blood glucose levels and identify the 
current situation of each individual, for example, showing EBG progress to T2DM; or 
remaining stable with EBG; or return to normoglycaemia having had lifestyle and/or 
medication management of their EBG. All information could be linked back to the patient’s 
record available for both patients and health professionals to access. 
 Heart Health Check (Medicare item 699) 
In April 2019, the Australian Government announced the government-funded Heart Health 
Check (Medicare item 699)(Australian Government, 2019a) for all individuals (aged 45 years 
and older) considered by their GP to be at risk for CVD events. This Check can be 
implemented once every 12 months. One of the eligibility criteria for this health check is 
“diabetes status”. In order to establish this, a blood glucose test should be performed. 
Therefore, by default, this program may provide a system for regular blood glucose 
measurement and monitoring. 
Professional attendance for a heart health assessment by a general practitioner at consulting 
rooms lasting at least 20 minutes and must include: 
a. collection of relevant information, including taking a patient history that is aimed 
at identifying cardiovascular disease risk factors, including diabetes status, 
alcohol intake, smoking status, cholesterol status (if not performed within the last 
12 months) and blood glucose 
b. a physical examination, which must include recording of blood pressure 
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c. initiating interventions and referrals to address the identified risk factors 
d. implementing a management plan for appropriate treatment of identified risk 
factors and 
e. providing the patient with preventative health care advice and information, 
including modifiable lifestyle factors with appropriate documentation. 
The rationale for, and consideration of, a Heart Health Check for individuals aged 45 years 
and older considered to be at risk for CVD events appears to be along the lines of the NHS 
Health Check programme (Martin et al., 2018). A report by Martin et al indicates that after 8 
years of implementation of the NHS Health Check programme, 45.0% of those invited had 
attended. Although the number of individuals completing the NHS Health Check programme 
was initially lower than expected, increased publicity and communication on the purpose of 
the programme has resulted in year-on-year improvement in attendance. This has led to  
improved outcomes on the previous opportunistic approach used by UK GPs in the National 
Health Service. From the viewpoint of the age of participants who attended, the highest rate 
of completion was shown to be for older individuals and females which would lend support to 
a similar implementation of a National Health Check programme in the 60–74 age group in 
Australia (Martin et al., 2018, Robson et al., 2016). A recent review undertaken on the NHS 
Health Check programme (Mytton et al., 2018) to assess the current and potential health 
benefits of the NHS Health Check programme also noted that the benefits were greatest for 
those from disadvantaged areas, thus the overall benefit of the program was reducing health 
inequalities. 
 Recent Australian T2DM screening studies identification of T2DM 
and preDM  
The NDS Goal 2 to establish a nationally coordinated detection program to identify HR 
individuals using the AUSDRISK screening tool has not yet been implemented. However, 
there have been a number of T2DM screening programs, some using AUSDRISK and others 
using direct implementation of a diagnostic HbA1c test. 
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 Community-based screening for T2DM 
A nationwide pharmacy-based T2DM screening program in 340 community pharmacies 
using AUSDRISK, with or without a follow-up HbA1c blood glucose test, was commenced in 
2017 (Krass et al., 2017). All states and territories were represented with participating 
pharmacies. Eligible clients were those aged 35–74 years who had not had a test for T2DM 
in the previous 12 months. There was high variability in numbers of participating clients and 
some pharmacies identified no individuals with T2DM. As yet no formal report has been 
published, although a short report was made available through the Australian Doctor 
magazine (Saxena, 2018). The Pharmacy Diabetes Screening Trial protocol (Krass et al., 
2017) utilised 3 variations of AUSDRISK presentation to individuals, either the AUSDRISK 
alone, AUSDRISK followed by a point-of-care HbA1c test or AUSDRISK followed by a point-
of-care blood glucose test. Over 14,000 customers were screened and 136 cases of T2DM 
(approximately 1%) were identified. The cost per case of T2DM identified was estimated to 
be $8217.00, which included costs associated with conducting the program. No details were 
available on identification of individuals (and their age) with preDM. The results of this 
screening program would appear to support the findings in my research with concerns 
regarding feasibility, acceptability and effectiveness of AUSDRISK in identifying people with 
or at HR for T2DM. 
 T2DM screening in an acute care hospital and primary care practices in 
Western Sydney, New South Wales, Australia 
This research on screening for T2DM in acute care (hospital) and primary care health (GP) 
services commenced in 2016. The rationale for the research was based on the under-
recognition of T2DM in individuals, and impact of this situation on the health services in a 
known “hot spot” for T2DM in Western Sydney. This initial research was followed by an 
analysis of the prevalence and management of T2DM in cardiology inpatients at Blacktown-
Mount Druitt Hospital in Western Sydney by Bishay et al. (Bishay et al., 2018). The 
background to the outpatient study was recognition that two-thirds of individuals presenting 
to the emergency department in Western Sydney had high blood glucose levels which 
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accelerated their risk for cardiovascular disease. The study by Bishay et al also showed that 
undiagnosed T2DM was prevalent and neglected in cardiology patients. In 2019, 
Meyerowitz-Katz et al. collated the results of screening for T2DM in both acute care at the 
ED at Blacktown Hospital Western Sydney (BHWS) and 11 general practices in Western 
Sydney Primary Health Network (PHN). The purpose was to examine preDM and T2DM 
rates using HbA1c testing for patients attending a hospital ED or a General Practice in the 
same local suburban area. 
 Emergency Department Blacktown Hospital Western Sydney 
The study design comprised an initial random blood glucose (RBG) test for all adult patients 
attending ED, followed by HbA1c testing if RBG >5.5mm/L. The study was initially over a 6-
week period (Hng et al., 2016) and then extended to 2 years (Meyerowitz-Katz et al., 2019). 
The research methodology designated that an HbA1c test be included in addition to other 
ordered blood tests unless any of these following exclusions were present – (1) the individual 
is <18 years (2) HbA1c test had been previously measured within the last 3 months (3) 
appropriate blood sample was not available or adequate. A total of 55,568 individuals were 
tested for T2DM in the ED. Results showed that 17.3% had T2DM (based on HbA1c of either 
= >6.5% or a prior diagnosis); and 30.2 % had preDM. Among those identified with T2DM, 
32.2% were previously undiagnosed. 
 T2DM screening in general practices, Western Sydney 
In the General Practice arm of the study, GPs added HbA1c testing for patients undergoing 
routine blood tests (initially over a 6-week period, but extended to a maximum of 11 months). 
This procedure was close to the opportunistic approach used by many GPs, but in this study, 
it was part of an established research system. Results from the GP checks showed that of 
the 6,000 individuals tested, 26.6 % had preDM and 17.4% had T2DM. During the trial period 
in GP practices the rate of diagnosed T2DM rose from 8.9% to 11.0%. 
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The AUSDRISK was not used to first identify HR (as recommended by Guidelines) instead 
direct biochemical assessment using HbA1c was implemented (Bishay et al., 2018, Hng et 
al., 2016, Meyerowitz-Katz et al., 2019). The two arms of the study (ED and GP practices) 
found that in the Western Sydney area, HbA1c testing for T2DM in ED and GP practices 
revealed similar results for T2DM prevalence (17.3% in ED and 17.4% in GP) across 
different areas of the health system (Meyerowitz-Katz et al., 2019). In comparison to the 
community-based Pharmacy Study (Krass et al., 2017), the ED/GP study used a targeted 
approach, addressing those who presented with some form of ill-health and identified a 
significantly higher number of those with or at HR of T2DM than those identified 
implementing AUSDRISK in community-based screening via pharmacies or had been found 
in my community-based research for older age individuals. 
The Western Sydney screening studies identified the effectiveness of implementing an 
HbA1c test (as part of a screening research system) to screen large numbers of adults to 
identify those with or at HR for T2DM. Based on the findings of my research, where the 
participants had great difficulty comprehending the concept of “T2DM risk” without a 
diagnosis, the immediacy of the blood glucose test result (without the need to understand 
T2DM risk) would likely appeal to most participants. However, without a regular repeated 
screening program and data recording there would be no ability to identify progressive 
dysglycaemia and intervene prior to development of T2DM. 
 Changes in early identification and early management of 
prediabetes 
Internationally, research findings are promoting greater emphasis on identification and 
treatment (with lifestyle intervention and/or metformin) of preDM which is not a benign 
condition as it increases the risk of cardiovascular disease. This change in the direction for 
T2DM prevention by early identification and management of preDM associated with 
increasing age, overweight and obesity (Apolzan et al., 2019, Herman et al., 2017) is seen by 
many researchers as the only way to prevent or reduce the impact of T2DM. Whilst lifestyle 
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initiatives have been found to be effective in achieving weight loss and reduction in blood 
glucose levels it is acknowledged that it is very difficult to maintain the level of lifestyle 
interventions that will gain and maintain an effective outcome (Aroda et al., 2017, Cefalu et 
al., 2019). In older individuals, the level of physical activity may be compromised by co-
morbidities such as musculo-skeletal limitations, including arthritis, and loss of muscle mass 
and strength (sarcopaenia) (Kalyani et al., 2015, Kalyani et al., 2014). Therefore, greater 
emphasis is being placed on introducing a combined approach of lifestyle and medication to 
maintain weight loss and normal blood glucose levels for those with EBG particularly 
impaired glucose tolerance (IGT) (Lean et al., 2018, Taylor et al., 2018b) (Sussman et al., 
2015). However, this approach has not been endorsed by a recent Cochrane Review on the 
development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Richter 
et al., 2018). The rationale being that as the intermediate hyperglycaemia and T2DM may 
transition between stages, GPs should give careful consideration before implementing active 
medication management. Whatever the clinical decision, it can only be made on the basis of 
regular screening and monitoring, which is the rationale for early identification of glycaemic 
status of individuals known to be at HR for T2DM. In view of the increasing prevalence and 
occurrence of T2DM in the older age cohort, this group should be targeted for early inclusion 
in a system of regular screening and active management if required. 
Asymptomatic individuals should be screened every 3 years. Individuals with preDM should 
be screened annually as should individuals with other metabolic risks. Therapeutic 
management would include both lifestyle and medical/pharmacological intervention as 
required. This comprehensive approach would provide a regular system of screening and 
management “personalised” to each individual’s therapeutic needs (Apolzan et al., 2019). 
 AUSDRISK 
In this time of personalised medicine, the AUSDRISK appears not be sufficiently precise for 
identifying those older age individuals who are at HR for progressing to T2DM, from those in 
the same age range, who are assessed as HR, but are not at risk for progressing to T2DM. 
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This is supported by results of my research showing that 85% of those assessed as HR by 
the AUSDRISK were normoglycaemic the at time of biochemical assessment. In addition, 
there was no significant difference in the AUSDRISK scores between those at HR, but 
normoglycaemic on biomedical assessment, from those at HR who were biomedically 
assessed as having an elevated blood glucose level. Both these findings would indicate that 
the AUSDRISK scores do not differentiate between those who require further biomedical 
assessment from those who do not. The finding that 85% of those assessed as HR were 
normoglycaemic on biomedical assessment makes it difficult to provide specific advice to the 
older age participant that is not personally confusing. Although the AUSDRISK is a predictor 
of T2DM risk over a 5-year period, rather than a diagnostic tool, for the older participant the 
result suggests that the AUSDRISK score “overdiagnoses” (Bulliard et al., 2015) the older 
individual’s T2DM risk. The most effective system for identification of those older individuals 
at HR (preDM) for T2DM would be along the lines of the NHS Health Check with direct 
regular/repeated implementation of a biochemical test on a 1–3 year basis for older 
individuals aged between 60–74 years (Martin et al., 2018, Robson et al., 2016). 
The AUSDRISK has been compared and validated with other risk assessment tests for 
predicting T2DM risk at a population level (Noble et al., 2011) with acknowledgement that the 
prediction is most accurate in the mid-years rather than younger or older (Noble et al., 2011). 
If AUSDRISK is not clinically effective for assessing older individuals for T2DM risk, it should 
be more actively utilised for health promotion and risk assessment for those aged under 60 
years where the balance of modifiable and non-modifiable risk factors is more equitable and 
where HR participants can act on the modifiable risk factors to reduce their overall risk for 
T2DM. 
As a result of the findings in this study I submit the following recommendations, with the 
acknowledgement that these recommendations, cover a wide range of initiatives and would 
depend on many Government and non-Government organisations for implementation. I hope 
the findings in my study encourage these organisations to consider and implement the 
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recommendations for the benefit of the health of older age Australians and the community in 
general. 
 RECOMMENDATIONS 
The findings of my research would strongly support the overall recommendations in the 
National Diabetes Strategy (NDS) 2016-2020 and in particular the objectives outlined in Goal 
2 of this Strategy (pages 160 – 161). But my findings do not support the approach to T2DM 
screening of one-size-fits-all in the use of AUSDRISK. Reference has been made for 
calibrating the AUSDRISK to more effectively identify HR in those of different ages (Lee et al, 
2018).   
Recommendation 1.  
My findings would suggest that the AUSDRISK would be best utilised for risk assessment of 
T2DM in individuals under the age of 60 years. That is,  in the mid-years where Risk 
Assessment Tools have been shown to be more accurate in prediction (Lee et al, 2018. Alva 
et al., 2017, Noble et al., 2011). The age range 40–60 years (and younger) is the period 
where the impact of T2DM risk is related to a greater extent to lifestyle than age and where 
participants have the opportunity to act to seek biomedical assessment if found to be at HR 
and reduce their risk for cardiometabolic conditions.  
Recommendation 2.  
My findings would support implementation of a multi-condition screening program along the 
lines of the NHS Health Check programme which would encompass screening pertinent to 
T2DM and cardiovascular conditions. 
This national program could be conducted along the lines of the Australian breast cancer and 
colorectal cancer screening programs with publicity, initial notification and reminder notices 
to facilitate participation. The program would include 1–3 yearly T2DM screening (depending 
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on individuals’ last recorded glycaemic status); and initially use an HbA1c test with 
confirmatory testing if required.  
Recommendation 3.  
The aim of the screening program for identifying older adults (60 – 74 years) would be to 
identify hyperglycaemia at the preDM stage and introduce management to revert the 
hyperglycaemic condition to normoglycaemia or effectively manage the hyperglycaemia to 
prevent complications.  
Such a program would also address the need for publicity, accurate information, initial and 
reminder notices so that T2DM screening becomes  “usual practice” for older persons. In so 
doing, it would avoid the targeting of ‘individual blame’ for so-called poor health practices. 
These negative behavioural components were frequently noted by older individuals who 
participated in my research. 
My findings also indicated that the older age cohort finds primary care medical management 
to be an acceptable and familiar system. The participants’ confidence in a system is essential 
to participation in regular screening (Usher-Smith et al., 2017).  
Recommendation 4.  
Guidelines are required to direct these changes in practices so it is timely to review the 
NHMRC Evidence based Guideline for Case Detection and Diagnosis of T2DM (2009) to 
reflect the major findings in recent international research on the heterogeneity of T2DM and 
the benefit of screening for risks associated with preDM,T2DM and cardiovascular disease. 
This review would align and provide consistency with the current review of the RACGP 
Guidelines for Prevention and Management of Diabetes 2016–18. It is hoped that both sets 
of Guidelines will reflect T2DM and its dysglycaemic precursors as an age-related chronic 
condition. In addition, to address the complexity of identification and the essential ongoing 
management of dysglycaemic states to prevent the onset of complications, and reduce 
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comorbidities such as dementia and frailty in an older age cohort, which is rapidly increasing 
in numbers and longevity.  
With the introduction of the My Health Record database, there is an opportunity to link patient 
pathology tests ( such as HbA1c, FBG, OGTT) and have current test results across Acute 
Care hospitals and Primary Care GP practices.  
Recommendation 5. 
Finally, the general public needs to know of recent advances in diagnosis and management 
of preDM/T2DM and learn that these conditions are reversible if identified in the early stages 
of dysglycaemia. Diabetes websites such as Diabetes Australia (Diabetes Australia, 2017a) 
and their state branches should promote the complexity of T2DM by recognizing the 
epigenetic, genetic, lifestyle and age-related risk factors for T2DM– with the aim to promote 
this complexity and reduce the popular and prevailing attitude towards “personal blame” 
associated with poor lifestyle choices for the onset of T2DM (Browne et al., 2017, Browne et 
al., 2013, Ventura Ad et al., 2016). This approach is particularly important for older 
individuals with late onset preDM/T2DM who may well have been following a healthy lifestyle 
which, for many years has compensated for non-modifiable risk factors. Similarly, it is 
important that individuals feel confident (not blame) to seek assistance to reduce their risk for 
preDM/T2DM. 
 STRENGTHS & WEAKNESSES 
This research was conducted in 2014-15 in 2 community-based health services and via a 
non-health statewide mail-out of the Seniors Card to older adults over the age of 60 years. 
Distribution of the AUSDRISK (plus information for completion) utilised existing systems, 
(other than medical) for distribution.  Whilst the methods of distribution were feasible, interest 
in completing the AUSDRISK was low. In the older age cohort approximately, half scored 
Intermediate Risk (IR) and half High Risk (HR). According to the AUSDRISK 
recommendations only those scoring HR are advised to attend their GP for a biomedical 
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assessment. This would be the case in all T2DM screening studies using AUSDRISK. Of 
those who completed the AUSDRISK and scored High Risk (HR) the positive predictive 
value of the AUSDRISK HR score was zero. At the time (2014-2015) this result was 
unexpected and thought possibly to be due to a small sample size. However, Noble et al, 
2011 had noted that Risk Assessment Tests were more effective in accurately identifying 
T2DM risk in individuals aged 40 - 60 years rather than those of older age. Subsequently the 
Pharmacy Diabetes Screening Trial in Australia by Krass et al 2017, using the AUSDRISK 
found a 1.0% detection of T2DM in a large study of 14,000 participants. Irrespective of 
participant numbers Community – based screening using AUSDRISK appears not to be 
effective or cost-effective.  
The information provided by the HR participants who attended their GP for a biomedical 
assessment, and pre-arranged to complete a survey after attending their GP and 
establishing their T2DM status, was invaluable. A large proportion had never heard of the 
AUSDRISK, and this situation appears not to have changed judging by the results from the 
Diabetes Australia, 2017. Most HR respondents relied on their GPs for information and 
direction for preventative care. So, the fact that there was a poor take-up response reflects 
the need to utilise a familiar process to engage older age persons.  
Subsequent research in Australia within primary health and acute care (Bishay et al., 2018, 
Hng et al., 2016, Meyerowitz-Katz et al., 2019) using direct biomedical assessment ( HbA1c) 
is more effective. The apparent negative results from my study and other community-based 
T2DM screening in Australia would appear to support the direction of T2DM screening being 
best utilised within primary health and acute care. Hence my recommendation for 
implementation of a system along the lines of the NHS Health Check programme and close 
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What is type 2 diabetes? 
Type 2 diabetes is a chronic Uong-term} disease marked 
by high levels of sugar in the blood. It occurs when the 
body does not produce enough insulin la honnone released 
by the pancreas} or respond well enough to insulin. 
Type 2 diabetes is the most common form of diabetes. 
There are approximately 1 mill ion people with type 2 diabetes 
currently. T his figure is expected to increase significantly in 
the coming years. 
People with diabetes have a higher risk of developing heart 
disease, stroke, high blood pressure, circulation problems, 
lower limb amputations, nerve damage and damage to the 
kidneys and eyes. 
Risk factors 
Many Australians, particularly those over 40, are at risk of 
developing type 2 diabetes through lifestyle factors such 
as physical inactivity and poor nutrition. Family history of 
diabetes and genetics also play a role in type 2 diabetes. 
What can you da to lower yo�r risk of 
dHelopcng type 2 diabetes? 
Your lifestyle choices can prevent or, at least, delay the onset 
of type 2 diabetes. 
You cannot change risk factors like age and your genetic 
background. You can do something about being overweight, 
your waist measurement. how active you are, eating habits, 
or smoking. 
If there is type 2 diabetes in your family, you should be careful 
not to put on weight. Reducing your waist measurement 
reduces your risk of type 2 diabetes. 
By increasing your physical activity and improving your eating 
habits you can lower your risk. Eat plenty of vegetables and 
high fibre cereal products f!,/ery day and use a small amount 
of fats and oils. Monounsaturated oils, such as olive or 
canola oil, are the best choice. 
You can have type 2 diabetes and not know it because there 
may be no obvious symptoms. 
The .Australian Type 2 Diabetes 
Rmsk Assessment Tool 1Aus□R1sK1
How do you score? 
Appendix 1 






If the patient has scored in the High Risk range, state: 
Your AUSDRISK score indicates that you have some risk factors for developing Type 2 
diabetes. It is not a diagnosis of diabetes. 
You are advised to see your doctor and have a medical assessment to determine if you 
have undiagnosed type 2 diabetes or not. Take your AUSDRISKform with you. 
The University of Tasmania is interested in conducting a follow-up telephone 
interview or short email survey, approximately 6 weeks after completing the 
AUSDRISK for those people who have scored in the High Risk range, to see if 
they have been diagnosed with type 2 diabetes or not. 
Participation in the follow-up 5 - 10 minute telephone interview or email 
survey is voluntary. Signing the Consent Form only indicates the patient is 
willing to have their AUSDRISK results (de-identified) made available to UTAS. 
Ask the patient to indicate whether they AGREE or NOT AGREE to being 
contacted for the 6 week follow-up telephone interview or short email survey. 
If the patient agrees to be contacted for follow-up email/phone call, please 
ensure they have circled AGREE and that their name and contact details are 
correct on the form and that they have signed the Consent Form. Their 
responses in the follow-up interview/email will still remain de-identified. 
Please thank the patient for participating in the follow-up part of the study. 
For all patients irrespective of their AUSDRISK score: 
The patient will return the yellow Information Sheets/Consent Forms and the 
clipboard to the Front Desk. The Front Desk staff will store the completed 
forms in a folder in a secure locked cupboard in the Team Leader's office. 
Documentation will be collected every week by the researcher. 
All patients retain their AUSDRISK form. 
It is up to the Health Professional's professional judgement as to whether the discussion 
about scoring in the High Risk range and participation in the follow-up study is done at the 
commencement or at the end of the patient consultation. 
For further information or enquiries please contact the UTAS researcher Liz 











Alex Schouten (Ms) 






Appendix 3: Follow up survey invitation for Direct recruited HR participants 
Appendix 3: HR participants’ follow up survey p 1 
Appendix 3: HR participants follow-up survey p 2 
Questionnaire by Phone 
Good afternoon/morning. My name is Liz Bingham. I am a researcher at the University of Tasmania School of Medicine. You 
participated in a Diabetes Survey – the AUSDRISK type 2 diabetes risk assessment tool -about 5-6 week’s ago. You scored 
High Risk on the AUSDRISK. You agreed to answer some questions after the survey.  
Introduction 
Q1 May I check your name? Site          CICC  OPTOM  Seniors’ Card 
Q 2 Do you still consent to 
answer 5-6 questions? 
YES 
Interviewer reiterates the purpose of the follow-
up telephone interview: 
To follow-up people who have scored in the HR 
range of the AUSDRISK to find out what actions 
they have taken or had been able to take, in 
determining their diabetes status  
Go to Q 3 
NO 
Could you advise why it is no longer convenient? 
? no time/no longer interested 
If not interested, why (gently) 
Q 3 Have you been able to see 
your GP to discuss further 
assessment as recommended 
by the AUSDRISK? Y/N 
YES -  GO to Q4 NO – why unable to see GP so far – 
Do you plan to see your GP? 
Y/N 
If Yes – appointment scheduled? 
If Y – date? 
May I contact you after that Date? 
If N – would you be happy to tell me why you don’t plan to see your GP? 
Go to Q 5 
Q 4 If Yes to Q 3 Did you have tests Y/N 
Yes – Results 
If No (to tests)-Did the GP give you any other 
directions Medication? Lifestyle? Tests later? 
Q 5 If No to Q 3  
NO – Do you plan to see another health/lifestyle professional? 
Q 6 May I just re-check the 
details you provided when you 
completed the AUSDRISK? 
Gender 
Age 
Family History of Diabetes 
May I ask how you felt when 
you scored in the HR range? 
Do you have any questions you would like to 
check with me? 
Lifestyle modifications 
Where to seek help 
Thank you for participating. The University of Tasmania Medical School 
really appreciates the time you have given to this research 
We hope the results of this research will help us promote the importance 
of knowing your diabetes status and help people manage diabetes well 
and lead a happy life. 
18 September 2013 
Dr Kate Macintyre 
C/- School of Medicine 
Sent via email 
Dear Dr Macintyre 
Document Version Date 
Low Risk Application Form - - 
AUSTOOL Flyer - - 
CICC Implementation of AUSDRISK - staff roles & responsibilities  Version 1 19 Aug 2013 
Clarence ICC  information and consent form 190813 Vers 01 Version 1 19 Aug 2013 
Mailout  information and consent form Version 1 19 Aug 2013 
Optomeyes  information and consent form Version 1 19 Aug 2013 
Optomeyes Implementation of AUSDRISK assessment tool Version 1 19 Aug 2013 
Six week post- AUSDRISK telephone or survey questions Version 1 19 Aug 2013 
The Tasmania Health and Medical Human Research Ethics Committee considered 
and approved the above documentation on 18 September 2013 to be conducted at 
the following site(s): 
Clarence Integrated Care Centre 
Optomeyes® optometry group (3 practices in Southern Tasmania) 
Please ensure that all investigators involved with this project have cited the approved 
versions of the documents listed within this letter and use only these versions in 
conducting this research project. 
This approval constitutes ethical clearance by the Health and Medical HREC.  The 
decision and authority to commence the associated research may be dependent on 
factors beyond the remit of the ethics review process. For example, your research 
may need ethics clearance from other organisations or review by your research 
governance coordinator or Head of Department.  It is your responsibility to find out if 
the approval of other bodies or authorities are required. It is recommended that the 
REF NO: H0013490 
TITLE: To develop reliable protocol(s) for the effective use of the 
AUSDRISK assessment tool as the initial step in screening for 
diabetes status in adults in Tasmania 
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proposed research should not commence until you have satisfied these 
requirements. 
All committees operating under the Human Research Ethics Committee (Tasmania) 
Network are registered and required to comply with the National Statement on the
Ethical Conduct in Human Research (NHMRC 2007 updated 2009).  
Therefore, the Chief Investigator’s responsibility is to ensure that: 
(1) The individual researcher’s protocol complies with the HREC approved
protocol.
(2) Modifications to the protocol do not proceed until approval is obtained in writing
from the HREC.  Please note that all requests for changes to approved documents
must include a version number and date when submitted for review by the HREC.
(3) Section 5.5.3 of the National Statement states:
Researchers have a significant responsibility in monitoring approved 
research as they are in the best position to observe any adverse events or 
unexpected outcomes.  They should report such events or outcomes 
promptly to the relevant institution/s and ethical review body/ies and take 
prompt steps to deal with any unexpected risks. 
The appropriate forms for reporting such events in relation to clinical and non-clinical 
trials and innovations can be located at the website below. All adverse events must 
be reported regardless of whether or not the event, in your opinion, is a direct effect 
of the therapeutic goods being tested. 
http://www.research.utas.edu.au/human_ethics/medical_forms.htm 
(4) All research participants must be provided with the current Patient Information
Sheet and Consent Form, unless otherwise approved by the Committee.
(5) The Committee is notified if any investigators are added to, or cease
involvement with, the project.
(6) This study has approval for 4 years contingent upon annual review.  A
Progress Report is to be provided on the anniversary date of your approval.
Your first report is due 18 September 2014. You will be sent a courtesy
reminder closer to this due date.
(7) A Final Report and a copy of the published material, either in full or
abstract, must be provided at the end of the project.




Ethics Officer, Health and Medical Human Research Ethics Committee 
Office of Research Services 
Tel: +61 (03) 6226 2764 
Email: lauren.black@utas.edu.au  
University of Tasmania 
Private Bag  01 Hobart Tas 7001 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in adults in 
Tasmania. Version 01. 19082013 
Tasmanian Health and Medical Human Research Ethics Committee 
Low Risk Application Form 
An electronic version of this Low Risk form and attachments must be emailed 
to Katherine.Shaw@utas.edu.au 
A signed hard copy should be mailed to Human Research Ethics, Pte Bag 1, Sandy Bay 7001 
If you have any questions please call 6226 7479 
1. TITLE OF PROPOSED INVESTIGATION
• To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the
initial step in screening for diabetes status in adults in Tasmania.
2. APPLICANTS
The term ‘investigator’ is used to cover staff and students in their roles as researchers or educators. 
The ‘Chief Investigator’ (sometimes referred to as the Principal Investigator’) is ultimately 
responsible for the conduct of the project and should be named first. A student cannot be the Chief 
Investigator on a project. 
All applicants must sign the form (Section C:  Declarations) 
Chief 
Investigator/Supervisor: 
Name:  Assoc. Prof.  Kate Macintyre 
Position: School of Medicine, University of Tasmania 
Phone: 
Email: Kate.Macintyre@utas.edu.au 
Other Investigator: Name:  Assoc. Prof.  Kelly Shaw  
Position:  Senior Clinical Lecturer, School of Medicine, UTAS 
Phone: 
Work:  (03) 62........ 
Mobile:04.. ... ... 
Email: kelly.shaw@dhhs.tas.gov.au  
Other Investigator: Professor J. R. Burgess 
HUMAN RESEARCH ETHICS COMMITTEE 
(TASMANIA) NETWORK 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in adults in 
Tasmania. Version 01. 19082013 
Position: Professor of Endocrinology, School of Medicine, University of Tasmania 
Phone: 
Email: J.R.Burgess@utas.edu.au 
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Date of birth 
Honours, 
PhD etc. 





Date of birth 
Honours, 
PhD etc. 
Student email address: Phone: Mobile: 
3. PURPOSE
What is the main purpose of this project? 
Research                Teaching 
Research for Thesis     √ Quality Assurance/Audit 
4. BRIEF OUTLINE OF PROPOSAL
Aims: 
1. Conduct a trial to test the feasibility of implementing the Australian Type 2 Diabetes Risk
Assessment Tool (AUSDRISK), to screen for type 2 diabetes in Tasmanian adults aged 18 years
and over in public and private primary health care settings, and via a mail-out to randomly
selected adults 60 years and over.
2. To determine the effectiveness and potential of each setting/approach for implementing the
AUSDRISK as an/the initial step in a national screening program for type 2 diabetes.
3. To follow-up a minimum of 50 adults in each of the primary healthcare settings who scored in
the High Risk range on the AUSDRISK and were advised to seek a biomedical assessment to
determine their diabetes status.
4. To document the investigation, diagnosis and management of those who scored in the High Risk
range.
5. To implement a mail-out of the AUSDRISK to 150 randomly selected adults over the age of 60
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in adults in 
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years in Southern Tasmania and evaluate the response rate. 
6. To investigate the personal and systemic factors which act as facilitators or barriers to utilisation




There is a current worldwide epidemic of type 2 diabetes. This is expected to increase significantly in the 
coming years due to the ageing population, increasing prevalence of obesity and other adverse lifestyle 
factors particularly poor nutrition and insufficient physical activity to gain health benefits.  
A National Diabetes Strategy and Action Plan has recently been released by Diabetes Australia® in June 2013 to 
provide a clear framework for a new national strategy for diabetes and a five year action plan. This 
framework is strongly aligned with the International Diabetes Federation and global priorities for diabetes 
prevention and management. There are five major goals, the first two of which highlight the need for 
prevention of diabetes and its complications. 
In Australia there are currently over one million adults over the age of 18 years diagnosed with type 2 
diabetes and registered on the National Diabetes Services Scheme managed by Diabetes Australia® (and its 
state-based branches) . However for every three (3) adults diagnosed with type 2 diabetes, it is estimated 
that there are another two adults with undiagnosed type 2 diabetes, as well as a proportion  who would have 
pre-diabetes, which places them at high risk of developing type 2 diabetes with early cardiovascular 
complications.  
The Australian Diabetes Obesity and Lifestyle Study “AusDiab” was conducted in the year 2000. It was the 
first national study of the prevalence of diabetes in Australia.   
In Tasmania the prevalence of diabetes in people aged 18 – 64 years was found to be 8.7% of population – an 
estimate at the time of 43,500 people. 
As at 31 March 2013 there were 25,125 people with diabetes (all types) registered on the National Diabetes 
Services Scheme (NDSS) in Tasmania of whom 21,472 were registered with type 2 diabetes.  
Diabetes Tasmania® estimates that based on the known prevalence of diabetes in Tasmania, only 60 per cent 
of those with type 2 diabetes have been diagnosed. Numerically, there could be another 16,000 – 17,000 
adults with undiagnosed type 2 diabetes and a further 40,000 at risk of developing diabetes or pre-diabetes.  
The major health issue with type 2 diabetes and pre-diabetes is that both conditions carry a high risk of 
vascular complications. A diagnosis of diabetes/pre-diabetes allows for implementation of medication and 
lifestyle measures to achieve good control of the metabolic status, and prevent or delay the onset of life-
threatening complications. 
Type 2 diabetes is bio-medically diagnosed via a series of fasting blood tests which are relatively costly and 
impractical for whole of population screening.  
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK)* was developed in 2008 to identify 
those people with or at high risk of developing type 2 diabetes. Those identified as at high risk are then 
advised to attend their General Practitioner to have a biomedical assessment (blood tests) to determine 
their diabetes status 
Since its development in 2008, the AUSDRISK has not been widely used in Australia for population screening 
or to raise people’s awareness of their risk of type 2 diabetes. Little is known as to why there has been poor 
utilisation of the AUSDRISK. A recent study (2011) amongst GPs in NSW found that only 22% were aware 
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of the AUSDRISK assessment tool. 
In Tasmania there is no population health screening for type 2 diabetes. Ad hoc opportunistic screening for 
type 2 diabetes is performed in general practices when time permits, and “finger prick” screening is 
performed on occasions such as during annual health promotion initiatives such as the National Diabetes 
Week and World Diabetes Day.  
In February-March 2011, a 6 week pilot “proof of concept” study for implementation of the AUSDRISK was 
conducted in the Southern Tasmania Health Area.  
The aim was to test the acceptability and feasibility for both clients and health professionals of implementing 
the AUSDRISK in two primary healthcare settings - a Community Health Nursing Service in the public health 
sector and in two (2) optometry practices in the private health sector. Diabetes screening was not part of 
routine practice in either setting.  
Forty two (42) adult clients voluntarily participated in the study. None was previously diagnosed with 
diabetes. Seventeen (17) adult clients were assessed in the optometry practices and 25 in the wound care 
management clinic of a community nursing service. Females represented 80% of the wound care and 100% of 
the optometry cohorts respectively. 
The findings of the trial suggested that implementation of the AUSDRISK in these healthcare settings was 
acceptable and effective for all participants, and identified people at high risk for type 2 diabetes.  
Forty-eight per cent (48%) of those assessed using AUSDRISK, scored in the high risk category. None of 
those who scored “high risk” had been previously tested for diabetes even if they had a family history of 
diabetes.  
All those identified as high risk stated their intention to follow up with their GP for biomedical assessment.  
The limitations were that the trial was designed as a “proof of concept” for the initial step in implementation 
of the AUSDRISK in primary healthcare settings and as such there was no capacity to take the next steps to 
investigate the client response and follow-up action, nor the action taken by the general practitioners for 
those who attended for a biomedical assessment.  
So whilst the proof of concept for initial implementation of the AUSDRISK was achieved there are many 
unanswered questions around the longer term effectiveness of implementing the AUSDRISK in these 
settings. The next step will be to extend the “proof of concept” implementation of the AUSDRISK by 
increasing the numbers of adults screened to develop a cohort of 150 who scored in the High Risk range.   
This proposed study will follow a cohort of 150 High Risk clients to determine client and GP responses and 
actions, for those individuals classified as High Risk on the AUSDRISK. 
In this extended study the same methodology (as pilot study 2011) will be used to implement the AUSDRISK 
assessment but additional consent for follow-up will be sought from all clients who score High Risk.  
The High Risk clients will be requested to provide contact details and permission to contact them by 
phone/email some 6 weeks after the AUSDRISK assessment to determine the outcome of their intention to 
seek biomedical assessment.   If they had been seen by a GP (Y/N); if they had received biomedical 
testing(Y/N); if tested, the results of test (diabetes Y/N or pre-diabetes Y/N); GP recommendations to client 
and ongoing management.  
In addition to extending the previous proof of concept trial, an additional potential source for implementing 
the AUSDRISK will be investigated.  
To date the AUSDRISK has not been used as a scheduled “mail out” to adults to invite their participation to 
self-assess their diabetes risk, in the manner of the current bowel cancer screening initiative which aims to 
reach all adults at age 55 and again at age 65 years. 
In this extended study a mail-out to 150 randomly selected adults aged 60 years or older will be utilised, as 
one of the potential ways of reaching adults at high risk of type 2 diabetes and responses/non response and 
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outcomes recorded and evaluated.  
 
 
                                                                                                                                                                               
Period of investigation: 
Please give expected commencement and completion dates of the investigation. 
Commencement 
date: 
1.2.2014      Completion 
date: 






5. REVIEW OF ETHICAL CONSIDERATIONS 
Research is only considered to be Low Risk if you answer in the negative to all the following 
questions.  If you answer in the positive, you must complete a full application using the NEAF 
(National Ethics Application Form) 
Is your research a clinical trial? (A clinical trial is a form of human 
research designed to find out the effects of an intervention, including a 
treatment or diagnostic procedure.  A clinical trial can involve testing a 
drug, a surgical procedure, other therapeutic procedure and devices, a 
preventative procedure or a diagnostic device or procedure) 
No   √  Yes     
Does your research involve the administration of medication or placebo 
beyond the normal routine care of the participant (if under medical care)? 
 
No   √  Yes    
Does your research involve an innovation in clinical practice or 
complementary medicine? (An innovation is defined as a new diagnostic 
or therapeutic method that aims to improve health outcomes but which 
has not yet been fully assessed for safety and/or efficacy.  The spectrum 
of innovations may range widely from minor variations or extensions of 




No  √Yes   
Does your research involve the collection of human tissue samples 
beyond the normal routine care of the participant (if under medical care)?  
Human tissue samples include blood and other bodily fluids. 
 
No   √  Yes    
Does your research involve the use of gametes and/or human embryos? 
 
No   √  Yes    
Does your research involve the use of human stem cells? No   √  Yes    
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Does you research involve genetic testing? No   √  Yes    
Does your research involve the deception of participants, including 
concealing the purposes of research, covert observation and/or audio or 
visual recording without consent? 
 
 
No   √  Yes    
Does your research involve the participation of people without their 
prior consent? 
 
No   √  Yes    
Does your research involve withholding from one group specific 
treatments or methods of learning from which they may benefit? 
 
No   √  Yes    
Does your research involve the access or use of medical records where 
participants can be identified or linked to their records in some way?  
 
No   √ Yes   
Does your research involve the use of ionising radiation? 
 
No  √  Yes    
Does your research involve the use of personal data obtained from a 
Commonwealth or State Government Department/Agency without the 
consent of the participants e.g. getting a list of addresses from the 
Australian Electoral Commission? 
 
No   √  Yes    
Does your research specifically target any of the following groups of 
people; (specifically target means they are the central group of 
participants, as opposed to potentially being incidentally recruited as 
part of the general population) 
 
• Women who are pregnant and the human foetus 
• Children and young people 
• Those highly dependent on medical care who are unable to give 
consent 
• People with a cognitive impairment, intellectual disability or 
mental illness 
• People who may be involved in illegal activities or residents of 
custodial institutions 
• Aboriginal and Torres Strait Islander Peoples 
• People in other countries 
• People who are unable to give informed consent because of 




No   √  Yes    
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Does your research pose any risks for participants under medical care 
beyond those of their routine care? (Risks include not only physical risks 
but also psychological, spiritual and social harm or distress eg 
stigmatisation or discrimination) 
 
No   √  Yes    
Does your research involve the in depth discussion of any of the 
following topics whether by interview or as part of a questionnaire or 
survey; 
 
• Parenting practices, 
• Sensitive personal issues,  
• Sensitive cultural issues,  
• Grief death or serious traumatic loss,  
• Depression mood states or anxiety,  
• Gambling,  
• Eating disorders,  
• Illicit drug taking or substance abuse,  
• Psychological disorders, 
• Suicide,  
• Gender identity and/or sexuality,  
• Race and/or ethnic identity, 
• Fertility and/or termination of pregnancy 
 
No   √  Yes    
Does your research involve the potential disclosure of illegal activities or 
criminal behaviour? 
 
No   √ Yes    
Are there any specific risks to the researcher (i.e. will the research involve 
the use of hazardous materials or be undertaken in a politically unstable 
area)? 
 
No   √  Yes    
If your research will take place in an overseas setting do any of the 
following apply: is the research to be undertaken in a politically unstable 
area? Does it involve sensitive cultural issues? And/or: will the research 
take place in a country in which criticism of the government and 
institutions might put participants and/or researchers at risk? 
 
No   √  Yes    
Does your research explore potentially confidential business practices or 




No   √  Yes    
Does your research explore potentially divergent political views or 
involve the collection of politically sensitive information? 
 
 
No   √  Yes    
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5. FUNDING   
Under the National Statement (2.2.6) a researcher must disclose: 
• the amount and sources or potential sources of funding for the research; and 
• financial or other relevant declarations of interest of researchers, sponsors or institutions 
Do the investigators have any financial interest in this project? No   √  Yes    
If this Application relates to a Grant(s) and/or Consultancies, please indicate the title and 
Number relating to it: 
Funding Body:                                                                                                    Amount:                         
Funding Body:                                                                                                     Amount:                         
If no external funding has been obtained, please indicate how any costs of research will be 
met: Costs covered by industry partners through in-kind contribution.                                                                                                                                                                               
 
6. RECRUITMENT  
Selection of subjects  
There will be two (2) recruitment processes for participants in this study/trial 
1. The initial selection of adults to complete the AUSDRISK will be from the two primary healthcare 
services (one in the public health sector, the other in the private health sector) plus those adults 
aged 60 years and over who receive an AUSDRISK via the mail-out. 
2. The second selection will be those subjects from the two primary healthcare sectors and the mail-
out who scored in the High Risk range on the AUSDRISK. They will be invited to participate in the 
follow-up component of the study.    
Initial recruitment: 
• Mail-out – random selection of 150 adults aged 60 years and over will receive an AUSDRISK 
assessment form with information regarding the trial and request to complete the AUSDRISK and 
an invitation to participate in a follow-up if scoring in the High Risk range. 
• Private healthcare sector - Clients aged 45 years and over attending for a full eye examination with 
pupil dilatation at three Optomeyes® group optometry practices in Southern Tasmania will be 
invited by their treating optometrist to participate. The commencement age for recruitment was 
recommended by the participating optometrists who advised that the through-put for full eye 
assessments was low for adults under the age of 45 years, along with the relatively lower type 2 
diabetes risk in the younger age groups. 
• Public healthcare sector - All new adult patients (adults 18+years) attending for health services 
conducted at the Clarence Integrated Care Centre (CICC), Bellerive, Tasmania will be invited by 
the CICC admission staff and their treating health professional to participate. The wider age range 
chosen for the new patients at Clarence Integrated Care Centre (CICC) is due to the CICC 
management wishing to trial the process of AUSDRISK implementation as a regular component for 
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ALL new patient assessments. 
There are no gender criteria and the age range chosen is mainly reflective of the 2013 registration of 
adults with type 2 diabetes, on the National Diabetes Services Scheme (NDSS) database in Tasmania.  
As at 31st May 2013 there were 21,728 adults over the age of 20 years with type 2 diabetes 11,527 males 
and 10,201 females.   
As indicated in the figures below there is low prevalence of type 2 diabetes in adults aged less than 40 
years. Finding a cohort of 100 people scoring at High Risk on the AUSDRISK is unlikely in the younger 
ages range. 
 21-39 yrs  40-49 yrs  50-59 years 60–69years 70-79years 80-81years 90+years   
Male 225 860 2244 3676 2978 1370 174 11 527 
Female 358 983 1812 2777 2500 1456 314 10 201 
Total 583 
 
1843 4056 6453 5478 2826 488 21 728 
Percentage 2.68% 8.57% 18.67% 29.69% 25.21% 13.0% 2.25% 100% 
                                                                                                                                                                               
Recruitment of subjects  
 
Following extensive discussion of the AUSDRISK trial aims and processes between the researcher and the 
managements of the Clarence Integrated Care Centre and the Optomeyes® optometry practices in 
southern Tasmania both organisations have agreed to participate in this AUSDRISK trial. Both 
organisations participated in the initial pilot study of the AUSDRISK implementation in 2011-12. 
All health professional staff members will be provided with written protocols to follow for introducing the 
trial and inviting the clients to participate (see documentation attached).  
All participants will be provided with an AUSDRISK ‘package’ in which is included: 
•  a Participant Information Sheet;  
•  a Consent Form to participate in the trial;  
•  an AUSDRISK assessment form;  
•  a paper tape measure and  instructions on how to measure waist circumference  
Optomeyes® clients: 
 All adult clients aged 45 years and over (not previously diagnosed with diabetes) attending for a full 
 eye examination with pupil dilation at  three Optomeyes® optometry practices (private health 
 sector) in Southern Tasmania will receive a personal invitation from their optometrist to participate 
 in the AUSDRISK trial. The optometrists, trained to implement the standardised introduction 
 procedure (see attached Implementation of AUSDRISK Assessment tool at Optomeyes®) will 
 explain the AUSDRISK trial and hand an AUSDRISK package to the client. The client will be invited 
 by the optometrist to read the information sheet; provide consent to participation in the trial  by 
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 signing the consent form and to complete the AUSDRISK. Each client will complete the AUSDRISK 
 assessment procedure prior to the dilation drops dilating their pupils (as part of the full eye health 
 assessment) and return the completed form back to the optometrist to check their AUSDRISK 
 score. 
Clarence Integrated Care Centre (CICC) new patients: 
 All New adult Patients (adults 18+years not previously diagnosed with diabetes) attending for health 
 services at the Clarence Integrated Care Centre (CICC), Bellerive, Tasmania will be advised by a 
 Front Desk administration officer trained in AUSDRISK Implementation at CICC, that the CICC 
 is conducting a trial implementation of the AUSDRISK as part of its new patient assessment.  All 
 new patients will be  invited to complete an AUSDRISK as part of their New Patient admission 
 process. The AUSDRISK ‘package’ will be handed to them. Each new patient will be invited by  the 
 Administration Officer to read the Information Sheet; provide consent to participation in the trial by 
 signing the Consent Form; complete the AUSDRISK and take it with them to their appointment with 




Mail-out – An AUSDRISK assessment form with instructions on completion will be mailed out to a 
random selection of 150 adults aged 60 years and over in Southern Tasmania. Recipients will be invited to 
participate in an AUSDRISK trial being conducted by the University of Tasmania. Included in the mail-out 
will be the AUSDRISK ‘package’ and a Reply Paid pre-addressed envelope. 
All mail-out recipients will be requested to return the documentation either completed or not completed 
to the addressee on the Reply paid envelope. 
                                                                                                                                                                               
 
 
Information about subjects 
Which of the following best describes the identifiability of the data (including tissues) 
collected? 
Non-identifiable data (which has never been labelled with individual 
identifiers, or from which identifiers have been permanently removed, and 
by means of which no specific individual can be identified) 
√ 
Re-Identifiable (from which identifiers have been removed and replaced 
by a code, but it remains possible to re-identify a specific individual by, for 
example, using the code or linking different data sets) 
 
Identifiable (where the identity of a specific individual can reasonable be 
ascertained. Examples of identifiers include the individuals name, image, 
date of birth or address). 
√  
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If the information is Re-Identifiable or Identifiable, please give details of the information that 
will be collected.   Also indicate how the confidentiality and anonymity of the participants 
will be protected: 
Participants who score in the High Risk range and consent to being followed up by 
telephone interview or email survey will be requested to supply their contact details. All 
personal information and data will be kept secure – see data storage information p 17. 
Analysis and reporting of data from all participants will be de-identifiable. 
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6. RELEVANT LITERATURE REFERENCES
Please list the most relevant and recent literature references, both by the investigator and/or 
by others, that support the justification for the study.   
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Adult clients attending practices in two primary healthcare sectors (one in the private health sector and one in 
the public health sector) will be recruited to complete an AUSDRISK assessment by their treating health 
professionals (as per Recruitment of Subjects ). 
It is expected that recruitment in the two primary healthcare sectors will continue over a period of six 
months or until fifty (50) clients/patients scoring in the High Risk category in each of the sectors (total 100 
High Risk) have consented to participate in the follow-up component of the study.   
The AUSDRISK assessment form will be mailed out to 150 adults over the age of 60 years in the Southern 
Tasmania region (random selection). The mail-out will be linked to the mail-out of Seniors’ Cards. The 
researcher will have no involvement in this process apart from providing the “AUSDRISK package”. 
All participants will receive information on the study with instructions on how to complete the AUSDRISK. 
All participants will be required to provide written consent to participate in the study. See protocols attached. 
Those who have scored in the High Risk range on the AUSDRISK will be invited to participate in the follow-
up segment of the study. They will have the opportunity to agree or not agree to participate by the choice of 
providing (or not) their phone or email contact details.  
Approximately 6 weeks after completion of the AUSDRISK, a UTAS researcher will conduct a standardised 
phone interview or send an electronic survey (see interview questions attached) to those clients (from all 
sectors) scoring in the High Risk range who have given their written consent and provided contact details 
(phone/email). 
The interview schedule template/electronic survey will be available electronically and participant responses 
will be added during the phone interview or online via email survey. All responses will be held in securely with 
access only via password on a computer hard drive. Printed copies will be stored in a locked cupboard with 
access only via a key held by a designated person (UTAS researcher).  
 
Clarence Integrated Care Centre – with new patients as part of their initial assessment,  
All front desk administration staff and all Health Professionals at CICC will be trained to implement the 
AUSDRISK as per protocols attached. 
 The AUSDRISK trial will be introduced to all New Patients by the front desk admission staff and,if the 
patient has not previously been diagnosed with diabetes, an AUSDRISK ‘package’ will be handed to 
them.  
New patients will be invited by the Administration Officer to read the information sheet; provide 
consent to participation in the trial by signing the consent form; and complete the AUSDRISK.   
New patients will complete the AUSDRISK prior to attending their appointment with the Health 
Professional and take the completed AUSDRISK plus all trial documentation to their appointment.  
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Health Professionals will check that the AUSDRISK documentation has been completed and write the 
TOTAL score on the AUSDRISK form and on the front of the Information sheet. 
Health professionals will emphasise that the AUSDRISK assessment tool provides an assessment of risk 
for developing diabetes it is NOT a diagnostic tool. Only a medical practitioner can diagnose diabetes. 
- If the AUSDRISK score is less than 12 points, the Health Professional will advise the patient to follow 
the instructions on the AUSDRISK assessment tool. 
- If the AUSDRISK score is 12 points or more, the health professional will discuss the follow-up 
component of the study for those who score in the High Risk range. The patient will be advised that 
participation is voluntary and should indicate on the consent form whether they (client)’AGREE‘ or 
“DO NOT AGREE” for follow up. If they ‘AGREE’, they will provide their contact details. 
- Health professionals will check that the AUSDRISK total score and the patient’s age, gender and 
family history for Type 2 diabetes are written on the front of the Information sheet.  
 Health Professionals will place the AUSDRISK trial documentation for each new patient, irrespective 
 of AUSDRISK score and whether patient agrees to further participation, (Information sheet; Consent 
 Form and Information sheet for those patients scoring in the High Risk range) in an envelope; seal it 
 and place it in a sealed container (see Data storage details). The patient will retain their completed 
 AUSDRISK assessment tool either to take to a medical practitioner for a biomedical assessment or 
 for future health assessments. 
Optomeyes® - clients having a full eye health assessment  
 During the first part of the full eye health assessment, the optometrist will check the client’s diabetes 
 status and if the client has not been diagnosed with diabetes, the optometrist will introduce the 
 AUSDRISK to the client, and emphasize its relationship to eye health and diabetes. 
 The optometrist will hand the AUSDRISK ‘package’ to the client and explain the details and 
 rationale (as per the Optometry Implementation form) and check that the client is willing to 
 participate in the AUSDRISK assessment. 
 The optometrist will emphasise that the AUSDRISK assessment tool provides an assessment of risk 
 for developing diabetes it is NOT a diagnostic tool. Only a medical practitioner can diagnose 
 diabetes. 
 The optometrist will advise that after the dilating drops are put in the eyes the client will go to the 
 waiting room and during the time prior to the drops taking effect the client is requested to: 
 Read the Information Sheet and sign the Consent Form to indicate agreement to participate in  the 
 trial and complete the AUSDRISK.  
 It takes approx. 10 minutes for the pupil to dilate so the client’s vision is fine to complete the forms. 
 (This is the advice from the participating optometry group).  
- The client will take the completed AUSDRISK and other forms back to the optometrist for the 
second part of the eye health assessment. 
- If the AUSDRISK score is less than 12 points, the client will be advised to follow the instructions on 
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the AUSDRISK assessment tool. 
- If the AUSDRISK score is 12 points or more, the health professional will discuss the follow-up 
component of the study for those who score in the High Risk range. The client will be advised that 
participation is voluntary and that they should indicate on the consent form  whether they 
(client)”AGREE” or “DO NOT AGREE” for follow up. If they ‘AGREE’ they will provide their contact 
details. 
- The optometrist will write the AUSDRISK total score and the patient’s age, gender and family history 
for Type 2 diabetes on the front of the Information sheet.  
- The optometrist will place the AUSDRISK trial documentation for ALL CLIENTS (Information sheet; 
Consent Form and Information sheet for those patients scoring in the High Risk range) in an envelope; 
seal it and place it in a sealed container (as per Data Storage). The client will keep/retain their 
completed AUSDRISK assessment tool either to take to a medical practitioner for a biomedical 













                                                                                                                                                                               
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in adults in 
Tasmania. Version 01. 19082013 
 
Mail-out  
An AUSDRISK assessment form with instructions on completion will be mailed out to a random selection 
of 150 adults aged 60 years and over in Southern Tasmania. The mail-out will be linked to the mail-out of 
Seniors’ Cards. The researcher will have no involvement in this process apart from providing the 
“AUSDRISK package”. Recipients will be invited to participate in an AUSDRISK trial being conducted by 
the University of Tasmania. Included in the mail-out will be the AUSDRISK ‘package’ and a Reply Paid pre-
addressed envelope. The trial information will include a request to read the Information Sheet and sign the 
Consent Form to indicate agreement to participate in the study; and instructions to complete the 
AUSDRISK including the waist circumference measurement; to write the total score on the AUSDRISK 
brochure and provide details of age, gender and family history on the Information Sheet; and follow the 
instructions for their score range provided on the AUSDRISK form.- Instructions for those who score 
High Risk, are to contact their medical practitioner to be considered for a biomedical assessment to 
determine their diabetes status. Those who score in the High Risk category will have the opportunity to 
participate in the follow-up telephone interview/electronic survey via email by providing their contact 
details. 
  The client will keep/retain their completed AUSDRISK assessment tool to either to take to a medical                
practitioner for a biomedical assessment or for future health assessments. 
All mail-out recipients will be requested to return the documentation (minus the AUSDRISK tool) either 






8. DATA STORAGE 
 
Where will the data be kept?  
 The data sheets for each client/patient will be placed in individual envelopes and sealed immediately and kept 
in a locked cupboard in each of the primary healthcare sites during the course of the trial. The UTAS 
researcher (Liz Bingham) will collect the sealed envelopes each week and on completion of the trial. . 
Responses from the primary health care sites and the mail-out will be kept in a locked cupboard at DHHS 
Population Health where the researcher is employed. 
 
                                                                                                                                                                               
How will the data be kept secure? As above 
The data will be kept in locked cupboards with access only via a key held by one designated person at each site 
and by Liz Bingham at Population Health. 
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How and when will the data be destroyed?  
The data will be shredded 7 years after completion of the project. 
                                                                                                                                                                               
Will any personal information be collected from sources other than the subjects themselves 
(Please refer to Privacy Legislation Section 95A - National Privacy Principles)?  
If YES, please declare the sources of the Information i.e. medical records, databases, registries, 
lists of members from Associations, clubs etc: 
No  √ Yes    (please detail)                                                                                                                      
Will data on individual subjects be obtained from any Commonwealth Government agency 
without seeking the consent of the individuals?   If yes, then please declare which agency and what 
information is being sought.  If you wish to obtain data containing personal information from any 
Commonwealth Government agency state the names of these agencies, describe the nature of this data 
and explain the justification for obtaining this information. At the Commonwealth level the collection, 
storage, use and disclosure of personal information by Commonwealth agencies is regulated by the 
Privacy Act 1988. The NHMRC requires the HREC to provide information on the cases in which it has 
approved access to, and use of, data held by Commonwealth Government agencies. 
 
No   √ Yes    (please detail)                                                                                                                      
 
11. INFORMATION SHEET  
With few exceptions, it is essential that subjects are provided with an information sheet about 
the study in which they are being asked to participate. The Chair of the HREC will pay close 
attention to the information that is given.   
A copy of the proposed information sheet must be attached to your application form.  
Is your proposed Information sheet attached to this application? 
Yes   √ No    (please provide an explanation as to why)                                                                           
 
12. CONSENT FORM  
Written evidence of consent is usually required for research involving human subjects. If 
written consent is to be obtained a copy of the actual consent form that you propose to use.  In 
certain circumstances, the HREC may give approval for consent to be waived (see Chapter 2.3 
of the National Statement).  While written consent is the norm, there are various kinds of 
studies for which other procedures for obtaining consent are more appropriate (See Chapter 
2.2 of National Statement). 
 
If you consider that written consent is inappropriate for this project please state your reasons 
clearly referring to the appropriate sections of the National Statement. 
 
Is a proposed consent form attached to this application? 
Yes  √     No    (please provide an explanation as to why)                                                                                                                      
 
13. APPROVALS FROM OTHER DEPARTMENTS/INSTITUTIONS 
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Does this project need the approval of any institution other than the University of 
Tasmania and/or the Department of Health and Human Services (i.e. Department of 
Education, particular wards in hospitals, prisons, government institutions, or businesses)? 
If ‘YES’, Please indicate below what Institutions are involved and what the status of the 
Approval. 
No   √ Yes    (please detail):   
              Name of Other Institution(s):                                                  Status:                                            
Does this project need the approval of any 
other HREC? 
If ‘YES’, Please indicate below which HREC 
and the status of the application. 
No  √   Yes    (please detail):   
Other HREC(s):                                                   





14.  DECLARATIONS 
The Head of School or the Head of Department is required to certify that: 
• He or she is familiar with this project and endorses its undertaking; 
• The resources required to undertake this project are available; 
• The researchers have the skill and expertise to undertake this project appropriately or 
will undergo appropriate training as specified in this application. 
If the Head of School/Department is one of the investigators, this statement must be signed by 
an appropriate person. This will normally be the Head of School/Department in a related area 
or by the Dean. 
Name  
Position   
Signature  
Date                                  
 
Conformity with NHMRC Guidelines  
The Chief Investigator is required to sign the following statement: 
I have read and understood the National Statement on Ethical Conduct in Human Research 2007 
and the Australian Code of Conduct for Responsible Research 2007. I accept that I, as Chief 
Investigator, am responsible for ensuring that the investigation proposed in this form is 
conducted fully within the conditions laid down in the National Statement and any other 
conditions specified by the HREC. 
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Signatures of Other Investigators  
The other investigators should sign to acknowledge their involvement in the project and to 
accept the role of the Chief Investigator. – N/A 
(Name) 
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Please ensure that the following documents are included with your application: 
Information sheet/s (if not attached ensure you have explained why in Section 11) √ 
Consent form/s (if not attached ensure you have explained why in Section 12) √ 
Questionnaires (if applicable) √ 
Interview schedules (if applicable) √ 
A copy of any permissions obtained i.e. Department of Education, Other HREC, Other 
Institutions (if applicable) 
N/A 
All documents relevant to the study, including all information provided to subjects.  √ 
Telephone Preambles (if applicable) √ 
Recruitment Advertisements (if applicable) N/A 
Email Contents (if applicable) N/A 
Has the 'Statement of Scientific Merit' been signed?  √ 




The Australian Type 2 Diabetes 
Risk Assessment Tool (AUSDRISK)
How do you score?
What is type 2 diabetes?
Type 2 diabetes is a chronic (long-term) disease marked  
by high levels of sugar in the blood. It occurs when the  
body does not produce enough insulin (a hormone released  
by the pancreas) or respond well enough to insulin.  
Type 2 diabetes is the most common form of diabetes.  
There are approximately 1 million people with type 2 diabetes 
currently. This figure is expected to increase significantly in 
the coming years.
People with diabetes have a higher risk of developing heart 
disease, stroke, high blood pressure, circulation problems, 
lower limb amputations, nerve damage and damage to the 
kidneys and eyes.
Risk factors
Many Australians, particularly those over 40, are at risk of 
developing type 2 diabetes through lifestyle factors such 
as physical inactivity and poor nutrition. Family history of 
diabetes and genetics also play a role in type 2 diabetes.
What can you do to lower your risk of 
developing type 2 diabetes?
Your lifestyle choices can prevent or, at least, delay the onset 
of type 2 diabetes.
You cannot change risk factors like age and your genetic 
background. You can do something about being overweight, 
your waist measurement, how active you are, eating habits, 
or smoking.
If there is type 2 diabetes in your family, you should be careful 
not to put on weight. Reducing your waist measurement 
reduces your risk of type 2 diabetes.
By increasing your physical activity and improving your eating 
habits you can lower your risk. Eat plenty of vegetables and 
high fibre cereal products every day and use a small amount 
of fats and oils. Monounsaturated oils, such as olive or 
canola oil, are the best choice.
You can have type 2 diabetes and not know it because there 
may be no obvious symptoms.
The Australian Type 2 Diabetes Risk Assessment Tool  
was developed by the Baker IDI Heart and Diabetes  
Institute on behalf of the Australian, State and Territory 
Governments as part of the COAG initiative to reduce  
the risk of type 2 diabetes
Current from: May 20106811 (1007)
The Australian Type 2 Diabetes  
Risk Assessment Tool (AUSDRISK)
1. Your age group
 Under 35 years   0 points
 35 – 44 years 2 points
 45 – 54 years 4 points
 55 – 64 years 6 points
 65 years or over 8 points
2. Your gender
 Female 0 points
 Male 3 points
3. Your ethnicity/country of birth:
3a. Are you of Aboriginal, Torres Strait Islander,  




3b. Where were you born?
 Australia  0 points 
 Middle East, North Africa, Southern Europe 2 points
 Other  0 points
4. Have either of your parents, or any of your brothers  
or sisters been diagnosed with diabetes  
(type 1 or type 2)?
 No 0 points
 Yes 3 points
5. Have you ever been found to have high blood glucose 
(sugar) (for example, in a health examination,  
during an illness, during pregnancy)?
 No 0 points
 Yes 6 points
6. Are you currently taking medication for high  
blood pressure?
 No 0 points
 Yes 2 points
7. Do you currently smoke cigarettes or any other 
tobacco products on a daily basis? 
 No 0 points
 Yes 2 points
8. How often do you eat vegetables or fruit?
 Every day  0 points
 Not every day  1 point
9. On average, would you say you do at least 2.5 hours  
of physical activity per week (for example, 30 minutes  
a day on 5 or more days a week)?
 Yes  0 points
 No  2 points
10. Your waist measurement taken below the ribs  
(usually at the level of the navel, and while standing)
Waist measurement (cm)  
  For those of Asian or Aboriginal or Torres Strait 
Islander descent:
 Men Women 
 Less than 90 cm Less than 80 cm 0 points
 90 – 100 cm 80 – 90 cm 4 points
 More than 100 cm More than 90 cm 7 points
 For all others:
 Men Women 
 Less than 102 cm Less than 88 cm 0 points
 102 – 110 cm 88 – 100 cm 4 points
 More than 110 cm More than 100 cm 7 points
Add up your points  
Your risk of developing type 2 diabetes within 5 years*:
5 or less: Low risk 
Approximately one person in every 100 will develop diabetes.
6-11: Intermediate risk 
For scores of 6-8, approximately one person in every 50 will 
develop diabetes. For scores of 9-11, approximately one person 
in every 30 will develop diabetes.
12 or more: High risk 
For scores of 12-15, approximately one person in every 14 will 
develop diabetes. For scores of 16-19, approximately one person 
in every 7 will develop diabetes. For scores of 20 and above, 
approximately one person in every 3 will develop diabetes.
*The overall score may overestimate the risk of diabetes in those aged less than 25 years.  
If you scored 6-11 points in the AUSDRISK you may be at 
increased risk of type 2 diabetes. Discuss your score and your 
individual risk with your doctor.  Improving your lifestyle may help 
reduce your risk of developing type 2 diabetes.
If you scored 12 points or more in the AUSDRISK you may have 
undiagnosed type 2 diabetes or be at high risk of developing the 
disease. See your doctor about having a fasting blood glucose 
test. Act now to prevent type 2 diabetes.
Asia (including the Indian sub-continent),
 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for 
diabetes status in adults in Tasmania. Version 01. 19082013 
Implementation of AUSDRISK Assessment Tool  
at the Clarence Integrated Care Centre for all new adult clients. 
Role of Front of House Service Staff
Introduce AUSDRISK to new adult clients 
Clarence Integrated Care Centre is introducing a type 2 diabetes risk 
assessment for all new adult clients. It’s called the AUSDRISK. It will take you a 
short time (2-5 minutes) to complete.  
First I just want to check: 
Question 1.  Have you been diagnosed with any form of diabetes? 
–if yes, ask - type 1, type2, Gestational Diabetes (GDM during pregnancy only)
If yes, to type 1 or type 2 – note on Information Sheet and do not proceed with 
AUSDRISK; ask approximately when were you diagnosed (by a doctor) with type 
1 or type 2 diabetes – note approximate date on the Information Sheet. 
If yes to GDM, only during pregnancy – suitable to complete the AUSDRISK 
(follow instructions as for No to diagnosed diabetes). 
If NO – to diagnosed with diabetes – hand the AUSDRISK ‘package’ to the new 
patient and ask them to read the Information Sheet, and complete the 
AUSDRISK assessment tool and take the papers with them to their appointment 
with the Health Professional. If they are disinclined to complete the form 
immediately e.g : If they say “will do it later” or “forgotten my glasses” – say it’s 
important to do it now before you start your appointment.   
Question 2.  Would you like some assistance?–– offer the front of house 
staff or suggest that an adult accompanying the client could read out the 
questions and assist in filling out the form. If they still indicate they do not want 
to complete the AUSDRISK, do not persist. Note they have DECLINED on the 
Information Sheet.  
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Implementation of AUSDRISK Assessment Tool  
at the Clarence Integrated Care Centre for all new adult clients  
 
Role of Health Professional staff 
Ask for the AUSDRISK documentation and thank the patient for completing it – 
or assist the patient if they have been unable to complete it. 
State that the Clarence Integrated Care Centre is conducting a trial for the 
AUSDRISK to be part of every new patient assessment. As this is a new initiative 
for CICC, the University of Tasmania (UTAS) is assisting to monitor and evaluate the 
introduction of the AUSDRISK. 
State that the AUSDRISK provides an assessment of the patient’s risk for 
developing type 2 diabetes. It is NOT used to diagnose type 2 diabetes that can 
only be done by a medical practitioner. 
 
Check that all the AUSDRISK questions have been answered. 
  
If not, offer assistance to complete the AUSDRISK 
 
Check that the patient’s waist has been measured. 
If not, please use the tape measure (supplied) and ask the patient if you may 
take a waist measurement in order to obtain an accurate score. 
 
Total the score on the completed AUSDRISK and complete the patient details 
on the front page of the Information Sheet. 
 
Return the completed AUSDRISK form to the patient 
 
Ask all patients to sign the Consent Form if they agree to their data (de-
identified) being provided to the University of Tasmania. 
 
Note on the Information Sheet if they DO NOT AGREE to releasing data. 
 
Read out the recommendations on the AUSDRISK for the risk range that the 
new patient has scored – irrespective of whether the client agrees to their data 
being used or not. 
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If the patient has scored in the High Risk range, refer to: 
INFORMATION FOR PEOPLE WHO HAVE SCORED IN THE HIGH RISK RANGE  
on the Information Sheet. 
 
‘The AUSDRISK score indicates that you have some risk factors for developing Type 2 
diabetes. It is not a diagnosis of diabetes. 
You are advised to see your doctor and have a medical assessment to determine if you 
have undiagnosed type 2 diabetes or not.’ 
 
The University of Tasmania is interested in conducting a follow-up telephone 
interview or short email survey, approximately 6 weeks after completing the 
AUSDRISK for those people who have scored in the High Risk range, to see if 
they have been diagnosed with type 2 diabetes or not. 
 
Participation in the follow-up 5 – 10 minute telephone interview or email 
survey is voluntary.  
 
Ask the patient to indicate whether they AGREE or NOT AGREE to being 
contacted for the 6 week follow-up telephone interview or short email survey. 
 
If the patient agrees to follow-up, please ensure they have circled AGREE and 
that their name and contact details are correct on the form and that they have 
signed the Consent Form. 
 
Place all the AUSDRISK documentation (except the AUSDRISK form which the 
patient retains) in the envelope provided; seal the envelope and place it in a 
sealed container to be kept in a secure locked cupboard. Documentation will 
be collected every week by the researcher.  
 
 
It is up to the Health Professional’s professional judgement as to whether the discussion 
about scoring in the High Risk range and participation in the follow-up study is done at the 
commencement or at the end of the patient consultation. 
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For further information or enquiries please contact the UTAS researcher 
Liz Bingham PH: (03) 62.. ..... 
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Type 2 diabetes screening at Clarence Integrated Care Centre   
 
Participant Information Sheet on the AUSDRISK assessment tool 
 
Clarence Integrated Care Centre (Clarence ICC) is introducing the AUSDRISK 
assessment tool as part of the assessment for all new adult clients attending the CICC. 
The aim is to identify adults at risk for developing Type 2 diabetes and assist them to manage their 
health risk.  
As this is a new initiative for the Clarence ICC, the University of Tasmania, School of Medicine 
(UTAS) is assisting to collect data, monitor and evaluate the introduction of the AUSDRISK.  
 
Type 2 diabetes is a health condition which has very few symptoms or warning signs to alert a 
person that they might be at risk. It is important for people to know their diabetes risk so that the 
risk can be managed and type 2 diabetes can be prevented/delayed.  
 
The AUSDRISK assessment tool (AUSDRISK) identifies if you are at risk of developing type 2 
diabetes. It is not a diagnostic test but it can indicate whether you would benefit from having 
medical tests to confirm whether you have diabetes or not. 
 
DIRECTIONS TO COMPLETE THE AUSDRISK:  
• You may gain assistance from a family member or a friend to complete the AUSDRISK. 
• Answer ALL the AUSDRISK questions.  
• Make sure you measure your waist (in cms) according to the instruction sheet, with the 
tape measure supplied.  
• Write your waist measurement (in cms) in the box and  
• Tick the small box that indicates the range for your waist measurement. 
• ADD UP all the points (in the small boxes ticked).  
• WRITE your final score in the last large box on the AUSDRISK form. 
• Keep your completed AUSDRISK form. 
  
 
ALL Participants are requested to write the following AUSDRISK details on this page 
 
    YOUR   AUSDRISK   SCORE  
 
Your gender (please circle whichever is correct):    Male  Female 
 
Your age …………..years. 
  
Have either of your parents, or any of your brothers or sisters been diagnosed with 
diabetes (type1 or type 2)?   Please circle whichever is correct.       NO      YES  
 
Please read the Consent Form (on the back of this page). 
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 Print and sign your name if you agree that your AUSDRISK score and details (gender, age, family 
history of diabetes) can be made available to the University of Tasmania, School of Medicine.  
 
CONSENT FORM (for all participants) 
 
1. I have understood the instructions and completed the AUSDRISK and written the
 details requested on page 1 of the 'Information Sheet'. 
2. I consent to my AUSDRISK score and details (gender, age-range, family history of 
 diabetes) on this sheet can be made available to the  University of Tasmania, School 
 of Medicine 
3. I understand the AUSDRISK is not a diagnostic test and that if I score in the High 
 Risk range I will be advised to see a medical practitioner for a medical assessment.   
4. I understand that if I scored in the High Risk range I will be invited to 
 participate in the follow-up study. This will involve volunteering a very short 
 amount of my valuable time for a telephone interview by a UTAS researcher or 
 completing a short email survey. 
5. I understand that participating in the follow up component of this study is voluntary. 
6. I understand that all my data and details will be securely stored on the University of 
 Tasmania premises for seven years, and will then be destroyed. 
7. I agree that research data gathered from me for the study may be published, 
 provided that I cannot be identified as a participant. 
8.  I understand I may withdraw at any time without any effect, and I may request that 













If you agree to have your answers made available to the University of Tasmania, 
School of Medicine, please sign the Consent Form and complete the AUSDRISK and 
fill out the details on the front page.  
 
If you have NOT scored in the High Risk range you have finished the AUSDRISK 
research.   
 
   Thank you for your participation 
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If you have scored in the High Risk range on the AUSDRISK, please 
continue on the next page. 
FOR PEOPLE WHO HAVE SCORED IN THE HIGH RISK RANGE 
 
• You are advised to see a medical practitioner to discuss your AUSDRISK score 
and find out whether further assessment is recommended.  
 
• Make sure you take your completed AUSDRISK assessment tool with you 
when you attend an appointment with a GP/medical practitioner.  
 
• Scoring at High Risk (12 or more) on the AUSDRISK does NOT mean you 
have type 2 diabetes. It shows you have some risk factors that put you at 
higher risk for developing type 2 diabetes.  
 
• The University of Tasmania, School of Medicine would like to conduct a short 
telephone interview with those people who score in the High Risk range, to 
find out if they had been able to see their GP or medical practitioner about their 
AUSDRISK result, and  whether they were diagnosed with type 2 diabetes or not.  
 
• The 5 - 10 minute telephone interview at a time convenient for you, would be 
conducted by a UTAS researcher, approximately 6 weeks after you have completed 
the AUSDRISK.  Alternatively an email survey would be available. 
 Information that is gathered during the interview or survey will not identify you. 
 
• It is important that you understand that although you have scored in the High Risk 
range, your participation in this follow-up part of the study is voluntary. Whilst 
we would be pleased to have you participate, we respect your right to decline.  
 
Please circle:  AGREE   or      DO NOT AGREE   to receiving  a telephone 
call or email from a University of Tasmania researcher to participate in a short 
follow-up telephone interview or completing a short email survey. 
 
Please provide you contact details if you agree to participate in a telephone interview 
or email survey. 
 
Contact details (Name and Phone Number or Email address):  
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…………………………………………………………………………………………………………. 
Thank you for your participation. 
If you have any queries, please contact UTAS researcher Liz Bingham (03) 62.. ..... 
Please return ALL the pages in the Reply Paid envelope as soon as possible. 
This study has been approved by the Tasmanian Health and Medical Human Research Ethics Committee. If you have concerns or 
complaints about the conduct of this study, you should contact the Executive Officer of the HREC (Tasmania) Network on (03) 6226 
7479 or email human.ethics@utas.edu.au 
P a g e  | 1 
 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes 
status in adults in Tasmania.Version 01. 19082013 
 
 
Type 2 diabetes screening 
 
Participant Information Sheet on the AUSDRISK assessment tool 
 
The University of Tasmania, School of Medicine (UTAS) is conducting research to determine an 
effective way of screening for Type 2 diabetes – that is to identify people at risk who don’t know it. 
 
This study is NOT for people who have already been diagnosed with Type 1 or Type 2 diabetes,  
If you have already been diagnosed, please write on the top of this page “DIAGNOSED WITH 
DIABETES” and return all the papers (uncompleted) in the Reply Paid envelope.  
  
Type 2 diabetes is a health condition which has very few symptoms or warning signs to alert a 
person that they might be at risk. It is important for people to know their diabetes risk so that the 
risk can be managed and type 2 diabetes can be prevented/delayed.  
 
The AUSDRISK assessment tool (AUSDRISK) identifies if you are at risk of developing type 2 
diabetes. It is not a diagnostic test but it can indicate whether you would benefit from having 
medical tests to confirm whether you have diabetes or not. 
 
DIRECTIONS TO COMPLETE THE AUSDRISK:  
• You may gain assistance from a family member or a friend to complete the AUSDRISK. 
• Answer ALL the AUSDRISK questions.  
• Make sure you measure your waist (in cms) according to the instruction sheet, with the 
tape measure supplied.  
• Write your waist measurement (in cms) in the box and  
• Tick the small box that indicates the range for your waist measurement. 
• ADD UP all the points (in the small boxes ticked).  
• WRITE your final score in the last large box on the AUSDRISK form. 
• Keep your completed AUSDRISK form 
  
 
ALL Participants are requested to write the following AUSDRISK details on this page 
 
    YOUR   AUSDRISK   SCORE  
 
Your gender (please circle whichever is correct):    Male  Female 
 
Your age ……………. years. 
  
Have either of your parents, or any of your brothers or sisters been diagnosed with 
diabetes (type1 or type 2)?   Please circle whichever is correct.       NO      YES  
 
Please read the Consent Form (on the back of this page).   
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Print and sign your name if you agree that your AUSDRISK score and details (gender, age, family 
history of diabetes) can be made available to the University of Tasmania, School of Medicine.  
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CONSENT FORM (for all participants) 
 
1. I have understood the instructions and completed the AUSDRISK and written the
 details requested on page 1 of the 'Information Sheet'. 
2. I consent to my AUSDRISK score and details (gender, age-range, family history of 
 diabetes) on this sheet can be made available to the  University of Tasmania, School 
 of Medicine 
3. I understand the AUSDRISK is not a diagnostic test and that if I score in the High 
 Risk range I will be advised to see a medical practitioner for a medical assessment.   
4. I understand that if I scored in the High Risk range I will be invited to 
 participate in the follow-up study. This will involve volunteering a very short 
 amount of my valuable time for a telephone interview by a UTAS researcher or 
 completing a short email survey. 
5. I understand that participating in the follow up component of this study is voluntary. 
6. I understand that all my data and details will be securely stored on the University of 
 Tasmania premises for seven years, and will then be destroyed. 
7. I agree that research data gathered from me for the study may be published, 
 provided that I cannot be identified as a participant. 
8.  I understand I may withdraw at any time without any effect, and I may request that 













If you agree to have your answers made available to the University of Tasmania, 
School of Medicine, please sign the Consent Form and complete the AUSDRISK and 
fill out the details on the front page.  
 
If you have NOT scored in the High Risk range you have finished the AUSDRISK 
research.   
 
   Thank you for your participation 
 
 
Please return ALL the pages in the Reply Paid envelope as soon as possible. 
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If you have scored in the High Risk range on the AUSDRISK, please 
continue on the next page. 
FOR PEOPLE WHO HAVE SCORED IN THE HIGH RISK RANGE 
 
• You are advised to see a medical practitioner to discuss your AUSDRISK score 
and find out whether further assessment is recommended.  
 
• Make sure you take your completed AUSDRISK assessment tool with you 
when you attend an appointment with a GP/medical practitioner.  
 
• Scoring at High Risk (12 or more) on the AUSDRISK does NOT mean you 
have type 2 diabetes. It shows you have some risk factors that put you at 
higher risk for developing type 2 diabetes.  
 
• The University of Tasmania, School of Medicine would like to conduct a short 
telephone interview with those people who score in the High Risk range, to 
find out if they had been able to see their GP or medical practitioner about their 
AUSDRISK result, and  whether they were diagnosed with type 2 diabetes or not.  
 
• The 5 - 10 minute telephone interview at a time convenient for you, would be 
conducted by a UTAS researcher, approximately 6 weeks after you have completed 
the AUSDRISK.  Alternatively an email survey would be available. 
 Information that is gathered during the interview or survey will not identify you. 
 
• It is important that you understand that although you have scored in the High Risk 
range, your participation in this follow-up part of the study is voluntary. Whilst 
we would be pleased to have you participate, we respect your right to decline.  
 
Please circle:  AGREE   or      DO NOT AGREE   to receiving a telephone 
call or an email from a University of Tasmania researcher to participate in a short 
follow-up telephone interview or completing a short email survey. 
 
Please provide you contact details if you agree to participate in a telephone interview 
or email survey. 
 
Contact details (Name and Phone Number or Email address):  
 
…………………………………………………………………………………………………………. 
Thank you for your participation. 
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If you have any queries, please contact UTAS researcher Liz Bingham (03) 62.. ..... 
Please return ALL the pages in the Reply Paid envelope as soon as possible. 
This study has been approved by the Tasmanian Health and Medical Human Research Ethics Committee. If you have concerns or 
complaints about the conduct of this study, you should contact the Executive Officer of the HREC (Tasmania) Network on (03) 6226 
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P a g e  | 1 
 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes 
status in adults in Tasmania.Version 01. 19082013 
 
 
Type 2 diabetes screening at Optomeyes®   
 
Participant Information Sheet on the AUSDRISK assessment tool 
 
Optomeyes® is introducing the AUSDRISK assessment tool as part of the assessment 
for all adult clients aged 45 years and over having a full eye health assessment. The aim is to 
identify adults at risk for developing Type 2 diabetes and assist them to manage their eye health 
risk.  
 
As this is a new initiative for Optomeyes®, the University of Tasmania, School of Medicine (UTAS) 
is assisting to collect data, monitor and evaluate the introduction of the AUSDRISK.  
 
Type 2 diabetes is a health condition which has very few symptoms or warning signs to alert a 
person that they might be at risk. It is important for people to know their diabetes risk so that the 
risk can be managed and type 2 diabetes can be prevented/delayed.  
 
The AUSDRISK assessment tool (AUSDRISK) identifies if you are at risk of developing type 2 
diabetes. It is not a diagnostic test but it can indicate whether you would benefit from having 
medical tests to confirm whether you have diabetes or not. 
 
DIRECTIONS TO COMPLETE THE AUSDRISK:  
• Complete the AUSDRISK in the waiting room while waiting for the dilating eye drops to 
take effect. 
• You may gain assistance from a family member or a friend to complete the AUSDRISK. 
• Answer ALL the AUSDRISK questions.  
• Make sure you measure your waist (in cms) according to the instruction sheet, with the 
tape measure supplied.  
• Write your waist measurement (in cms) in the box and  
• Tick the small box that indicates the range for your waist measurement. 
• ADD UP all the points (in the small boxes ticked).  
• WRITE your final score in the last large box on the AUSDRISK form. 
• Keep your completed AUSDRISK form. 
  
 
ALL Participants are requested to write the following AUSDRISK details on this page 
 
    YOUR   AUSDRISK   SCORE  
 
Your gender (please circle whichever is correct):    Male  Female 
 
Your age   ……….. years  
 
Have either of your parents, or any of your brothers or sisters been diagnosed with 
diabetes (type1 or type 2)?   Please circle whichever is correct.       NO      YES  
 
Please read the Consent Form (on the back of this page).   
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CONSENT FORM (for all participants) 
 
1. I have understood the instructions and completed the AUSDRISK and written the
 details requested on page 1 of the 'Information Sheet'. 
2. I consent to my AUSDRISK score and details (gender, age, family history of 
 diabetes) on this sheet can be made available to the  University of Tasmania, School 
 of Medicine 
3. I understand the AUSDRISK is not a diagnostic test and that if I score in the High 
 Risk range I will be advised to see a medical practitioner for a medical assessment.   
4. I understand that if I score in the High Risk range I will be invited to 
 participate in the follow-up study. This will involve volunteering a very short 
 amount of my valuable time for a telephone interview by a UTAS researcher or 
 completing a short email survey. 
5. I understand that participating in the follow up component of this study is voluntary. 
6. I understand that all my data and details will be securely stored on the University of 
 Tasmania premises for seven years, and will then be destroyed. 
7. I agree that research data gathered from me for the study may be published, 
 provided that I cannot be identified as a participant. 
8.  I understand I may withdraw at any time without any effect, and I may request that 













If you agree to have your answers made available to the University of Tasmania, School of Medicine, 
please sign the Consent Form and complete the AUSDRISK and fill out the details on the front 
page.  
 
Give this completed Information Sheet to your optometrist. 
 
Keep your completed AUSDRISK form. 
  
If you have NOT scored in the High Risk range, you have finished the AUSDRISK research.   
 
   Thank you for your participation 
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If you have scored in the High Risk range on the AUSDRISK, please 
continue on the next page. 
FOR PEOPLE WHO HAVE SCORED IN THE HIGH RISK RANGE 
• You are advised to see a medical practitioner to discuss your AUSDRISK score and
find out whether further assessment is recommended.
• Make sure you take your completed AUSDRISK assessment tool with you when you
attend an appointment with a GP/medical practitioner.
• Scoring at High Risk (12 or more) on the AUSDRISK does NOT mean you have type
2 diabetes. It shows you have some risk factors that put you at higher risk for
developing type 2 diabetes.
• The University of Tasmania, School of Medicine would like to conduct a short telephone
interview with those people who score in the High Risk range, to find out if they had
been able to see their GP or medical practitioner about their AUSDRISK result, and  whether
they were diagnosed with type 2 diabetes or not.
• The 5 - 10 minute telephone interview at a time convenient for you, would be
conducted by a UTAS researcher, approximately 6 weeks after you have completed
the AUSDRISK.  Alternatively an email survey would be available.
Information that is gathered during the interview or survey will not identify you.
• It is important that you understand that although you have scored in the High Risk
range, your participation in this follow-up part of the study is voluntary. Whilst
we would be pleased to have you participate, we respect your right to decline.
Please circle: AGREE   or      DO NOT AGREE   to receiving a telephone 
call or email from a University of Tasmania researcher to participate in a short 
follow-up telephone interview or completing a short email survey. 
Please provide you contact details if you agree to participate in a telephone interview 
or email survey. 
Contact details (Name and Phone Number or Email address): 
…………………………………………………………………………………………………………. 
Thank you for your participation. 
If you have any queries, please contact UTAS researcher Liz Bingham (03) 62.. ..... 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes 
status in adults in Tasmania.Version 01. 19082013 
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IMPLEMENTATION OF AUSDRISK ASSESSMENT TOOL AT OPTOMEYES® 
FOR ALL ADULT CLIENTS HAVING A FULL EYE HEALTH ASSESSMENT 
ROLE OF OPTOMETRIST 
 Introduce AUSDRISK to adult clients having a full eye health assessment  
 
Optomeyes® is introducing a type 2 diabetes risk screening assessment for all adult clients 
having a full eye health assessment which includes dilating the pupil so that the back of the eye 
can be fully examined.  It’s called the AUSDRISK. It will only take you a short time (2-5 minutes) to 
complete and you do it here.  
As this is a new initiative for Optomeyes®, the University of Tasmania (UTAS) is assisting to monitor 
and evaluate the introduction of the AUSDRISK. Would you like to participate? If NO, do not 
proceed with AUSDRISK and write “DECLINED” on top of the Information Sheet.  
If YES - First I just want to check: 
Have you been diagnosed with any form of diabetes? 
If YES, ask - Type 1, Type 2, or Gestational Diabetes (GDM during pregnancy only) 
 If YES to Type 1 or Type 2 – NOTE this on the Information Sheet. Do not proceed with AUSDRISK.  
Also note approximately when client was diagnosed (by a doctor) with Type 1 or Type 2 diabetes.  
 If yes to GDM, only during pregnancy – it is suitable to complete the AUSDRISK, follow the 
instructions as for ‘No’ to diagnosed diabetes (see below). 
If NO to diagnosed with diabetes, do the following: 
• Handout the AUSDRISK ‘package’ which contains:  the AUSDRISK assessment tool and the 
INFORMATION SHEET which includes the CONSENT FORM; and the instructions for clients 
who score in the High Risk range. 
• Read out the DIRECTIONS TO COMPLETE THE AUSDRISK to the client. 
• Answer any queries the client may have by referring to the Information Sheet. 
• Advise the client that they will be able to complete the AUSDRISK in the waiting room whilst 
they are waiting for the pupil dilating drops to take effect (5-10 minutes).  
After inserting the pupil dilation drops –  
• Request the client return to the waiting room and complete the required paper work in the 
next five minutes BEFORE the dilation drops take effect. They may gain assistance from an 
adult person accompanying them or an Optomeyes® staff member if they need help with 
filling in the forms. 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in 






When client returns the completed AUSDRISK and other forms to you:   
Check they have answered all the questions and recorded their waist measurement on the 
AUSDRISK. 
If they don’t know their waist measurement, please use the tape measure (supplied) – ask if you 
may measure their waist size and record (cms) on the AUSDRISK. 
ADD up the individual scores to give a TOTAL SCORE. 
Copy the TOTAL SCORE and the patient details (de-identified) – age, gender, family history, onto 
the front page of the Information Sheet. 
Check that the Consent Form has been signed if they agree to their data (de-identified) being 
provided to the University of Tasmania.  
RETURN the completed AUSDRISK form to the client.  RETAIN the completed Information Sheet. 
Note on the Information Sheet if the client DOES NOT AGREE to the use of their data. 
Read out the recommendations on the AUSDRISK for whichever risk range was scored by the client 
– Do this whether the client agrees to their data being used or not. 
If the client has scored in the High Risk range, refer to the INFORMATION FOR PEOPLE 
WHO HAVE SCORED IN THE HIGH RISK RANGE on the Information Sheet. 
Advise the client that the AUSDRISK score indicates that they have some risk factors for developing 
Type 2 diabetes. It is not a diagnosis of diabetes. 
Advise the client to take their completed AUSDRISK form when they consult their doctor and 
have a medical assessment to determine if they have undiagnosed type 2 diabetes or not.’ 
The University of Tasmania is interested in conducting a follow-up telephone interview/email 
survey for those people who have scored in the High Risk range (and have agreed to the use of 
their de-identified data) to see if they have been diagnosed with type 2 diabetes or not. 
Participation in the follow-up telephone interview/email survey component is voluntary.  
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in 
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Ask the client to indicate whether they AGREE or NOT AGREE to being contacted for the post-
AUSDRISK short 5 – 10 minute follow-up telephone interview/email survey (at approx. 6-weeks). 
If the client agrees to participate in the follow-up, please ensure they have circled AGREE and 
that their name and phone/email contact details are correct on the form and that they have 
signed the Consent Form. 
Place all the AUSDRISK documentation (but not the AUSDRISK form which all clients should retain) 
in the envelope provided; seal the envelope and place it in a sealed container to be kept in a 
secure locked cupboard.  Documentation will be collected every week by the researcher. 
It is up to the Optometrist’s professional judgement as to whether the discussion about the High Risk score and 
participation in the follow-up study is done at the time of first handing the paperwork to the client or at the end of 
the client’s consultation. 
For further information or enquiries please contact the UTAS researcher: Liz Bingham PH: (03) 62.. ..... 
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Tasmanian Health and Medical Human Research Ethics Committee 
Low Risk Application Form 
An electronic version of this Low Risk form and attachments must be emailed to 
Katherine.Shaw@utas.edu.au 
� signed hard copy should be mailed to Human Research Ethics, Pte Bag 1, Sandy Bay 7001 
If ou have an uestions lease call 6226 7479 
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Name: Assoc. Prof. Kate Macintyre 
School of Medicine, University of Tasmania 
Kate.Macintyre@utas.edu.au 
Name: Assoc. Prof. Kelly Shaw 
Specialist Medical Advisor, DHHS, Public and Environmental Health 
Services 
Work: (03) 62...... 
Mobile:04.. ... ... 
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Page 1 of 21 
Email: kelly.shaw@dhhs.tas.gov.au 
Other Investigator: Professor J. R. Burgess 
Position: Professor of Endocrinology, School of Medicine, University of Tasmania 
Phone: 
Email: J.R.Burgess@utas.edu.au 
TTTas StudPnt Investi2:ator Details (if annlicablP) 
Student Student ID 
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Phone: (03) 
Student email address: 
622.. ....
Student Student ID 
Date of birth 
Name No. 
Student email address: Phone: 
Student Student ID 




Student email address:· Phone: 
What is the main purpose of this project? 
Research _: 


















I. Conduct a trial to test the feasibility of implementing the Australian Type 2 Di.abetes Risk
Assessment Too] (AUSDRISK), to screen for type 2 diabetes in Tasmanian adults aged 18 years
and over in publ\c and private primary health care settings, and via a mail-out to randomly
selected adults � years and over.
2. To determine th-e .effectiveness and potential of each setting/approach for implementing the
AUSDRISK as an/the initial step in a national screening program for type 2 diabetes.
3. To follow-up a minimum o/50 adults in each of the primary healthcare settings who scored.in
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Investigator, am responsible for ensuring that the investigation proposed in this form is conducted fully within the conditions laid down in the National Statement and any other conditions specified by the HREC. 
Name of chief investigator Assoc. Prof Kate Macintyre 
Signature 
Date 19/08/2013 
Signatures of Other Investigators 
The other investigators should sign to acknowledge their involvement in the project and to accept the role of the Chief Investigator. - N/A 
(Name) (Signature) (Date) 
Assoc. Prof Kelly Shaw 19/08/2013 
(Name) (Signature) (Date) 
Professor J R Burgess 19/08/2013 
(Name) (Date) 
Liz Bingham 19/08/2013 
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14. DECLARATIONS
The Head of School or the Head of Department is required to certify that: 
• He or she is familiar with this project and endorses its undertaking;
• The resources required to undertake this project are available;
• The researchers have the skill and expertise to undertake this project appropriately or· will undergo appropriate training as specified in this application.





Conformity with NHMRC Guidelines 
The Chief Investigator is required to sign the following stateme!,t: 
I have read and understood the National Statement on Ethical Conduct in Human Research 2007 
and the Australian Code of Conduct for Responsible Research 2007. I accept that I, as Chief Investigator, am responsible for ensuring that the investigation proposed in this form is conducted fully within the conditions laid down in the Nat,ional Statement and any other conditions specified by the HREC. 
Name of chief investigator 
Signature 
Date I 4-/ � ( I 'S 1
Signatures of Other Investigators 
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To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in 
adults in Tasmania. Version 01. 19082013 
 
 
Follow-up Questions for telephone interview/email survey for people who scored in the High Risk range 
of the AUSDRISK.  
 
The telephone interview/survey would be conducted by a UTAS researcher approximately 6 weeks 
after the client had completed the AUSDRISK. At that time the participant had agreed to participate in 
the follow-up interview by signing the Consent Form and providing their name and contact details.  
 
Interviewer identifies and introduces herself as a UTAS researcher for the AUSDRISK trial. Checks the 
name of the interviewee and that the interviewee still consents to participating in the telephone 
interview. 
 
• Q1 –Name - may I check your name 
 







NO,  if no – could you advise why it is 
  no longer convenient? Answers
 Time  - ?reschedule  
 No longer interested – are you 
 able to tell me why you are no 
 longer interested?  
      
• If YES  
            
 Interviewer re-iterates the purpose of the follow-up telephone interview: 
 
• To follow-up people who have scored in the High Risk range of the AUSDRISK to find out what 
actions they had taken or had been able to take in determining their diabetes status. 
 
• Q3 Have you been able to see your GP to discuss further assessment as recommended 
by the AUSDRISK? 
YES       
? Tests Y/N 
If Y Results of tests Diabetes/pre-diabetes/no 
diabetes 
 
If N (to tests)     
Any other directions -? Re-test 12/12 
     
Treatment/management options 
 Medication – type 
 Lifestyle – 
      
NO – why unable to see GP so far – write 
responses  
Do you plan to see your GP? Y/N 
If Yes 
Appointment scheduled? Y/N 
If No -  Plan to see another health/lifestyle 
professional? Y/N 
If Appointment scheduled  – date – may I 




• Q4 May I just re-check the details you provided when you completed the AUSDRISK 
 Gender 
 Age 
 Family history of diabetes 
 
To develop reliable protocol(s) for the effective use of the AUSDRISK assessment tool as the initial step in screening for diabetes status in 
adults in Tasmania. Version 01. 19082013 
Thank you for participating in this interview. It is very important to the research that the University of 
Tasmania, School of Medicine is conducting. 
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SECTION 6 · ETHICS APPROVAL INFORMATION 
You need to consider if your project has ethics implications. The UTAS Research Ethics Policy, information and forms 
for both Animal and Human (Social Science and Health and Medical) research projects are available from the 
fol lowing web site: http://www.utas.edu.au/resea rch/integrity-and-eth ics 
If you and your supervisor are uncertain about whether ethics approval is required, please call Integrity and Ethics on 
6226 1832 to inquire about ethics requirements. If you require ethics approval, your supervisor and Head of School 
will need to complete an ethics application. 
Note: research that requires ethics approval must not commence until approval has been granted. It is University 
policy that theses cannot be approved for submission to examiners unless all relevant research ethics approvals 
have been granted. 
SECTION 7 - WORK HEALTH AND SAFETY 
Please describe how you will manage any work health and safety issues that will need to be attended to in relation 





I certify that this plan has been discussed with my Supervisors and Graduate Research Coordinator. I have kept a 
copy of this document. 
Candidate: Date: 
Supervisor/s Signature 
I certify that this Research Plan complies with disciplinary norms and established guidelines. I have viewed and 





Graduate Research Co-ordinator's Signature 
I certify that I have viewed and 
Graduate Research 
Co-ordinator 
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Note: You may add any other relevant additional comments or information and send with this document. 
Please scan and return the signed Research Plan by email to: 
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virtual Tasmanian Academic Health Science Precinct 
Final Research Report – end April 2015 
Title Improving prevention and early intervention for type 2 diabetes in 
Tasmania 
Funding Amount 
Completion Date April 2015 
Prepared By Liz Bingham, A/P Kate Macintyre, A/P Kelly Shaw and Prof John Burgess 
Research Aims - please 
provide summary 
comments for each of 
the Aims/Deliverables 
in your original funding 
application and any 
other outcomes from 
your research, if 
applicable.  
• To extend the 2011 “proof of concept” AUSDRISK study (52
participants) by increasing the numbers of adults assessed in
primary healthcare settings and including a mail-out to randomly
selected adults aged 60 years and over.
o Total AUSDRISK completion – 309 participants (1417
invitations)
o Primary Healthcare (PH) – 108 participants (217
invitations)
o Seniors’ Card (SC) mailout – 201 participants (1200
invitations)
• To evaluate the response rate to an invitation to participate in a
UTAS study of AUSDRISK including follow-up of those who score
High Risk (HR), and consent to participate in the follow-up
component of the study.
• Overall Participation rate  = 21.8% (consistent with initial
participation rates in other national screening studies) 
• PH participation rate = 49.77%
• SC mailout participation rate = 16.77%
• Follow-up survey
• Total HR Consent to survey = 144 (46.6%)
• Total HR Completed survey = 79 (79/144; 54.86%)
• PH HR completed survey = 11/44; Rate = 25.0%
• SC mailout HR completed survey = 68/100; Rate = 68%
• Summary
Appendix 6
• In Primary Healthcare, the initial participation rate was
greater than the initial participation rate gained via the Seniors’ 
Card mailout. However the completion rate to biomedical 
assessment was greater for the Seniors’ Card mailout participants 
than for the Primary Healthcare participants. 
• To determine the effectiveness (case finding High Risk), cost-
effectiveness and potential of each setting/approach for
implementing the AUSDRISK as an/the initial step in a national
screening program for type 2 diabetes (2).
• Total cost SC mailout = $3045.19
• PH cost was administration costs which were absorbed into
usual duties 
• Printing information/instruction forms = $1871.19
• AUSDRISK = free (Australian Government)
Setting effectiveness = HR/total AUSDRISK completion
• PH effectiveness = 44/108 = 40.74%
• SC mailout effectiveness = 100/201 = 49.75%
Summary HR case finding rate
• SC HR case finding rate was greater than the PH case
finding rate 
• No cases of Type 2 Diabetes were identified in
individuals classified as High Risk by the AUSDRISK 
• Pre-diabetes was diagnosed in 7 of the 79 individuals,
classified as High Risk on the AUSDRISK   (8.86%) 
• Of those diagnosed with pre-diabetes, 6 were identified
via the SC mailout  (6/68=8.82%) and one (1/11) was identified via 
Primary Healthcare (1/11 = 9.09%). 
• PH AUSDRISK distribution spread is local and related to
health (illness) services 
• SC AUSDRISK distribution spread is statewide, not
related to health services and has greater potential to impact on 
and identify those older individuals in the general community. 
• To investigate the personal and systemic factors which act as
facilitators or barriers t o utilisation of the AUSDRISK as a national
type 2 diabetes screening program and compare these factors
across the three settings.
Personal factors (all settings) – 
• Older people have a negative attitude towards type
2 diabetes (DM2);
• There is limited health literacy and poor knowledge
of DM2; 
 Sample population were ambivalent towards 
prevention and management of DM2 and risk 
averse to addressing a potential health problem 
(males more so than females) 
Systemic benefits – 
• PH AUSDRISK face-to-face presentation was more
effective for initial participation than the mailout
due to health professional positive endorsement of
screening;
• The SC mailout was superior (to primary health) in
its ability to deliver AUSDRISK questionnaires
statewide with its established mailout system;
access to the general community and being
independent of demands on health professional
time.
Systemic barriers – 
• Opt-in participation for completing AUSDRISK (both
settings) limited the participation rate, with SC
mailout more affected than PH;
• No current commitment to routine type 2 diabetes
screening in PH with community health setting more
affected than optometry practices.
• Format and scoring of AUSDRISK acted as a barrier
to older people participating, in that age and gender
(particularly male) both unmodifiable risks which
scored very high, and older people felt
disempowered to investigate further if they had
limited opportunity to reduce their risk. Not all
diabetes risk questionnaires rate age and gender as
high as the AUSDRISK.
Barrier - Validity of AUSDRISK questionnaire – 
• AUSDRISK identified individuals at high risk but on
biomedical assessment none were diagnosed with
diabetes; 7 with pre-diabetes and 36/43 tested as
having normal blood glucose levels.
• AUSDRISK questionnaire allocates high scores for
the age and gender risk factors. This may affect the
discriminatory capacity of the AUSDRISK to identify
diabetes when used with an older population.
• Lack of consistency in diabetes risk prediction
between different diabetes risk assessment
questionnaires. Comparing AUSDRISK age and risk
factor scores with those of other validated diabetes 
screening questionnaires revealed some individuals 
who had been being classified as HR on the 
AUSDRISK had lower risk ratings for type 2 diabetes 
than those estimated by AUSDRISK.   
• To establish a database both quantitative and qualitative for the
implementation and outcomes of AUSDRISK screening in different
healthcare and non-healthcare settings for type 2 diabetes in
Tasmania with a view to implementation of AUSDRISK nationally.
• Individual and systemic barriers need to be addressed and other
methods need to be investigated before continuing with planning
to formally embed type 2 diabetes screening assessment using
the AUSDRISK into routine clinical practice.
Funding - please 
provide summary 
comments accounting 
for the expenditure of 
allocated funds.  
Total Funding  $ 54,672.50  
Expenditure in T1 
Salaries  $ 10,407.08  
Mail/Postage  $   3,045.19  
Printing  $   1,871.19  
 $ 15,323.46  
plus costs not yet in T1 
Statistical support  $   5,000.00  
K Macintyre salary costs  $   7,758.24  
 $ 12,758.24  
Total Expenditure  $ 28,081.70  
ACTUAL FUNDS 
REMAINING 
 $ 26,590.80  
Please also complete one of the following statements. 
I confirm that all funding allocated to this research has been fully 
expended on the research activity as outlined in my original funding 
submission. 
Or 
XX has been expended on this research project. Residual funds of YY 
will be returned to the Commonwealth.  
Publication – please 
provide summary 
information on any 
presentations or 
publications relating to 
your vTAHSP research.  
Please also append any 
abstracts, publications, 
reports, presentations 
etc that relate to your 
vTAHSP research.  
Abstract submitted for the Public Health Association of Australia 
conference September 2015. 
Draft journal article to be submitted ……….to be advised 
Translation – please 
provide summary 
information on how 
your research 
outcomes have been or 
will be translated or on 
how the need for 




 This study provides valuable insight into the feasibility, uptake and 
efficacy of implementing the AUSDRISK for the older age group through 
different settings as well as the follow up of high risk individuals. 
The older age cohort is the most rapidly increasing age-group in 
Tasmania Currently this cohort has the highest incidence of type 2 
diabetes whilst the prevalence of undiagnosed type 2 diabetes and 
elevated blood glucose is unknown. Both conditions, if untreated lead 
to a high risk of cardiovascular complications.  
AUSDRISK questionnaire: 
Initial findings indicate that the AUSDRISK questionnaire can be 
implemented at low cost via healthcare and non-healthcare settings to 
increase accessibility and improve uptake of to type 2 diabetes 
screening, for an older cohort. However the uptake rate is low and 
further consideration should be given to alternative and additional 
strategies such as opportunistic multiple risk factor screening as part of 
routine clinical assessment on an opt out basis in the absence of a 
national screening program. 
Our study results have also shown that there are questions around the 
validity of the AUSDRISK for diabetes screening in the older age group, 
which need further investigation prior to any further implementation of 
the AUSDRISK. 
Further Research  
Investigate the validity and appropriateness of AUSDRISK for type 2 
diabetes screening in an older age cohort 
• Review the literature on prediction models to estimate future
development of type 2 diabetes, with particular reference to
individuals in the 55+years age group.
• Review and compare the scoring on the AUSDRISK and the
FINDRISC or CANRISK and other type 2 diabetes prediction
models for similar populations, which have reduced emphasis
on age and gender as non-modifiable risk factors.
• Determine if the AUSDRISK is the most appropriate screening
questionnaire for the older age cohort
• Investigate the effectiveness, advantages/disadvantages of
other diabetes risk questionnaires (particularly those with less
emphasis on age and gender) and other methods of screening
such as point of care testing for HbA1c – for impact,
effectiveness, cost and settings.
• Conduct focus groups with community groups of older people
for feedback on acceptability of completing the AUSDRISK in
comparison with other risk screening questionnaires eg
CANRISC and/or FINDRISC.
• Increase the participation rate by adding a diabetes
information leaflet (FAQs) along with the AUSDRISK to improve
knowledge and benefits of effective prevention and
management of type 2 diabetes.
Promote need to implement diabetes risk screening in Tasmania 
• Liaise with Diabetes Tasmania to discuss having a more positive
approach to the value of older people knowing their blood
glucose level and if high, providing strategies to reduce it. Take
a more positive approach to show the value of early
identification of diabetes and promote the “good news” stories
of effective management of diabetes. Reduce the strongly
“negative” view that is currently held.
• Liaise with GPs and GP organisations to promote a more
educative and collaborative approach with patients to diabetes
risk screening, prevention and management.
• Seek GP champions to promote this collaborative approach.
• Liaise with State health organisations in their promotion of
improve health literacy particularly in the older age group.
• Liaise with Diabetes Tasmania re reviewing literacy standards
for diabetes information on screening, prevention and
management of type 2 diabetes. 
• Promote the potential for diabetes screening to be included
routinely in all new patient assessments in community health
centres.
• Investigate the potential for optometrists to implement the
AUSDRISK for all clients over 45 years having a full eye
assessment.
• Utilise the Seniors’ Card mailout to provide information about
the benefits of effective prevention and management of type 2
diabetes
Evaluation - please 
provide a short 
evaluation of your 
research projects 
overall success.  
To our knowledge this is the first study in Australia to implement the 
AUSDRISK type 2 diabetes risk questionnaire in the older age group 55 
to 75+ years.  
The AUSDRISK questionnaire was distributed to 1417 older adults via 
face-to-face interviews as part of a healthcare assessment and via a 
well-established Seniors’ card mailout. 
A total of 401 older adults (28.3%) responded to the initial invitation to 
participate, of whom 65 had diabetes and were ineligible to participate 
and 27 subsequently chose to withdraw.  The total of 309 older adults 
(21.8%) completed the AUSDRISK questionnaire. Of those who 
completed the AUSDRISK, 144 individuals (10.16%) scored in the High 
Risk (HR) range (≥12 points); 152 (10.7%) scored in the Intermediate 
Risk range (6-11 points) and 12 (0.8%) scored in the Low Risk range (5 
points or less).  
6-8 weeks after completion of the AUSDRISK all those who scored High
Risk (HR) on the AUSDRISK were invited to participate in a short follow-
up survey, to document their actions to being advised of their high-risk
status.
76 HR participants completed the follow-up survey, 44 of whom
attended their GPs for biomedical assessment and all but one had
blood tests. The HR diabetes risk status on AUSDRISK did not reflect
the current glycaemic status of the participant. No HR participant was
diagnosed with diabetes, but 7 HR participants were diagnosed with
elevated blood glucose.
The poor initial response rate indicated that completion of the
AUSDRISK alone was not sufficient to encourage older people to
participate in diabetes pre-screening and survey results highlighted the
individual and systemic barriers to completing biomedical assessment
in order to achieve effective implementation.
Furthermore the results indicated that the validity of the AUSDRISK,
when used in an older population, needed further investigation before
proceeding with future AUSDRISK diabetes screening in this cohort.
This study has established baseline findings for implementing
AUSDRISK in the older population. In addition to resolving the specific 
issue of validity with AUSDRISK, we need to address the individual and 
systemic barriers and investigate other methods before continuing to 
plan for formally embedding type 2 diabetes screening assessment into 
routine clinical practice.  
Media – please indicate 
if you would be willing 
to be involved in media 
and communications 
on behalf of the project 




AUSTRALIAN TYPE 2 DIABETES RISK 
ASSESSMENT TOOL
OLDER ADULTS
• YOUNG - OLD = 60 - 74 YEARS
• M I D - O L D  =  7 5 - 8 4  Y E A R S
• OLD-OLD =  85+  YEARS
• No national screening program for type 2 diabetes
SCREENING OLDER ADULTS FOR TYPE 2 
DIABETES: MORE THAN AUSDRISK
Elizabeth Bingham, Kate Macintyre, Kelly Shaw, John Burgess 
University of Tasmania & Department of Health & Human Services, Hobart, Tasmania.
Why screen “young-old” adults for T2DM? 
 Ageing is an independent risk factor for type 2
diabetes (T2DM).
 Rapidly increasing older age population with
increasing longevity.
 Screen for early identification, monitoring and
management of those with or at high risk of T2DM
 Currently no Medicare-supported T2DM screening





How to reach “young-old adults …..
 Continue opportunistic screening via GPs
 Utilize existing systems within public/private health
or non-health sectors.
 AUSDRISK – health assessments of new patients.
 Include AUSDRISK with Seniors’ Cards (96,000)
in Tasmania. Regular statewide mail-out
new/renewed cards every 4-6 weeks.
AUSDRISK Summary Results
All settings
Total distribution   1417
T2DM   65 
Participants 309 (21.8%)
Active Decline      135 (9.5%)
Nonresponse        908 (63.5%)
Participants        309 
High Risk (>12)  144 (46.6%) 
HR Survey   76    %   
Attend  GP       43 %
Blood tests            42 %
Normal BG 35 %
Elevated BG   7 %






























=  24 (11.88%)
= 202 (16.83%)














 AUSDRISK distribution to 1417 young - old adults;
 309 participants
 High Risk: 144 participants
76 HR participants completed 6 week follow-up survey
43 HR had attended GPs for biomedical assessment
42 HR had blood tests
35 HR had normal blood glucose levels
7 HR had elevated blood glucose
No HR participant diagnosed with diabetes
AUSDRISK High Risk Survey Issues 
 Young-old adults
 ambivalent attitudes towards screening and T2DM
 unaware of “increasing age” and “male gender” as
independent risk factors for T2DM – so don’t see relevance
 don’t understand concept of “risk” and “ongoing risk”.
 ? health literacy /knowledge of Diabetes
 General Practitioners
 ? inadvertently supporting older patients’ beliefs
 ? few incentives to monitor High Risk ($)
 AUSDRISK implementation in “young-old” cohort (60-75 years)
 ? validity of AUSDRISK for T2DM risk in “young-old” group




Improving prevention and early intervention for type 2 diabetes in 
Tasmania 
virtual Tasmanian Academic Health Science Precinct research Report 2015 
Introduction 
Type 2 diabetes is a current major public health problem. The number of people with 
DM2 is increasing in every country (International Diabetes Federation Diabetes Atlas 
sixth edition 2013)1. Worldwide there are 387 million people living with diabetes; by 
2035 the number is expected to rise to 592 million; 179 million are undiagnosed (IDF 
atlas 2014).  
An estimated 1.7 million Australians have type 2 diabetes. This number is predicted to 
increase to 3.3 million by 2031. A further 2 million have pre-diabetes which puts them at 
high risk of developing type 2 diabetes and associated complications  (ref 2)  
In Tasmania, there are over 22,000 individuals with type 2 diabetes and an estimated  
10 000 people with undiagnosed type 2 diabetes and additionally over 45,000 
Tasmanians with pre-diabetes – a condition which, if not identified and well-managed 
puts them at high risk for developing type 2 diabetes (Ref 2). 
The high prevalence of Type 2 diabetes is attributable to both genetic and 
environmental factors - older age, a family history of diabetes, high blood glucose,  
hypertension, low HDL-C, obesity, insufficient physical activity and smoking.(Refs)  
Diabetes is the leading cause of kidney failure, non-traumatic lower limb amputations 
and blindness and is a major cause of cardiovascular diseases. 
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Prevention and management of type 2 diabetes and its precursor condition pre-diabetes 
is a global, national, and local challenge. 
The highest prevalence of type 2 diabetes is in the older age population and is driven in 
part by an absolute increase in the incidence among those aged 60 years and older due 
to ageing effects on the pancreatic β cell function, β cell mass, insulin secretion and 
insulin sensitivity and environmental factors such as rising rates of obesity, and 
increasing sedentary behavior often caused by other chronic conditions associated with 
ageing such as arthritis4. 
The flow-on effect of this glycaemic dysfunction (pre-diabetes, type 2 diabetes) is not 
benign and increases the immediate risk for other age-related conditions such as cancer, 
cardiovascular diseases and Alzheimer’s Disease and reduces the quality of life in the 
older age group. 
Type 2 diabetes  is symptomless in the early stages of the condition and has few unique 
symptoms even when well established.   
Tasmania has the oldest population of all states and territories and nationally, and the 
number in the 60 plus age cohort is increasing more rapidly than the young and mid-age 
groups.   In Tasmania, the highest incidence of newly diagnosed type 2 diabetes is in the 
older age groups where the newly diagnosed incidence in the 50-59 year group is 23%; 
in the 60-69 year group is 30% and in the 70–79 year group is 17%2. It is unknown how 
many in the mid- older age group would be at high risk for type 2 diabetes or pre-
diabetes but undiagnosed due to the symptomless nature of the glycaemic dysfunction 
and there being no system within the public health system for diabetes risk assessment. 
3 
Type 2 diabetes is clearly an important health problem and as such meets the Australian 
criteria for the assessment of population screening regarding condition, test, 
assessment, treatment and ongoing management.  
However, Australia, unlike most European countries, UK and the US, does not have a 
national screening program for type 2 diabetes. The NHMRC Evidence-based Guidelines 
for the Detection and Diagnosis of Type 2 diabetes in Australia (2009)5 recommend that 
a 2 stage targeted screening approach be utilized to identify those people at high risk for 
developing type 2 diabetes. The first stage is a pre-screening stage to identify individuals 
at High Risk for developing diabetes or pre-diabetes. The second stage occurs after the 
High Risk status is identified when individuals would then be advised to see their 
medical practitioner for a biomedical assessment of their diabetes status. This  targeted 
screening approach widely used by other countries, has not been used systematically on 
a national basis in Australia.  
The Australian Government provides Medicare funding on a limited basis for type 2 
diabetes screening of people aged 40 – 49 years who score High Risk on the Australian 
Type 2 Diabetes Risk Assessment Tool (AUSDRISK)6.  
The major unresolved issues for implementing a national screening program for type 2 
diabetes include defining a target population to be screened; how best to access the 
target population; and how to increase uptake and follow-up for screening. 
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Development of AUSDRISK 
- a pre-screening questionnaire to determine diabetes risk.
The first national Australian Diabetes Obesity and Lifestyle Study (AUSDIAB) was 
conducted in 1999 - 2000 and its 5 -year follow-up study of 70 percent of the original 
cohort AUSDIAB-2.  Both studies gathered biomedical and lifestyle data from a stratified 
sample of 11,247 Australians aged 25 years or over in 42 randomly selected urban and 
non-urban areas of the six states of Australia7. 
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK), based on the findings 
of the AUSDIAB and AUSDIAB-2 studies, was developed in 2008 as a screening tool to 
identify those at High Risk for developing type 2 diabetes8.  
The AUSDRISK has been validated as a predictor of diabetes risk at 5-year follow-up and 
has been acknowledged internationally as a valid and reliable pre-screening test to 
identify people at High Risk for developing type 2 diabetes9.  
The AUSDRISK is a simple paper-based screening tool. Risk factors for type 2 diabetes 
are each given a weighted numeric value and the total of the Risk Factor points provides 
an estimate of the risk for an individual’s development of type 2 diabetes over a 5year 
period. The quantified total risk levels are designated Low, Intermediate and High.  
Within the High Risk range (≥ 12 points) there are three categories reflecting increasing 
risk of developing Type 2 diabetes - HR1 =12-15 points (approximately 1 in 14 will 
5 
develop diabetes); HR2 = 16-19 points (approximately 1 in 7 will develop diabetes) and 
HR3 = 20 points or more where the risk is that 1 person in every 3 will develop diabetes.  
People scoring High Risk are advised to attend their General Practitioner for a 
biomedical assessment of their diabetes status. However, most General Practitioners 
identify the diabetes status of individuals via opportunistic screening and rarely utilize 
the AUSDRISK10. 
Although recommended by the NHMRC Guidelines, the AUSDRISK has not been used for 
population screening. To date it has only been used for health promotion initiatives to 
raise diabetes awareness and also to provide the criteria for inclusion of HR participants 
in a small number of diabetes prevention programs for individuals aged 40 – 49 years in 
some Australian states but not Tasmania. 
In Tasmania, the AUSDRISK has been used infrequently for health promotion activities 
only.  
In 2011, a 6 - week trial in Southern Tasmania showed the AUSDRISK questionnaire 
could be effectively implemented into non-medical settings - a community nursing 
service and three optometry practices, and it identified participants at high risk. The 
AUSDRISK was incorporated as part of an assessment for new patients receiving wound 
care in the nursing service and in the optometry practices for clients having a full eye 
assessment including pupil dilatation.   Those identified as High Risk stated their 




This current study sought to increase the numbers (sample) of mid-older people in the 
target population; to determine effective methods to reach this adult group; and to 
identify the diabetes risk status of mid-older age respondents. The study also sought to 
document the responses of those scoring High Risk (HR -12+ points) by inviting them to 
complete a follow-up survey to identifying their actions to the recommendation that 
they seek biomedical assessment to determine their diabetes status.  
Whilst this study used the same sites and methodology as the 2011 pilot study to 
implement the AUSDRISK, the number of participants was increased by inviting new 
patients from a wider range of services within the Community Integrated Care Centre 
service; inviting patients having a full eye assessment at the same optometry sites, and 
inviting participants aged 60 years and over via  three Seniors’ Card statewide mail-outs 
to investigate the potential to reach older adults who may or may not be attending 
General Practitioners or health services on a regular basis.  
Objectives 
We had three main objectives in this study. First, to determine the feasibility and 
acceptability of implementing the AUSDRISK in non-medical settings in order to identify 
older individuals at High Risk for developing diabetes. Secondly, to determine the 
uptake and effectiveness of the AUSDRISK by following the actions of those assessed as 
being at High Risk, (and those of their General Practitioners) to the older individual 
being advised to seek biomedical assessment of their glycaemic status.  Finally, to 
review knowledge (health literacy) and beliefs about Type 2 diabetes, held by those 
recently assessed as High Risk for this condition. 
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Design, setting and participants 
The AUSDRISK study was conducted over a 7-month period in 2014 (April/ May – mid 
November) in Tasmania, Australia, at a public health Community Integrated Care Centre 
(CICC), two private optometry practices in Southern Tasmania and via three statewide 
mail-outs of the Tasmanian Government Seniors’ Card11. 
This study received Ethics Approval (H0013490) from the Human Research Ethics 
Committee (Tasmania) Network. In addition the study received approval from the 
Tasmania Health Organization South (THO-S) Research Governance Committee (for the 
CICC); the management of OPSM/Optomeyes optometry group and the Tasmanian 
Government Department of Premier and Cabinet (DPaC), Seniors’ Bureau Manager for 
the mail-outs.  
Study design 
Cross sectional survey and follow-up using the AUSDRISK type 2 diabetes risk 
assessment questionnaire. 
Participants 
The AUSDRISK questionnaire was distributed to 1717 adults, as part of a routine new 
patient assessment process in two community healthcare settings- one in the public 
health system – a Community Integrated Care Centre (177 participants) and two 
optometry practices in the private health sector (40 participants). In addition, the 
AUSDRISK was included with an instruction/consent form and a pre-paid envelope in 
three Seniors’ Card mail-outs (1500 potential participants) to eligible adults aged 60 
years and over, with an invitation to participate and self-assess their diabetes risk 
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status. The cost per mail-out to 500 potential participants was $1600.00. Consent was 
obtained from all participants who completed an AUSDRISK. All those who scored High 
Risk (12 points or more) on the AUSDRISK were invited to participate in a short follow-
up survey, 6-8 weeks after completion of the AUSDRISK. The survey took approximately 
5 minutes to complete and comprised eight questions relating to the HR participant 
follow-up actions and biomedical results, and was completed either by phone or on the 
web via Survey Monkey. 
Exclusion criteria 
 Exclusion criteria for participants recruited via the health service settings included any 
new patient admitted for community palliative care treatment at home; cardiovascular 
diseases or neurologic diseases that would compromise one’s ability to participate in 
the study; being pregnant; being unable to reliably understand the English language; 
having been diagnosed with diabetes (any forms). 
Participants recruited via the Seniors’ Card mail-outs were advised via the AUSDRISK 
Study Information Sheet that being diagnosed with any form of diabetes was the only 
exclusion criteria. 
Materials 
The AUSDRISK -Australian Government Department of Health and Ageing. The 
Australian Type 2 Diabetes Risk Assessment Tool. Canberra: DoHA 2008. Available at 
www.health.gov.au/internet/main/publishing.nsf/Content/diabetesRiskassessmentTool  
(accessed 3 March 2015) 
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Follow-up survey  
All those who scored High Risk were invited to participate in a short follow-up survey, 6-
8 weeks after completion of the AUSDRISK. The survey took approximately 5 minutes to 
complete and comprised eight questions relating to the HR participant follow-up actions 
and biomedical results, and was completed either by phone or on the web via Survey 
Monkey.  
Provider training 
In each setting, at least one staff member was designated and trained (by LB) to be the 
clinical/administrative coordinator of the AUSDRISK project. Community Service Officers 
(CSO) manage all new patient admission for the Community Integrated Care Centre 
(CICC). Thus the CSO Team Leader and her deputy were best placed to introduce the 
AUSDRISK questionnaire and were trained accordingly.  
Procedure 
Community Integrated Health Centre: 
Over an eight-week period in July-August 2014, the CSO Team Leader and her deputy 
advised all new patients that the CICC was conducting a trial of the AUSDRISK 
questionnaire with a view to incorporating it on a regular basis as part of the New 
Patient Assessment. Typed and laminated administrative procedures for implementing 
the AUSDRISK were used to ensure reliability. The AUSDRISK was described to each new 
patient as a questionnaire for assessing a patient’s risk for developing type 2 diabetes; it 
was a risk assessment not a diagnosis of diabetes, that (diagnosis) could only be done by 
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a GP. If the client had diagnosed diabetes (either type 1 or type 2) they were ineligible 
to participate.  This was recorded on an instruction sheet and retained. 
For all eligible patients the CSO team leader/deputy checked that the new patient could 
read and understand English language and advised that the patient could seek 
assistance from the TL/D or an accompanying friend/relative if the patient reported any 
difficulties.  During the trial period all new patients were invited to participate. 
Participation was voluntary. The team leader/deputy handed a clipboard on which an 
AUSDRISK questionnaire, an instruction/reporting sheet/consent form, a paper tape 
measure and a biro were attached. The team leader/deputy (TL/D) asked the new 
patient to read the instructions; sign the Consent Form after having the reason for this 
explained; and complete the AUSDRISK questionnaire, including taking a waist 
measurement.  After the AUSDRISK was completed the TL/D checked that all questions 
were answered; checked the waist measurement; checked the points total; checked 
that the patient had written their age, gender, familial risk and points total on the front 
of the instruction sheet and that the consent form had been signed to agree to 
participation and permit the researchers to use the de-identified data. Those patients 
who had scored in the High Risk range were reminded of the AUSDRISK 
recommendation that they contact their GP for blood testing to determine their 
diabetes status, and then the TL/D asked if they would participate in a short 8-10 
question follow-up survey to be conducted in 6-8 weeks. If they agreed, they needed to 
provide additional signed agreement and their preferred contact details (phone/email). 
All participants were advised to keep their completed AUSDRISK questionnaire and 
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those scoring HR were advised to take their completed AUSDRISK questionnaire to their 
GP. The completed Instruction sheet/consent form was collected by the TL/D and kept 
in a locked cupboard. On completion of the admission procedures and the AUSDRISK 
questionnaire, the new patient progressed to the first treatment session. At a 
convenient point in the treatment session, the Health Professional (HP) concerned 
reinforced the importance of knowing your diabetes risk status and if it were High Risk, 
the Health Professional would reiterate the importance of the patient attending their GP 
for biomedical assessment. The Health Professionals were not prepared to participate in 
the actual administration of the AUSDRISK as they considered this to reduce their 
treatment time with the patient.  
Optometry practices 
In the optometry practices, the optometrists provided an explanation and presentation 
of the AUSDRISK questionnaire at a time deemed suitable in the full eye assessment 
consultation and followed the same process as described previously for CICC.  
The optometry clients were asked to complete the AUSDRISK in the period before the 
eye dilating drops took effect. This timing for completing the AUSDRISK was decided as 
suitable by the optometrists. The optometrists administered the AUSDRISK as part of 
the full assessment as this gave them the opportunity to discuss the importance of 
regular screening for any vision changes, which may highlight risks for a number of 
medical conditions including diabetes/pre-diabetes. Again the clients scoring in the HR 
range were requested to participate in the follow-up survey. If they agreed the same 
procedure as described for CICC previously was implemented.  
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Unfortunately there was a change in ownership of the optometry branches during the 
course of AUSDRISK data collection, which limited the participation of the practices and 
health professionals. 
There was no further contact with the participants at CICC and optometry practices 
except for those who had provided signed written consent to participate in the follow-
up survey. 
 
Seniors’ Card mail-outs 
In order to utilize the Seniors’ Card mail-out11, the Manager of the Seniors’ Bureau in 
the Tasmanian Government Department of Premier and Cabinet provided written 
consent to the AUSDRISK study using 3 mail-outs of the Seniors’ Cards to facilitate 
statewide distribution of the AUSDRISK questionnaires. This requirement was in 
addition to the ethics approval, which covered all settings. A Tasmanian Government 
Senior’s Card (SC) is available on application to any person aged 60 years or over who is 
not in more than 20 hours paid employment per week. It is not a pension but is 
supported by Tasmanian Government and non-Government businesses, which provide a 
discount for their services or sales on presentation of the SC. Every six to eight weeks, 
400-500 new or renewed Senior’s Cards are mailed out statewide to eligible older adults 
in Tasmania.  The SC mail-out has been used on occasions for distribution of health 
promotion material of relevance to older individuals such as information on Falls 
Prevention.   
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The AUSDRISK questionnaire and instruction sheet/consent form, and Reply Paid 
envelope were included with a Senior’s Card and an accompanying letter from the 
Manager of the Seniors’ Bureau which included a recommendation for consideration by 
the recipients to participate in the AUSDRISK study.  
There were three mail- outs in 2014 in April, July/August and November which together 
provided a convenience sample of 1500 older adults from which participants could self-
select to participate.  
The instruction sheet/consent form provided the eligibility criteria and instructions to 
complete the AUSDRISK; complete the demographic information (age, gender, familial 
risk and total points score) on the front of the information sheet; sign the consent form 
to participate; and if scoring HR and agreeing to participate in a follow-up survey, 
provide written agreement and preferred contact details and return all in the Reply Paid 
envelope. 
Data entry and analysis 
De-identified quantitative data were recorded from the Information/Consent forms and 
Survey Monkey forms and compiled into Microsoft Excel spreadsheets. 
De-identified qualitative data were compiled from paper-based records of interview for 
the follow-up survey. 
De-identified data were also compiled from paper-based records of the participating 
health professional and administrative staff. 
14 
RESULTS 
Over a 6 month period (May – November 2014) a total of 1717 adults mean age 64.5 
years were offered the opportunity to participate in the AUSDRISK study conducted by 
the University of Tasmania, School of Medicine. Invitations to participate were sent via 
three statewide Seniors’ Cards mail-outs to 1500 older adults; to a further 177 adults 
attending a local Community Integrated Care Centre in Southern Tasmania and another 
40 adults were invited when they attended two optometry practices in the greater 
Hobart area. 
A total of 401 adults (401/1417; 28.3%) responded to the initial invitation to participate, 
of whom 65 had diabetes and were ineligible to participate and 27 subsequently chose 
to withdraw.  The total of 309 adults (21.8%) completed the AUSDRISK questionnaire. Of 
those who were invited to complete the AUSDRISK, 144 individuals (144/1417; 10.16%) 
scored in the High Risk (HR) range (≥12 points); 152 (152/1417; 10.7%) scored in the 
Intermediate Risk range (6-11 points) and 12 (12/1417; 0.8%) scored in the Low Risk 
range (5 points or less) (ref Table 1).  
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Results from Clarence Integrated Care Centre: 
A total of 177 new patients were invited to participate in the AUSDRISK study at 
Clarence Integrated Care Centre. The age range was 28 – 85 years.  
Twenty-eight new patients (15.8%) had previously been diagnosed with diabetes (23 
Type 2 diabetes; 5 Type 1 diabetes). Fifty–four new patients (30.5%) declined to 
participate. Ninety-five new patients (53.7%) completed the AUSDRISK, however 14 
questionnaires were incomplete and could not be included in the analysis. Thus a total 
of 81 participants (45.8%) provided AUSDRISK results. 
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Thirty-two participants scored High Risk (12 points or more); 38 participants scored at 
Intermediate Risk (6-11 points) and 11 participants scored at Low risk (5 points or less). 
High Risk (12 points or more) 32 individuals (age range x – y) 
Table2: Results Clarence Integrated Care Centre 
Clarence Integrated Care Centre  
AUSDRISK questionnaires    177 
Response rate    95 53.7% 
AUSDRISK completion   81  45.8% 
High Risk % completers 32 39.0% 
High Risk 1 (12-15 points) 14 
High Risk 2 (16-19 points) 11 
High Risk 3 (20+ points) 7 
Intermediate Risk 38 46.0% 
Low Risk  11 13.0% 
Type 2 diabetes 23  13% 
Type 1 5 
Total diabetes  28 15.8% 
Active non-participation 54 
Incomplete responses   14 
Non response rate 68 38.4% 
Within the High Risk category: 14 participants scored High Risk 1 (12-15 points); 
11 participants scored High Risk 2 (16-19 points); and 7 participants scored High Risk 3 
(20 points or more). Of the 32 participants who scored in the High Risk range only 10 
(12.3%) agreed to complete the follow-up survey. Survey results showed that 7 
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individuals attended a GP for a blood test and 3 individuals chose not to attend (2xHR1; 
1xHR2). Seven HR individuals who attended for a blood test - 6 HR (3xHR3; 2xHR2; 
1xHR1) showed normal blood glucose levels. The only HR individual who showed an 
elevated blood glucose (EBG) level was a female who scored 13 (HR1); aged 75 years 
and had a family history of diabetes. 12 HR clients had a family history of diabetes but 
only 5 had blood glucose testing; 4 had normal blood glucose results.  
Intermediate Risk (6-11 points): 38 individuals (age range 30 – 84 years).  
Under 35 years – 7 females (2 with family history; all had risk factors) 
35-44 years – 2 females; 3 males (1 female with family history)
45-54 years – 4 females (1 with family history); 6 males (1 with family history)
55-64 years – 5 females (1 with family history)
65 years and over – 6 females; 5 males . 
Low Risk (5 points or less) – 11 (age range 23-40 years)  
8 females (2 with family history; 5 with risk factors); 3 males (2 with risk factors) 
Family History – In the CICC group, 20/81 participants (25%) reported a Family History 
of diabetes and additional modifiable Risk factors for type 2 diabetes. 
Results from the Optometry practices. 
During the period July- August 2014 there were 40 clients who attended the optometry 
practices for a full eye assessment with dilatation of pupils. Of those, thirteen clients 
(13) were previously diagnosed with type 2 diabetes and were attending as part of a
care plan for diabetes management.  Of the remaining clients during this period all
agreed to participate.
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Optometrists completed 26 AUSDRISK assessments. 
Results (Table 3): 
o 13 previously diagnosed with type 2 diabetes
o 26 eligible to complete AUSDRISK
o 26 clients completed AUSDRISK
 12 clients scored in the High Risk range
 13 clients scored in the Intermediate Risk range
 1 client scored in the Low Risk range
 3 HR clients agreed to follow-up
 1 HR client completed the follow-up survey
Table 3. Optometry practice results. 
Optometry Practices  
AUSDRISK 
questionnaires/total 
clients   40 
Response rate   27 67.0% 
AUSDRISK completion  26   65.0% 
High Risk 12 46.0% 
High Risk 1 (12-15 points) 9 75.0 % 
High Risk 2 (16-19 points) 2 16.0 % 
High Risk 3 (20+ points) 1 8.0 % 
Intermediate Risk (IR) 13 50.0 % 
Low Risk (LR) 1    3.0 %  
Type 2 diabetes 13    32.5% 
Type 1 0 
Total diabetes  13 
Active non-participation 0 
Incomplete responses   1  2.5% 
Non response rate 0    0 
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High Risk 
Within the HR group (12 clients), 6 reported a Family History and 10, including those 
with a Family History had additional multiple modifiable Risk Factors. 
Of the HR clients, 9 declined to complete the follow-up survey – HR3 = 1; HR2=1; HR1=7. 
Three HR clients agreed to follow-up – 2 completed the survey; none completed 
biomedical assessment. The 6 HR clients with a Family History did not complete the 
follow-up survey. 
Intermediate Risk 
Of the 13 Intermediate Risk (IR) clients, 3 reported a Family History including one 
individual with additional modifiable risk factors. Eight IR clients had modifiable Risk 
Factors. 
Diabetes 
The 13 clients diagnosed with type 2 diabetes were attending for a full eye assessment 
as part of their diabetes management. 
Family History: 
In the optometry group, 9 clients (22.5%) reported having a Family History and seven of 
these nine had additional modifiable Risk Factors. 
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Results from the Seniors’ Card mail-outs (table 4) 
Approximately 23.0 % of recipients mean age 65.5 years completed and returned the 
AUSDRISK. Of the responders 24 (10.6%) had diabetes; 101 participants (44.7%) were 
assessed HR (65 males: 46 females) and 101 were identified as having an Intermediate 
Risk (IR).  
  Table 4 Seniors’ Card results: 




  401    26.0% 
AUSDRISK completion     309 20.0% 
High Risk 101 32.0% 
High Risk 1 (12-15 points) 48 
High Risk 2 (16-19 points) 37 
High Risk 3 (20+ points) 16 
Intermediate Risk 101 32.0% 
Low Risk  0 
Type 2 diabetes 23 
Type 1 1 
Total diabetes  24 5.00% 
Active non-participation 67 16.0% 
Non response rate   74.0% 
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Follow-up Survey results 
Those individuals who scored High Risk on the AUSDRISK were invited to participate in a 
follow-up survey. Of the 144 HR individuals who completed the AUSDRISK, one hundred 
and ten provided their preferred contact details – email or phone –to participate in a 
follow-up survey 6-8 weeks post AUSDRISK completion. Subsequently, when these HR 
individuals were contacted to complete the survey only 79 HR individuals (thirty-three 
females and forty-six males) agreed to participate in the survey. Participation in the 
follow-up survey was not evenly distributed across all settings – 62.4 % SC completed 
the survey, whereas only 31.3% of those at the Community ICC and 8.3% at Optometry 
practices completed the survey (ref Table 5).  
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Table 5: Number of HR participants who completed AUSDRISK x setting x High Risk 
level x survey completion (%) 






(≥ 20 points) 
TOTAL 
CICC COMMUNITY CARE 
SURVEY (S)    % 
14 
S = 4 (1)* 
11 
S = 3 
7 
S = 3 
32  
S = 10 (1)*  31.3% 
OPTOMETRY 
SURVEY         % 
9 
S = 1 
2 
S = 0 
1 
S = 0 
12 
S = 1   8.3% 
SENIORS’ CARD MAIL-
OUT 1 
SURVEY   % 
11 
S = 11 
8 
S = 7(1)* 
9 
S = 8(2)* 
28  





S = 8 
12 
S = 7(1)* 
3 
S = 3 
35  





S =11 (1)* 
17 
S = 9(1)* 
4 
S = 4 
37  
S = 24 (2)*64.9% 
TOTAL HR 
Survey completion 
% of total 
70 
S = 35 (2)* 
50.% 
50 
S = 26 (3)* 
52.0% 
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S = 18 (2)* 
75.0% 
144 
S = 79(7)* 
55.2% 
• Number of participants diagnosed with elevated blood glucose (in brackets)
Results from the survey showed that 44 HR participants (53.8%) had attended their GP 
for biomedical assessment with 43 of the attendees having diagnostic blood tests. 
Following the blood tests, 36 individuals (85.4%) were advised by their GP that they did 
not have type 2 diabetes; 7 individuals (14.6 %) had “elevated blood glucose/pre-
diabetes”. No HR participants who had blood tests were diagnosed with diabetes. 
Approximately 50 percent of those who completed the follow-up survey but had not 
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attended for biomedical assessment stated they planned to request blood tests when 
they had their regular annual or bi-annual appointment with their GP. However the 
remainder indicated they would not be attending for biomedical assessment. 
Within the High Risk range (≥ 12 points) there are three categories reflecting increasing 
risk of developing Type 2 diabetes - HR1 =12-15 points (approximately 1 in 14 will 
develop diabetes); HR2 = 16-19 points (approximately 1 in 7 will develop diabetes) and 
HR3 = 20 points or more where the risk is that 1 person in every 3 will develop diabetes. 
There was no association between the levels of High Risk and pre-diabetes (elevated 
blood glucose) and no association between the settings and elevated blood glucose 
(Table 6). 
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Table 6: HR survey completers x setting x HR category x glycaemic status (elevated 




CICC OPTOM Senior’s Card Percentage (%) 
EBG/Normal Glucose level 
Glycaemic 
status 




HR1 = 34 1 3 0 1 1 29 2 33 5.71% 94.28% 
HR2 = 0 3 0 0 3 20 3 23 11.53% 88.46% 
HR3 0 3 O 0 2 13 2 16 11.11% 88.88% 
Total 1 9 0 1 6 62 7 72 8.86% 91.13% 
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Of those diagnosed with elevated blood glucose or “pre-diabetes”, two participants (one 
male: one female) were in category HR1; three participants (2 male: 1 female) were in 
HR2 and two participants (2 females) were in HR3. One participant with elevated blood 
glucose was a patient of the Community Integrated Care Centre and the other six were 
from the Seniors’ Card mail-out groups There was no association between risk score and 
family history or age or gender (Table 4). 
Table 7: Participants: rated High Risk on AUSDRISK; diagnosed elevated blood glucose 
on biomedical assessment  




CICC 75 years 13 Female Yes 
Seniors’ Card 63 years 13 Male No 
Seniors’ Card 67 years 16 Male Yes 
Seniors’ Card 76 years 17 Male No 
Seniors’ Card 60 years 18 Female No 
Seniors’ Card 60 years 21 Female No 
Seniors’ Card 70 years 23 Female No 
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Overall the rate of attendance to non-attendance for biomedical assessment increased 
as the level of High Risk increased from HR1 to HR2 and HR3. However this pattern was 
not reflected across both genders. There was a noticeable interaction between gender, 
risk level and attendance or non-attendance. The male response pattern of attending or 
not attending for biomedical assessment showed that as the level of risk increased, the 
level of GP attendance decreased. Whereas the female response rate pattern of 
attending to not attending increased uniformly as the levels within high risk increased, 
with 100 % attendance at HR3 (Table 8). 
Table 8: Gender HR survey responders x GP attendance/non-attendance x HR risk level 
HR participants in follow-up 
survey  
46 HR Male 33 HR Female 80 HR  
(male + female) 
Attendance vs  
non-attendance to GP  



































50.0% 50.0% 69.7% 30.3% 56.3% 43.7% 
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Results  
Analysis of AUSDRISK results 
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Flowchart 
































0/43 = 0% 









• Agreed to follow-up
110/144=76.6% 





• 55.7%(44/79) had attended their GP
• 44% (35/79) did not see their GP.
o Of those who didn’t see their GP, 54% (19/35) (or 24% (19/79) of the total))
did not have the intention of seeing their GP.
• So half had acted on seeing a GP, another quarter still had the intention to go, while
the last quarter did not have the intention to go at all.
 GP actions  
 44 participants presented to their GP 
• In 98% (43/44) of the instances, the GP acted by ordering a blood test
• In 73% (33/44) of the instances, the GP discussed lifestyle changes
• Of those who received a blood test, 70% also received lifestyle advice
• The person who did not receive a blood test, did receive lifestyle change advice
Differences in the follow-up survey participants 
Compared to those who did not participate, those who participated in the follow up were: 
• 3.36 years older (p=0.057)
• More often males (p=0.04)
• Had a similar diabetes risk score (p=0.40)
• Were more likely to have a family history of diabetes but this difference was not
significant (p=0.07)
• Very different in type/setting (p<0.01): Most likely to be Senior Card participants
and least likely to be Optometry participants Differences by GP attendance
• No significant difference by age (p=0.81)
• No significant difference by gender (p=0.19)
• No significant difference by risk score (p=0.46)
• People with a family history were more likely to attend a GP, but this difference was
not significant (p=0.09).
• No significant difference by GP type/setting (p=0.35)
Interaction effect of gender by GP attendance 
• The difference in pattern of attendance at GP between males and females was
statistically significant (p=0.01)
• Males with increasing risk score were less likely to see their GP (test for trend
p=0.37)





No association between the risk score and pre-diabetes. 
  
• Compared to those who did not have pre-diabetes, those who did not know whether 
they had pre-diabetes/high blood sugar had a risk score that was on average 0.94 
units higher  (p=0.50). 
• Compared to those who did not have pre-diabetes, those who had pre-diabetes/high 
blood sugar had a risk score that was on average 0.95 units higher (p=0.50). 
 
No association between gender and pre-diabetes.  
 
• Compared to those who did not have pre-diabetes, those who did not know whether 
they had pre-diabetes/high blood sugar were more likely to be female but this was 
not significant (p=0.10). 
• Compared to those who did not have pre-diabetes, those who had pre-diabetes/high 
blood sugar were more likely to be female but this was not significant (p=0.26). 
 
No association between the type/setting and risk score (continuous measure) (p=0.13, 
p=32) or between type/setting and risk score category (p=0.37)  
Effectiveness of the screening among those who had a blood test done 
Of the 44 blood tests, none came back as diabetes 
Positive predictive value=  
False discovery rate= 
 
 




high risk  
0 43 
False positive 
Type 1 error 
43 
Screen showed 










Survey results of participant beliefs and attitudes 
Most survey respondents were unaware of the AUSDRISK questionnaire and its role as a 
pre-screening tool for assessing diabetes risk. Apart from those participants who had a 
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family history of diabetes, there were few participants who had an informed understanding 
of type 2 diabetes, diabetes risk factors, continuum of risk and the benefits of having normal 
blood glucose levels. The majority of participants did not know that increasing age was a risk 
factor for type 2 diabetes. Their overall attitude towards Type 2 diabetes was one of being 
risk averse on multiple levels – concern that increasing age was a risk factor and was not 
modifiable; fear of complications; concern of individual blame for having diabetes or being 
at risk, concern that they would have to make significant changes to their lifestyle and 
ambivalent, in that they were not sure how this could be done or how type 2 diabetes could 
be effectively managed. The HR individuals who had a normal blood glucose result were 
relieved, and believed that this result gave them protection from developing type 2 




To our knowledge the AUSDRISK questionnaire developed in 2008 has not been used in 
Australia in a systematic manner to identify older people with undiagnosed type 2 diabetes 
or at high risk for developing this condition and follow them through to biomedical 
assessment. The prevalence for type 2 diabetes is known to be high (17-20%) in this age 
group both in Tasmania and nationally, considered to be due to increasing age and rising 
rates of obesity. Potentially the effect of other chronic conditions associated with ageing 
and lifestyle restrictions add to the risk factor burden, for example, arthritis and 
osteoporosis which may lead to reduced physical activity and reduced exercise tolerance, 
increased sedentary behavior, and overweight/obesity all of which are considered to 
increase the risk for type 2 diabetes.   
We had three main objectives in this study. First, to determine the feasibility and 
acceptability of utilising the AUSDRISK in healthcare and non-healthcare settings to identify 
older individuals at High Risk for developing diabetes. Secondly, determine the uptake and 
effectiveness of the AUSDRISK by following-up those assessed as being at High Risk, to 
determine their follow-up actions, and those of their General Practitioners, to the older 
individual being advised to seek biomedical assessment of their glycaemic status.  Finally, to 
examine the knowledge and beliefs about Type 2 diabetes, held by those just recently 
assessed as High Risk for this condition. 
This study achieved its first aim by finding that implementing the AUSDRISK questionnaire 
was a feasible process face-to-face as part of routine patient health assessments in both the 
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public and private health sectors and for the first time it showed that a routine, well 
established non-healthcare mail-out could be effectively utilized to provide a low cost 
means for state-wide distribution of the AUSDRISK to the older population in Tasmania, 
which would potentially include those people not currently interacting with the healthcare 
system.  
The second aim to determine the follow-up actions of HR participants and their GPs found 
that of the 79 individuals who completed the follow-up survey only 44 HR individuals 
attended their GP for a biomedical assessment. When this result was considered in the light 
of the 144 individuals who scored High Risk, it showed that only one-third of those 
individuals who scored High Risk attended their GP for a biomedical assessment.  This 
response pattern clearly indicates that distributing an AUSDRISK questionnaire does not 
facilitate recipients to seek further clarification of their diabetes risk status. 
General Practitioners responded as recommended by NHMRC Guidelines for the Prevention 
and Management of Type 2 diabetes (2009) by ordering blood glucose tests, and providing 
lifestyle modification recommendations to the majority of those who attended. GPs also 
indicated that they would continue to monitor those participants who had been diagnosed 
with an elevated blood glucose level. Thus, a regular management program for a previously 
unrecognized risk condition for developing type 2 diabetes was established.   
The final aim to examine the knowledge and beliefs about Type 2 diabetes, held by those 
just recently assessed as High Risk for this condition revealed that older people generally 
have a risk averse and ambivalent attitude towards type 2 diabetes, its management  and its 
potential severe complications. They had little or no knowledge and understanding of 
diabetes risk nor the potential for its effective management.  
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Type 2 Diabetes Risk Status 
The diabetes risk level status (Intermediate or High) of older adults was identified in both 
non-medical healthcare settings and via the non-healthcare mail-outs. Results indicated that 
36 of the survey respondents (83 %) who had registered as High Risk on the AUSDRISK were 
found to be normo-glycaemic on biomedical assessment. Seven participants assessed as 
High Risk were advised they had elevated blood glucose. No participant was diagnosed with 
type 2 diabetes. These results raised the question of the discriminative ability of the 
AUSDRISK questionnaire when implemented in a limited age range cohort (only those over 
50 years). Whilst the age range limitation may have had an impact on the current study, the 
poor initial and follow-up response rates would likely also be contributing factors. 
 The fact that no individuals were diagnosed with diabetes might suggest that within the 
cohort tested there were more participants in the HR1 and HR2 categories and this was the 
case (35 HR1:26 HR2:18 HR3). However diagnosed elevated blood glucose/pre-diabetes was 
identified at all HR levels not just HR3 and not all those identified as HR3 were identified 
with elevated blood glucose. The results were found to have no predictive value for type 2 
diabetes or elevated blood glucose.   
Response Rates 
In all settings (health and non-health), the limited response rate of older adults to the initial 
introduction of the AUSDRISK questionnaire suggested that the questionnaire and its role in 
assessing diabetes risk prior to diagnostic testing was not well known or understood. The 
initial uptake of the AUSDRISK, from a distribution of 1717 questionnaires was only 401 
responses (23.4 %), and of those, 309 individuals (18.0 %) were eligible to participate.  
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The limited initial and subsequent participation rates to determine participants’ diabetes 
risk status reflected findings in other national and international screening studies. The 
ADDITION Diabetes study in the United Kingdom (2012)12 found that mail-out 
questionnaires yielded a relatively poor rate compared with the national diabetes risk 
screening program conducted on a regular basis within GP practices. That no HR participants 
were diagnosed with diabetes may be due to the limited age range of the participants and 
the small size of the final cohort of 44 individuals (44/79; 44/144) who completed the 
AUSDRISK, the follow-up survey and were bio-medically assessed. It may also reflect self-
selection not to participate. According to the Theory of Planned Behaviour13 those adults 
who perceived high personal risk associated with the AUSDRISK questionnaire would likely 
either not participate at all, or if initially participating, would not proceed to a biomedical 
assessment with a GP.   
Although the follow-up survey in this study was completed by a small number of 
participants, the negative attitudes and beliefs in relation to type 2 diabetes were consistent 
and clearly identified those issues that would need to be addressed to improve the uptake 
and full participation rate for this age cohort14,.  
Follow-up Survey  
A total of 79 participants completed the follow-up survey- 33 female and 46 male. 
Distribution across the risk levels showed 35 HR1 (17 female: 18 male); 26 HR2 (10 female: 
16 male) and 18 HR3 (7 female: 11 male). This numerical pattern of HR levels reflected those 
of the larger group of 145 AUSDRISK HR participants (numbers of participants in HR levels 
HR1>HR2>HR3). Forty-four HR individuals (21 female: 23 male) completed the survey, and 
attended the GP for biomedical assessment and 35 (12 female: 23 male) did not. Thus 
slightly over half (56.3 cent) of those HR individuals who scored HR and completed the 
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survey took action to seek a biomedical assessment of their diabetes assessment. Whilst 
more males than females completed the survey (46 males: 33 females), females were more 
likely to follow up by attending their GP (64.7%) whereas there was only a 50:50 chance that 
males would see their GP. Survey results showed there was an increase in rate of 
attendance to non-attendance for biomedical assessment as the level of High Risk increased 
from HR1 to HR2 and HR3. However this pattern was not reflected across both genders. 
There was a significant interaction between gender, risk level and attendance or non-
attendance. The male response pattern of attending or not attending for biomedical 
assessment showed an approximate 50:50 not attend/attend across all levels but at HR3 the 
level of attendance decreased further. Whereas the female response pattern of attending or 
not attending increased uniformly with the increasing level of high risk, with 100 % 
attendance at HR3. This male response pattern has been well-recognized in other chronic 
condition screening and clinical settings. As men have a higher prevalence of type 2 
diabetes, the male response pattern of reduced engagement with increased personal health 
risk would be a challenge to address for any diabetes screening program.  
 
General Practitioner response 
The response of general practitioners to the High Risk score of their patients showed that 
GPs were following the Guidelines5 with 43 of the 44 HR individuals receiving blood glucose 
testing. The GPs also indicated the importance of lifestyle modification. However lifestyle 
modification information was not universally provided as only 33 of the 44 HR individuals 
who had a biomedical assessment received this recommendation. This lack of or limited 
reinforcement on the part of GPs, of the importance and benefit of lifestyle changes, may 
inadvertently reduce an individual’s perception of their diabetes risk. Those individuals who 
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did not receive lifestyle advice included 3 HR2 and 1 HR3. GPs appeared to be responding to 
the current normo-glycaemic status of the patient rather than their ongoing High Risk 
status. 
Participant Knowledge  
Participants assessed as being at High Risk appeared to have no understanding of the 
concept of ongoing diabetes/pre-diabetes risk, nor the continuum of risk and, that they 
would remain at high risk despite being normo-glycaemic at time of testing. Those 
individuals who were bio-medically assessed as not having type 2 diabetes felt “relieved” 
and considered that this result gave them some form of protection from ever developing 
diabetes. They were somewhat confused that they had scored High Risk on the AUSDRISK 
but that they didn’t have diabetes nor pre-diabetes when their blood glucose was tested. 
Many of the HR participants who completed the AUSDRISK also felt disempowered to make 
a change to their situation when age alone was a major risk factor component that was non-
modifiable15,16,17,18..  
This lack of knowledge about diabetes and diabetes risk and fearful attitude towards type 2 
diabetes would need to be addressed/overcome as part of and prior to, implementing a 
systematic diabetes risk screening process for older adults. From a health benefit viewpoint 
it is difficult to promote the concept of risk over an extended period, which may be 
perceived by some to be longer than their expected lifespan. There was no understanding of 
the immediate benefits of having a blood glucose level within the normal range.  
For the first time in history people in the older age group are living longer than any previous 
generation, screening and assessment offers an opportunity to promote the immediate 
benefits to their quality of life and facilitate their independence from having normal blood 
glucose levels.  
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Validity of the AUSDRISK Questionnaire 
Although the AUSDRISK can be implemented via all settings studied, on biomedical testing 
no HR individuals were found to have diabetes. The AUSDRISK scores of those diagnosed 
with elevated blood glucose was spread across all HR categories rather than in the highest 
HR score. Both findings suggest a lack of discriminative capacity in the AUSDRISK. The results 
of our study would lend support to earlier studies8,19 which found that most basic diabetes 
screening questionnaires can identify people at high risk of developing diabetes in a 5-10 
year time frame, but at the time of implementation most screening questionnaires over-
estimate the actual risk of diabetes.  
In a post hoc analysis we reviewed our results against the Finnish Diabetes Risk Score 
(FINDRISC)20, (validated within a comparable population to the AUSDRISK ) and on which the 
concept of the AUSDRISK was based. We found that in particular, the scoring for “age” and 
“gender” in the AUSDRISK could account for 4-7 points in excess of those allocated in the 
FINDRISC. Thus in our study, a number of participants classified HR on the AUSDRISK would 
have scored in the Intermediate Risk range of the FINDRISC or at a lower classification in the 
High Risk range. These findings and the lack of discriminatory ability of the AUSDRISK in an 
older age cohort needs further investigation. 
CONCLUSION 
Whilst this study found that the AUSDRISK could be implemented in settings other than 
medical and in so doing  would increase the potential access to the older population, this 
study identified individual and systems barriers, which would need to be addressed for 
AUSDRISK screening to be implemented effectively. The validity of AUSDRISK for use as a 
screening tool for assessing diabetes risk in an older age group is a priority for further 
investigation. Whilst addressing the issues identified in this study, other diabetes screening 
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methods such as point-of-care testing with HbA1c warrant consideration for the older age 
cohort, with reference to   advantages/disadvantages for participants, health professionals, 
settings, cost and impact as a way forward for determining effective identification of 
diabetes risk in the older age group.   
This study found that including the AUSDRISK in regular healthcare settings and in a non-
health-related mail-outs was feasible and low cost for inviting older adults to assess their 
diabetes risk. However completion of the AUSDRISK, whilst identifying those at HR, was not 
perceived by participants as being reflective of current and/or future diabetes risk, and for 
the most part did not promote most HR participants to seek biomedical assessment.  
Pre-screening education is clearly required for older people to reduce their aversion and 
ambivalence to type 2 diabetes prevention and management and facilitate informed choice 
towards diabetes/pre-diabetes screening. 
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Appendix 10 Screening costs  
The costs for the AUSDRISK questionnaires and the Instruction sheet/Consent form were the 
same for both the direct (healthcare-related) and indirect (mail-out) recruitment. The 
AUSDRISK tool is supplied free and free of delivery charges from the National Mailing and 
Marketing Centre (health@nationalmailing.com.au). In total, 2000 x Instruction  
sheet/consent forms and 1500 Reply-paid envelopes cost $1,871.19.  
In addition, the cost of the three mail-outs was $3,045.19 for contracted mailing services. 
The costs for direct recruitment by healthcare staff was estimated (15 minutes per patient 
and 3 hours staff training and support per setting) and were covered within usual services in 
the healthcare centre and optometry practices.  
The cost for biomedical assessment, comprising GP consultation and pathology tests, was 
covered in full, or part, by Medicare (Australian Government Health Services).  
At the time of this study, many older persons were “bulk-billed” for short GP consultations. 
Similarly, the pathology tests were “bulk-billed”. The term bulk-billing refers to the services 
being paid a standard fee under the Australian Government Health Services Medicare with 
the patient having no out-of-pocket expenses. This cost arrangement is no longer current.  
In November 2014 (after this study had been completed), Medicare introduced a new 
pathology item for the use of the HbA1c test for diagnosis of T2DM (MBS* item 66841), 
which may be requested by the GP for diagnostic purposes of T2DM for asymptomatic at-
risk patients, once every 12 months. This annual test is free for those patients who fulfil the 
following criteria. These are patients with either (i) a medical condition or ethnic 
background associated with high rates of type 2 diabetes, or (ii) an Australian type 2 
diabetes risk (AUSDRISK) score of 12 points or greater, placing them at increased risk of 
diabetes – (Reimbursed by Medicare). 
